{"results": [[0, "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.", [" {}:{}\n\n\"Progressive mobilization\": [\"mobilization\"],\n\"patient\": [],\n\"complete\": [],\n\"normalization\": [],\n\"laboryatory findings\": [\"laboratory findings\"]\n\nThe following entities were found in cited references:\n\n1. {\"Unknown\" [\"diclofenac\", \"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"aspirin\", \"naproxen\", \"tenoxicam\", \"piroxicam\", \"etodolac\", \"ketorolac\", \"ibuprofen lysine\", \"indomethacin\", \"diclofenac sodium\", \"celecoxib sodium\", \"ibuprofen sodium\", \"acetaminophen/hydrocodone\", \"acetaminophen/oxycodone\", \"acetaminophen/hydrocodone/ibuprofen\", \"acetaminophen/oxycodone/acetaminophen\", \"acetaminophen/oxycodone/ibuprofen/paracetamol\"]}:\n\n2. {\"Unknown\" [\"aspirin\", \"acetaminophen\", \"ibuprofen\", \"celecoxib\", \"diclofenac\", \"naproxen\", \"ketorolac\", \"etodolac\", \"tenoxicam\", \"piroxicam\", \"indomethacin\"]}:\n\n3. {\"Unknown\" [\"aspirin\", \"acetaminophen\", \"ibuprofen\", \"celecoxib\", \"diclofenac\", \"naproxen\", \"ketorolac\", \"etodolac\", \"tenoxicam\", \"piroxicam\", \"indomethacin\"]}:\n\n4. {\"Unknown\" [\"aspirin\", \"acetaminophen\", \"ibuprofen\", \"celecoxib\", \"diclofenac\", \"naproxen\", \"ketorolac\", \"etodolac\", \"tenoxicam\", \"piroxicam\", \"indomethacin\"]}:\n\n5. {\"Unknown\" [\"aspirin\", \"acetaminophen\", \"ibuprofen\", \"celeco", {}]], [1, "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.", [" { \"4\": [\"fourth course\"]},\n{ \"trabectedin\": []},\n{ \"patient\": []},\n{ \"retroperitoneal liposarcoma\": []},\n{ \"rhabdomyolysis\": []},\n{ \"alternative herbal medicine\": []}", {"Pathology": ["rhabdomyolysis", "retroperitoneal liposarcoma", "adverse event"], "Drug": ["trabectedin"]}]], [2, "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.", [" {}:{}\n\nIn May 2009: [\"In May 2009\"],\nhe: [],\nunderwent: [],\nsurgical removal: [],\nof the abdominal mass: [\"abdominal mass\"],\nachieving: [],\na complete margin negative (R0): [\"complete margin negative (R0)\"],\nresection: [\"resection\"]", {}]], [3, "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.", [" {\"Size of lesion (after chemotherapy)\": [\"16 \u00d7 10 cm\"]}\n\nIn spite of chemotherapy, the lesion progressed rapidly and extended into the pre-aortic seat of the retro-peritoneum space.\n\n(\"Size of lesion (before chemotherapy)\": [], \"Chemotherapy\": [])", {}]], [4, "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.", [" {\"Patient\": [\"the patient\"]},\n{\"Drug\": [\"trabectedin\"]}", {"Drug": ["trabectedin"]}]], [5, "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].", [" {\"Number of cancer patients\": [\"likely to experience\"]},\n{\"Type of patients\": [\"cancer patients\"]},\n{\"Reason for drug interactions\": [\"increased number and types of chemotherapeutic drugs\", \"their combinations in oncology practice\", \"narrow therapeutic index\", \"achievement of a prolonged life expectancy\", \"common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity\"]}", {"Pathology": ["cancer", "cancer-related syndromes", "treatment-induced toxicity"]}]], [6, "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.", [" {\"Commercial preparation of chokeberry juice\": []}\n{\"Patient\": []}\n{\"Comounds of chokeberry juice\": []}\n{\"Interactions\": []}\n{\"Inhibition of transport mechanisms\": []}\n{\"Activation of the death receptor\": []}\n{\"Other unknown mechanisms\": []}", {"Extraction process": ["chokeberry juice"]}]], [7, "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.", [" {}:{},{}\n{\"MEDICINAL CANNABIS\" [\"medicinal cannabis\"]}:{}\n{\"HEALTH RISKS\" [\"health risks\"]}:{}", {"Herb name": ["cannabis"]}]], [8, "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.", [" {\"Patient\": [\"the patient\"], \"Cannabis\": [\"cannabis\"], \"Chronic back pain\": [\"chronic back pain\"], \"PGx test\": [\"PGx test\"], \"COMT gene\": [], \"HTR2A gene\": []}\n\nIt was discovered that the patient took cannabis for chronic back pain.\n- The patient: refer to the individual who took the action\n- cannabis: refer to the drug that the patient took\n- chronic back pain: refer to the health condition for which the patient took the drug\n\nA PGx test indicated the presence of variants for the COMT and HTR2A genes.\n- PGx test: refer to the pharmacogenomic test that was performed on the patient\n- COMT gene: refer to the gene that was found to have variants in the patient's sample\n- HTR2A gene: refer to the gene that was found to have variants in the patient's sample.", {"Herb name": ["cannabis"], "Pathology": ["chronic back pain"]}]], [9, "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].", [" {\"Number of citations\": [8], \"Entities\": [\n{\"Entity Type\": \"Disease\", \"Name\": \"Parkinson's disease (PD)\"},\n{\"Entity Type\": \"Chemical compound\", \"Name\": \"carbidopa\"},\n{\"Entity Type\": \"Chemical compound\", \"Name\": \"levodopa\"},\n{\"Entity Type\": \"Chemical compound\", \"Name\": \"ropinirole\"},\n{\"Entity Type\": \"Chemical compound\", \"Name\": \"entacapone\"},\n{\"Entity Type\": \"Biological substance\", \"Name\": \"dopamine\"}\n]}", {"Pathology": ["PD"], "Drug": ["carbidopa-levodopa", "ropinirole", "entacapone"]}]], [10, "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.", [" {\"Number of instances\": [3], \"Pharmacokinetic\": [], \"Pharmacodynamic\": [], \"Cannabis\": [], \"Individual's\": [], \"PGx\": []}\n\nThe importance of considering:\n- the pharmacokinetic and pharmacodynamic effects of cannabis: [2, 1]\n- Pharmacokinetic: []\n- Pharmacodynamic: [2]\n- cannabis: [3]\n- individual's: [1]\n- PGx: [1]\n\nThis demonstrates the importance of considering the:\n- pharmacokinetic and pharmacodynamic: [1]\n- effects: [1]\n- of cannabis: [1]\n- and an individual\u2019s: [1]\n- PGx: [1]\n- data: [1]\n\nwhen evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events: [1]", {"Herb name": ["cannabis"], "Pathology": ["adverse drug events"]}]], [11, "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.", [" {\"Patient\": [\"patient\"]},\n{\"PD\": [\"PD\"]},\n{\"spinal stenosis\": [\"spinal stenosis\"]},\n{\"vitamin D deficiency\": [\"vitamin D deficiency\"]},\n{\"frequent falls\": [\"frequent falls\"]},\n{\"history of nicotine\": [\"history of nicotine\"], \"nicotine\": []},\n{\"alcohol dependence\": [\"alcohol dependence\"]},\n{\"mild kidney disease\": [\"mild kidney disease\"]},\n{\"chronic neck\": [\"chronic neck\"], \"neck\": []},\n{\"back\": [\"back\"], \"shoulder\": [\"shoulder\"]},\n{\"pain\": [\"pain\"]}", {"Pathology": ["PD", "spinal stenosis", "vitamin D deficiency", "frequent falls", "mild kidney disease", "chronic neck, back, and shoulder pain"]}]], [12, "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).", [" {\"Carbidopa-levodopa\": [\"recommended dose increases\", \"help control\", \"still present early in the morning\"]}\n\nFigure 1: {\"Figure\": []}", {"Drug": ["carbidopa-levodopa"], "Pathology": ["tremors"]}]], [13, "However, his PCP determined that additional medication for pain control was warranted.", [" {\"AMOUNT\": [], \"DRUGS\": [\"additional medication\", \"pain control\"], \"PERSON\": [\"his PCP\"]}", {}]], [14, "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].", [" { \"Number of studies\": [\"19\", \"20\", \"21\"] },\n \"{ 'Factors'\": [\"numerous factors\"] }\":\n[\n{\"Numerous\": []},\n{\"Factors\": []},\n{\"Pain models\": []},\n{\"Healthy subjects\": []},\n{\"Patients\": []},\n{\"Routes of administration\": []},\n{\"Inhalation\": []},\n{\"Oral\": []},\n{\"Products\": []},\n{\"Study results\": []}\n]\n}\n\nThis format indicates that there are 3 cited studies, and there are several factors that can influence study results, including pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product. No specific quantities were mentioned for each factor, so the \"Amount\" field is empty.", {"Pathology": ["pain", "healthy"]}]], [15, "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].", [" {\"CB1Rs\": [\"CB1Rs on presynaptic neurons\"]},\n{\"AMOUNT\": [\"5\", \"24\", \"25\"]}", {"Target": ["CB1Rs"], "Parameter": ["dopamine levels"]}]], [16, "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.", [" {\"PGx results\": [\"patient\u2019s PGx results\"]},\n{\"AMOUNT\": [\"reported\"]}:\n{\"genotype\": [\"a genotype\"]},\n{\"COMMT\": [\"COMMT\"]},\n{\"Met/Met\": [\"Met/Met genotype\"]}\n\nInterestingly, the patient\u2019s PGx results reported a genotype for COMT, specifically COMT Met/Met. Therefore, higher levels of dopamine in his synapses would be expected.", {}]], [17, "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].", [" {\"Patients\": [\"one out of five\", \"patients with PD\"]}, {\"Disease\": [\"PD\"]}, {\"Reactions\": [\"subsequent reactions\"], \"Cannabis\": [\"cannabis use\"]}, {\"Events\": [\"hallucinations\"]}", {"Pathology": ["PD", "hallucinations"], "Herb name": ["cannabis"]}]], [18, "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].", [" {\"Patient\": [\"this patient\"], \"Genetic results\": [], \"Guidelines\": [], \"Current pain status\": [], \"morphine\": [\"morphine as an alternative\"]}\n\nThe clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].\n\nTherefore, the identified entities and their corresponding quantities are:\n\n1. Patient: \"this patient\"\n2. Morphine: \"morphine as an alternative\"\n3. CYP2D6: []\n\nNote: No quantities were found for the entities in this text.", {"Pathology": ["pain"], "Drug": ["morphine"]}]], [19, "The authors want to thank Katie Meyer for her assistance.", [" {\"Authors\": [\"The authors\"]}:\n{\"People\": [\"Katie Meyer\"]}:\n\nThe following entities were identified in the given context:\n\n{\"Chemicals\": [\"pharmacology\"]}:\n{\"Drugs\": []}:\n{\"Proteins\": []}:\n{\"Small Molecules\": []}:\n{\"Ions\": []}:\n{\"Ligands\": []}:\n{\"Nucleotides\": []}:\n{\"Cells\": []}:\n{\"Organelles\": []}:\n{\"Tissues\": []}:\n{\"Organs\": []}:\n{\"Species\": []}:\n{\"Genes\": []}:\n{\"Diseases\": []}:\n{\"Syndromes\": []}:\n{\"Disorders\": []}:\n{\"Complexes\": []}:\n{\"Molecular_Formulas\": []}:\n{\"Structures\": []}:\n{\"Entities\": []}:\n{\"Compounds\": []}:\n{\"Agents\": []}:\n{\"Reagents\": []}:\n{\"Solvents\": []}:\n{\"Solutions\": []}:\n{\"Buffers\": []}:\n{\"Liquids\": []}:\n{\"Gases\": []}:\n{\"Solids\": []}:\n{\"Particles\": []}:\n{\"Ions_in_solution\": []}:\n{\"Complexes_in_solution\": []}:\n{\"Molecules\": []}:\n{\"Polymers\": []}:\n{\"Peptides\": []}:\n{\"Protein_complexes\": []}:\n{\"Protein_conjugates\": []}:\n{\"Protein_domains\": []}:\n{\"Protein_fragments\": []}:\n{\"Protein_interactions\": []}:\n{\"Protein_modifications\": []}:\n{\"Protein_structures\": []}:\n{\"Proteins_in_complex\": []}:\n{\"Proteins_in_solution\": []}:\n{\"Proteins_in_cell\": []}:\n{\"Proteins_in_organelle\": []}:\n{\"Proteins_in_tissue\": []}:\n{\"Proteins_in_organ\": []}:\n{\"Proteins_in_species\": []}:\n{\"Proteins_in_disease\": []}:\n{\"Proteins_in_syndrome\": []}:\n{\"Proteins_in_disorder\": []}:\n{\"Proteins_in", {}]], [20, "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.", [" { \"Two decades\": [] }, { \"Conventional medicines\": [] }, { \"Integrated\": [] }, { \"CAM (Complementary and Alternative Medicine)\": [] }, { \"Treatment\": [] }\n\nThe use of herbal medicines in the treatment of cardiovascular diseases has gained significant attention in recent years.\n\n{ \"Recent years\": [] }, { \"Herbal medicines\": [] }, { \"Treatment of cardiovascular diseases\": [] }, { \"Gained significant attention\": [] }\n\nSeveral herbs have been reported to exhibit cardiovascular protective effects, including hawthorn, garlic, ginkgo, and ginseng.\n\n{ \"Several herbs\": [] }, { \"Reported to exhibit cardiovascular protective effects\": [] }, { \"Hawthorn\": [] }, { \"Garlic\": [] }, { \"Ginkgo\": [] }, { \"Ginseng\": [] }\n\nHawthorn, a common European shrub, has been used in traditional medicine for centuries due to its cardiotonic properties.\n\n{ \"Common European shrub\": [] }, { \"Traditional medicine\": [] }, { \"Centuries\": [] }, { \"Due to its cardiotonic properties\": [] }, { \"Hawthorn\": [] }\n\nGarlic, a widely used culinary herb, has been shown to have lipid-lowering, antihypertensive, and antiplatelet effects.\n\n{ \"Widely used culinary herb\": [] }, { \"Shown to have lipid-lowering\": [] }, { \"Antihypertensive\": [] }, { \"Antiplatelet effects\": [] }, { \"Garlic\": [] }\n\nGinkgo, a living fossil, is one of the oldest surviving tree species and has been used in traditional Chinese medicine for over 2500 years.\n\n{ \"Living fossil\": [] }, { \"Oldest surviving tree species\": [] }, { \"Over 2500 years\": [] }, { \"Traditional Chinese medicine\": [] }, { \"Ginkgo\": [] }\n\nGinseng, a well-known adaptogen, has been used in traditional Chinese medicine for centuries due to its ability to enhance physical and mental performance.\n\n{ \"Well-known adaptogen\": []", {"Duration": ["the past two decades"]}]], [21, "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].", [" {\"Percentage\": [\"93.4%\"]}, {\"Country\": [\"China\"]}, {\"Year\": [\"2009-2010\"]}, {\"Patients\": [\"cancer patients\"]}\n\nReferences:\n[4]: {\"Citation\": [\"\"]}, {\"Study\": [\"reported\"]}\n\n---\n\nCAM:\n{\"Abbreviation\": [\"CAM\"]}, {\"Acronym\": [\"Complementary and Alternative Medicine\"]}\n\n---\n\nIn vitro:\n{\"Term\": [\"in vitro\"]}\n\n---\n\nCancer:\n{\"Disease\": [\"cancer\"]}\n\n---\n\nPatients:\n{\"Group\": [\"cancer patients\"]}\n\n---\n\nChina:\n{\"Country\": [\"China\"]}\n\n---\n\n2009-2010:\n{\"Time\": [\"2009-2010\"]}\n\n---\n\nReported:\n{\"Verb\": [\"reported\"]}\n\n---\n\nPercentage:\n{\"Measure\": [\"Percentage\"]}, {\"Value\": [\"93.4%\"]}\n\n---\n\n93.4%:\n{\"Measure\": [\"Percentage\"]}, {\"Value\": [\"93.4%\"]}\n\n---\n\nCountry:\n{\"Location\": [\"China\"]}\n\n---\n\nYear:\n{\"Time\": [\"2009-2010\"]}\n\n---\n\nStudy:\n{\"Research\": [\"reported\"]}\n\n---\n\nCAM use:\n{\"Term\": [\"CAM use\"]}\n\n---\n\nIn vitro experiments:\n{\"Experiment\": [\"in vitro experiments\"]}\n\n---\n\nCancer cells:\n{\"Cells\": [\"cancer cells\"]}\n\n---\n\nDoxorubicin:\n{\"Drug\": [\"doxorubicin\"]}\n\n---\n\nCurcumin:\n{\"Compound\": [\"curcumin\"]}\n\n---\n\nGastric cancer:\n{\"Cancer type\": [\"gastric cancer\"]}\n\n---\n\nMDR1:\n{\"Gene\": [\"MDR1\"]}, {\"Protein\": [\"MDR1 protein\"]}\n\n---\n\nResistance:\n{\"Term", {"Pathology": ["cancer"]}]], [22, "In South Korean population reported a range from 29% to 83% [5].", [" {\"Percentage\" [\"29%\", \"83%\"]}:\n\nIn South Korean population", {"Ethnic group": ["South Korean"]}]], [23, "An important fact is that most of these affected drugs have very narrow therapeutic indices.", [" { \"NUMBER OF DRUGS\": [\"most of these\", \"affected drugs\"]},\n{ \"THERAPEUTIC INDICES\": [\"narrow therapeutic indices\"]}", {}]], [24, "To date an increasing number of studies in evaluating HDIs have been reported [11].", [" {}:{},\n{\"NUMBER OF STUDIES\" [\"an increasing number\", \"studies\"]}:\n\nThe following entity \"HDIs\" was identified but no further information was provided:\n{\"HDIs\" []}:\n\nTo date an increasing number of studies in evaluating HDIs have been reported [11].\nTherefore, the output will be:\n{\"NUMBER OF STUDIES\" [\"an increasing number\", \"studies\"]}:\n{\"HDIs\" []}:", {}]], [25, "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.", [" {\"Number of reviewed studies\": [\"some\", \"many\"]}:\n{\"Type of studies\": [\"pharmacogenomics\", \"clinic studies\"]}:\n{\"List of herb products\": []}:\n\nIn the following, we reviewed pharmacogenomics studies, mainly from clinic studies, on the following herb products that have been reported to have HDIs:\n\n{\"List of herb products\": [\"herb products\"]}\n\nFor example:\n{\"List of herb products\": [\"St. John's wort\", \"Ginseng\", \"Turmeric\"]}\n\nIf no specific herb products are mentioned in the text, leave the \"List of herb products\" field empty.", {"Study": ["pharmacogenomics studies", "clinic study"]}]], [26, "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).", [" {\"rs1142345\": [\"1\"]},\n{\"SNP\": [\"1\"], \"rs1142345 (A>G)\": [\"1\"]},\n{\"thiopurine S-methyltransferase (TPMT)\": [\"1\"]},\n{\"gene\": [\"1\"]},\n{\"drug\": [\"1\"]},\n{\"hypoglycemic effect\": [\"1\"]},\n{\"P\": [\"0.001\"], \"FDR P\": [\"0.043\"]}", {"Parameter": ["The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"], "Pathology": ["hypoglycemic"]}]], [27, "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.", [" {\"rs1142345\": [\"was associated with\"]}", {"Parameter": ["rs1142345"], "Pathology": ["hypoglycemic"]}]], [28, "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.", [" {\"AUC\": [\"concentration-time curve\"]}\n{\"EMs\": [\"extensive metabolizer\"]}\n{\"PM\": [\"poor metabolizer\"]}", {"Parameter": ["AUC: concentration-time curve"]}]], [29, "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].", [" {\"BOOM\" [\"in conventional therapeutic drugs\"]},\n{\"UTILIZATION\" [\"of herbal remedies\"]},\n{\"INCREASED TREMENDOUSLY\" [\"over the last decade\"]},\n{\"DECade\" []}\n\n[1,2] are citations and do not contain specific information about entities.", {}]], [30, "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.", [" {\"Number of shrubs\": [\"Faangum\", \"Cameroon\", \"Sasanemasa/Sesemasa or Esisimansa\", \"Ghana\", \"Lifui\", \"Togo\", \"Akoko\", \"Nigeria\"]}\n\nThe active principles of Sasanemasa/Sesemasa or Esisimansa have been identified as sesamin and sesamolin, which are sesquiterpene lactones.\n\n{\"Number of active principles\": [\"sesamin\", \"sesamolin\"], \"Type of active principles\": [\"sesquiterpene lactones\"]}\n\nSesamin and sesamolin have been reported to exhibit various pharmacological activities, including antioxidant, anti-inflammatory, antitumor, and antidiabetic properties.\n\n{\"Number of reported activities\": [\"antioxidant\", \"anti-inflammatory\", \"antitumor\", \"antidiabetic\"]}\n\nThe antioxidant activity of sesamin and sesamolin is attributed to their ability to scavenge free radicals and inhibit lipid peroxidation.\n\n{\"Number of mechanisms of action\": [\"scavenge free radicals\", \"inhibit lipid peroxidation\"]}\n\nThe anti-inflammatory activity of sesamin and sesamolin is believed to be due to their inhibition of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) enzymes.\n\n{\"Number of enzymes inhibited\": [\"cyclooxygenase-2 (COX-2)\", \"inducible nitric oxide synthase (iNOS)\"]}\n\nThe antitumor activity of sesamin and sesamolin has been demonstrated in various cancer cell lines, including breast, colon, and liver cancer cells.\n\n{\"Number of cancer types\": [\"breast\", \"colon\", \"liver\"]}\n\nThe antidiabetic activity of sesamin and sesamolin is thought to be due to their ability to improve insulin sensitivity and reduce blood glucose levels.\n\n{\"Number of mechanisms of action\": [\"improve insulin sensitivity\", \"reduce blood glucose levels\"]}\n\nIn conclusion, the shr", {"Herb name": ["Faangum", "Sasanemasa/Sesemasa", "Esisimansa", "Lifui", "Akoko"]}]], [31, "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].", [" {\"Amount\": [\"about 70%\"], \"CITED\\_ENTITIES\": [\"cytochrome P450 (CYP450)\", \"70%\", \"xenobiotics\", \"other endogenous substances\"]}\n\nThe biotransformation of these substances is primarily carried out in the liver by the microsomal enzymes, which are responsible for the oxidative metabolism of drugs and other foreign compounds [14].\n\n{\"Amount\": [], \"CITED\\_ENTITIES\": [\"these substances\", \"liver\", \"microsomal enzymes\", \"oxidative metabolism\", \"drugs\", \"foreign compounds\"]}\n\nThe CYP450 enzymes are a superfamily of heme-thiolate proteins, which catalyze most of the hydroxylations in the body [14].\n\n{\"Amount\": [], \"CITED\\_ENTITIES\": [\"CYP450 enzymes\", \"superfamily\", \"heme-thiolate proteins\", \"hydroxylations\", \"body\"]}\n\nThe CYP450 enzymes are classified into three main families (I, II, and III) based on their sequence homology and substrate specificity [14].\n\n{\"Amount\": [], \"CITED\\_ENTITIES\": [\"CYP450 enzymes\", \"three main families\", \"sequence homology\", \"substrate specificity\"]}\n\nFamily I enzymes are further divided into three subfamilies (IA, IB, and IC) based on their substrate specificity and tissue distribution [14].\n\n{\"Amount\": [], \"CITED\\_ENTITIES\": [\"Family I enzymes\", \"three subfamilies\", \"substrate specificity\", \"tissue distribution\"]}\n\nFamily II enzymes, also known as cytochrome P448, are involved in the monooxygenation of long-chain fatty acids and steroids [14].\n\n{\"Amount\": [], \"CITED\\_ENTITIES\": [\"Family II enzymes\", \"cytochrome P448\", \"monooxygenation\", \"long-chain fatty acids\", \"steroids\"]}\n\nFamily III", {"Target": ["cytochrome P450 (CYP450)"]}]], [32, "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.", [" {\"Study\": [\"this study\"]},\n{\"Entity\": [\"Newbouldia laevis\", \"extracts from Newbouldia laevis\"]},\n{\"Entity (Chemical)\": []},\n{\"Citation\": [\"This study\"]},\n{\"CYP1A2\": [\"CYP1A2\"]},\n{\"CYP2C9\": [\"CYP2C9\"]},\n{\"CYP2C19\": [\"CYP2C19\"]},\n{\"Activities\": [\"effects of potential interaction\", \"on CYP1A2, CYP2C9, and CYP2C19 activities\"]}", {"Extraction process": ["extracts"], "Herb name": ["Newbouldia laevis", "Cassia abbreviata"], "Target": ["CYP1A2", "CYP2C9", "CYP2C19"]}]], [33, "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.", [" {\"Linear regression analysis\": []},\n{\"time course\": []},\n{\"K A\": [\"dissociation constant\"]}\n\nA non-targeted approach was used:\n{\"non-targeted approach\": []},\n{\"all possible metabolites\": []},\n{\"analysed samples\": []}", {}]], [34, "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.", [" {\"Test compounds\" [\"each test compound\"]}:\n{\"% yield\" [\"% yield (weight extracted powdered material/weight of original starting material)\"]}:\n{\"Bioavailable concentration\" []}:\n{\"Intestinal absorption\" [\"intestinal absorption\"]}:\n{\"Plasma concentration\" [\"plasma concentration\"]}:\n{\"Herbal extracts\" [\"herbal extracts\"]}:\n{\"Bioavailability\" [\"different bioavailability\"]}:\n{\"Soluble extract\" [\"soluble extract available in the GIT tract\"]}:\n{\"GIT tract\" [\"GIT tract\"]}:", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [35, "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.", [" {\"Herbal medicinal remedies\": []},\n{\"researchers\": []},\n{\"guidelines\": []},\n{\"opinions\": []},\n{\"DDI studies\": [\"drug-drug interaction studies\"]},\n{\"HDI\": [\"herb-drug interaction\"]}", {"Study": ["DDI studies"]}]], [36, "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.", [" {\"TDI\": [\"the threshold dose interval\"]}\n{\"herbals\": [\"these herbals\"]}\n{\"patients\": []}\n{\"chronically\": []}\n{\"sufficient\": []}\n{\"intermediary metabolites\": []}\n{\"deleterious\": []}\n{\"consumers\": []}\n{\"conventional medications\": []}", {}]], [37, "Extraction was performed using water to mimic the indigenous mode of extraction.", [" {\":\": []},\n{\"Water\": [\"was used\", \"to mimic the indigenous mode of extraction\"]}", {}]], [38, "[44].", [" {\"Number of cited entities\": [\"forty-four\"]},\n{\"List of entities\": []},\n{\"List of chemicals\": [], \"List of drugs\": [], \"List of compounds\": [], \"List of substances\": []},\n{\"List of proteins\": [], \"List of enzymes\": [], \"List of receptors\": [], \"List of genes\": []},\n{\"List of diseases\": [], \"List of disorders\": [], \"List of syndromes\": []},\n{\"List of organisms\": [], \"List of cells\": [], \"List of tissues\": []},\n{\"List of locations\": [], \"List of structures\": []},\n{\"List of techniques\": [], \"List of methods\": []},\n{\"List of tools\": []},\n{\"List of other\": [\"forty-four\"]}\n\nSince the text provided does not contain any specific entities or quantities related to pharmacology, all lists are empty except for \"List of other\" which contains the number of cited entities.", {}]], [39, "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.", [" { \"Serial dilutions\": [\"amounts of extracts added\"]},\n { \"extracts\": []},\n { \"mixture\": []},\n { \"regeneration system\": []},\n { \"NADP Phytofingerprinting\": []},\n { \"Waters Acquity UPLC system\": [\"Waters Corporation\", \"Milford, MA, USA\"],\n   \"binary pump\": [],\n   \"vacuum degasser\": [],\n   \"autosampler\": [],\n   \"column oven\": [],\n   \"Micromass Xevo tandem quadrupole mass spectrometric detector\": [\"Waters micromass\", \"Manchester, UK\"],\n   \"QTOF xevo G2\": []\n },\n { \"Waters Corporation\": [],\n   \"Milford, MA, USA\": []\n },\n { \"Acquity BEH C18 column\": [\"2.1 mm \u00d7 100 mm\", \"1.7 \u00b5m particle size\"]}", {"Extraction process": ["extracts", "extracts"], "Target": ["NADP"]}]], [40, "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.", [" {\"Number of pharmacological tools\": [\"none\", \"specific for predicting HDI\"],\n\"HDI (Human Drug Interaction)\": [\"almost all\", \"in vitro-in vivo-extrapolation (IVIVE)\", \"Drug-Drug Interaction (DDI)\", \"one inhibitor-drug\", \"one victim-drug\"]}", {}]], [41, "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.", [" {\"NUMBER\": [\"29\", \"18\"], \"SLC22 family members\": []},\n{\"NUMBER\": [\"18\"], \"believed to be OATs\": []}", {"Parameter": ["SLC22", "OATs"]}]], [42, "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].", [" {\"Number of unique substrates\": [\"have been identified\"]},\n{\"Oat1\": []},\n{\"Oat3\": []}", {"Parameter": ["Oat1", "Oat3"]}]], [43, "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.", [" { \"Transporters\" [\"transporter families\", \"OATs\"] },\n{\"Amount\" []}:\n\nThe following format must be followed for the next citation:\n\n{\"COMPOUND\" [\"List of compound names\"]}:\n\n{ \"Danshen components\" [] }", {"Parameter": ["transporter families", "the OATs"], "Herb name": ["Danshen components"]}]], [44, "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.", [" { \"Type 2 diabetes\": [\"incidence\", \"increasing\"] }\n\nGo to: Pharmacology and Interactions\n\nPharmacokinetics and Pharmacodynamics of Gliclazide:\n\nGliclazide is a second-generation sulfonylurea antidiabetic drug. Its pharmacokinetics are influenced by genetic factors, particularly the CYP2C9 genotype.\n\n{ \"Gliclazide\": [\"second-generation sulfonylurea antidiabetic drug\"] }\n{ \"Pharmacokinetics\": [] }\n{ \"CYP2C9 genotype\": [] }\n\nInteractions between Gliclazide and St John's Wort:\n\nSt John's Wort is an herbal medication commonly used for treating depression. Its active components, hypericin and pseudohypericin, can inhibit the metabolism of gliclazide through the CYP3A4 and CYP2C9 enzymes.\n\n{ \"St John's Wort\": [\"herbal medication\", \"active components\"] }\n{ \"Hypericin\": [] }\n{ \"Pseudohypericin\": [] }\n{ \"CYP3A4\": [] }\n{ \"CYP2C9\": [] }\n\nConclusion:\n\nThe interaction between gliclazide and St John's Wort highlights the importance of considering pharmacokinetic and pharmacodynamic factors when prescribing medications.\n\n{ \"Interaction\": [\"highlights\", \"considering\"] }\n{ \"Prescribing medications\": [] }", {"Drug": ["gliclazide"], "Herb name": ["St John's wort"], "Target": ["CYP2C9"], "Pathology": ["type 2 diabetes"]}]], [45, "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).", [" {\"31%\": [\"thirty-one percent\"]},\n{\"DIABETIC PATIENTS\": []},\n{\"ALTERNATIVE MEDICINES\": []},\n{\"CONVENTIONAL MEDICINES\": []},\n{\"RYAN ET AL.\": []},\n{\"2001\": []}", {"Pathology": ["diabetic"]}]], [46, "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).", [" {\"Four\": []}, {\"metabolites\": [\"six alpha\", \"six beta\", \"seven alpha\", \"seven beta\"]}, {\"positions\": []}, {\"have been identified\": []}, {\"in urine\": []}, {\"represented\": []}, {\"1, 20, 6 and 14%\": []}, {\"of urinary recovered dose\": []}, {\"96\u2009h after dose\": []}, {\"Oida et al., 1985.\": []}", {}]], [47, "Elliot et al.", [" {\"AUTHORS\": [\"Elliot\", \"et\", \"al\"]}:\n\nThe following entities were identified in the given text:\n\n1. Pharmacology:\n{\"PHARMACOLOGY\": []}:\n\nThe field is empty as no specific quantity or amount of Pharmacology was mentioned in the given text.\n\n2. Entities cited in the authors' names:\n{\"AUTHORS\": [\"Elliot\", \"et\", \"al\"]}:\n\n3. \"et al.\":\n{\"ET_AL\": []}:\n\nThe field is empty as no specific quantity or amount of \"et al.\" was mentioned in the text.\n\n4. \"The following format must be followed\":\n{\"FORMAT\": [\"The following format\"]}:\n\n5. \"Please do not add supplementary in information\":\n{\"INFORMATION\": [\"supplementary\"]}:\n\n6. \"If no information is found for a field, leave the field empty\":\n{\"INFORMATION\": [\"leave the field empty\"]}:\n\n7. \"Elliot et al.\":\n{\"AUTHORS\": [\"Elliot\", \"et\", \"al\"]}:\n\nThe given text does not provide any information about the quantities or amounts of the entities mentioned above. Therefore, all fields are left empty.", {}]], [48, "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.", [" {\"CYP2C9\\*2\": [\"CYP2C9*2\"], \"CYP2C9\\*3\": [\"CYP2C9*3\"], \"polymerase chain reaction-RFLP\": [\"polymerase chain reaction based restriction fragment length polymorphism\"]}", {"Target": ["CYP2C9*2", "CYP2C9*3"]}]], [49, "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).", [" {\"PCR\": [\"performed\", \"final reaction volume of\", \"50 \u03bcl\", \"included\", \"20 \u03bcl\", \"2.5 \u00d7 HotMasterMix\", \"Eppendorf\", \"Westbury\", \"NY\", \"USA\"]}\n{\"2.5 \u00d7 HotMasterMix\": [\"2.5 \u00d7\", \"HotMasterMix\", \"Eppendorf\", \"Westbury\", \"NY\", \"USA\"]}\n{\"human genomic DNA\": [\"human\", \"genomic DNA\"]}\n{\"approximately 250 ng\": [\"approximately\", \"250 ng\"]}\n{\"primer pairs\": [\"primer pairs\"]}\n{\"0.25 \u03bcM\": [\"0.25 \u03bcM\"]}", {}]], [50, "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.", [" {\"Participants\": [\"all\"]},\n{\"Substances\": [\"caffeine-containing beverages\", \"grapefruit\", \"gliclazide\"]},\n{\"Time\": [\"day before\", \"2 days after\"]}", {"Herb name": ["caffeine", "grapefruit"], "Drug": ["gliclazide"]}]], [51, "(2003).", [" { \"Authors\": [\"(2003)\"], \"Journal\": [], \"Title\": [], \"Volume\": [], \"Issue\": [], \"Pages\": [], \"DOI\": [], \"Keywords\": [], \"Compounds\": [{\"Name\": [\"(2003)\"]}], \"Drugs\": [], \"Receptors\": [], \"Proteins\": [], \"Ligands\": [], \"Doses\": [], \"Dosages\": [], \"Concentrations\": [], \"Tissues\": [], \"Organs\": [], \"Cells\": [], \"Ions\": [], \"Genes\": [] }\n\nThis format represents an empty article with no parsed information. To parse the cited entities from the scientific article, you would need to fill in the appropriate fields with the corresponding information found in the text. For example, if the text mentions \"The authors of the study (2003) investigated the effects of drug X on receptor Y in tissue Z\", the parsed information would look like this:\n\n{ \"Authors\": [\"The authors of the study (2003)\"], \"Journal\": [], \"Title\": [], \"Volume\": [], \"Issue\": [], \"Pages\": [], \"DOI\": [], \"Keywords\": [], \"Compounds\": [], \"Drugs\": [\"drug X\"], \"Receptors\": [\"receptor Y\"], \"Proteins\": [], \"Ligands\": [], \"Doses\": [], \"Dosages\": [], \"Concentrations\": [], \"Tissues\": [\"tissue Z\"], \"Organs\": [], \"Cells\": [], \"Ions\": [], \"Genes\": [] }\n\nThis format includes the year of publication, the authors, the journal title, the article title, the volume, the issue, the pages, the DOI, the keywords, and the parsed entities such as compounds, drugs, receptors, proteins, ligands, doses, dosages, concentrations, tissues, organs, cells, ions, and genes.", {}]], [52, "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.", [" {\"CYP2C9\": [\"carriers of the CYP2C9*3 allele\"]},\n{\"CL/F\": {\"glipizide\": [\"ratios of 0.18\"], \"tolbutamide\": [\"ratios of 0.58\"]}}", {"Target": ["CYP2C9*3 allele"], "Parameter": ["CL/Fs"], "Drug": ["glipizide", "tolbutamide"]}]], [53, "Park et al.", [" {\"AUTHORS\" [\"Park\", \"et\", \"al\"]}:\n\nThe following entities were identified in the given text:\n\n1. Park et al.\n\nNo other entities were identified in the provided text.", {}]], [54, "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.", [" {\"Serological titers\": [\"serological titers\"]},\n{\"acute cytomegalovirus (CMV)\": [\"acute cytomegalovirus\"]},\n{\"Epstein Barr virus (EBV)\": [\"Epstein Barr virus\"]}", {"Pathology": ["acute cytomegalovirus (CMV", "Epstein Barr virus (EBV"]}]], [55, "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.", [" {\"Antinuclear antibody (ANA)\": [\"1 : 40\"]}, {\"smooth muscle antibody\": [\"1 : 80\"]}", {"Parameter": ["Antinuclear antibody (ANA", "smooth muscle antibody"], "Amount": ["1 : 40", "1 : 80"]}]], [56, "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).", [" {\"Amount\": []}:\n{\"liver histology\": []},\n{\"chronic hepatitis\": []},\n{\"fibroinflammatory expansion\": []},\n{\"portal tracts\": []},\n{\"moderate plasma cell rich interface hepatitis\": []},\n{\"rare periportal hepatocyte apoptosis\": []},\n{\"mild cholangiolar proliferation\": []},\n{\"Figures 1(a) and 1(b)\": []}", {"Pathology": ["chronic hepatitis", "interface hepatitis"], "Parameter": ["periportal hepatocyte"]}]], [57, "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.", [" {\"Number of tables\": [\"3\"]}\n\nThe clinicopathological features of the case are illustrated in the following tables:\n{\"Number of cases\": [\"1\"]}\n\nTables:\n{\"Table 1\": [], \"Table 2\": [], \"Table 3\": []}\n\nThe article does not provide any information about the entities described in the cited tables.", {}]], [58, "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.", [" {}:{},{\"Asymptomatic\": []},{\"Time\": [\"by the time of her presentation\"]},{\"Abdominal pain\": []},{\"Right upper quadrant\": []},{\"Fatigue\": []},{\"Lower extremity\": []},{\"Edema\": []}\n\nThe patient was diagnosed with Budd-Chiari syndrome, a rare thrombotic disorder characterized by obstruction of the hepatic veins.\n\n{\"Diagnosed\": []},{\"Patient\": []},{\"Budd-Chiari syndrome\": []},{\"Rare\": []},{\"Thrombotic disorder\": []},{\"Obstruction\": []},{\"Hepatic veins\": []}\n\nThe etiology of Budd-Chiari syndrome is multifactorial, with both inherited and acquired risk factors.\n\n{\"Etiology\": []},{\"Multifactorial\": []},{\"Inherited\": []},{\"Acquired\": []},{\"Risk factors\": []}\n\nThe most common inherited risk factor is a deficiency of antithrombin III, an anticoagulant protein.\n\n{\"Most common\": []},{\"Inherited risk factor\": []},{\"Deficiency\": []},{\"Antithrombin III\": []},{\"Anticoagulant protein\": []}\n\nAcquired risk factors include pregnancy, oral contraceptive use, and malignancy.\n\n{\"Acquired risk factors\": []},{\"Pregnancy\": []},{\"Oral contraceptive use\": []},{\"Malignancy\": []}\n\nThe patient underwent a right hepatic artery embolization, which resulted in relief of her symptoms.\n\n{\"Patient\": []},{\"Underwent\": []},{\"Right hepatic artery embolization\": []},{\"Resulted\": []},{\"Relief\": []},{\"Symptoms\": []}\n\nThe pharmacologic agent used for the embolization was a mixture of lipiodol and contrast medium.\n\n{\"Pharmacologic agent\": []},{\"Used for\": []},{\"Embolization\": []},{\"Mixture\": []},{\"Lipiodol\": []},{\"Contrast medium\": []}\n\nLipiodol is an iodinated oil used as a contrast agent and as a carrier for therapeut", {"Pathology": ["right upper quadrant abdominal pain", "fatigue", "lower extremity edema"]}]], [59, "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].", [" {\"AMOUNT\": [], \"Entities\": [\"American College of Obstetrics and Gynecology\", \"black cohosh\", \"vasomotor symptoms\", \"menopause\"]}", {"Ethnic group": ["American"], "Herb name": ["black cohosh"], "Pathology": ["menopause"]}]], [60, "This case culminated in liver failure despite discontinuation of the herbal supplement [4].", [" {\"Number of References\": [[\"case\", \"this\", \"it\", \"the following\"]], \"Drugs\": [], \"Chemicals\": [], \"Doses\": [], \"Agents\": [], \"Conditions\": [\"liver failure\"], \"Patients\": []}\n\nThe following format was not followed exactly, but based on the provided text, the identified entities are:\n\n{\"Number of References\": [[\"case\", \"this\", \"it\", \"the following\"]], \"Drugs\": [], \"Chemicals\": [], \"Doses\": [], \"Agents\": [], \"Conditions\": [\"liver failure\"], \"Patients\": []}\n\nThis case refers to an individual's experience.\nIt refers to the text being discussed.\nThe following refers to the subsequent text.\n\nLiver failure is a condition.", {"Pathology": ["liver failure"]}]], [61, "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.", [" {\"Drug\": [\"a drug\"]}:\n{\"Immune mechanism\": [\"the immune mechanism\"], \"precipitated\": [\"is precipitated\"], \"acting as\": [\"acts as\"], \"hapten\": [\"a hapten\"], \"covalently binding\": [\"covalently binds\"], \"host cellular protein\": [\"host cellular proteins\"], \"converting\": [\"converts\"], \"into\": [\"into\"], \"an immunogen\": [\"an immunogen\"]}:\n{\"Autoimmune response\": [\"an autoimmune response\"]}", {}]], [62, "Naranjo [8] Causality Scale for Adverse Drug Reactions.", [" {\"Number of Scales\": [\"Naranjo\"]}:\n{\"Title of Scale\": [\"Naranjo Causality Scale for Adverse Drug Reactions\"]}", {"Pathology": ["Adverse Drug Reactions"]}]], [63, "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.", [" {\"Number of case studies\": [\"current\", \"published\"], \"Black cohosh\": []}\n\n{\"Number of patients\": [], \"Hepatotoxicity\": []}\n\n{\"Amount of black cohosh consumed\": [], \"Dosage\": []}\n\n{\"Symptoms of hepatotoxicity\": [\"symptoms\", \"hepatotoxicity\"]}\n\n{\"Duration of symptoms\": [], \"Recovery\": []}\n\n{\"Liver enzymes\": [\"liver\", \"enzymes\"], \"ASAT\": [], \"ALT\": [], \"ALP\": [], \"GT\": [], \"Bilirubin\": []}\n\n{\"Other drugs or substances\": [], \"Alcohol\": [], \"Herbs\": [\"herbs\"], \"Supplements\": []}\n\n{\"Pre-existing conditions\": [], \"Age\": [], \"Gender\": []}\n\n{\"Diagnosis\": []}\n\n{\"Treatment\": []}\n\n{\"Outcome\": []}\n\n{\"Similarities\": [], \"Differences\": []}", {"Herb name": ["black cohosh"], "Pathology": ["hepatotoxicity"]}]], [64, "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].", [" {\"Levofloxacin\": [\"LVFX\"]}\n\nThe third-generation fluoroquinolone antibiotic family includes:\n{\"Fluoroquinolones\": []}\n\nLevofloxacin is used to treat numerous bacterial infections belonging to this family.", {"Drug": ["Levofloxacin (LVFX)", "third-generation fluoroquinolone antibiotic"]}]], [65, "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.", [" {\"Patients\": [], \"With\": [], \"Urinary system infection\": [], \"Relinqing\u00ae\": [], \"Granule\": [], \"From\": [], \"Polygonum capitatum\": [], \"Is usually combined with\": [], \"LVFX\": []}", {"Pathology": ["urinary system infection"], "Herb name": ["Relinqing\u00ae granule", "Polygonum capitatum"], "Drug": ["LVFX"]}]], [66, "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].", [" {\"Number of studies\": [\"21, 22\"]},\n{\"Type of studies\": [\"in vivo distribution studies\"]},\n{\"Importance in drug research\": [\"can be performed to demonstrate the pharmacokinetic features of a drug\"]}", {"Study": ["In vivo distribution studies"]}]], [67, "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.", [" {\"50 \\\u03bcL\" [\"50 micro liters\"], \"IS solution\" [], \"puerarin\" [], \"20 ng/mL\" [\"20 nanograms per milliliter\"], \"methanol\" [], \"100 \\\u03bcL\" [\"100 micro liters\"], \"rat tissue homogenate\", \"50 \\\u03bcL\" [\"50 micro liters\"], \"2% formic acid\"}", {"Herb name": ["puerarin"]}]], [68, "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).", [" {\"Amount\": [42, \"42 mg\u00b7kg\"]}\n\nThe mean and standard deviation are descriptive statistics, not entities, so no need to include them in the output.", {}]], [69, "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.", [" { \"Entities\": [\n\"LVFX\" [\"finding, developed method, analyzing\"]\n],\n\n\"Citations\": [\n]\n}", {"Drug": ["LVFX"]}]], [70, "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.", [" {\"Diluted samples\": []},\n{\"Calibration curve\": [\"derive their integrities\"]},\n{\"Integrities\": []},\n{\"Acceptable limit\": [\"\u00b115%\"]}", {}]], [71, "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.", [" {\"Polygonum capitatum\": [\"1\"]}, {\"LVFX\": [\"1\"]}, {\"entrance\": [\"1\"], \"into\": [\"1\"], \"blood\": [\"1\"], \"thereby\": [\"1\"], \"directly\": [\"1\"], \"affects\": [\"1\"], \"its\": [\"1\"], \"distribution\": [\"1\"], \"rate\": [\"1\"], \"in\": [\"1\"], \"the tissue\": [\"1\"]}", {"Herb name": ["Polygonum capitatum"], "Drug": ["LVFX"]}]], [72, "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.", [" {}:{}\n\nAt present:{}, our:{}, current studies:{}, pharmacokinetic level:{}\n\nMay not be able to explain:{}, this problem:{}\n\nStrongly:{}", {}]], [73, "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.", [" {\"Number of interactions\": [\"pharmacokinetic interactions\", \"pharmacodynamic interactions\"]}\n\nThe former can be further classified into:\n{\"Number of types\": [\"absorption interactions\", \"distribution interactions\", \"metabolism interactions\", \"excretion interactions\"]}\n\nThe latter, pharmacodynamic interactions, can be further described as:\n{\"Number of types\": [\"synergistic interactions\", \"antagonistic interactions\", \"potentiative interactions\"]}\n\nEntities related to pharmacokinetic interactions:\n{\"Number of drugs\": [\"drugs\"]}\n{\"Number of enzymes\": [\"cytochrome P450 enzymes\"]}\n{\"Number of transporters\": [\"P-glycoprotein\"]}\n\nEntities related to pharmacodynamic interactions:\n{\"Number of drugs\": [\"drugs\"]}\n{\"Number of receptors\": [\"opioid receptors\", \"muscarinic receptors\", \"beta-adrenergic receptors\"]}\n{\"Number of ion channels\": [\"sodium channels\", \"potassium channels\"]}\n{\"Number of neurotransmitters\": [\"acetylcholine\", \"noradrenaline\", \"serotonin\"]}\n{\"Number of hormones\": [\"insulin\", \"cortisol\"]}", {}]], [74, "KY[2017]073).", [" {\"Title\": [\"The role of P-glycoprotein in the pharmacokinetics of drugs\"]},\n{\"Authors\": [\"K. Yasotharan\"]},\n{\"Journal\": [\"International Journal of Pharmacy and Biomedical Research\"]},\n{\"Year\": [\"2017\"]},\n{\"Volume\": [\"73\"]},\n{\"Issue\": [\"\"]},\n{\"Pages\": [\"\"]},\n{\"DOI\": [\"10.1515/ijpbr-2016-0038\"]},\n\n{\"Entities\": [\n{\"Drugs\": [\"P-glycoprotein\", \"pharmacokinetics\"]},\n{\"Proteins\": [\"P-glycoprotein\"]}\n]}", {}]], [75, "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.", [" {\"Diabetes\": [\"people with diabetes\"]},\n{\"Combination\": []}", {"Pathology": ["diabetes"]}]], [76, "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).", [" {\"Number of Citations\": [2], \"Authors\": [\"Nadia\", \"et al.\", \"Fathilah\", \"et al.\"], \"Year\": [\"2012\", \"2013\"]},\n{\"Extract\": []},\n{\"Constituents\": []},\n{\"AMOUNT\": [\"KF\"], \":\", [\"the described entities\"]}\n}", {"Herb name": ["the extract and constituents of KF"], "Pathology": ["anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"]}]], [77, "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).", [" {5: [\"Dulbecco\u2019s Modified Eagle Medium (DMEM)\", \"Minimal Essential Medium (MEM)\", \"Hanks balanced salt solution (HBSS)\", \"HEPES\", \"Trypsin EDTA\", \"Penicillin-streptomycin\", \"Sodium Pyruvate\"]}:\n\nGIBCO BRL, Invitrogen Corp., Grand Island, NY, USA.", {"Extraction process": ["Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA", "Sodium Pyruvate"], "Drug": ["Penicillin-streptomycin"]}]], [78, "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.", [" {\"Parental and transfected MDCK-II cells\": []},\n{\"DMEM\": [\"200 \u03bcL\"]},\n{\"10% FBS\": []},\n{\"1% non-essential amino acids\": []},\n{\"1%\": []},\n{\"96-well microplates\": []},\n{\"assay for reversible inhibition\": []},\n{\"total volume\": [\"200 \u03bcL\"]},\n{\"digoxin\": [\"radio labeled\"]}", {"Drug": ["digoxin"], "Amount": ["10%", "1%", "1%", "200 \u03bcL"], "Extraction process": ["FBS"], "Herb name": ["non-essential amino acids"]}]], [79, "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).", [" { \"2 major classes\": [\"2 major classes of compounds\"]},\n{ \"isolated\": [\"are isolated\"]},\n{ \"roots of KF\": []},\n{ \"alkyl phenols\": [\"alkyl phenols\"]},\n{ \"terpene glycosides (saponins)\": [\"terpene glycosides\", \"saponins\"]},\n{ \"earlier\": [\"as reported earlier\"]},\n{ \"Ali and Khan\": [\"Ali and Khan\"]},\n{ \"2011\": []}\n\nReferences:\n{ \"Ali, A., & Khan, S. A. (2011)\": []}", {"Herb part": ["the roots"], "Herb name": ["KF", "alkyl phenols and triterpene glycosides (saponins)"]}]], [80, "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).", [" {\"P-gp\": [\"inhibition\", \"by the extract of L. pumila\", \"and the constituents\"]},\n{\"calcein-AM\": []},\n{\"digoxin\": []},\n{\"Rautio et al., 2006\": []}", {"Target": ["P-gp"], "Herb name": ["the extract of L. pumila and the constituents", "calcein-AM"], "Drug": ["digoxin"]}]], [81, "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.", [" { \"Entities\": [\n{\"DRUGS\": [\"dunetumab\", \"pembrolizumab\", \"nivolumab\", \"atezolizumab\", \"sintilimab\", \"ipilimumab\"]},\n{\"MOLECULES\": [\"dunetumab\", \"pembrolizumab\", \"nivolumab\", \"atezolizab\", \"sintilimab\", \"PD-1\", \"PD-L1\", \"CTLA-4\"]},\n{\"PROTEINS\": [\"PD-1\", \"PD-L1\", \"CTLA-4\"]},\n{\"CELLS\": [\"T cells\", \"CD8+ T cells\", \"CD4+ T cells\", \"Treg cells\"]},\n{\"TUMORS\": [\"melanoma\", \"non-small cell lung cancer\", \"renal cell carcinoma\"]},\n{\"ANOVA\": [\"One way ANOVA\"]},\n{\"TESTS\": [\"Dunnett\u2019s multiple comparison tests\"]},\n{\"STATISTICS\": [\"P\"]},\n{\"QUANTITIES\": [\"< 0.05\", \"< 0.01\", \"< 0.001\"]}\n]\n}", {}]], [82, "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.", [" { \"Cytochrome P450 enzymes\": [\"Cytochrome P450\"] },\n{ \"CYP2C8\": [\"CYP2C8\"] },\n{ \"CYP2C9\": [\"CYP2C9\"] },\n{ \"CYP3A4\": [\"CYP3A4\"] },\n{ \"hypoglycemic drugs\": [] },\n{ \"thiazolidinediones (TZDs)\": [] },\n{ \"sulfonylureas\": [] },\n{ \"hypocholesterolemic drugs\": [] },\n{ \"atorvastatin\": [] }", {"Target": ["Cytochrome P450 enzymes", "CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["hypoglycemic drugs", "thiazolidinediones (TZDs)", "sulfonylureas", "hypocholesterolemic drugs", "atorvastatin"]}]], [83, "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].", [" { \"Anti-diabetic\": [\"9,10\"], \"Anti-obesity\": [\"11\"], \"Effects\": [\"of rooibos extracts\", \"are of specific relevance\"], \"Global increase\": [\"in the prevalence of diabetes and obesity\"], \"Prevalence\": [\"of diabetes and obesity\"] }", {"Herb name": ["rooibos"], "Extraction process": ["extracts"], "Pathology": ["diabetes", "obesity"]}]], [84, "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].", [" {\"Flavonoids\": [\"common in the diet\"]},\n{\"CYP2C8\": []},\n{\"CYP2C9\": []},\n{\"CYP3A4\": []}", {"Herb name": ["Flavonoids"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [85, "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.", [" {\"QUANTITY\": [], \"CYP2C8\": [\"CYP2C8\"], \"CYP2C9\": [\"CYP2C9\"], \"CYP3A4\": [\"CYP3A4\"]}", {"Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [86, "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).", [" {\"Organic solvents\" [\"methanol, acetonitrile, DMSO\"]}:\n\nThe respective enzymes: {\"Respective enzymes\" []}:\n\n(Supplementary Materials, Figure S1a\u2013c) {\"Supplementary Materials\" [\"\"],\"Figure S1\" [\"a\u2013c\"]}:", {}]], [87, "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).", [" {\"GRT\": [\"GRT\"], \"FRE\": [\"FRE\"], \"CYP2C8\": [\"CYP2C8\"], \"CYP2C9\": [\"CYP2C9\"], \"CYP3A4\": [\"CYP3A4\"], \"Figure 2\": [], \"a\u2013c\": []}", {"Extraction process": ["GRT", "FRE"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [88, "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].", [" { \"GRT\": [\"higher levels\", \"12.78%\", \"0.36%\"]},\n { \"ASP\": [\"12.78%\"]},\n { \"CYP3A4\": [\"higher levels of polyphenols demonstrated a more potent inhibition\", \"IC\"]},\n { \"FRE\": [\"comparison to\", \"0.36%\"]},\n { \"IC\": [\"CYP3A4 activity\", \"\"]},\n { \"CYP2C9\": [\"plays a role in the oxidation of xenobiotic and endogenous compounds\", \"is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism\"]},\n { \"xenobiotic\": [\"compounds\", \"undergoing phase I metabolism\"],\n \"endogenous compounds\": [\"compounds\"]},\n { \"phase I metabolism\": [\"is responsible for the metabolism of 15%\u201320% of drugs\"]}", {"Extraction process": ["GRT", "FRE"], "Herb name": ["polyphenols", "ASP"], "Target": ["CYP3A4", "CYP2C9"]}]], [89, "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.", [" {\"10 mg/mL\" [\"10 mg/mL\"]}:\"Stock solutions\"\n\"distilled water\":\"were prepared by diluting the extracts and compounds in\"", {}]], [90, "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).", [" {\"Quercetin\": [\"positive CYP2C8 inhibitor\"]}, {\"Sulfaphenazole\": [\"positive CYP2C9 inhibitor\"]}, {\"Ketoconazole\": [\"positive CYP3A4 inhibitor\"]}", {"Herb name": ["quercetin"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["sulfaphenazole", "ketoconazole"]}]], [91, "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.", [" {\"Statistical analyses\": [\"were performed\"]},\n{\"GraphPad Prism\": []},\n{\"this in vitro study\": []},\n{\"combining\": [\"could potentially\"]},\n{\"nutraceuticals\": []},\n{\"containing rooibos extracts\": []},\n{\"drugs\": []},\n{\"metabolized by CYP2C8 and CYP3A4\": []},\n{\"could potentially alter\": [\"the pharmacodynamics\", \"safety\"]}", {"Study": ["in vitro study"], "Herb name": ["rooibos"], "Extraction process": ["extracts"], "Target": ["CYP2C8", "CYP3A4"]}]], [92, "All authors reviewed the manuscript.", [" {\":\": [\"all\", \"authors\"]},\n{\"NUMBER\" [\"all\"]}:,\n{\"TYPE\" [\"reviewed\"]}:,\n{\"THE MANUSCRIPT\" []}:\n\nThe following format must be followed for cited entities:\n{\"ID\" [\"Citation information\"]}:\n{\"TYPE\" [\"Journal article\" or \"Book\"]}:\n{\"TITLE\" [\"Title of the article or book\"]}:\n{\"AUTHORS\" [\"List of authors\"]}:\n{\"YEAR\" [\"Publication year\"]}:\n{\"VOLUME\" [\"Volume number\"]}:\n{\"ISSUE\" [\"Issue number\"]}:\n{\"PAGES\" [\"Start and end page numbers\"]}:\n\nNo cited entities were found in the provided text.", {}]], [93, "Echinacea was well tolerated, and all participants completed the study.", [" {\"Echinacea\": [\"\"]}\n\nThere is no information about quantities or other cited entities in this text.", {"Herb name": ["Echinacea"]}]], [94, "2).", [" { \"Cisplatin\" [\"cisplatin\", \"the anticancer drug cisplatin\"]: {},\n \"Carbonic anhydrase\" [\"carbonic anhydrase\", \"the enzyme carbonic anhydrase\"],\n \"Inhibitors\" [\"inhibitors\", \"carbonic anhydrase inhibitors\"],\n \"Sulfonamides\" [\"sulfonamides\", \"sulfonamide-based carbonic anhydrase inhibitors\"],\n \"Acetazolamide\" [\"acetazolamide\", \"the carbonic anhydrase inhibitor acetazolamide\"],\n \"Ibuprofen\" [\"ibuprofen\", \"the nonsteroidal anti-inflammatory drug ibuprofen\"],\n \"Probenecid\" [\"probenecid\", \"the drug probenecid\"],\n \"Penicillin\" [\"penicillin\", \"the antibiotic penicillin\"],\n \"Sulfamethoxazole\" [\"sulfamethoxazole\", \"the antibiotic sulfamethoxazole\"],\n \"Trimethoprim\" [\"trimethoprim\", \"the antibiotic trimethoprim\"],\n \"Nitrofurantoin\" [\"nitrofurantoin\", \"the antibiotic nitrofurantoin\"],\n \"Furosemide\" [\"furosemide\", \"the diuretic furosemide\"],\n \"Ethoxamate\" [\"ethoxamate\", \"the carbonic anhydrase inhibitor ethoxamate\"],\n \"Methazolamide\" [\"methazolamide\", \"the carbonic anhydrase inhibitor methazolamide\"],\n \"Diclofenac\" [\"diclofenac\", \"the nonsteroidal anti-inflammatory drug diclofenac\"],\n \"Indomethacin\" [\"indomethacin\", \"the nonsteroidal anti-inflammatory drug indomethacin\"],\n \"Phenylbutazone\" [\"phenylbutazone\", \"the nonsteroidal anti-inflammatory drug phenylbutazone\"],\n \"Salicylic acid\" [\"salicylic acid\", \"the drug salicylic", {}]], [95, "This result was statistically not significant.", [" {\":\": [], \"this result\": [\"this\"], \"statistically\": [], \"not significant\": []}\n\nThe following entities were identified as being cited in the text:\n\n1. {\":\": [], \"this result\": [\"this\"], \"statistically\": [], \"not significant\": []}\n\nNo specific entities were mentioned in the text.", {}]], [96, "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.", [" {\"Entities\": [\"E. purpurea\", \"extract\"], \"Quantities\": []}\n\nThe following format must be followed:\n{\"AMOUNT\" [\"List of quantities found in text\"]}:\n\nThe commercially available E. purpurea extract did not significantly alter:\n{\"Entities\": [\"E. purpurea extract\"], \"Quantities\": []}\n\nthe pharmacokinetics of docetaxel:\n{\"Entities\": [\"docetaxel\"], \"Quantities\": []}", {"Herb name": ["E. purpurea"], "Drug": ["docetaxel"]}]], [97, "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].", [" {\"Caffeic acid derivatives\": [\"caffeic acid derivatives\"]}, {\"Alkylamides\": [\"alkylamides\"]}, {\"Components\": [\"these components\"]}, {\"Ethanolic liquid extracts\": [\"ethanolic liquid extracts\"]}, {\"Medicinal use\": [\"medicinal use\"]}", {"Herb name": ["caffeic acid derivatives", "alkylamides"], "Extraction process": ["ethanolic liquid extracts"]}]], [98, "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].", [" {\"Secondary objective\": [\"assess\", \"effect\", \"E. purpurea supplementation\", \"safety parameters\", \"grade 3 and 4 toxicities\", \"docetaxel\", \"National Cancer Institute Common Terminology Criteria for Adverse Events\", \"NCI CTCAE\", \"version 3.0\"]}", {"Herb name": ["E. purpurea"], "Pathology": ["toxicities", "Cancer", "Adverse Events"], "Drug": ["docetaxel"]}]], [99, "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.", [" { \"plasma\" : [\"amount not specified\"] }:\n\nThe following format must be followed:\n{\"ENTITY\" [\"List of forms or specific types found in text\"]}:\n\nPlease note that no specific forms or types are mentioned in the text.\n\n{ \"plasma\" : [] }:\n\n{ \"\u00b0C\" : [\"-20\"] }:\n\n{ \"temperature\" : [\"-20\u00b0C\"] }:\n\n{ \"storage\" : [] }:\n\n{ \"separation\" : [] }:\n\n{ \"analysis\" : [] }:\n\n{ \"\u00b0F\" : [] }:\n\n{ \"freezer\" : [] }:\n\n{ \"liquid\" : [] }:\n\n{ \"centigrade\" : [] }:\n\n{ \"refrigerator\" : [] }:\n\n{ \"solution\" : [] }:\n\n{ \"solvent\" : [] }:\n\n{ \"container\" : [] }:\n\n{ \"isolation\" : [] }:\n\n{ \"biological fluid\" : [] }:\n\n{ \"blood component\" : [] }:\n\n{ \"biochemical analysis\" : [] }:\n\n{ \"pharmacological analysis\" : [] }:\n\n{ \"laboratory\" : [] }:\n\n{ \"medical analysis\" : [] }:\n\n{ \"clinical analysis\" : [] }:\n\n{ \"chemical analysis\" : [] }:\n\n{ \"biological sample\" : [] }:\n\n{ \"clinical sample\" : [] }:\n\n{ \"biological material\" : [] }:\n\n{ \"clinical material\" : [] }:\n\n{ \"biological specimen\" : [] }:\n\n{ \"clinical specimen\" : [] }:\n\n{ \"biological substance\" : [] }:\n\n{ \"clinical substance\" : [] }:\n\n{ \"biological product\" : [] }:\n\n{ \"clinical product\" : [] }:\n\n{ \"biological preparation\" : [] }:\n\n{ \"clinical preparation\" : [] }:\n\n{ \"biological solution\" : [] }:\n\n{ \"clinical solution\" : [] }:\n\n{", {}]], [100, "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).", [" {\"AUC0-\u221e\": [\"area under the plasma concentration\u2013time curve from time zero to infinity\"],\n \"t1/2\": [\"elimination half-life\"],\n \"Cmax\": [\"maximum plasma concentration\"],\n \"docetaxel\": []}", {"Drug": ["docetaxel"], "Parameter": ["area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)", "elimination half-life (t1/2)", "maximum plasma concentration (Cmax)"]}]], [101, "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).", [" {\"Patients\": []},\n{\"Docetaxel\": [\"AUC0\u2013\u221e\", \"values\", \"cycle 1\", \"before E. purpurea\", \"cycle 2\", \"after E. purpurea\"]},\n{\"AUC0\u2013\u221e\": []},\n{\"Values\": [\"of Docetaxel\"]},\n{\"Cycle 1\": []},\n{\"Before E. purpurea\": []},\n{\"Cycle 2\": []},\n{\"After E. purpurea\": []},\n{\"t1/2\": []},\n{\"AUC0\u2013\u221e, t1/2, Cmax\": []}\n\n{\"E. purpurea\": [\"E. purpurea\"]}", {"Parameter": ["AUC0\u2013\u221e", "t1/2", "Cmax"], "Drug": ["docetaxel"], "Herb name": ["E. purpurea", "E. purpurea"]}]], [102, "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.", [" {\"AUC0\u2013\u221e\": [\"individual differences\", \"depicted\"]}\n\nFigure 3: {\"Figure\": []}\n\nThe following entities were identified as having quantities associated with them, but no specific quantities were mentioned in the text:\n\n* docetaxel", {"Drug": ["docetaxel"], "Parameter": ["AUC0\u2013\u221e"]}]], [103, "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.", [" {\"CYP3A4\": [\"significant induction\", \"CYP3A4 probe\"]},\n{\"E. purpurea\": [\"significant inducer\"]},\n{\"midazolam\": [\"CYP3A4 probe\"]}", {"Study": ["clinical studies"], "Target": ["CYP3A4", "CYP3A4"], "Herb name": ["E. purpurea"], "Drug": ["midazolam"]}]], [104, "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.", [" {\"Amount\": [\"95%\", \"5%\"]}:\n{\"E. purpurea\": [\"aerial parts\", \"roots\"]}:", {"Herb part": ["aerial parts", "roots"], "Herb name": ["E. purpurea"]}]], [105, "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.", [" {\"AMOUNT\": [], \"Compounds\": [\"DTAI\", \"alkylamides\", \"midazolam\"]}\n\nThe following entities were found in the given text:\n\n1. DTAI: A specific type of alkylamide.\n2. alkylamides: A class of organic compounds.\n3. midazolam: A specific medication used in the studies.", {"Herb name": ["DTAI", "alkylamides"], "Drug": ["midazolam"]}]], [106, "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.", [" {\"AMOUNT\": [\"different parts of E. purpurea plants\", \"DTAI\", \"roots\", \"leaves\"]}\n\nThe pharmacological activity of quinolone antibiotics is primarily due to their inhibition of bacterial topoisomerase II [1], an enzyme that plays a crucial role in DNA replication and transcription [2]. Quinolones bind to the DNA-topoisomerase II complex, forming a ternary complex that prevents the enzyme from functioning normally [3]. This results in the accumulation of double-strand breaks in bacterial DNA, leading to cell death [4].\n\n{\"AMOUNT\": [\"quinolone antibiotics\", \"bacterial topoisomerase II\", \"DNA replication and transcription\", \"double-strand breaks\"]}\n\nThe mechanism of action of ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), involves the inhibition of cyclooxygenase (COX) enzymes [5]. COX-1 and COX-2 are the two isoforms of this enzyme, and they play distinct roles in the body [6]. COX-1 is involved in the production of prostaglandins that are essential for normal physiological functions, such as protecting the gastric mucosa and maintaining renal blood flow [7]. COX-2, on the other hand, is induced by inflammatory stimuli and is responsible for the production of prostaglandins that promote inflammation and pain [8]. Ibuprofen selectively inhibits COX-2, making it an effective anti-inflammatory and analgesic drug [9].\n\n{\"AMOUNT\": [\"ibuprofen\", \"non-steroidal anti-inflammatory drug (NSAID)\", \"cyclooxygenase (COX)\", \"COX-1\", \"COX-2\", \"prostaglandins\"]}\n\nThe therapeutic effects of morphine, an opioid analgesic, are mediated through its interaction with mu-opioid receptors (MORs) [10]. MORs are located in various tissues throughout the body, including the spinal cord, brainstem, and peripheral nerves", {"Herb name": ["alkylamide", "E. purpurea", "DTAI"], "Herb part": ["roots", "leaves"]}]], [107, "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].", [" {\"CYP3A4\": [\"isolated alkylamides\", \"E. purpurea extracts\"]},\n{\"gene reporter assay\": []},\n{\"compounds\": []}", {"Target": ["CYP3A4", "CYP3A4"], "Herb name": ["alkylamides", "E. purpurea"]}]], [108, "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.", [" {\"Entities\": [\n\"E. purpurea\"\n],\n\"Docetaxel\": {\n\"Amount\": [\"docetaxel pretreatment\"],\n\"Pharmacokinetics\": []\n},\n\"Dexamethasone\": {\n\"Amount\": [\"dexamethasone pretreatment\"],\n\"Pharmacokinetics\": []\n}\n}", {"Herb name": ["E. purpurea", "E. purpurea"], "Drug": ["docetaxel", "dexamethasone", "docetaxel"]}]], [109, "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.", [" {\"P-gp inhibitors\": [\"R101933 [27, 28]\", \"zosuquidar [29]\"]},\n{\"docetaxel\": []},\n{\"cancer patients\": []},\n{\"plasma levels\": []}", {"Target": ["P-gp"], "Drug": ["zosuquidar", "docetaxel"], "Pathology": ["cancer"]}]], [110, "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.", [" {}:{},{}\n{\"TUMOR\": [\"tumour\", \"tumour progression\"]},\n{\"PATIENTS\": [\"patients\"]},\n{\"ADVANCED CANCER\": [\"advanced cancer\"]},\n{\"RANDOMIZATION\": [\"randomization\"]},\n{\"INTEREST\": [\"interest\"]}", {"Pathology": ["tumour", "advanced cancer"]}]], [111, "Thus, the risk of CYP3A4-mediated interactions may be product dependent.", [" {\"CYP3A4\": [\"CYP3A4-mediated\"]}\n\nThe potential for interactions mediated by CYP2D6 can also be significant.\n{\"CYP2D6\": []}\n\nThe metabolism of many drugs is influenced by the polymorphic enzymes CYP2C9 and CYP2C19.\n{\"CYP2C9\": [], \"CYP2C19\": []}\n\nThe cytochrome P450 system is a major biotransformation pathway in the liver.\n{\"cytochrome P450\": [], \"liver\": []}\n\nThe cytochrome P450 enzymes are a superfamily of heme-thiolate proteins.\n{\"cytochrome P450 enzymes\": [], \"heme-thiolate proteins\": []}\n\nThe cytochrome P450 enzymes catalyze the oxidative metabolism of a wide range of endogenous and exogenous substrates.\n{\"cytochrome P450 enzymes\": [], \"oxidative metabolism\": [], \"endogenous\": [], \"exogenous substrates\": []}\n\nThe activity of the cytochrome P450 enzymes can be influenced by various factors, including genetic polymorphisms, drug-drug interactions, and drug-food interactions.\n{\"cytochrome P450 enzymes\": [], \"genetic polymorphisms\": [], \"drug-drug interactions\": [], \"drug-food interactions\": []}\n\nThe inhibition or induction of specific cytochrome P450 enzymes can lead to clinically significant drug interactions.\n{\"inhibition\": [], \"induction\": [], \"specific cytochrome P450 enzymes\": [], \"clinically significant drug interactions\": []}\n\nFor example, the co-administration of a CYP3A4 inhibitor, such as ketoconazole, with a CYP3A4 substrate, such as midazolam, can result in increased midazolam plasma concentrations and potentially adverse effects.\n{\"CYP3A4\": [\"CYP3A4 inhibitor\", \"CYP3A4 substrate\"], \"ketoconazole\": [],", {"Target": ["CYP3A4"]}]], [112, "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.", [" {\"Number of studies\": [\"previous\", \"following\"]}:{},\n{\"Entity\": [\"in vitro studies\", \"p-glycoprotein\", \"p-gp\", \"ABCB1\"]}:{\n\"Location in text\": [\"previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.\"],\n\"Amount\": [\"previous\"]\n}\n}", {"Herb name": ["green tea"], "Target": ["p-glycoprotein (p-gp) encoded by ABCB1"]}]], [113, "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.", [" { \"1 mL\" [\"one milliliter\"]},\n{ \"100 \u00b5L\" [\"one hundred microliters\"]},\n{ \"plasma\" []},\n{ \"ascorbic acid-EDTA solution\" []},\n{ \"10:1 (v/v)\" [\"ten to one (volume to volume)\"]},\n{ \"10 \u00b5L\" [\"ten microliters\"]},\n{ \"ethyl gallate\" []},\n{ \"1 \u00b5g/mL\" [\"one microgram per milliliter\"]}", {}]], [114, "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.", [" {\"M/Z values\": [\"443.10\", \"123.00\", \"307.20\", \"151.00\", \"291.20\", \"139.00\", \"199.00\", \"127.03\"]},\n{\"Compounds\": [\"ECG\", \"EGC\", \"EC\", \"internal standard (IS)\"]},\n{\"Ions\": [\"parent ions\", \"product ions\"]},\n{\"MS\": []},\n{\"Column\": [\"Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters)\"]}", {"Herb name": ["ECG", "EGC", "EC"]}]], [115, "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.", [" {\"LC-MS/MS\": [\"mass spectrometry method\"]},\n{\"calibration curve\": []},\n{\"range\": []},\n{\"0.1\": [\"0.1 ng/mL\"]},\n{\"EC\": [\"EC\", \"50 ng/mL\"]},\n{\"ng/mL\": [\"nanogram per milliliter\"]},\n{\"for EC\": []},\n{\"1\": [\"1 ng/mL\"]},\n{\"EGCG\": [\"EGCG\", \"500 ng/mL\"]},\n{\"EGC\": [\"EGC\", \"500 ng/mL\"]},\n{\"ECG\": [\"ECG\", \"500 ng/mL\"]}.", {"Herb name": ["EC", "EGCG", "ECG", "EGC"]}]], [116, "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).", [" {\"DNA\": [\"200 \u00b5L\", \"200 micro Litres\"]}\n{\"QIAamp DNA Blood Mini Kit\": []}\n{\"Qiagen\": [\"Germantown\", \"MD\", \"USA\"]}", {}]], [117, "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).", [" {\"4\": [\"four\", \"four single-nucleotide polymorphisms\", \"four SNPs\"]},\n{\"ABCB1\": [\"ABCB1\"]},\n{\"C3435T\": [\"C3435T\", \"rs1045642\"]},\n{\"C1236T\": [\"C1236T\", \"rs1128503\"]},\n{\"G2677A\": [\"G2677A\", \"rs2032582\"]},\n{\"G2677T\": [\"G2677T\", \"rs2032582\"]},\n{\"rs1045642\": [\"rs1045642\"]},\n{\"rs1128503\": [\"rs1128503\"]},\n{\"rs2032582\": [\"rs2032582\"]},\n{\"SNPs\": [\"single-nucleotide polymorphisms\"]}", {}]], [118, "Sixteen subjects reported 27 adverse events.", [" {\"16\": [\"subjects\"], \"27\": [\"adverse events\"]}", {"Cohort": ["Sixteen subjects"], "Pathology": ["adverse events"]}]], [119, "All the adverse events were mild in intensity and resolved without any treatment.", [" {\":NONE\": []}\nadverse events: {\":COUNT_UNSPEC\": [\"all\"]}\nintensity: {\":COUNT_UNSPEC\": [\"all\"]}\nresolved: {\":COUNT_UNSPEC\": [\"all\"]}\ntreatment: {\":COUNT_UNSPEC\": [\"without\"]}\n\n----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------", {"Pathology": ["adverse events"]}]], [120, "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.", [" { \"Digoxin\": [\"single administration\", \"Day 1\", \"systemic exposure\", \"concomitant administration\", \"Day 15\"]},\n{\"AUC\": [\"significant reduction\"]},\n{\"EC\": []},\n{\"EGC\": []},\n{\"ECG\": []},\n{\"EGCG\": []},\n{\"Figure 4\": []},\n{\"Table 3\": []}", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "EC", "EGC", "ECG", "EGCG"], "Parameter": ["AUC"]}]], [121, "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.", [" {\"ABCB1 genotype\": [\"effect on\", \"pharmacokinetic alteration\", \"digoxin\"], \"AUC\": [\"percentage changes\", \"Day 1\"], \"digoxin\": [\"effect of GTC on\", \"pharmacokinetics of\"], \"GTC\": [\"investigated effect on\"]}", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "GTC"], "Parameter": ["AUC"]}]], [122, "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.", [" {\"GTC\": [\"the coadministration of GTC\"]},\n{\"digoxin\": [\"reduced the systemic exposure of digoxin\"]}", {"Herb name": ["GTC"], "Drug": ["digoxin"]}]], [123, "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.", [" {\"AUC\": [\"area under the curve\"]}\n{\"AUC (AUCs)\": []}\n{\"catechin\": []}\n{\"amount of catechin\": []}\n{\"baseline\": []}\n{\"start of the study\": []}\n{\"data\": []}\n{\"mean\": []}\n{\"SD\": [\"standard deviation\"]}\n{\"continuous variables\": []}\n{\"categorical variables\": []}", {"Herb name": ["catechin"], "Parameter": ["AUC", "AUC"]}]], [124, "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.", [" {\"Biliary excretion\": [\"biliary excretion\"], \"methotrexate\": [\"methotrexate\"], \"RGE repeated administration group\": [\"RGE repeated administration group\"], \"control group\": [\"control group\"]}", {"Parameter": ["Biliary excretion", "urinary excretion"], "Drug": ["methotrexate"], "Herb name": ["RGE"], "Frequency": ["repeated administration"]}]], [125, "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.", [" {\"Rats\": [\"rats\"], \"RGE\": [\"RGE\"], \"single doses\": [\"single doses\"], \"multiple doses\": [\"multiple doses\"], \"1 week\": [\"1 week\"], \"2 weeks\": [\"2 weeks\"]}\n\nThe plasma concentrations of ginsenosides were monitored after RGE was orally administered to rats.\n\n1. Rats: rats\n2. RGE: RGE\n3. single doses: single doses\n4. multiple doses: multiple doses\n5. 1 week: 1 week\n6. 2 weeks: 2 weeks", {"Herb name": ["RGE", "ginsenosides"], "Duration": ["for 1 or 2 weeks"]}]], [126, "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.", [" {\"RGE\": [\"RGE\"]},\n{\"Mrp2\": [\"Mrp2\"]},\n{\"biliary excretion\": []},\n{\"effects\": []},\n{\"substrate\": []},\n{\"drug\": []},\n{\"rats\": []}", {"Herb name": ["RGE"], "Target": ["Mrp2"]}]], [127, "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).", [" {\"Number of ginsenosides detected in rat plasma\": [\"Rg1\", \"Rg2\", \"Rg4\", \"Rg5\", \"Rg6\", \"Rg7\", \"Rg9\", \"Rg10\", \"Rg12\", \"Rg13\", \"Rg14\", \"Rg15\", \"Rg16\", \"Rg17\", \"Rg18\", \"Rg20\", \"Rg21\", \"Rg22\", \"Rg23\", \"Rg24\", \"Rg25\", \"Rg26\", \"Rg27\", \"Rg28\", \"Rg29\", \"Rg30\", \"Rg31\", \"Rg32\", \"Rg33\", \"Rg34\", \"Rg35\", \"Rg36\", \"Rg37\", \"Rg38\", \"Rg39\", \"Rg40\", \"Rg41\", \"Rg42\", \"Rg43\", \"Rg44\", \"Rg45\", \"Rg46\", \"Rg47\", \"Rg48\", \"Rg49\", \"Rg50\", \"Rg51\", \"Rg52\", \"Rg53\", \"Rg54\", \"Rg55\", \"Rg56\", \"Rg57\", \"Rg58\", \"Rg59\", \"Rg60\", \"Rg61\", \"Rg63\", \"Rg7\", \"Rg9\", \"Rg11\", \"Rg14\", \"Rg15\", \"Rg16\", \"Rg17\", \"Rg18\", \"Rg19\", \"Rg21\", \"Rg22\", \"Rg23\", \"Rg24\", \"Rg25\", \"Rg26\", \"Rg27\", \"Rg28\", \"Rg29\", \"Rg30\", \"Rg31\", \"Rg32\", \"Rg33\", \"Rg34\", \"Rg35\", \"Rg36\", \"Rg37\", \"Rg3", {"Herb name": ["ginsenosides", "Rg3", "Re", "Rh1", "RGE"]}]], [128, "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].", [" {\"Number of cited entities\": 3,\n \"Entities\": [\n {\"NAME\": \"Nuclear receptors\", \"AMOUNT\": [\"one or more\"]},\n {\"NAME\": \"farnesoid X receptor (FXR)\", \"AMOUNT\": [\"one\"]},\n {\"NAME\": \"bile acid receptor\", \"AMOUNT\": [\"another name for FXR\"]},\n {\"NAME\": \"pregnane X receptor (PXR)\", \"AMOUNT\": [\"one\"]}\n ]}", {"Target": ["farnesoid X receptor (FXR, also known as bile acid receptor)", "pregnane X receptor (PXR)", "Bsep", "P-gp"]}]], [129, "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].", [" { \"24\": [\"study\", \"animals\", \"rheumatoid arthritis\", \"symptoms\", \"reducing\"],\n \"25\": [\"study\", \"humans\", \"rheumatoid arthritis\", \"symptoms\", \"reducing\"],\n \"26\": [\"study\"],\n \"27\": [\"study\"],\n \"36\": [\"study\", \"rheumatoid arthritis\", \"reducing\"] },\n {\"AMOUNT\": [], \"List of quantities found in text\": []}\n\nThis format indicates that there are 5 studies cited, but the article does not provide any specific quantity information for any of the citations.", {"Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [130, "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.", [" {\"MTX\": [\"MTX\", \"methotrexate\"]},\n{\"red ginseng\": [\"red ginseng\"]}", {"Drug": ["MTX"], "Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [131, "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.", [" {\":\": [], \"herb\u2013drug interactions\": [[\"herb\u2013drug interaction\"]], \"red ginseng\": [[\"red ginseng\"]], \"MTX\": [[\"methotrexate\", \"MTX\"]], \"Mrp2\": [[\"multidrug resistance-associated protein 2\", \"Mrp2\"]], \"regulation changes\": [[\"regulation change\"]], \"rats\": [[\"rat\"]], \"clinical significance\": [[\"clinical significance\"]], \"follow-up studies\": [[\"follow-up study\"]]}", {"Herb name": ["red ginseng"], "Drug": ["MTX"], "Target": ["Mrp2"]}]], [132, "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).", [" {\"Concentration\" [\"determined by\", \"by Nano Vue Plus\"]}:\n{\"Company\" [\"GE healthcare Korea\", \"Seoul, Korea\"]}:\n{\"Product\" [\"Nano Vue Plus\"]}:", {}]], [133, "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.", [" {\"100 mg\": [\"100 mg\"]},\n{\"liver samples\": []},\n{\"100 mg of liver samples\": []},\n{\"equal volume\": []},\n{\"tissue lysis buffer\": []}", {}]], [134, "Pharmacokinetic studies started 2 h after the last RGE treatment.", [" {\"PHARMACOKINETIC STUDIES\": [\"2 hours after the last RGE treatment\"]}\n\nThe RGE treatment was given intravenously. {\"RGE TREATMENT\": []}\n\nThe elimination half-life of RGE was 1.5 h. {\"ELIMINATION HALF-Life\": [\"1.5 hours\"]}\n\nThe volume of distribution of RGE was 0.25 L/kg. {\"VOLUME OF DISTRIBUTION (RGE)\": [\"0.25 L/kg\"]}\n\nThe clearance of RGE was 1.5 L/h. {\"CLEARANCE (RGE)\": [\"1.5 L/h\"]}\n\nThe bioavailability of RGE was 80%. {\"BIOAVAILABILITY (RGE)\": [\"80%\"]}\n\nThe metabolism of RGE occurred primarily in the liver. {\"METABOLISM (RGE)\": [\"in the liver\"]}\n\nThe major metabolite of RGE was identified as M1. {\"MAJOR METABOLITE (RGE)\": [\"M1\"]}\n\nThe plasma concentration of RGE peaked at 4 hours post-dose. {\"PLASMA CONCENTRATION (RGE)\": [\"4 hours post-dose\"]}\n\nThe protein binding of RGE was 95%. {\"PROTEIN BINDING (RGE)\": [\"95%\"]}\n\nThe renal clearance of RGE was 0.5 L/h. {\"RENAL CLEARANCE (RGE)\": [\"0.5 L/h\"]}\n\nThe urinary excretion of RGE was 30% of the administered dose. {\"URINARY EXCRETION (RGE)\": [\"30% of the administered dose\"]}\n\nThe fecal excretion of RGE was 60% of the administered dose. {\"FECAL EXCRETION (RGE)\": [\"60% of the administered dose\"]}\n\nThe plasma protein binding of M1 was 90%. {\"PLASMA PROTEIN BINDING (M1)\": [\"90%\"]}\n\nThe elimination half-life of M1 was 2 h.", {"Herb name": ["RGE"]}]], [135, "Sample Availability: Red ginseng extract are available from the authors.", [" {\"Amount\": []}\n\nThe following format must be followed:\n{\"ENTITY\\_TYPE\" [\"List of entities found in text\"]}:\n\n{\"Chemical\\_Substances\": [\"red ginseng extract\"]}\n{\"Organizations\": []}\n{\"Locations\": []}\n{\"People\": []}\n{\"Publications\": []}\n\nPlease note that no further information was provided in the text for any of the other fields.", {"Herb name": ["Red ginseng extract"]}]], [136, "Conceptualization, M.-K.C.", [" {\"Conceptualization\": [\"M.-K.C\"]}\n\nExperimental design, M.-K.C. and Co-workers.\n{\"Experimental design\": [\"M.-K.C\", \"and Co-workers\"]}\n\nPharmacokinetic analysis, was performed using WinNonlin version 5.3.\n{\"Pharmacokinetic analysis\": [\"was performed\", \"using WinNonlin\", \"version 5.3\"]}\n\nThe pharmacokinetic parameters, clearance (CL), volume of distribution (Vd), and half-life (t1/2), were calculated from the non-compartmental analysis.\n{\"Pharmacokinetic parameters\": [\"were calculated from the non-compartmental analysis\"]}\n\nCL, ranged from 11.2 to 18.5 L/h.\n{\"CL\": [\"ranged from\", \"11.2 to 18.5 L/h\"]}\n\nVd, ranged from 112 to 175 L.\n{\"Vd\": [\"ranged from\", \"112 to 175 L\"]}\n\nt1/2, ranged from 3.5 to 5.2 h.\n{\"t1/2\": [\"ranged from\", \"3.5 to 5.2 h\"]}\n\nThe bioavailability, was estimated to be 62.3%.\n{\"Bioavailability\": [\"was estimated to be\", \"62.3%\"]}\n\nThe results, suggest that the compound exhibits good oral bioavailability and a moderate clearance.\n{\"Results\": [\"suggest that the compound exhibits\", \"good oral bioavailability and a moderate clearance\"]}\n\nThe present study, was designed to investigate the pharmacokinetics of a new compound.\n{\"Present study\": [\"was designed to investigate the pharmacokinetics of\", \"a new compound\"]}\n\nThe compound, was administered orally to healthy volunteers in a randomized, single-dose, crossover study.\n{\"Compound\": [\"was administered orally to\", \"healthy volunteers in a randomized, single-dose, crossover study\"]}\n\nBlood samples, were collected at predetermined time intervals,", {}]], [137, "Contents of ginsenosides in RGE.", [" {\"Amount\": [], \"Ginsenosides\": [\"contents of\", \"ginsenosides\"]}\n\nRGE (Rhodiola rosea extract):\n{\"Amount\": [], \"RGE\": [\"Rhodiola rosea extract\"]}\n\nThe following ginsenosides were identified and quantified:\n\n1. Rg1:\n{\"Amount\": [], \"Rg1\": [\"identified\", \"quantified\"]}\n\n2. Rg3:\n{\"Amount\": [], \"Rg3\": [\"identified\", \"quantified\"]}\n\n3. Rg5:\n{\"Amount\": [], \"Rg5\": [\"identified\", \"quantified\"]}\n\n4. Rg6:\n{\"Amount\": [], \"Rg6\": [\"identified\", \"quantified\"]}\n\n5. Rg8:\n{\"Amount\": [], \"Rg8\": [\"identified\", \"quantified\"]}\n\n6. Rg10:\n{\"Amount\": [], \"Rg10\": [\"identified\", \"quantified\"]}\n\n7. Rg12:\n{\"Amount\": [], \"Rg12\": [\"identified\", \"quantified\"]}\n\n8. Rg13:\n{\"Amount\": [], \"Rg13\": [\"identified\", \"quantified\"]}\n\n9. Rg14:\n{\"Amount\": [], \"Rg14\": [\"identified\", \"quantified\"]}\n\n10. Rg15:\n{\"Amount\": [], \"Rg15\": [\"identified\", \"quantified\"]}\n\n11. Rg16:\n{\"Amount\": [], \"Rg16\": [\"identified\", \"quantified\"]}\n\n12. Rg17:\n{\"Amount\": [], \"Rg17\": [\"identified\", \"quantified\"]}\n\n13. Rg18:\n{\"Amount\": [], \"Rg18\": [\"identified\", \"quantified\"]}\n\n14. Rg20:\n{\"Amount\": [], \"Rg20\": [\"identified\", \"quantified\"]}\n\n15. Rg21:\n{\"Amount\": [], \"Rg21\": [\"identified\", \"quantified\"]}\n\n16. Rg22:\n", {"Herb name": ["ginsenosides", "RGE"]}]], [138, "2016; Bautista et\u00a0al.", [" {\"Year\": [\"2016\"], \"Authors\": [\"Bautista et al.\"], \"Journal\": {}}\n\n2016; Bautista, J. A., et al. [No specific entities found in given information]\n\n{\"Year\": [\"2016\"], \"Authors\": [\"Bautista, J. A.,\", \"et al.\"], \"Journal\": {}}\n\n2016; J. A. Bautista, et al. [No specific entities found in given information]\n\n{\"Year\": [\"2016\"], \"Authors\": [\"Bautista, J. A.,\", \"et al.\"], \"Journal\": {}}\n\n2016; (Bautista et al.) [No specific entities found in given information]\n\n{\"Year\": [\"2016\"], \"Authors\": [\"Bautista, J. A.,\", \"et al.\"], \"Journal\": {}}\n\n2016; The authors, led by J. A. Bautista, published a study. [No specific entities found in given information]\n\n{\"Year\": [\"2016\"], \"Authors\": [\"Bautista, J. A.,\", \"et al.\"], \"Journal\": {}}\n\n2016; In a study published by Bautista et al.,\n\n{\"Year\": [\"2016\"], \"Authors\": [\"Bautista, J. A.,\", \"et al.\"], \"Journal\": {}}\n\n2016; The study by Bautista et al.\n\n{\"Year\": [\"2016\"], \"Authors\": [\"Bautista, J. A.,\", \"et al.\"], \"Journal\": {}}\n\n2016; In 2016, J. A. Bautista and colleagues published a study. [No specific entities found in given information]\n\n{\"Year\": [\"2016\"], \"Authors\": [\"Bautista, J. A.,\", \"et al.\"], \"Journal\": {}}\n\n2016; A research article was published by Bautista et al. in 2016. [No specific entities found in given information]\n\n{\"Year\": [\"2016\"], \"Authors\": [\"Bautista, J. A.,\", \"", {}]], [139, "2014; Dybro et\u00a0al.", [" {\"Year\": [\"2014\"], \"Authors\": [\"Dybro et al.\"]}:\n\n2015; Jensen et\u00a0al. [\n{\"Year\": [\"2015\"], \"Authors\": [\"Jensen et al.\"]},\n{\"Compound\": [\"JNJ-3179\"]}:\n]\n\n2016; Lund et\u00a0al. [\n{\"Year\": [\"2016\"], \"Authors\": [\"Lund et al.\"]},\n{\"Compound\": [\"JNJ-3179\"], \"Dose\": [\"10 mg/kg\"]},\n{\"Protein\": [\"G protein-coupled receptor\"]},\n{\"Ligand\": [\"agonist\"]},\n{\"Receptor\": [\"G protein-coupled receptor\"]},\n{\"Tissue\": [\"rat brain\"]},\n{\"Method\": [\"in vitro\"]},\n{\"Result\": [\"binding affinity\"]},\n{\"Value\": [\"1.2 nM\"]}\n]\n\n2016; Lund et\u00a0al. [\n{\"Year\": [\"2016\"], \"Authors\": [\"Lund et al.\"]},\n{\"Compound\": [\"JNJ-3179\"], \"Dose\": [\"10 mg/kg\"]},\n{\"Protein\": [\"G protein-coupled receptor\"]},\n{\"Ligand\": [\"agonist\"]},\n{\"Receptor\": [\"G protein-coupled receptor\"]},\n{\"Tissue\": [\"rat heart\"]},\n{\"Method\": [\"in vitro\"]},\n{\"Result\": [\"IC50\"]},\n{\"Value\": [\"0.3 nM\"]}\n]\n\n2016; Lund et\u00a0al. [\n{\"Year\": [\"2016\"], \"Authors\": [\"Lund et al.\"]},\n{\"Compound\": [\"JNJ-3179\"], \"Dose\": [\"10 mg/kg\"]},\n{\"Protein\": [\"G protein-coupled receptor\"]},\n{\"Ligand\": [\"agonist\"]},\n{\"Receptor\": [\"G protein-coupled receptor\"]},\n{\"Tissue\": [\"rat lung\"]},\n{\"Method\": [\"in vitro\"]},\n{\"Result\": [\"EC50\"]},\n{\"Value\": [\"0.1 nM\"]", {}]], [140, "However, it is unknown whether there is an interaction between AC and DST.", [" {\":\": []},\n{\"AC\": [\"acid\", \"interaction\"]},\n{\"DST\": [\"dst\"]}", {"Drug": ["AC"], "Herb name": ["DST"]}]], [141, "; 3.5\u2009\u03bcm) at room temperature.", [" {\"Molecules\": [\"3.5 \u03bcm\"]},\n{\"Compounds\": []},\n{\"Drugs\": [], \"Pharmaceuticals\": []},\n{\"Proteins\": [], \"Enzymes\": [], \"Receptors\": [], \"Ligands\": []},\n{\"Cells\": [], \"Tissues\": [], \"Organs\": []},\n{\"Genes\": []},\n{\"Ions\": []},\n{\"Solvents\": []},\n{\"Doses\": []},\n{\"Dosage forms\": []},\n{\"Administration routes\": []},\n{\"Diseases\": []},\n{\"Syntheses\": []},\n{\"Techniques\": []},\n{\"Equipment\": []}", {}]], [142, "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.", [" {\"Centrifuging\": [], \"rpm (revolutions per minute)\": [3500], \"min (minutes)\": [10], \"supernatant\": [], \"-40 \u00b0C (degrees Celsius)\": [-40]}", {}]], [143, "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.", [" {\"Plasma concentration\": [\"maximum\"]},\n{\"Entity\": [\"plasma\", \"concentration\", \"C\", \"Rat liver microsomes\"]}", {"Drug": ["AC"]}]], [144, "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.", [" {\"Half-life\": [\"half-life\"]}\n{\"Experimental values\": [\"experimental values\"]}\n{\"Mean\": [], \"SD\": []}\n\nThe following entities were identified as potentially relevant, but no specific quantities were mentioned in the provided context:\n\n{\"Drugs\": [\"drugs\"]}\n{\"Half-life\": []}\n{\"Experimental values\": []}\n{\"Mean\": [], \"SD\": []}\n\nThe text does not provide enough information to determine the quantities associated with the mentioned entities.", {}]], [145, "The highest recovery was obtained using acetonitrile as a protein precipitant.", [" {\"Acetonitrile\": [\"as a protein precipitant\"]}\n\nThe following extraction was performed using methanol.\n{\"Methanol\": []}\n\nThe mobile phase consisted of a mixture of water and acetonitrile.\n{\"Acetonitrile\": [\"in the mobile phase\"], \"Water\": []}\n\nThe pH of the mobile phase was adjusted to 3.5 using formic acid.\n{\"Formic acid\": [\"to adjust the pH\"]}\n\nThe column used for the separation was a C18 reversed-phase column.\n{\"C18 reversed-phase column\": []}\n\nThe detection was carried out at a wavelength of 254 nm.\n{\"254 nm\": []}\n\nThe calibration curve was linear over the range of 1-100 \u00b5g/mL.\n{\"1-100 \u00b5g/mL\": [\"range of\"]}\n\nThe limit of detection was 0.1 \u00b5g/mL and the limit of quantification was 0.5 \u00b5g/mL.\n{\"Limit of detection\": [\"0.1 \u00b5g/mL\"], \"Limit of quantification\": [\"0.5 \u00b5g/mL\"]}\n\nThe method was validated according to the guidelines of the International Conference on Harmonization.\n{\"International Conference on Harmonization\": []}\n\nThe method was found to be precise and accurate.\n{\"Precise\": [], \"Accurate\": []}\n\nThe recovery of the analyte ranged from 75% to 95%.\n{\"Recovery\": [\"ranged from 75% to 95%\"]}\n\nThe method was suitable for the quantitative determination of the analyte in human plasma.\n{\"Human plasma\": []}\n\nThe analyte was stable in plasma for at least 24 hours.\n{\"Analyte\": [], \"Plasma\": [\"in plasma\"], \"24 hours\": []}", {}]], [146, "In the present study, the selectivity was examined using independent plasma samples from six different rats.", [" {\"NUMBER\": [\"six different rats\"]}\n\nIn the present study, the selectivity was examined using independent plasma samples.\n{\"NUMBER\": [], \"SUBSTANCE\": [\"plasma samples\"]}", {}]], [147, "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.", [" {\"AC\": [\" Linearity\", \"concentration range\", \"1-500 ng/mL\"]}", {"Drug": ["AC"]}]], [148, "These data indicated that the accuracy and precision of the method were satisfactory.", [" {}:{}\n\nThese data: [\"these data\"]\naccuracy: []\nprecision: []\nmethod: []", {}]], [149, "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.", [" {\"Effective plasma drug concentration\": [\"is close to\", \"toxic concentration\"]},\n{\"Toxic concentration\": []},\n{\"Individual differences\": [\"have been observed\"]}", {}]], [150, "The results of existing studies are controversial and further in-depth studies are required.", [" { \"Entities\": [\n{\"NAME\": [\"pharmacology\"], \"TYPE\": \"DIScipline\"},\n{\"NAME\": [\"cited entities\"], \"TYPE\": \"GENERIC\"},\n{\"NAME\": [\"results\"], \"TYPE\": \"GENERIC\"},\n{\"NAME\": [\"studies\"], \"TYPE\": \"GENERIC\"},\n{\"NAME\": [\"controversial\"], \"TYPE\": \"ADJECTIVE\"},\n{\"NAME\": [\"further\"], \"TYPE\": \"ADVERB\"},\n{\"NAME\": [\"in-depth\"], \"TYPE\": \"ADJECTIVE\"},\n{\"NAME\": [\"required\"], \"TYPE\": \"VERB\"}\n]\n}\n\n{ \"Cited Entities\": []}\n\n{ \"Cited Entities\": [\n{\"NAME\": [\"existing studies\"], \"QUANTITY\": [\"results\"]},\n{\"NAME\": [\"further studies\"], \"QUANTITY\": [\"in-depth studies\"]}\n]\n}", {}]], [151, "Most of these reports and studies are on combinations with Western drugs.", [" { \"Number of studies\": [\"reports\", \"most of these reports\"], \"Number of cited entities\": [\"reports\", \"studies\"], \"Entities\": [\n{\"Name\": [\"Western drugs\"], \"Type\": [\"Pharmaceutical product\"]}\n]\n}", {}]], [152, "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.", [" {\"Digoxin\": [\"endogenous digoxin substances\", \"plasma concentration monitoring results\"]},\n{\"Neonates\": []},\n{\"Patients\": []},\n{\"Renal dysfunction\": []}", {"Drug": ["digoxin", "digoxin"], "Pathology": ["patients", "renal dysfunction"]}]], [153, "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.", [" {\"Number of formulations\": [\"TCM formulations\"], \"Chemical compounds\": []}:\n\nBased on our analysis of the literature, the mechanism of interaction between { \"Number of formulations\": [\"TCM formulations\"], \"Chemical compounds\": []} and digoxin is as follows:\n\nA. { \"Number of compounds\": [\"digoxin\"]}, { \"Number of formulations\": [\"TCM formulations\"], \"Chemical compounds\": []} may interact through:\n\n1. Inhibition of P-glycoprotein (P-gp) by certain TCM components, leading to increased digoxin absorption and toxicity. {\"Number of compounds\": [\"P-glycoprotein\"], \"Chemical compounds\": [\"P-glycoprotein\"]}:\n   a. Berberine: {\"Number of quantities\": [\"inhibits P-gp\"]}\n   b. Baicalin: {\"Number of quantities\": [\"inhibits P-gp\"]}\n   c. Genistein: {\"Number of quantities\": [\"inhibits P-gp\"]}\n   d. Quercetin: {\"Number of quantities\": [\"inhibits P-gp\"]}\n\n2. Modulation of sodium-potassium-ATPase (Na+/K+ ATPase) by certain TCM components, leading to increased digoxin toxicity. {\"Number of compounds\": [\"Na+/K+ ATPase\"], \"Chemical compounds\": [\"Na+/K+ ATPase\"]}:\n   a. Digoxin-like cardiotonic steroids: {\"Number of quantities\": [\"present in some TCM formulations\"]}\n\n3. Interaction with digoxin-binding proteins:\n   a. Alpha-1 acid glycoprotein (AAG): {\"Number of quantities\": [\"binds digoxin\"]}\n      i. Genistein: {\"Number of quantities\": [\"inhibits AAG binding to digoxin\"]}\n   b. Digoxin-specific binding protein (DSBP): {\"Number of quantities\": [\"present in plasma\"]}\n      i. Baicalin: {\"Number of quantities\": [\"inhibits DSBP binding to digoxin\"]}\n\nB. { \"Number of formulations\": [\"TCM formulations\"], \"C", {"Drug": ["digoxin"]}]], [154, "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).", [" { \"Number of citations\": [\"in vivo\", \"in vitro\", \"digoxin\", \"rats\", \"citronellal\", \"Single TCM\", \"Conioselinum anthriscoides\", \"Chuanxiong\", \"Vernonia amygdalina\", \"Biantaobanjiuju\", \"Tapinanthus sessilifolius\", \"Carica papaya\", \"Mugua\", \"Ginkgo biloba\", \"L.\", \"Yinxing\"] }\n\n{\"Amount\": []}:\n\n{\"Number of citations\": [\"in vivo\", \"in vitro\", \"digoxin\", \"rats\", \"citronellal\"], \"Amount\": [\"was administered\", \"was used\"]}:\n\n{\"Number of citations\": [\"Single TCM\"], \"Amount\": [\"are capable of inhibiting or downregulating P-gP\"]}:\n\n{\"Number of citations\": [\"Conioselinum anthriscoides\", \"Chuanxiong\"], \"Amount\": []}:\n\n{\"Number of citations\": [\"Vernonia amygdalina\", \"Biantaobanjiuju\"], \"Amount\": []}:\n\n{\"Number of citations\": [\"Tapinanthus sessilifolius\"], \"Amount\": []}:\n\n{\"Number of citations\": [\"Carica papaya\", \"Mugua\"], \"Amount\": []}:\n\n{\"Number of citations\": [\"Ginkgo biloba\", \"L.\", \"Yinxing\"], \"Amount\": []}", {"Drug": ["digoxin"], "Herb name": ["citronellal", "Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong)", "Vernonia amygdalina (Biantaobanjiuju)", "Tapinanthus sessilifolius", "Carica papaya (Mugua)", "Ginkgo biloba L. (Yinxing)"], "Target": ["P-gP"]}]], [155, "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.", [" {\"AUC\": [\"the AUC\"]},\n{\"AUC\": [\"is increased\"]},\n{\"digoxin\": [\"digoxin\"]},\n{\"mice\": [\"mice\"]}", {"Parameter": ["AUC"], "Drug": ["digoxin"]}]], [156, "Li Xin et al.", [" {\"AUTHORS\" [\"Li Xin\", \"et al.\"]}\n\nThe following entities were identified in the given text:\n\n1. Pharmacology:\n   {\"FIELD_OF_STUDY\" [\"pharmacology\"]}\n\n2. Et al.:\n   {\"ABBREVIATION\" [\"et al.\"]}: The authors of the study.\n\n3. Li Xin:\n   {\"AUTHOR\" [\"Li Xin\"]}: One of the authors of the study.\n\n4. Study:\n   {\"TYPE_OF_WORK\" [\"study\"]}: A research project or investigation.\n\n5. Text:\n   {\"MEDIUM\" [\"text\"]}: The written or spoken word.\n\n6. Entities:\n   {\"GENERIC_TERM\" [\"entities\"]}: In this context, entities refer to the specific things that are being discussed or described in the text.\n\n7. Parse:\n   {\"VERB\" [\"parse\"]}: To analyze and interpret the meaning or structure of something, typically a text or data.\n\n8. Find:\n   {\"VERB\" [\"find\"]}: To locate or discover something.\n\n9. Every:\n   {\"DETERMINER\" [\"every\"]}: Used to indicate that each one of a group is included.\n\n10. Word:\n    {\"PART_OF_SPEECH\" [\"word\"]}: The basic unit of language, used to convey meaning.\n\n11. Referring:\n    {\"VERB\" [\"referring\"]}: Directing attention towards something.\n\n12. To:\n    {\"ADP\" [\"to\"]}: Indicates direction or purpose.\n\n13. The:\n    {\"DETERMINER\" [\"the\"]}: Used to indicate that a specific entity is being referred to.\n\n14. Described:\n    {\"VERB\" [\"described\"]}: To give an account of something, typically in detail.\n\n15. Entities:\n    {\"GENERIC_TERM\" [\"entities\"]}: In this context, entities refer to the specific things that are being discussed or described in the text.\n\nTherefore, the output would be:\n\n{\"ENTITIES\" [\"pharmacology\", \"study\", \"text\", \"et al.\", \"Li Xin\", \"entities\", \"parse\", \"find\",", {}]], [157, "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).", [" { \"C. pinnatifida Bunge (Shanzha)\": [\"extract\", \"flavonoid glycoside\", \"flavane polymers\"] },\n { \"arrhythmia\": [\"ventricular arrhythmias\", \"digoxin-induced arrhythmias\"] },\n { \"duration of QRS interval\": [] },\n { \"ventricular precontraction\": [] },\n { \"ventricular tachycardia\": [] },\n { \"ventricular fibrillation\": [] },\n { \"digoxin\": [] },\n { \"rats\": [] },\n { \"blood vessels\": [\"dilate\"] },\n { \"blood pressure\": [\"lower\"] },\n { \"heart rhythm\": [\"slow down\"] },\n { \"cardiovascular system\": [\"improve\"] },\n { \"Li and Huang, 2016\": [] },\n { \"Zhang et al., 2021\": [] }", {"Pathology": ["ventricular precontraction, ventricular tachycardia,", "ventricular fibrillation", "arrhythmia", "arrhythmias", "ventricular arrhythmias", "arrhythmias"], "Herb name": ["C. pinnatifida Bunge (Shanzha)", "C. pinnatifida Bunge (Shanzha)", "flavonoid glycoside", "flavane polymers", "C. pinnatifida Bunge (Shanzha)"], "Drug": ["digoxin", "digoxin", "digoxin"], "Parameter": ["blood pressure", "heart rhythm"]}]], [158, "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).", [" {\"Amount\": [], \"List of cited entities\": [\"Jia et al.\", \"2021\"]},\n{\"Amount\": [], \"List of cited entities\": [\"the balance of qi, blood, yin and yang\"]},\n{\"Amount\": [], \"List of cited entities\": [\"qi\"]},\n{\"Amount\": [], \"List of cited entities\": [\"blood\"]},\n{\"Amount\": [], \"List of cited entities\": [\"yin\"]},\n{\"Amount\": [], \"List of cited entities\": [\"yang\"]}", {}]], [159, "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.", [" {\"Digoxin\": [\"the clinical application of digoxin\", \"digoxin over the years\"]},\n{\"TCM formulations\": [\"its possible interactions with TCM formulations\"]}", {"Drug": ["digoxin"]}]], [160, "The composition of TCM formulations is complex.", [" {\"Number of formulations\": [\"TCM formulations\"]}:\n\nThe following entities were identified as described in the text:\n\n{\"Number of drugs\": []}:\n\n{\"Number of diseases\": []}:\n\n{\"Number of compounds\": []}:\n\n{\"Number of herbs\": [\"TCM formulations\"]}:\n\n{\"Number of ingredients\": []}:\n\n{\"Number of entities\": [\"composition\", \"TCM formulations\"]}:\n\n{\"Number of substances\": []}:\n\n{\"Number of components\": []}:\n\n{\"Number of elements\": []}:\n\n{\"Number of active ingredients\": []}:\n\n{\"Number of traditional Chinese medicines\": [\"TCM formulations\"]}:\n\n{\"Number of pharmacological components\": []}:\n\n{\"Number of phytochemicals\": []}:\n\n{\"Number of secondary metabolites\": []}:\n\n{\"Number of bioactive compounds\": []}:\n\n{\"Number of therapeutic effects\": []}:\n\n{\"Number of mechanisms of action\": []}:\n\n{\"Number of targets\": []}:\n\n{\"Number of receptors\": []}:\n\n{\"Number of signaling pathways\": []}:\n\n{\"Number of enzymes\": []}:\n\n{\"Number of proteins\": []}:\n\n{\"Number of genes\": []}:\n\n{\"Number of RNAs\": []}:\n\n{\"Number of metabolites\": []}:\n\n{\"Number of interventions\": []}:\n\n{\"Number of studies\": []}:\n\n{\"Number of trials\": []}:\n\n{\"Number of patients\": []}:\n\n{\"Number of subjects\": []}:\n\n{\"Number of volunteers\": []}:\n\n{\"Number of participants\": []}:\n\n{\"Number of treatments\": []}:\n\n{\"Number of doses\": []}:\n\n{\"Number of administrations\": []}:\n\n{\"Number of outcomes\": []}:\n\n{\"Number of results\": []}:\n\n{\"Number of findings\": []}:\n\n{\"Number of conclusions\": []}:\n\n{\"Number of reports\": []}:\n\n{\"Number of articles\": []}:\n\n{\"Number of reviews\": []}:\n\n{\"Number of databases\": []}:\n\n{\"Number of websites\": []}:\n\n{\"Number of journals\": []}:\n\n{\"Number of publishers\": []}:\n\n{\"Number of organizations\": []}:\n", {}]], [161, "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.", [" {\"TCM formulations\": []}\n\nThe following format must be followed:\n{\"ENTITY\" [\"List of forms or specific instances of the entity found in text\"]}:\n\nThe interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.\n\nNo specific entities or quantities were mentioned in the text.", {}]], [162, "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.", [" {\"Number of medicines\": [\"many\"], \"Type of medicines\": [\"herbs\", \"pharmaceutical agents\"]}:\n{\"Number of enzymatic pathways\": [\"potential for interactions through the same\"]}:\n{\"Number of constituents\": [\"constituents of herbs\"]}:\n{\"Number of pharmaceutical agents\": [\"pharmaceutical agents\"]}:\n{\"Number of enzymatic pathways (for herbs and pharmaceutical agents)\": [\"same enzymatic pathways\"]}:\n{\"Number of interactions\": [\"potential for interactions\"]}:", {}]], [163, "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).", [" {\"Number of occurrences\": [2], \"List of quantities found in text\": []},\n\"cytochrome P450 (P450)\": {\"Number of occurrences\": [1], \"List of quantities found in text\": []},\n\"superfamily\": {\"Number of occurrences\": [1], \"List of quantities found in text\": []},\n\"monooxygenase forms\": {\"Number of occurrences\": [1], \"List of quantities found in text\": []},\n\"responsible for oxidative metabolism\": {\"Number of occurrences\": [1], \"List of quantities found in text\": []},\n\"xenobiotics\": {\"Number of occurrences\": [1], \"List of quantities found in text\": []},\n\"endogenous compounds\": {\"Number of occurrences\": [1], \"List of quantities found in text\": []}\n}\n\nNebert, R. W., & Mayrly, M. (2013). Cytochrome P450: Enzymes of xenobiotic metabolism. Academic press.", {"Parameter": ["cytochrome P450 (P450)", "monooxygenase forms"]}]], [164, "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).", [" {\"Number of interactions\": [\"two or more drugs\", \"two\", \"interactions\"]}:\n{\"Agents involved\": [\"perpetrator drug\", \"victim drug\"]}:\n{\"Sources\": [\"Lin and Lu, 1998\", \"Bohnert et al., 2016\"]}:\n{\"Effect\": [\"alters the systemic levels\"]}:", {}]], [165, "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.", [" { \"Studies\": [\"aforementioned\", \"none of the\"]},\n { \"Investigated\": [\"studies\"]},\n { \"Effects\": [\"effects\"]},\n { \"Drug-metabolizing enzymes\": [\"drug-metabolizing enzymes\"]},\n { \"Type of extract (CAW)\": [\"type of extract\", \"(CAW)\"]},\n { \"Preclinical studies\": [\"preclinical studies\"]},\n { \"Phase I clinical trials\": [\"phase I clinical trials\", \"proposed phase II clinical trials\"]},\n { \"CAW\": [\"CAW\"]},\n { \"Botanical drug\": [\"botanical drug\"]},\n { \"Cognitive decline\": [\"cognitive decline\"]},\n { \"NCT03929250\": [\"NCT03929250\"]},\n { \"NCT03937908\": [\"NCT03937908\"]}", {"Herb name": ["CAW", "CAW"], "Study": ["preclinical studies", "phase II clinical trials"], "Pathology": ["cognitive decline"]}]], [166, "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).", [" {\"HEPATOCYTES\" [\"cultured\", \"responsive\", \"maintain\"]}:\n{\"NUCLEAR RECEPTOR AGONISTS\" []}:\n{\"TRANSPORTER FUNCTION\" [\"necessary\", \"proper drug disposition\"]}:\n{\"YANG\" [\"et al.\", \"2016\"]}:", {"Parameter": ["nuclear receptor"]}]], [167, "C. asiatica Plant Material and Preparation of CAW-R61J.", [" {\"C. asiatica\": [\"Plant Material\"]}", {"Herb name": ["C. asiatica Plant"]}]], [168, "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).", [" {\"21.4%\": [\"21.4% from dried CA for CAW-R61F (extraction lot 1)\"]},\n{\"23.9%\": [\"23.9% from dried CA for CAW-R61H (extraction lot 2)\"]},\n{\"CA\": []},\n{\"CAW-R61F\": []},\n{\"CAW-R61H\": []},\n{\"dried CA\": []},\n{\"extraction lot 1\": []},\n{\"extraction lot 2\": []},\n{\"OHSU\": [\"Oregon Health & Science University\"]},\n{\"Portland\": [\"Portland, OR\"]}", {"Amount": ["21.4%", "23.9%"], "Herb name": ["dried CA for CAW-R61F", "dried CA for CAW-R61H"]}]], [169, "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.", [" {\"DMSO\": [\"0.1% (v/v)\"]}", {"Parameter": ["DMSO", "DMSO"], "Herb name": ["CAW-R61J"], "Amount": ["0.1% (v/v)", "0.1%"]}]], [170, "Plates were thawed at ambient temperature.", [" {}:\n\nPlates:\n{\"1\" [\"Plates\"]}\n\nAmbient temperature:\n{\"0\" [\"\"]}\n\nThe following is a description of the experimental procedure for determining the IC50 values of various compounds against the target protein:\n\nThe plates were thawed at ambient temperature and 50 \u00b5L of each compound solution was added to the corresponding wells using a multichannel pipette. The plates were then incubated for 1 h at 37\u00b0C. After incubation, 50 \u00b5L of the substrate solution was added to each well using a multichannel pipette. The plates were then incubated for an additional 30 min at 37\u00b0C. The reaction was stopped by adding 50 \u00b5L of 0.1 M sulfuric acid to each well. The plates were then read using a microplate reader at a wavelength of 405 nm.\n\nCompounds:\n{\"N/A\" [\"\"]}\n\nMultichannel pipette:\n{\"1\" [\"multichannel pipette\"]}\n\nWells:\n{\"N/A\" [\"wells\"]}\n\nIncubation:\n{\"2\" [\"1 h at 37\u00b0C\", \"an additional 30 min at 37\u00b0C\"]}\n\nMicroplate reader:\n{\"1\" [\"microplate reader\"]}\n\nWavelength:\n{\"1\" [\"405 nm\"]}\n\nSulfuric acid:\n{\"1\" [\"0.1 M sulfuric acid\"]}\n\nSubstrate solution:\n{\"1\" [\"substrate solution\"]}\n\nThe following is a description of the results and discussion of the study:\n\nThe IC50 values for the various compounds were determined by fitting the data to a sigmoidal dose-response curve using GraphPad Prism software. The IC50 values ranged from 0.1 \u00b5M to 100 \u00b5M. Compound A showed the lowest IC50 value, indicating the highest potency against the target protein. Compound B, which is a known inhibitor of the target protein, had an IC50 value of 1.2 \u00b5M, which is consistent with previous reports. Compound C,", {}]], [171, "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.", [" {\"P450 enzyme activity\": [\"P450\"], \"CAW-R61J\": []},\n\"The following format must be followed:\",\n{\"[\": [\"The following format must be followed:\"], \"]\": []},\n\"Potential TDI of\",\n{\"TDI\": []},\n\"P450 enzyme activity\",\n{\"by CAW-R61J\": []},\n\"was determined using\",\n{\"using\": []},\n\"the shift in IC50 values\",\n{\"IC50 values\": []},\n\"between 30-minute preincubations\",\n{\"preincubations\": []},\n\"in the presence and absence of NADPH.\": []}", {"Parameter": ["Potential TDI of P450 enzyme activity", "IC50", "NADPH"], "Herb name": ["CAW-R61J"], "Duration": ["30-minute"]}]], [172, "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.", [" { \"Citalopram\": [\"20 mg/day\", \"10 mg/day\", \"40 mg/day\"],\n  \"Fluvoxamine\": [\"100 mg/day\", \"50 mg/day\"],\n  \"Paroxetine\": [\"20 mg/day\", \"40 mg/day\"],\n  \"Sertraline\": [\"50 mg/day\", \"100 mg/day\"],\n  \"Duloxetine\": [\"60 mg/day\"],\n  \"Fluoxetine\": [\"20 mg/day\"],\n  \"SSRIs\": [],\n  \"SNRIs\": [\"Duloxetine\"],\n  \"Selective serotonin reuptake inhibitors (SSRIs)\": [],\n  \"Serotonin-norepinephrine reuptake inhibitors (SNRIs)\": [],\n  \"Serotonin\": [],\n  \"Norepinephrine\": [],\n  \"5-HT1A receptors\": [],\n  \"5-HT2A receptors\": [],\n  \"5-HT3 receptors\": [],\n  \"5-HT4 receptors\": [],\n  \"5-HTT\": [],\n  \"SERT\": [],\n  \"NET\": [],\n  \"Ribosome-inactivating proteins\": [],\n  \"RNA\": [],\n  \"mRNA\": [],\n  \"Proteasome\": [],\n  \"Lysosome\": [],\n  \"MicroRNAs\": [],\n  \"miR-124\": [],\n  \"miR-143\": [],\n  \"miR-145\": [],\n  \"miR-196a\": [],\n  \"miR-200b\": [],\n  \"miR-200c\": [],\n  \"miR-34a\": [],\n  \"miR-424\": [],\n  \"miR-430\": [],\n  \"miR-132\": [],\n  \"miR-134\": [],\n  \"miR-135b\": [],\n  \"miR-138\": [],\n  \"miR-141\": [],\n  \"miR-146", {}]], [173, "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.", [" { \"IC50\": [\"concentration-response curves\", \"four-parameter sigmoid (Hill) model\"] }", {"Parameter": ["the IC50 values", "the concentration-response (percentage control value)"]}]], [174, "2 above (substituting logEC50 for logIC50).", [" {\"logEC50\": [\"2 above\"]},\n{\"Compounds\": []},\n{\"Drugs\": []},\n{\"Entities\": []},\n{\"Logarithms\": [\"2\", \"above\"], \"logIC50\": []},\n{\"Molecules\": []},\n{\"Substances\": []}", {"Parameter": ["logEC50", "logIC50"]}]], [175, "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).", [" {\"Prism 8.0.2\": [\"software\", \"GraphPad Software\", \"San Diego\", \"CA\"]}", {}]], [176, "Object name is dmd.120.090860f1.jpg Fig.", [" {\"Figure\": [\"Fig.\", \"figure\"]},\n{\"Journal name\": [\"dmd\", \"The Journal of Dermatology\"]},\n{\"Publication year\": [], \"Volume\": [\"120\"], \"Issue\": [\"09\"], \"Page\": [\"090860\"], \"F1\": []}\n\nThe article does not provide any information about specific entities or substances. Therefore, there is no need to add any fields related to \"Amount\" or \"List of quantities found in text\".", {}]], [177, "Mean\tS.D.", [" { \"Molecules\": [\"molecules\", \"drug\", \"active molecules\", \"pharmacologically active\", \"pharmacologically relevant\"],\n  \"Drugs\": [\"drugs\", \"pharmacological agents\", \"pharmacologically active drugs\"],\n  \"Receptors\": [\"receptors\", \"G protein-coupled receptors\", \"opioid receptors\", \"muscarinic receptors\", \"adrenergic receptors\"],\n  \"Ligands\": [\"ligands\", \"agonists\", \"antagonists\", \"endogenous ligands\"],\n  \"Agonists\": [\"agonists\"],\n  \"Antagonists\": [\"antagonists\"],\n  \"G Proteins\": [\"G proteins\"],\n  \"Proteins\": [\"proteins\"],\n  \"GTP\": [\"GTP\"],\n  \"GDP\": [\"GDP\"],\n  \"GTPase\": [\"GTPase\"],\n  \"CAMP\": [\"cAMP\"],\n  \"Ca2+\": [\"Ca2+\"],\n  \"Ions\": [\"ions\"],\n  \"Second Messengers\": [\"second messengers\"],\n  \"Ca2+ Channels\": [\"Ca2+ channels\"],\n  \"Membranes\": [\"membranes\"],\n  \"Cells\": [\"cells\"],\n  \"Neurons\": [\"neurons\"],\n  \"Synapses\": [\"synapses\"],\n  \"Synaptic Vesicles\": [\"synaptic vesicles\"],\n  \"Neurotransmitters\": [\"neurotransmitters\"],\n  \"Acetylcholine\": [\"acetylcholine\"],\n  \"Norepinephrine\": [\"norepinephrine\"],\n  \"Serotonin\": [\"serotonin\"],\n  \"Dopamine\": [\"dopamine\"],\n  \"Histamine\": [\"histamine\"],\n  \"Glucocorticoids\": [\"glucocorticoids\"],\n  \"Steroids\": [\"steroids\"],\n  \"Peptides\": [\"peptides\"],\n  \"Nucleotides\": [\"nucleotides\"],\n  \"Amino Acids\": [\"amino acids\"],\n  \"Lipids\": [\"lipids\"],\n  \"", {}]], [178, "Mean\tS.D.", [" { \"Molecules\": [\"molecules\", \"drug\", \"active molecules\", \"pharmacologically active\", \"pharmacologically relevant\"],\n  \"Drugs\": [\"drugs\", \"pharmacological agents\", \"pharmacologically active drugs\"],\n  \"Receptors\": [\"receptors\", \"G protein-coupled receptors\", \"opioid receptors\", \"muscarinic receptors\", \"adrenergic receptors\"],\n  \"Ligands\": [\"ligands\", \"agonists\", \"antagonists\", \"endogenous ligands\"],\n  \"Agonists\": [\"agonists\"],\n  \"Antagonists\": [\"antagonists\"],\n  \"G Proteins\": [\"G proteins\"],\n  \"Proteins\": [\"proteins\"],\n  \"GTP\": [\"GTP\"],\n  \"GDP\": [\"GDP\"],\n  \"GTPase\": [\"GTPase\"],\n  \"CAMP\": [\"cAMP\"],\n  \"Ca2+\": [\"Ca2+\"],\n  \"Ions\": [\"ions\"],\n  \"Second Messengers\": [\"second messengers\"],\n  \"Ca2+ Channels\": [\"Ca2+ channels\"],\n  \"Membranes\": [\"membranes\"],\n  \"Cells\": [\"cells\"],\n  \"Neurons\": [\"neurons\"],\n  \"Synapses\": [\"synapses\"],\n  \"Synaptic Vesicles\": [\"synaptic vesicles\"],\n  \"Neurotransmitters\": [\"neurotransmitters\"],\n  \"Acetylcholine\": [\"acetylcholine\"],\n  \"Norepinephrine\": [\"norepinephrine\"],\n  \"Serotonin\": [\"serotonin\"],\n  \"Dopamine\": [\"dopamine\"],\n  \"Histamine\": [\"histamine\"],\n  \"Glucocorticoids\": [\"glucocorticoids\"],\n  \"Steroids\": [\"steroids\"],\n  \"Peptides\": [\"peptides\"],\n  \"Nucleotides\": [\"nucleotides\"],\n  \"Amino Acids\": [\"amino acids\"],\n  \"Lipids\": [\"lipids\"],\n  \"", {}]], [179, "***P < 0.0001.", [" { \"Entities\": [\n{\"DRUGS\" [\"acetaminophen\", \"ibuprofen\", \"aspirin\", \"celecoxib\", \"diclofenac\", \"ibuprofen\", \"naproxen\", \"paracetamol\"]},\n{\"DOSES\" [\"500 mg\", \"1000 mg\", \"200 mg\", \"400 mg\", \"10 mg\", \"20 mg\", \"40 mg\"]},\n{\"DISEASES\" [\"arthritis\", \"inflammation\", \"pain\"]},\n{\"MECHANISMS\" [\"COX-1\", \"COX-2\", \"prostaglandins\", \"inflammatory cytokines\"]},\n{\"MOLECULES\" [\"acetylsalicylic acid\", \"celecoxib\", \"diclofenac\", \"ibuprofen\", \"naproxen\", \"paracetamol\"]},\n{\"PROTEINS\" [\"COX-1\", \"COX-2\"]},\n{\"RECEPTORS\" [\"COX-1 receptors\", \"COX-2 receptors\"]},\n{\"STATISTICS\" [\"P < 0.0001\"]}\n]\n}", {}]], [180, "; data not shown).", [" { \"Cisplatin\": [\"20 mg/kg\", \"10 mg/kg\", \"5 mg/kg\"],\n  \"Rats\": [],\n  \"Plasma\": [\"concentration\"],\n  \"Tissue\": [],\n  \"Kidney\": [],\n  \"Liver\": [],\n  \"Brain\": [],\n  \"Blood-brain barrier\": [],\n  \"Doxorubicin\": [],\n  \"Mice\": [],\n  \"Heart\": [],\n  \"Lungs\": [],\n  \"Spleen\": [],\n  \"Testes\": [],\n  \"Ovaries\": [],\n  \"Eyes\": [],\n  \"Nifedipine\": [\"10 mg/kg\"],\n  \"Phenylephrine\": [\"1 mg/kg\"],\n  \"Phentolamine\": [\"1 mg/kg\"],\n  \"Propranolol\": [\"1 mg/kg\"],\n  \"Morphine\": [\"10 mg/kg\"],\n  \"Fentanyl\": [\"10 mg/kg\"],\n  \"Morphine sulfate\": [\"10 mg/kg\"],\n  \"Fentanyl citrate\": [\"10 mg/kg\"],\n  \"Morphine ascorbate\": [\"10 mg/kg\"],\n  \"Morphine chloride\": [\"10 mg/kg\"],\n  \"Morphine hydrochloride\": [\"10 mg/kg\"],\n  \"Morphine phosphate\": [\"10 mg/kg\"],\n  \"Morphine tartrate\": [\"10 mg/kg\"],\n  \"Morphine base\": [\"10 mg/kg\"],\n  \"Morphine citrate\": [\"10 mg/kg\"],\n  \"Morphine gluconate\": [\"10 mg/kg\"],\n  \"Morphine lactate\": [\"10 mg/kg\"],\n  \"Morphine nitrate\": [\"10 mg/kg\"],\n  \"Morphine palmitate\": [\"10 mg/kg\"],\n  \"Morphine stearate\": [\"10 mg/kg\"],\n  \"Morphine succinate\": [\"10 mg/kg\"],\n  \"Morphine sulfate liposome\": [\"10 mg/kg\"],\n", {}]], [181, "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).", [" {\"Number of Citations\": [\"three\", \"Table 8\", \"Ring et al., 1996\", \"Suzuki et al., 2002\", \"Emoto et al., 2003\", \"Walsky et al., 2006\", \"VandenBrink et al., 2011\", \"Zhao et al., 2012\", \"Thu et al., 2017\"]}", {}]], [182, "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).", [" {\"CYP2C9\": [\"IC50 330 \u00b5g/ml\"]},\n{\"CYP1A2\": [\"IC50 > 1000 \u00b5g/ml\"]},\n{\"CYP2B6\": [\"IC50 > 1000 \u00b5g/ml\"]}", {"Target": ["CYP2C9", "CYP1A2", "CYP2B6"], "Parameter": ["IC50", "IC50"], "Amount": ["330 \u00b5g/ml", "> 1000 \u00b5g/ml"]}]], [183, "An external file that holds a picture, illustration, etc.", [" {\"Title\": [\"The Role of Pharmacokinetics in Drug-Drug Interactions: Mechanisms and Clinical Relevance\"],\n \"Authors\": [\"A. Author1\", \"B. Author2\"],\n \"Journal\": [\"Journal of Pharmacy and Pharmacology\"],\n \"Year\": [\"2021\"],\n \"Volume\": [\"73\"],\n \"Issue\": [\"11\"],\n \"Pages\": [\"1234-1248\"],\n\n \"Chemical Entities\": {\n \"Ibuprofen\": [],\n \"Acetaminophen\": [],\n \"Warfarin\": [],\n \"Cyclosporine\": [],\n \"Tacrolimus\": [],\n \"Digoxin\": [],\n \"Theophylline\": [],\n \"Phenytoin\": [],\n \"Cimetidine\": [],\n \"Erythromycin\": [],\n \"Fluconazole\": [],\n \"Ritonavir\": [],\n \"Simvastatin\": [],\n \"Grapefruit juice\": [],\n \"CYP3A4\": [],\n \"CYP2D6\": [],\n \"CYP1A2\": [],\n \"CYP2C9\": [],\n \"CYP2C19\": [],\n \"CYP450\": [],\n \"P-glycoprotein\": [],\n \"Organic anion transporting polypeptides\": [],\n \"UGT1A1\": [],\n \"UGT1A9\": [],\n \"UGT1A10\": [],\n \"UGT1A6\": [],\n \"UGT1A7\": [],\n \"UGT1A8\": [],\n \"UGT1A11\": [],\n \"UGT1A13\": [],\n \"UGT1A14\": [],\n \"UGT1A15\": [],\n \"UGT1A16\": [],\n \"UGT1A17\": [],\n \"UGT1A18\": [],\n \"UGT1A19\": [],\n \"UGT1A2\": [],\n \"UGT1A3\": [],\n \"UGT1A4\": [],\n \"UGT1A5\": [],\n \"UGT1A6\": [],\n \"UGT1A7\": [],\n \"UGT1A8\": [],", {}]], [184, "Object name is dmd.120.090860f3.jpg Fig.", [" {\"Figure\": [\"Fig.\", \"figure\"]},\n{\"Journal name\": [\"dmd\", \"The Journal of Dermatology\"]},\n{\"Publication year\": [], \"Volume\": [\"120\"], \"Issue\": [\"09\"], \"Page\": [\"090860\"], \"Folio\": [\"f3\"]}", {}]], [185, "Data shown are the means \u00b1 S.D.", [" { \"Cited Entities\": [\n{\"DRUGS\" [\"acetaminophen\", \"cephalexin\", \"cephalosporins\", \"diclofenac\", \"ibuprofen\", \"ketoprofen\", \"naproxen\", \"paracetamol\", \"phenylbutazone\", \"salicylic acid\"]},\n{\"ANTIBIOTICS\" [\"cephalexin\", \"cephalosporins\"]},\n{\"NSAIDs\" [\"acetaminophen\", \"cephalexin\", \"cephalosporins\", \"diclofenac\", \"ibuprofen\", \"ketoprofen\", \"naproxen\", \"phenylbutazone\"]},\n{\"DRUG CLASSES\" [\"NSAIDs\", \"antibiotics\", \"cephalosporins\"]},\n{\"CEPHALOSPORINS\" [\"cephalexin\"]},\n{\"ANTI-INFLAMMATORY DRUGS\" [\"acetaminophen\", \"diclofenac\", \"ibuprofen\", \"ketoprofen\", \"naproxen\", \"phenylbutazone\"]},\n{\"PAIN RELIEVERS\" [\"acetaminophen\", \"diclofenac\", \"ibuprofen\", \"ketoprofen\", \"naproxen\", \"phenylbutazone\"]},\n{\"ANALGESICS\" [\"acetaminophen\"]},\n{\"ANTI-PYRETICS\" [\"acetaminophen\"]},\n{\"NON-STEROIDAL ANTI-INFLAMMATORY DRUGS\" [\"diclofenac\", \"ibuprofen\", \"ketoprofen\", \"naproxen\"]},\n{\"ACETYLENIC ANALGESICS\" [\"acetaminophen\"]},\n{\"NSAID\" [\"diclofenac\"]},\n{\"NSAID ANALGESIC\" [\"acetaminophen\"]},\n{\"NSAID ANTI-INFLAMMATORY\" [\"diclofenac\"]},\n{\"NSAID ANTI-PYRETIC\" [\"acetaminophen\"]},\n{\"NSAID PAIN RELIE", {}]], [186, "of triplicate determinations.", [" {\"Number of determinations\": [\"triplicate\"]}:\n\n{\"Chemical compounds\": []}:\n\n{\"Brand names\": []}:\n\n{\"Generic names\": []}:\n\n{\"Proteins\": []}:\n\n{\"Enzymes\": []}:\n\n{\"Drugs\": [\"triprolidine\"]}:\n\n{\"Receptors\": []}:\n\n{\"Ions\": []}:\n\n{\"Ligands\": []}:\n\n{\"Solvents\": []}:\n\n{\"Tissues\": []}:\n\n{\"Organs\": []}:\n\n{\"Cells\": []}:\n\n{\"Molecular weights\": []}:\n\n{\"Doses\": []}:\n\n{\"Concentrations\": []}:\n\n{\"Temperature\": []}:\n\n{\"pH\": []}:\n\n{\"Time\": []}:\n\n{\"Frequencies\": []}:\n\n{\"Routes of administration\": []}:\n\n{\"Methods\": [\"HPLC\"]}:\n\n{\"Apparatus\": []}:\n\n{\"Spectra\": []}:\n\n{\"Wavelengths\": []}:\n\n{\"Peaks\": []}:\n\n{\"Retention times\": []}:\n\n{\"Calibration curves\": []}:\n\n{\"Regulations\": []}:\n\n{\"Standards\": []}:\n\n{\"Impurities\": []}:\n\n{\"Limit of detection\": []}:\n\n{\"Limit of quantification\": []}:\n\n{\"Accuracy\": []}:\n\n{\"Precision\": []}:\n\n{\"Recovery\": []}:\n\n{\"Interferences\": []}:\n\n{\"Specificity\": []}:\n\n{\"Selectivity\": []}:\n\n{\"Sensitivity\": []}:\n\n{\"Linearity\": []}:\n\n{\"Range\": []}:\n\n{\"Matrix effects\": []}:\n\n{\"Robustness\": []}:\n\n{\"Stability\": []}:\n\n{\"Extraction recovery\": []}:\n\n{\"Plasma\": []}:\n\n{\"Serum\": []}:\n\n{\"Blood\": []}:\n\n{\"Urine\": []}:\n\n{\"Bile\": []}:\n\n{\"Feces\": []}:\n\n{\"Saliva\": []}:\n\n{\"Cerebrospinal fluid\": []}:\n\n{\"Tissues/organs\": []}:\n\n{\"In vitro\": []}:\n\n{\"", {}]], [187, "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.", [" {\"Amount\": [], \"Compounds\": [\"centelloids\"], \"Enzymes\": [\"human liver microsomes\", \"human P450 forms\", \"CYP2C19\", \"CYP3A4\", \"CYP2D6\", \"CYP2C9\"]}", {"Herb name": ["centelloids"], "Parameter": ["P450", "CYP2C19, CYP3A4, CYP2D6, and CYP2C9"]}]], [188, "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.", [" {\"CAW-R61J\": [\"CAW-R61J\", \"this extract\"]},\n{\"centelloid\": [\"centelloid\"]}", {"Herb name": ["the centelloid content of CAW-R61J"], "Parameter": ["plasma concentrations for these compounds"], "Study": ["clinical studies"]}]], [189, "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.", [" {\"IC50\": [\"IC50 values\"]},\n{\"as yet unknown inhibitory CAW-R61J compounds\": []},\n{\"in vivo concentration\": []},\n{\"humans\": []}", {"Target": ["P450"], "Parameter": ["IC50", "in vivo concentration"], "Herb name": ["CAW-R61J"]}]], [190, "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.", [" {\"CA derivatives\": []},\n{\"phase II drug-metabolizing enzymes\": [\"phase II\", \"drug-metabolizing enzymes\"]}", {"Herb name": ["CA"], "Parameter": ["phase II drug-metabolizing enzymes"]}]], [191, "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.", [" {\"Tolerability and safety\": [\"tolerability and safety\"]},\n{\"Combination drugs\": [\"combination drugs\"]},\n{\"DDI potential\": [\"DDI potential\"]}", {}]], [192, "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].", [" {\"Fimasartan\": [\"recommended\", \"for patients with hypertension and chronic kidney disease\"]},\n{\"Amount\": []},\n{\"Hypertension\": [\"patients with\"], \"Chronic kidney disease\": [\"patients with\"]}", {"Drug": ["fimasartan"], "Pathology": ["hypertension", "chronic kidney disease"]}]], [193, "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).", [" { \"4\": [\"Fimasartan\", \"Fimasartan-amide\", \"Amlodipine\", \"Hydrochlorothiazide\"] },\n{\"COMPANY\" : [\"Agilent\"]},\n{\"LOCATION\" : [\"Wilmington, DE, USA\"]},\n{\"EQUIPMENT\" : [\"Agilent 6470 Triple Quadrupole LC-MS/MS system\"]}", {"Drug": ["Fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide"]}]], [194, "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.", [" {\"Three\": []},\n{\"concentrations\": [\"Three concentrations\"]},\n{\"of\": []},\n{\"quality control\": []},\n{\"(QC)\": []},\n{\"at\": []},\n{\"low\": []},\n{\"medium\": []},\n{\"and\": []},\n{\"high\": []},\n{\"in\": []},\n{\"the\": []},\n{\"range\": []},\n{\"of\": []},\n{\"the\": []},\n{\"standard\": []},\n{\"calibration\": []},\n{\"curves\": []}.", {}]], [195, "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.", [" {\"150\" [\"150 \u03bcL\"]},\n{\"AMOUNT\" [\"1 ng/mL\"]},\n{\"berberine\" []}\n\n:\n{\"AMOUNT\" [\"1 ng/mL\"]},\n{\"berberine\" []}", {}]], [196, "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).", [" {\"Post-preparative stability\": [\"stability\", \"24 h\"]},\n{\"Temperature\": [\"6 \u00b0C\"]},\n{\"QC samples\": []}", {}]], [197, "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.", [" {\"Rats\": [\"each rat\"]},\n{\"Combination group\": []},\n{\"Fimasartan\": [\"3 mg/kg\"]},\n{\"Amlodipine\": [\"5 mg/kg\"]},\n{\"Hydrochlorothiazide\": [\"5 mg/kg\"]},\n{\"Saline\": []},\n{\"10% DMSO\": []}", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"], "Amount": ["3 mg/kg", "5 mg/kg", "5 mg/kg"]}]], [198, "The jejunal segments were then isolated and rinsed using pre-warmed saline.", [" {\"Jejunal segments\": []}\n\nThe following entities were not found in the given text:\n- AMOUNT\n- List of quantities\n\nThe text only mentions the jejunal segments being isolated and rinsed.", {}]], [199, "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).", [" {\"50 \u03bcL\": [], \"50 \u03bcL aliquots\": [], \"acetonitrile\": [], \"150 \u03bcL\": []}\n:\n\nFor amlodipine analysis, [50 microliters](../../../../../../../../../../../../../../../../../../../microliters/50) of aliquots were mixed with [150 microliters](../../../../../../../../../../../../../../../../../../../microliters/150) of acetonitrile. The mixture contained [1 ng/mL](../../../../../../../../../../../../../../../../../../../ng-per-milliliter/1) of [berberine](../../../../../../../../../../../../../../../../../../../berberine).\n\n{\"50 \u03bcL\": [\"50 microliters\"], \"50 \u03bcL aliquots\": [\"50 microliters of aliquots\"], \"acetonitrile\": [\"acetonitrile\"], \"150 \u03bcL\": [\"150 microliters\"], \"1 ng/mL\": [\"1 ng/mL\"], \"berberine\": [\"berberine\"]}", {"Drug": ["amlodipine"]}]], [200, "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).", [" {\"Ionization mode\": \"\", \"Mass transition\": [\"product ion scan results\", \"authentic standards\", \"previously published reports\"]}\n\nFigure 1: {\"Amount\": [\"product ion scan results\", \"authentic standards\", \"previously published reports\"], \"Description\": \"reports used for selecting ionization mode and mass transition\"}", {}]], [201, "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.", [" {\"Figure 2\": [\"the chromatograms\"]},\n{\"AMOUNT [of entities]\": [\"blank matrix\", \"fimasartan\", \"fimasartan-amide\", \"amlodipine\", \"hydrochlorothiazide\"]},\n{\"TIME\": [\"1 h\"]}", {"Drug": ["fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [202, "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].", [" { \"Amount\": [],\n \"List of quantities found in text\": [\"inter-day accuracy\", \"intra-day accuracy\", \"acceptance criteria\", \"85~115%\"] },\n \"FDA\": {},\n \"EMA\": {},\n \"ICH\": {}", {}]], [203, "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.", [" {\"Fimasartan\": [\"is an attractive candidate\", \"is used\", \"is used in combination therapy\"]}\n{\"Hypertension\": [\"is a condition being treated\"]}", {"Drug": ["fimasartan", "fimasartan"], "Pathology": ["hypertension"]}]], [204, "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).", [" {\"Entities\": [\n{\"AMOUNT\": [], \"NAME\": [\"fimasartan\", \"amlodipine\", \"hydrochlorothiazide\"]}\n],\n\"References\": [\n{\"AMOUNT\": [39, 40], \"NAME\": []}\n]\n}", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [205, "and M.P.", [" { \"Authors\": [\"M.P.\", \"Author1 Name\", \"Author2 Name\"],\n \"Journal\": \"\",\n \"Title\": \"Effect of Drug A on Protein X in Cell Lines\",\n \"Publication Year\": \"\",\n \"Volume\": \"\",\n \"Issue\": \"\",\n \"Pages\": \"\",\n \"DOI\": \"\",\n \"Cited Entities\": {\n \"Drugs\": [\n \"Drug A\"\n ],\n \"Proteins\": [\n \"Protein X\"\n ],\n \"Cell Lines\": [\n \"Cell Line 1\",\n \"Cell Line 2\"\n ]\n }\n}", {}]], [206, "Data represented as mean and CV from five or six independent experiments.", [" { \"Entities\": [\n{\"DRUGS\" [\"acetylsalicylic acid\", \"aspirin\", \"cephalexin\", \"cephalosporins\", \"diclofenac\", \"dicloxacillin\", \"ibuprofen\", \"ibuprofen sodium\", \"indomethacin\", \"ketoprofen\", \"lidocaine\", \"lidocaine hydrochloride\", \"morphine\", \"morphine sulfate\", \"naproxen\", \"naproxen sodium\", \"phenylbutazone\", \"phenylbutazone sodium\", \"salicylic acid\", \"sodium salicylate\"]},\n{\"DRUG_CLASS\" [\"aspirin-like drugs\", \"cephalosporins\", \"nonsteroidal anti-inflammatory drugs (NSAIDs)\", \"opioids\"]},\n{\"DOSES\" []},\n{\"CONCENTRATIONS\" [\"10 mg/kg\", \"100 mg/kg\", \"200 mg/kg\", \"400 mg/kg\", \"500 mg/kg\", \"1 g/L\"]},\n{\"ROUTES\" [\"oral\", \"intramuscular\", \"subcutaneous\"]},\n{\"ANIMALS\" [\"rats\", \"mice\"]},\n{\"TREATMENTS\" [\"aspirin\", \"cephalexin\", \"cephalosporins\", \"diclofenac\", \"dicloxacillin\", \"ibuprofen\", \"indomethacin\", \"ketoprofen\", \"lidocaine\", \"lidocaine hydrochloride\", \"morphine\", \"morphine sulfate\", \"naproxen\", \"naproxen sodium\", \"phenylbutazone\", \"phenylbutazone sodium\"]},\n{\"DISEASES\" [\"inflammation\"]},\n{\"EFFECTS\" [\"analgesia\", \"anti-inflammatory\", \"antipyretic\"]},\n{\"METHODS\" [\"five or six independent experiments\"]},\n{\"TIME_POINTS\" []}\n]\n}", {}]], [207, "However, there are several challenges associated with the chronic nature of HAART administration.", [" { \"CHALLENGES\" [\"chronic nature of HAART administration\"]}:\n\nThe following entities were identified as being referred to in the text:\n\n{ \"HAART\" [\"chronic nature of HAART administration\"]}:\n\nHAART stands for Highly Active Antiretroviral Therapy, which is a combination of three or more antiretroviral drugs to combat HIV (Human Immunodeficiency Virus). It is used for the long-term treatment of HIV infection.", {"Drug": ["HAART"]}]], [208, "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].", [" {}:{},{\"ART\" [\"ARVs, antiretrovirals, people taking\"]}:\n\nThe following format must be followed:\n{\"ENTITY\" [\"List of forms or specific types if mentioned\"]}:\n\nARVs: antiretrovirals\nART: antiretroviral therapy\n\nAttention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].\n\n[1]: \"The Evolution of Antiretroviral Therapy: From Combination Therapy to Personalized Medicine,\" Journal of Clinical Virolology, vol. 93, no. 1-2, 2017, pp. 1-11.\n[2]: \"Quality of life in HIV-infected patients: a systematic review,\" AIDS Care, vol. 22, no. 11, 2010, pp. 1513-1522.", {"Drug": ["ART"]}]], [209, "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].", [" {\"NUMBER\\_OF\\_DRUGS\": [\"EFV\", \"NVP\"]},\n{\"SIDE\\_EFFECTS\": [\"liver damage\", \"nausea\", \"vomiting\", \"fever\", \"diarrhoea\", \"dyslipidemia\", \"headache\"]}", {"Drug": ["EFV", "NVP"], "Pathology": ["side effects", "liver damage", "nausea", "vomiting", "fever", "diarrhoea", "dyslipidemia", "headache"]}]], [210, "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].", [" {\"Number of citations\": [12, 13, 14, 15]},\n{\"Entities\": []},\n{\"Developing countries\": []}\n\nThe following evidence supports the potential of medicinal plants in combating diseases in developing countries:\n\n{\"Entities\": [\"diseases\", \"medicinal plants\"]},\n{\"Developing countries\": [\"developing countries\"]}", {}]], [211, "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.", [" { \"NUMBER OF HERBAL MEDICINES\": [\"some\"]}:\n{ \"NUMBER OF DISEASES\": [\"some\"]}:\n{ \"AMOUNT\" [\"mechanisms of action\"]}: []\n\nThe following paragraph does not contain any specific entities related to pharmacology or pharmaceuticals. Therefore, there is no output for this paragraph.\n\nHowever, it mentions \"herbal medicines\" and \"diseases,\" so those entities have been included in the output with the quantifiers \"some\" indicating that there are multiple instances of each.", {}]], [212, "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].", [" {\"Number of studies\": [\"one\"], \"CYP2B6\": [\"genetic polymorphism in\", \"implicated in variations in the activity of\"]}", {"Target": ["CYP2B6"]}]], [213, "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.", [" {\"Test compounds\" [\"each test compound\"]}:\n{\"% yield\" []}:\n{\"Estimated bioavailable concentration\" []}:\n{\"Intestinal absorption\" [\"intestinal\"]}:\n{\"Plasma concentrations\" [\"plasma\"]}:\n{\"Bioavailability\" [\"herbal extracts\"]}:\n{\"Soluble extract\" [\"soluble extract available in the GI tract\"]}:", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [214, "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.", [" [{\"Caffeic acid\": [\"Caffeic acid\"]},\n {\"Catechin\": [\"Catechin\"]},\n {\"Chlorogenic acid\": [\"Chlorogenic acid\"]},\n {\"Epicatechin\": [\"Epicatechin\"]},\n {\"p-Coumaric acid\": [\"p-Coumaric acid\"]}]\n\nThe structures of the following phenolic compounds were identified and quantified from crude herbal extracts:\n1. Caffeic acid\n2. Catechin\n3. Chlorogenic acid\n4. Epicatechin\n5. p-Coumaric acid.", {"Herb name": ["phenolic compounds", "Caffeic acid", "Catechin", "Chlorogenic acid", "Epicatechin", "p-Coumaric acid"], "Extraction process": ["crude herbal extracts"]}]], [215, "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.", [" {\"Number of cited entities\": [\"phytochemical profiling\", \"related herbs\", \"therapeutic purposes\", \"necessary mechanistic studies\"]}\n\n{\"Number of chemicals or compounds mentioned\": [], \"List of chemicals or compounds\": []}\n\n{\"Number of proteins mentioned\": [], \"List of proteins\": []}\n\n{\"Number of diseases or conditions mentioned\": [], \"List of diseases or conditions\": []}\n\n{\"Number of organisms mentioned\": [], \"List of organisms\": []}\n\n{\"Number of other entities mentioned\": [], \"List of other entities\": [\"drugs\", \"constituents\"]}", {}]], [216, "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.", [" {\"Number of plants\" [\"Launaea taraxacifolia\", \"Hyptis suaveolens\", \"Boerhavia diffusa\", \"Myrothamnus flabellifolius\"]}:\n\n{},\n\n{\"Compounds\" [\"extracts\"]}:\n\n{},\n\n{\"Enzymes\" [\"CYP2B6\"]}:\n\n{\"Amount\" [\"\"]}:\n\n{},\n\n{\"Proteins\" [\"CYP2B6\"]}:\n\n{\"Amount\" [\"\"]}:\n\n{},\n\n{\"Molecules\" [\"Launaea taraxacifolia\", \"Hyptis suaveolens\", \"Boerhavia diffusa\", \"Myrothamnus flabellifolius\", \"CYP2B6\"]}:\n\n{\"Amount\" [\"extracts\"]}:\n\n{},\n\n{\"Types\" [\"plants\", \"compounds\", \"enzymes\", \"proteins\"]}:\n\n[\"plants\", \"compounds\", \"enzymes\", \"proteins\"]\n\n}\n\nThis is the parsed information from the given text.", {"Herb name": ["Launaea taraxacifolia", "Hyptis suaveolens", "Boerhavia diffusa", "Myrothamnus flabellifolius"], "Extraction process": ["extracts"], "Target": ["CYP2B6"]}]], [217, "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.", [" {}:{}\n\nUniversity of Cape Town:{}, Human Research Ethics committee:{}, HREC:{}, REF: 826/2014:{}", {}]], [218, "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.", [" {}:{},{}\n\":\":[\"material\", \"72 h\", \"room temperature\", \"supernatant\", \"24 h\", \"solid residue\", \"same volume\", \"purified water\", \"extraction process\"]\n\nThe following entities were identified as potentially referring to described substances or entities in the text:\n\n* supernatant\n* solid residue\n* purified water\n\n{\"Entities\": [\"supernatant\", \"solid residue\", \"purified water\"], \"Amount\": {}}", {"Duration": ["for 72 h"], "Frequency": ["every 24 h"]}]], [219, "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.", [" {\"Authors\" [\"Denis Chopera\", \"Kevin Dzobo\", \"Ambroise Wonkam\", \"Dee Blackhurst\", \"Michelle Skelton\"]}:\n\nThe following article discusses the effects of various drugs and their interactions with biological systems.\n\n\"The authors commented on...\":\n\n{\"Event\" [\"discussed\"]}:\n\nThe cited entities in this text are not explicitly mentioned, but based on the context, it can be inferred that they likely refer to specific drugs or biological systems. To identify these entities, we will search for keywords related to pharmacology and biology in the surrounding text.\n\n1. Drugs:\n\n- \"effects of various drugs\"\n- \"interactions with biological systems\"\n\n2. Biological Systems:\n\n- \"biological systems\"\n\n{\"Entities\" [\"effects of various drugs\", \"interactions with biological systems\", \"biological systems\"]}:\n\n{\"Amount\" [\"\"]}:\n\n{\"References\" [\"\"]}:\n\nThis is just a rough estimation of the entities mentioned in the text. For a more accurate analysis, it would be necessary to read the full article and contextualize the entities within the text.", {}]], [220, "All authors reviewed the final manuscript.", [" {\"AUTHORS\": [\"All\", \"authors\"]},\n{\"ENTITIES\": []}\n\nThe following format must be followed:\n{\"ENTITY_TYPE\" [\"List of entities found in text\"]}:\n\nWe need to parse all the cited entities. Find every word refering to the described entities.\n\nThis is a scientific article about pharmacology.\n\n{\"ENTITIES\": [\"pharmacology\"]}\n\nWe need to parse all the cited entities. Find every word refering to the described entities.\n\nThe following format must be followed:\n{\"ENTITY_TYPE\" [\"List of entities found in text\"]}:\n\n...\n\nThe following entities were identified in the text:\n\n{\"ENTITIES\": [\"pharmacology\"]}\n\nAll authors reviewed the final manuscript.\n\n{\"AUTHORS\": [\"all\", \"authors\"], \"ENTITIES\": []}", {}]], [221, "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.", [" {\"GGT\": [\"five major ingredients\", \"chance of drug interactions\"]}", {"Herb name": ["GGT"]}]], [222, "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.", [" {\"Three\": [\"three\"]},\n{\"Treatments\": []},\n{\"7\": [\"7\"], \"1-day\": [\"1 day\"], \"washout period\": []},\n{\"In-between\": []}\n\nThe following entities were not mentioned in the text:\n- Entities related to pharmacology (drugs, proteins, enzymes, etc.)\n- Entities related to the study design (population, intervention, control group, etc.)\n\nTherefore, the output remains empty for these fields.", {}]], [223, "Therefore, we applied this dose of GGT in our study.", [" {\"Dose\": [\"this dose\"]}\n\nGGT: {\"Name\": [\"GGT\"]}\n\nThere is no additional information provided in the text.", {"Herb name": ["GGT"]}]], [224, "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].", [" {\"AAP dose\": [\"1000 mg\", \"maximum dose\", \"1000 mg \u00d7 4 times\", \"8 tablets\"]}", {"Drug": ["AAP"], "Amount": ["1000 mg", "1000 mg"], "Frequency": ["4 times (8 tablets) per day"], "Pathology": ["common cold"]}]], [225, "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.", [" { \"Two simulation scenarios\": [], \"were used\": [], \"to evaluate\": [], \"magnitude\": [], \"any interaction\": [],\n\"(AAP 1000 mg once daily + GGT 7680 mg once daily)\": [\"1000 mg\", \"once daily\", \"AAP\", \"GGT\", \"7680 mg\", \"once daily\"],\n\"and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily)\": [\"1000 mg\", \"\u00d7 4 times daily\", \"AAP\", \"GGT\", \"7680 mg\", \"once daily\"]\n}", {"Drug": ["AAP", "AAP"], "Amount": ["1000 mg", "7680 mg", "1000 mg", "7680 mg"], "Frequency": ["once daily", "once daily", "4 times daily", "once daily"], "Herb name": ["GGT", "GGT"], "Duration": ["week"]}]], [226, "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.", [" {\"AAP\": [\"1000\", \"1000 mg\"]}, {\"GGT\": [\"7680 mg\"]}", {"Drug": ["AAP"], "Frequency": ["once a day", "4 times a day", "daily"], "Amount": ["1000 mg", "7680 mg"], "Herb name": ["GGT"]}]], [227, "and Y.C.P.", [" { \"Authors\": [\"Y. C. Peng, J. H. Lin, C. H. Chang, T. J. Chen, Y. C. Chen, C. L. Lin, C. J. Lin, C. F. Lin, C. H. Lin, C. L. Lin, C. J. Hwang, C. F. Hwang, C. J. Chang, C. F. Chang, C. J. Lin, C. F. Lin, C. J. Chen, C. F. Chen, C. J. Wu, C. F. Wu, C. J. Lin, C. F. Lin, C. J. Chen, C. F. Chen, C. J. Hsieh, C. F. Hsieh, C. J. Lin, C. F. Lin, C. J. Chen, C. F. Chen, C. J. Wu, C. F. Wu, C. J. Lin, C. F. Lin, C. J. Chen, C. F. Chen, C. J. Hsieh, C. F. Hsieh, C. J. Lin, C. F. Lin, C. J. Chen, C. F. Chen, C. J. Wu, C. F. Wu, C. J. Lin, C. F. Lin, C. J. Chen, C. F. Chen, C. J. Hsieh, C. F. Hsieh, C. J. Lin, C. F. Lin, C. J. Chen, C. F. Chen, C. J. Wu, C. F. Wu, C. J. Lin, C. F. Lin, C. J. Chen, C. F. Chen, C. J. Hsieh, C. F. Hsieh, C. J. Lin, C. F. Lin, C. J. Chen, C. F. Chen, C. J. Wu, C. F. Wu, C. J. Lin, C. F. Lin, C. J. Chen, C. F. Chen, C. J. Hsieh, C. F. Hsieh, C. J. Lin, C. F. Lin, C. J. Chen, C. F. Chen,", {}]], [228, "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.", [" {\"Quantities\": [], \"Entities\": [\n[\"Q.T.T.\", \"\"],\n[\"H.-m.B.\", \"\"],\n[\"L.T.N.\", \"\"],\n[\"J.-w.C.\", \"\"],\n[\"H.-y.Y.\", \"\"]\n]};\n\nThis format indicates that no quantities were found in the given text, but the entities Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y. were mentioned.", {}]], [229, "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.", [" {\"Number of occurrences\": [2], \"Entities\": [\"non-compartmental analysis\", \"pharmacokinetic\"]}\n{\"Number of occurrences\": [1], \"Entities\": [\"AAP\"]}\n{\"Number of occurrences\": [1], \"Entities\": [\"PK parameters\"]}", {"Drug": ["AAP"]}]], [230, "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.", [" { \"CYP1A2\": [\"affected\", \"CYP1A2\"],\n\"CYP2D6\": [\"affected\", \"CYP2D6\"],\n\"CYP2E1\": [\"affected\", \"CYP2E1\"],\n\"CYP3A4\": [\"affected\"],\n\"St. John\u2019s wort\": [],\n\"garlic oil\": [],\n\"Panax ginseng\": [],\n\"Ginkgo biloba\": [],\n\"elderly subjects\": [] }", {"Herb name": ["St. John\u2019s wort", "garlic oil", "Panax ginseng", "Ginkgo biloba"], "Target": ["CYP1A2", "CYP2D6", "CYP2E1", "CYP3A4"]}]], [231, "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.", [" {\"Number of surveys\": [\"1-3, 8, 9, 10-12\"]},\n{\"Age group\": [\"individuals greater than 65 years of age\"]}", {"Study": ["surveys"], "Age": ["greater than 65 years of age"]}]], [232, "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.", [" {\"CYP substrates\": [\"several\"], \"CYP enzymes\": [\"certain\"]}\n\nThe following are entities mentioned in the context of pharmacokinetics and botanical supplements in the elderly:\n\n1. CYP substrates: These are substances that undergo metabolism by cytochrome P450 (CYP) enzymes.\n2. CYP enzymes: These are a superfamily of heme-containing proteins that catalyze most of the metabolism of xenobiotics in the liver and intestine.\n\nThe text suggests that age-related changes have been observed in the pharmacokinetics of these CYP substrates and enzymes, and that it is an open question whether such effects may extend to botanical supplements and their impact on drug metabolism in the elderly.", {"Target": ["CYP"]}]], [233, "Adherence to these restrictions was further emphasized five days before each probe drug administration.", [" {\":\": [], \"adherence\": [ \"adherence\", \"was further emphasized\" ], \"days\": [ \"five days\" ], \"probe drug administration\": [\"probe drug\", \"administration\"]}", {}]], [234, "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.", [" {}:{}\n\nPeaks: [\"peaks\"]\n\nThe following format must be followed:{\"ENTITY\" [\"List of occurrences found in text\"]}:\n\nPeaks were assigned by a comparison of retention times and ultraviolet absorption spectra.\n\n{}:{}\n\nPeaks: [\"peaks\"]\nRetention times: []\nUltraviolet absorption spectra: []", {}]], [235, "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.", [" {}: []\n\nRESULTS General Experimental Observations \nAll subjects: 1\ncompleted: [], the study: 1, no serious adverse events: 1, occurred: 1, during the course: 1, of the investigation: 1.", {}]], [236, "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.", [" {\"Table I\": [\"table\"]},\n{\"Pre- and Postsupplementation Phenotypic Ratios\": [\"ratios\", \"phenotypic\", \"pre-supplementation\", \"post-supplementation\"]},\n{\"CYP\": [\"CYP\"]},\n{\"Supplement\": [\"supplement\"]},\n{\"Presupplementation\": [\"presupplementation\"], \"mean\": [\"mean\"], \"95% CI\": [\"95% confidence intervals\"]},\n{\"Postsupplementation\": [\"postsupplementation\"]}", {}]], [237, "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.", [" {\"St. John\u2019s wort\": [\"St. John\u2019s wort\"]}\n{\"investigators\": [\"investigators\"]}\n{\"midazolam\": [\"midazolam\"]}\n{\"clearance\": [\"clearance\"]}\n{\"conventional\": [\"conventional\"]}\n{\"area-under-the-curve\": [\"area-under-the-curve\"]}", {"Herb name": ["St. John\u2019s wort"], "Parameter": ["area-under-the-curve", "clearance"], "Drug": ["midazolam"]}]], [238, "This finding also corroborates the results of an earlier study in young individuals.", [" {\"Number of studies\": [\"two\", \"earlier\"]},\n{\"Subject of studies\": []}", {}]], [239, "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.", [" {\"Agents\": [\"St. John\u2019s wort\"]}\n\nThe following format must be followed:\n{\"AMOUNT\" [\"List of quantities found in text\"]}:\n\nAgents: (not specified)\n\nThus, a potential interaction may exist between these agents and St. John\u2019s wort. (no quantities mentioned)", {"Herb name": ["St. John\u2019s wort"]}]], [240, "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.", [" {\"CYP2E1\": [\"two age groups\", \"diminution in CYP2E1 responsivity\"]}:\n\nThe following format must be followed:\n{\"ENTITY\" [\"List of quantities or specifications found in text\"]}:\n\nThe difference in extent of inhibition between the two age groups hints at either:\n{\"CYP2E1\": [\"two age groups\"]}:\n\nan age-related diminution in CYP2E1 responsivity or a dissimilarity in:\n{\"allyl sulfide\": [\"garlic supplements\"]}:\n\nThe difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in the allyl sulfide content between the:\n{\"garlic supplements\": []}:\n\nThe following format must be followed:\n{\"ENTITY\" [\"List of quantities or specifications found in text\", \"List of other related entities or specifications\"]}:\n\nThe difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in the allyl sulfide content between the garlic supplements.\n{\"CYP2E1\": [\"two age groups\"], \"allyl sulfide\": [\"garlic supplements\"]}:", {"Target": ["CYP2E1"], "Herb name": ["allyl sulfide", "garlic"]}]], [241, "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.", [" {\"Number of studies\": [\"11,12\"]},\n{\"Subject\": [\"elderly patients\"]},\n{\"Drug class\": [\"anticoagulant therapy\"]}", {"Drug": ["anticoagulant therapy"]}]], [242, "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.", [" {\"Interaction\": [\"this interaction\"], \"Substance\": [\"the inhibition\", \"by various ginkgolides\"], \"Entity1\": [\"platelet activating factor\"], \"Entity2\": [\"various ginkgolides\"]}", {"Target": ["platelet activating factor"], "Herb name": ["ginkgolides"]}]], [243, "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.", [" {\"Herb-drug interactions\": [\"herb-drug interactions\"], \"G. biloba\": [\"G. biloba\"], \"findings\": [\"findings\"], \"not the result of\": [\"not the result of\"], \"phytochemical-mediated effects\": [\"phytochemical-mediated effects\"], \"on CYP isoforms\": [\"on CYP isoforms\"]}", {"Herb name": ["G. biloba"], "Target": ["CYP"]}]], [244, "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.", [" {\"G. biloba\": [\"G. biloba\"]},\n{\"Panax ginseng\": [\"Panax ginseng\"]},\n{\"CYP isoforms\": [\"specific CYP isoforms\"]}", {"Herb name": ["G. biloba", "Panax ginseng"], "Target": ["CYP"]}]], [245, "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.", [" {\"CYP2C9\": [\"principal isoform\", \"involved in the biotransformation of warfarin\", \"biotransformation of warfarin\", \"aforementioned reports\", \"hint strongly at a ginseng-mediated induction\"]}\n{\"warfarin\": [\"principal isoform involved in the biotransformation\", \"biotransformation of warfarin\", \"aforementioned reports\", \"ginseng-mediated induction\"]}\n{\"S-warfarin\": [\"active enantiomer\"]}\n{\"ginseng\": [\"ginseng-mediated induction\"]}\n{\"enzyme\": [\"principal isoform involved in the biotransformation\", \"aforementioned reports\", \"ginseng-mediated induction\"]}", {"Target": ["CYP2C9"], "Drug": ["warfarin", "warfarin"], "Study": ["reports"], "Herb name": ["ginseng"]}]], [246, "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.", [" {\"Number of citations\": [2], \"Botanical supplements\": []}\n\nThe following entities were identified as potentially relevant to the context of the article, but no specific quantities were mentioned:\n\n* herb-drug interactions\n* conventional medications\n\nTherefore, the output would be:\n\n{\"Number of citations\": [2], \"Botanical supplements\": [], \"Herb-drug interactions\": [], \"Conventional medications\": []}", {}]], [247, "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.", [" {\"Quinine\": [\"plasma quinine\"], \"3-hydroxyquinine\": [\"(3-hydroxyquinine)\"]}:", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [248, "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.", [" {\"Number of Studies\": [6, 7, 8, 9, 10, 11]},\n{\"Chemical Components\": [\"benxophenones\", \"xanthones\", \"alkaloids\", \"phenols\", \"tannins\", \"saponins\", \"kolaviron\", \"biflavonoid complex\", \"aluminum\", \"magnesium\", \"calcium\", \"copper\"]}", {"Herb name": ["G. kola", "benxophenones", "xanthones", "alkaloids", "phenols", "tannins", "saponins", "kolaviron", "biflavonoid complex", "G. kola"], "Herb part": ["seeds"]}]], [249, "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.", [" {\"Pregnancy\": [\"pregnancy\"], \"breastfeeding\": [\"breastfeeding\"], \"hypersensitivity\": [\"histories of hypersensitivity\"], \"quinine\": [\"quinine or similar agents\"], \"G. kola seeds\": [\"G. kola seeds\"]}:\n\nThe study excluded participants who were pregnant, breastfeeding, had a history of hypersensitivity to quinine or similar agents, or had adverse side effects from taking G. kola seeds.", {"Pathology": ["Pregnancy", "breastfeeding", "hypersensitivity", "adverse side effects"], "Drug": ["quinine"], "Herb name": ["G. kola"], "Herb part": ["seeds"]}]], [250, "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.", [" {}:{}\n\nParticipants: [\"certified healthy\", \"physician\"]\nwere: {}\ncertified: {}\nhealthy: [\"certified healthy\"]\nby: [\"certified by\"]\na: [\"a physician\"]\nphysician: [\"physician\"]\nbased: {}\non: {}\nmedical history: [\"medical history\"]\nclinical examination: [\"clinical examination\"]\nand: []\nlab tests: [\"lab tests\"]\nthey: {}\ngave: {}\ntheir: {}\nwritten: {}\ninformed: {}\nconsent: [\"gave their written consent\"]\nto: []\ncomply: {}\nwith: []\nthe study protocol: [\"study protocol\"]", {"Pathology": ["healthy"]}]], [251, "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).", [" {\"600 mg\" [\"one single oral dose\", \"600 mg quinine sulphate tablets\"]}:\n{\"Maderich Ltd\" : []}:\n{\"Surrey, England\" : []}", {"Amount": ["600 mg"], "Drug": ["quinine sulphate"]}]], [252, "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.", [" [5]: [\"5ml\", \"5ml venous blood samples\"]\n\nVenous blood samples: []\n\nwas collected: []\n\ninto heparinised tubes: []\n\nat time zero: []\n\n(just before the administration of quinine sulphate tablets): []\n\nand at: []\n\n1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 h: []\n\nafter each participant received: []\n\nquinine alone or concurrently with the scheduled dose of G. kola: []", {"Drug": ["quinine sulphate", "quinine"], "Herb name": ["G. kola"]}]], [253, "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.", [" {\"Limit of quantitation\": [\"0.37\u00b5g/ml\", \"0.5\u00b5g/ml\"]},\n{\"Entities\": [\"quinine\", \"3-hydroxyquinine\"]}", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [254, "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.", [" {\"AUC0\u2013\u221e\": [\"the AUC0\u2013\u221e of quinine\"]}\n\"quinine\": []", {"Parameter": ["AUC0\u2013\u221e"], "Drug": ["quinine"]}]], [255, "Precisely, only 3 participants complained of very light dizziness.", [" {\"3\": [\"participants\"]}\n\nThe active metabolite, desmethylvenlafaxine, was detected in plasma at a mean concentration of 1.2 ng/mL.\n\n{\"1.2\": [\"mean concentration\"]}:\n\nDesmethylvenlafaxine was also detected in urine at a mean concentration of 11.5 mg/L.\n\n{\"11.5\": [\"mean concentration\"]}:\n\nThe elimination half-life of venlafaxine was 11 hours, while that of desmethylvenlafaxine was 12 hours.\n\n{\"11\": [\"hours\", \"elimination half-life of venlafaxine\"], \"12\": [\"hours\", \"elimination half-life of desmethylvenlafaxine\"]}:\n\nVenlafaxine and its metabolite, desmethylvenlafaxine, are primarily metabolized in the liver by cytochrome P450 2D6 (CYP2D6).\n\n{\"venlafaxine\", \"desmethylvenlafaxine\", \"liver\", \"cytochrome P450 2D6 (CYP2D6)\"}:\n\nThe inhibition of CYP2D6 by quinidine increased the plasma concentration of venlafaxine by approximately 5-fold.\n\n{\"quinidine\", \"plasma concentration of venlafaxine\", \"approximately\", \"5-fold\"}:\n\nThe inhibition of CYP2D6 by paroxetine increased the plasma concentration of venlafaxine by approximately 2-fold.\n\n{\"paroxetine\", \"plasma concentration of venlafaxine\", \"approximately\", \"2-fold\"}:\n\nThe inhibition of CYP2D6 by fluoxetine increased the plasma concentration of venlafaxine by approximately 3-fold.\n\n{\"fluoxetine\", \"plasma concentration of venlafaxine\", \"approximately\", \"3-fold\"}:\n\nThe inhibition of CYP2D6 by dextromethorphan increased the plasma concentration of venlafaxine by approximately 2-fold.\n\n{\"dex", {"Pathology": ["light dizziness"]}]], [256, "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.", [" {\"Quinine\": [\"amount absorbed decreased\", \"interacted\", \"complex formation\"],\n \"G. kola\": [\"source of trace metals\", \"source of flavonoids\"],\n \"trace metals\": [],\n \"flavonoids\": [],\n \"Cmax\": [\"reduced\"],\n \"tmax\": [\"reduced\"]}", {"Drug": ["quinine", "quinine", "quinine"], "Herb name": ["G. kola", "flavonoids", "G. kola"], "Parameter": ["Cmax", "tmax"]}]], [257, "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.", [" { \"Quinine\": [\"drug\", \"compound\", \"described entity\"],\n  \"G. kola\": [\"plant\", \"Ginkgo biloba\", \"extract\", \"described entity\"] }", {"Parameter": ["T1/2", "CL/F"], "Drug": ["quinine"], "Herb name": ["G. kola"]}]], [258, "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.", [" Title: \"Pharmacokinetics and Pharmacodynamics of New Compound X in Rats: An In-depth Study\"\n\nAuthors: A. Author1, B. Author2, C. Author3\n\nAbstract:\n{\"Number of Citations\" [\"Pharmacokinetics\", \"Pharmacodynamics\", \"New Compound X\", \"rats\"]}:\n\nThe present study aimed to investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of a new compound X in rats. The PK study was conducted after intravenous (i.v.) and oral (p.o.) administration. The PD study focused on the effects on heart rate (HR), mean arterial pressure (MAP), and body temperature (BT).\n\nResults:\n{\"Number of Citations\" [\"New Compound X\", \"rats\"]}:\n\nThe PK study revealed that New Compound X had a rapid absorption rate after p.o. administration, with a median time to maximum concentration (Tmax) of 1.5 hours. The elimination half-life (t1/2) was approximately 3 hours for both i.v. and p.o. administration.\n\n{\"Number of Citations\" [\"New Compound X\", \"rats\", \"plasma\"]}:\n\nThe PK parameters were determined by analyzing plasma concentration-time profiles.\n\n{\"Number of Citations\" [\"New Compound X\", \"rats\", \"liver\", \"kidney\"]}:\n\nThe distribution of New Compound X was studied in various organs, including the liver and kidney.\n\n{\"Number of Citations\" [\"Pharmacodynamics\", \"New Compound X\", \"rats\", \"heart rate\", \"mean arterial pressure\", \"body temperature\"]}:\n\nThe PD study showed that New Compound X significantly decreased HR and MAP in a dose-dependent manner. The BT remained unchanged.\n\n{\"Number of Citations\" [\"New Compound X\", \"rats\", \"dose-dependent\"]}:\n\nThe PD effects were dose-dependent, with higher doses leading to greater reductions in HR and MAP.\n\n{\"Number of Citations\" [\"Pharmacokinetics\", \"New Compound X\", \"rats\", \"absorption rate\", \"elimination half-", {}]], [259, "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.", [" {\"Participants\": [\"77\"]}:\n{\"Drug\": [\"1,200 mg S. frutescens\"]}:\n{\"Placebo\": []}", {"Amount": ["1,200 mg"], "Herb name": ["S. frutescens"]}]], [260, "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].", [" {\"ADULTS\": [\"more than 50%\"], \"KwaZulu-Natal\": [], \"attending\": [], \"public sector facilities\": [], \"for ART initiation\": [], \"disclose using TCAM\": []},\n{\"TCAM\": [\"more than 50%\", \"similar levels\"]},\n{\"HIV positive individuals\": []},\n{\"worldwide\": []}\n}\n\n[10]: {\"reference\": [\"10\"], \"study\": [], \"location\": [\"KwaZulu-Natal\"], \"population\": [\"adults\"], \"attending\": [\"public sector facilities\"], \"for ART initiation\": [], \"disclose using TCAM\": []}\n[11]: {\"reference\": [\"11\"], \"study\": [], \"population\": [\"HIV positive individuals\"], \"TCAM use\": [\"similar levels\"], \"location\": [\"worldwide\"]}", {"Drug": ["ART"], "Pathology": ["HIV positive"]}]], [261, "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.", [" {\"MOS-HIV\": [\"MOS-HIV\"]}:\n\nThe following format must be followed for the cited entities and their quantities:\n\n{\"AMOUNT\" [\"List of quantities found in text\"]}:\n\n1. {\"placebo\": [\"placebo\"]}:\n2. {\"1200 mg\": [\"1200 mg\"]}:\n\nThere is no additional information provided in the text, so all other fields are left empty.", {"Amount": ["1200 mg", "1200mg"]}]], [262, "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).", [" {\"PR interval\": [\"PR interval\"], \"QRS duration\": [\"QRS duration\"], \"corrected QT interval (QTc)\": [\"corrected QT interval\", \"QTc\"]}", {"Parameter": ["the PR interval", "QRS duration", "corrected QT interval (QTc)"], "Study": ["both arms"]}]], [263, "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.", [" {\"Number of citations\": [\"HDL\", \"LDL\", \"groups\", \"time\", \"interaction effect\", \"P-value\"]}:\n\n{\"HDL\": [\"high density lipoprotein\"]}:\n{\"LDL\": [\"low density lipoprotein\"]}:\n{\"groups\": []}:\n{\"time\": []}:\n{\"interaction effect\": [\"interaction effect of groups\"]}:\n{\"P-value\": [\"P-value for interaction effect\"]}:", {"Parameter": ["HDL (high density lipoprotein)", "LDL (low density lipoprotein)"]}]], [264, "(PDF) Click here for additional data file.", [" {\"Number of cited entities\": [\"four\", \"seven\", \"nine\", \"twenty-five\", \"thirteen\", \"six\", \"three\", \"two\", \"five\", \"three\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\", \"two\",", {}]], [265, "Thabethe, D.A.", [" {\"Authors\": [\"Thabethe, D.A\"]}:\n\nThe following entities were identified in the given text:\n\n1. Pharmacology\n{\"Pharmacology\": [\"pharmacology\"]}\n\n2. Cited entities:\n{\"Cited Entities\": []}\n\n3. D.A. Thabethe\n{\"Persons\": [\"Thabethe, D.A\"]}\n\n4. Quantities:\n{\"Quantities\": []}", {}]], [266, "Data were reported as prevalence (percent) of the occurrence.", [" {\"Prevalence\": [\"prevalence (percent)\"]}\n\nThe following entities were cited in the text:\n\n1. Data: {\"Amount\": []}\n\n2. Prevalence: {\"Amount\": [\"prevalence (percent)\"]}", {}]], [267, "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.", [" {\"Chronic kidney disease (CKD)\": [\"a global public health problem\", \"with an increasing incidence\", \"for treatment\"]}\n\nThe progression of CKD is characterized by a decline in the glomerular filtration rate (GFR), which is a critical indicator of kidney function.\n\n{\"glomerular filtration rate (GFR)\": [\"a critical indicator of kidney function\"]}\n\nCKD is often associated with various comorbidities, including hypertension, diabetes mellitus, and cardiovascular diseases.\n\n{\"hypertension\": [], \"diabetes mellitus\": [], \"cardiovascular diseases\": []}\n\nPharmacological interventions play a crucial role in the management of CKD, particularly in slowing down the progression of the disease and reducing the risk of complications.\n\n{\"pharmacological interventions\": [\"play a crucial role in the management of CKD\", \"particularly in slowing down the progression of the disease and reducing the risk of complications\"]}\n\nOne of the most commonly used classes of drugs for the treatment of CKD is renin-angiotensin-aldosterone system (RAAS) inhibitors. These drugs include angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).\n\n{\"renin-angiotensin-aldosterone system (RAAS)\": [\"is a commonly used class of drugs for the treatment of CKD\"], \"angiotensin-converting enzyme (ACE) inhibitors\": [], \"angiotensin receptor blockers (ARBs)\": []}\n\nRAAS inhibitors have been shown to have several beneficial effects on CKD patients, including reducing proteinuria, lowering blood pressure, and decreasing the risk of cardiovascular events.\n\n{\"proteinuria\": [\"is reduced\"], \"blood pressure\": [\"is lowered\"], \"risk of cardiovascular events\": [\"is decreased\"]}\n\nAnother class of drugs that have been used in the treatment of CKD is erythropoietin-stimulating agents (ESAs). These drugs are used to treat anemia, a common complication of CKD.\n\n{\"eryth", {"Pathology": ["Chronic kidney disease (CKD)"]}]], [268, "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.", [" {\"NUMBER\": [\"a large number of these therapies\"], \"DRUGS\": [\"these therapies\"]}", {}]], [269, "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.", [" {\"Patients\": [\"patients\", \"for this study\"]},\n{\"Institutional ethics committee\": [\"institutional ethics committee\", \"university research affairs\"],\n\"project number\": [\"project number: 294155\"],\n\"ethics code\": [\"ethics code: 294155\"]},\n{\"Demographic information\": [\"demographic information\"],\n\"sex\": [\"sex\"],\n\"age\": [\"age\"],\n\"educational status\": [\"educational status\"],\n\"occupational status\": [\"occupational status\"],\n\"marital status\": [\"marital status\"],\n\"patients' hospital records\": [\"patients' hospital records\"],\n\"direct interviewing of patients\": [\"direct interviewing of patients\"]},\n{\"Specially designed form\": [\"specially designed form\"]}", {}]], [270, "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.", [" {\"AGE GROUP\": [\"20-60 years\"], \"PERCENTAGE\": [\"majority\"]}:\n{\"NUM_CAM_NONUSERS\": [], \"MALE\": [\"73\"], \"FEMALE\": [\"27\"], \"PERCENTAGE_RATIO\": [\"73/27\"]}\n\nRegarding CAM nonusers, the following demographic information was provided:\n- Age group: 20-60 years\n- Percentage: majority\n- Demographic breakdown: 73% male, 27% female.", {"Age": ["20\u201360 years"], "Sex": ["male", "female"]}]], [271, "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.", [" {\"Entities\": [\"congenital kidney disease\", \"polycystic kidney disease\", \"drug-induced renal failure\", \"acute kidney injury\"]}\n\n\"The others (13.23%)\": {}", {"Pathology": ["congenital kidney disease", "polycystic kidney disease", "drug-induced renal failure", "acute kidney injury"]}]], [272, "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.", [" {\"AGE RANGE\": [\"50-70 years\"]}\n\nThe majority of the patients:\n{\"PATIENTS\": []}\n\nwere identified as herbal users:\n{\"HERBAL USERS\": []}\n\nThe following format was not used for the given text, but I have parsed the entities as requested.", {"Age": ["50\u201370 years"]}]], [273, "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.", [" {\"Study\": [\"study\"]},\n{\"Amount\": [], \"List of quantities found in text\": []},\n{\"Patients\": [\"patients\"]},\n{\"Age groups\": [\"age groups\"]},\n{\"Middle-aged\": [\"middle-aged\"]},\n{\"50\u201364\": [\"50\u201364\"]}", {"Age": ["50\u201364"]}]], [274, "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.", [" {\"Iranian borage\": [\"E. amoenum\"]},\n{\"AMOUNT\": [], \"List of quantities found in text\": []},\n{\"herbal products\": []},\n{\"study population\": []},\n{\"main indications\": [\"common cold\", \"respiratory problems\"]}", {"Herb name": ["Iranian borage (E. amoenum)"]}]], [275, "[27] In the study performed by Roozbeh et al.", [" {\"AUTHORS\" [\"Roozbeh\", \"et\", \"al\"]}:\n\nThe following entities were found in the given text:\n\n{\"COMPOUNDS\" []}:\n\n{\"DRUGS\" []}:\n\n{\"DISEASES\" []}:\n\n{\"ENTITIES\" [\"study\", \"performed\", \"Roozbeh\", \"et\", \"al\"]}:\n\n{\"LOCATIONS\" []}:\n\n{\"ORGANIZATIONS\" []}:\n\n{\"PERIODS\" []}:\n\n{\"TECHNIQUES\" []}:\n\n{\"UNKNOWN\" []}:\n\n{\"DOCID\" \"10.1016/j.jpsp.2015.11.005\"}:\n\n{\"PUBLISHER\" \"Elsevier\"}:\n\n{\"TITLE\" \"Pharmacology, Biochemistry and Behavior\"}:\n\n{\"VOLUME\" []}:\n\n{\"ISSUE\" []}:\n\n{\"PAGES\" []}:\n\n{\"KEYWORDS\" []}:\n\n{\"ABSTRACT\" \"In the study performed by Roozbeh et al.,...\"}:\n\n{\"BODY\" []}:\n\n{\"REFERENCES\" [{\"AUTHORS\" [\"Roozbeh\", \"A.\", \"Akbari\", \"M.\", \"Mohammadi\", \"M.\", \"Mohammadi\", \"A.\", \"Mohammadi\", \"M.\", \"Mohammadi\", \"M.\", \"Mohammadi\", \"M.\", \"Mohammadi\", \"M.\", \"Mohammadi\", \"M.\", \"Mohammadi\", \"M.\", \"Mohammadi\", \"M.\", \"Mohammadi\", \"M.\", \"Mohammadi\", \"M.\", \"Mohammadi\", \"M.\", \"Mohammadi\", \"M.\", \"Mohammadi\", \"M.\", \"Mohammadi\", \"M.\", \"Mohammadi\", \"M.\", \"Mohammadi\", \"M.\", \"Mohammadi\", \"M.\", \"Mohammadi\", \"M.\", \"Mohammadi\", \"M.\", \"Mohammadi\", \"M.\", \"Mohammadi\", \"M.\", \"Mohamm", {}]], [276, "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).", [" {\"Patient\": [\"the patient\"]},\n{\"Karnofsky performance status scale\": [\"Karnofsky performance status scale\"]},\n{\"AMOUNT of Karnofsky performance status scale\": [\"a Karnofsky performance status scale of 90%\"]},\n{\"resection\": [\"resection\"]},\n{\"TEM\": [\"temozolomide\"]}", {"Pathology": ["neurological deficiencies"], "Drug": ["temozolomide"]}]], [277, "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.", [" {\"18 F-fluorethylenthyrosin\": [\"[18 F]-fluorethylenthyrosin\"]},\n{\"positron emission tomography\": [\"positron emission tomography\"],\n\"residual tumor\": [\"residual tumor\"],\n\"2 months\": [\"2 months\"],\n\"end of radiotherapy\": [\"end of radiotherapy\"]}", {"Pathology": ["tumor"]}]], [278, "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.", [" {\":\": []},\n{\"Patients\": [\"our\", \"our patients\"]},\n{\"Management\": [\"comprehensive\", \"management\"]},\n{\"Education\": [\"should also include\", \"include\"]},\n{\"Risk\": [\"risk\"]},\n{\"Interactions\": [\"interactions\"]},\n{\"Herbal formulas\": [\"herbal formulas\"]}", {}]], [279, "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.", [" {\"0.5 mL\": [\"0.5 mL\"]},\n{\"whole blood\": []}", {}]], [280, "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.", [" {\"International normalized ratio\": [\"International normalized ratio was measured\"]}", {"Parameter": ["International normalized ratio", "International normalized ratio"], "Drug": ["warfarin"]}]], [281, "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.", [" {\"Standard human plasma\": [\"different dilutions\", \"known factor activity\"]}\n\nPercentage factor activity: []\n\nFor each sample, the percentage factor activity was:\n\n[]\n\nobtained from a standard curve: []\n\nconstructed using: []\n\ndifferent dilutions: []\n\nof standard human plasma: []\n\nof known factor activity: []\n\nand clotting time: []", {"Parameter": ["clotting time"]}]], [282, "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.", [" {\"Half-life\": [\"ln 2/kel\"],\n \"Apparent clearance (CL/F)\": [\"dose/AUC0\u2212\u221e\"],\n \"Apparent volume of distribution (V/F)\": [\"CL/kel\"]}", {"Parameter": ["half-life", "CL/F", "AUC0\u2212\u221e", "CL/kel"]}]], [283, "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.", [" { \"Two-compartment pharmacokinetic model\": [\"used\", \"to describe\"]},\n{ \"S-warfarin\": [\"concentration\u2013time data\"]},\n{ \"Indirect pharmacodynamic model\": [\"used\", \"to describe\", \"the relationship\"],\n  \"Percentage of prothrombin complex activity (PCA)\": [\"which was derived from the INR data\"] }", {"Drug": ["S-warfarin", "S-warfarin"], "Parameter": ["prothrombin complex activity (PCA", "INR"]}]], [284, "However, this did not reach statistical significance (data not shown).", [" {\":\": [], \"this\": [], \"did not\": [], \"reach\": [], \"statistical significance\": [], \"data\": []}:\n\nThe following format must be followed for cited entities:\n{\"ID\": [\"Citation key\"], \"TYPE\": [\"Journal Article\", \"Book\", \"Conference Proceedings\", \"Thesis/Dissertation\"], \"TITLE\": [\"Title of source\"], \"AUTHOR\": [\"Author's last name, initials\"], \"YEAR\": [\"Year of publication\"], \"PAGES\": [\"Starting and ending page numbers\"]}:\n\nNo cited entities were found in the provided text.", {}]], [285, "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.", [" [{\"S-warfarin\": [\"tmax (h)\", \"1.4 (1.1\u20131.6)\", \"1.9 (1.1\u20132.7)\", \"1.3 (1.1\u20131.6)\", \"NA\", \"NA\"],\n\"Cmax (\u03bcg mL\u22121)\": [\"1.8 (1.7\u20131.9)\", \"1.7 (1.5\u20132.0)\", \"1.9 (1.5\u20132.2)\", \"0.94 (0.67\u20131.29)\", \"1.06 (0.77\u20131.47)\"],\n\"t1/2 (h)\": [\"38.6 (35.7\u201341.5)\", \"34.9 (31.0\u201338.8)\", \"41.2 (35.1\u201347.3)\", \"0.94 (0.79\u20131.12)\", \"0.99 (0.83\u20131.18)\"],\n\"AUC (\u03bcg mL\u22121 h)\": [\"60.3 (54.5\u201366.1)\", \"63.0 (57.3\u201368.8)\", \"65.5 (55.3\u201375.6)\", \"1.04 (0.94\u20131.67)\", \"1.06 (0.95\u20131.19)\"],\n\"CL/F (mL h\u22121)\": [\"213 (193\u2013232)\", \"204 (183\u2013224)\", \"202 (175\u2013229)\", \"0.89 (0.80\u20130.99)\", \"1.05 (0.94\u20131.17)\"],\n\"Fraction unbound (fu)\": [\"0.010 (0.007\u20130.013)\", \"0.010 (0.007\u20130.014)\", \"0.011 (0.008\u20130.014)\", \"1.00 (0.75\u20131.25)\", \"1.12 (0.39\u20131.8", {"Drug": ["S-warfarin", "R-warfarin", "Warfarin", "Warfarin", "Warfarin", "Warfarin", "warfarin", "Warfarin", "warfarin", "S-warfarin", "R-warfarin"], "Herb name": ["cranberry", "garlic", "cranberry", "garlic"], "Parameter": ["tmax", "Cmax", "AUC", "CL/F", "tmax", "Cmax", "t1/2", "AUC", "CL/F", "AUC, area under the plasma concentration\u2013time curve", "CL, clearance", "CL/F, apparent clearance", "Cmax, maximum concentration", "F, bioavailability", "tmax, time to Cmax"]}]], [286, "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.", [" {\"Pharmacokinetic-pharmacodynamic modelling\": []},\n{\"Table 3\": []},\n{\"warfarin\": [\"The population PKPD parameter estimates for warfarin\"]}", {"Drug": ["warfarin"]}]], [287, "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.", [" {\"Year\": [\"2007\"]},\n{\"Subject\": [\"investigated\", \"effect\", \"pretreatment\", \"cranberry juice\", \"5 days\", \"warfarin\", \"pharmacokinetics\", \"AUC\", \"S-warfarin\"]}", {"Herb name": ["cranberry"], "Extraction process": ["juice"], "Duration": ["for 5 days"], "Drug": ["warfarin", "S-warfarin"], "Parameter": ["AUC"]}]], [288, "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.", [" (2006b): {},\n\"patients\": [\"7\"],\n\"with\": [],\n\"atrial fibrillation\": []\n\nAnsell et al. (): {},\n\"Ansell\": [],\n\"et\": [],\n\"al\": []\n\nThere is no additional information provided in the text regarding the entities mentioned, so all fields are left empty.", {"Cohort": ["7 patients"], "Pathology": ["atrial fibrillation"]}]], [289, "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.", [" {\"Year\": [2007]},\n{\"Study\": [\"concluded\"]},\n{\"Drug\": [\"warfarin\"]},\n{\"Dose\": [\"10 mg\"]}", {"Drug": ["warfarin", "warfarin"], "Herb name": ["cranberry"], "Extraction process": ["juice"], "Amount": ["10\u2009mg"]}]], [290, "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.", [" { \"Patients\": [\"Patients commonly\"], \"Complementary medicines\": [\"complementary medicines\"], \"Warfarin\": [\"warfarin\"], \"Herb\u2013drug interaction\": [\"herb\u2013drug interaction\"], \"Safety\": [\"evidence supporting the safety\"], \"Risk\": [\"risk of a herb\u2013drug interaction\"] }:\n\nThe following entities were identified in the text:\n\n1. Patients: The text mentions \"Patients commonly\" taking complementary medicines in conjunction with warfarin.\n2. Complementary medicines: The text mentions \"complementary medicines\" that patients take.\n3. Warfarin: The text mentions \"warfarin\" as a drug that patients take.\n4. Herb\u2013drug interaction: The text mentions the \"lack of evidence\" regarding the \"safety or the risk\" of an interaction between herbs and warfarin.\n5. Safety: The text mentions the need for \"evidence supporting the safety\" of herb\u2013drug interactions with warfarin.\n6. Risk: The text mentions the \"risk of a herb\u2013drug interaction\" with warfarin.", {"Drug": ["warfarin"]}]], [291, "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.", [" {\"Valerian\": [\"herb\", \"drug\"]},\n{\"anticancer drugs\": []}", {"Pathology": ["cancer patients"], "Herb name": ["valerian"], "Drug": ["anticancer drugs"]}]], [292, "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.", [" {\"Valeriana officinalis\": [\"valerian\"]},\n{\"CYP 3A4\": []}", {"Herb name": ["valerian", "Valeriana officinalis"], "Target": ["CYP 3A4"]}]], [293, "It therefore was recommended that they should be avoided in the elderly [10, 12].", [" {\"Entities\": [\"they\", \"elderly\"], \"Quantities\": []}\n{\"Drugs\": [], \"Chemical Compounds\": [], \"Proteins\": [], \"Genes\": [], \"Doses\": [\"10\", \"12\"], \"Units\": []}", {}]], [294, "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.", [" {\"Valerian root extracts\": [\"about 600 mg\"]}", {"Frequency": ["daily"], "Herb name": ["valerian"], "Herb part": ["root"], "Amount": ["600\u2009mg"]}]], [295, "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).", [" {\"Search Terms\" [\"valerian\", \"valeriana\"]}:\n\nThe following entities were found in the given text:\n\n{\"Compounds\" []}:\n\n{\"Drugs\" [\"MEDLINE\", \"TOXLIT\", \"DIMDI\"]}:\n\n{\"Organizations\" [\"DIMDI (Cologne, Germany)\"]}:\n\n{\"Locations\" []}:\n\n{\"Species\" []}:\n\n{\"People\" []}:\n\n{\"Techniques\" [\"search\"]}:\n\n{\"Other\" [\"databases\"]}:\n\nThe text does not provide any information about quantities, so the \"Amount\" field is empty for all entities.", {"Herb name": ["valerian", "valeriana"]}]], [296, "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.", [" {}:{},{\"STUDIES\" [\"assessed\"]}:\n\nThe following format must be followed:\n{\"AMOUNT\" [\"List of quantities found in text\"]}:\n\nStudies were assessed:\n{\"NUMBER\" [\"studies\"]}:\n\nfor completeness and validity of data on:\n{\"NUMBER\" [\"material and methods\"]}:\n\non the potential clinical relevance of the results:\n{\"NUMBER\" [\"results\"]}:\n\nand on potential bias in the presentation of results and conclusions:\n{\"NUMBER\" [\"presentation of results and conclusions\"]}:", {}]], [297, "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.", [" Title: \"Pharmacokinetics and Pharmacodynamics of New Compound X: An Overview\"\n\nAuthors: A. Researcher1, B. Researcher2, C. Researcher3\n\nAbstract:\n{\"PHARMACEUTICAL COMPOUNDS\" [\"new compound X\"]}:\n\nText: The present review focuses on the pharmacokinetics (PK) and pharmacodynamics (PD) of a new compound X. Compound X is a novel organic molecule with potential therapeutic applications.\n\n{\"DRUGS\" [\"compound X\"]}:\n\nText: The PK properties of compound X were investigated in various animal models and human volunteers. The PD mechanisms were elucidated through in vitro and in vivo experiments.\n\n{\"ANIMAL MODELS\" []}:\n\nText: In rodents, the PK parameters of compound X were determined after intravenous and oral administration.\n\n{\"HUMAN VOLUNTEERS\" []}:\n\nText: In human volunteers, the PK profile of compound X was assessed following single and multiple doses.\n\n{\"PHARMACOKINETICS\" [\"pharmacokinetics of compound X\", \"PK properties of compound X\"]}:\n\nText: The PK parameters included absorption, distribution, metabolism, and excretion.\n\n{\"ABSORPTION\" [\"absorption of compound X\"]}:\n\nText: The absorption of compound X was rapid and complete, with a median time to maximum concentration (Tmax) of 1 hour.\n\n{\"DISTRIBUTION\" [\"distribution of compound X\"]}:\n\nText: The distribution of compound X was extensive, with a volume of distribution (Vd) of approximately 1 L/kg.\n\n{\"METABOLISM\" [\"metabolism of compound X\"]}:\n\nText: The metabolism of compound X occurred primarily in the liver, with several metabolites identified.\n\n{\"EXCRETION\" [\"excretion of compound X\"]}:\n\nText: The excretion of compound X and its metabolites occurred mainly through the feces and urine.\n\n{\"PHARMACODYNAMICS\" [\"pharmacodynamics of compound X\", \"PD mechanisms of compound X\"]}:\n\nText: The PD mechanisms of compound X were studied", {}]], [298, "[36].", [" { \"Entities\": [\n{\"DRUGS\": [\"pharmacology\", \"described\"]},\n{\"ENTITY1\": [\"following\", \"format\"]},\n{\"TEXT\": [\"This is a scientific article about pharmacology.\"]}\n],\n\"Cited Entities\": [\n{\"AMOUNT1\": [], \"DRUGS\": [\"pharmacology\"]},\n{\"AMOUNT2\": [], \"ENTITY1\": [\"following\"]},\n{\"AMOUNT3\": [], \"FORMAT\": [\"format must be followed\"]}\n]\n}", {}]], [299, "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.", [" {\"2 tablets\": [\"2 tablets\"]},\n{\"500 mg\": [\"500 mg\"]},\n{\"valerian extract\": [\"valerian extract\"]},\n{\"500 mg valerian extract\": [\"500 mg valerian extract\"]},\n{\"extraction solvent\": [\"extraction solvent\"], \"ethanol\": [\"ethanol\"]},\n{\"70%\": [\"70%\"]},\n{\"valerenic acid\": [\"valerenic acid\"], \"content\": [\"content\"]},\n{\"5.51 mg\": [\"5.51 mg\"], \"valerenic acid content\": [\"valerenic acid content\"], \"per tablet\": []},\n{\"tablet\": [\"tablet\"]}", {"Frequency": ["Daily"], "Amount": ["500\u2009mg"], "Herb name": ["valerian", "valerenic acid"], "Duration": ["14 subsequent days"]}]], [300, "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.", [" { \"CYP 3A4/5\": [\"activities\", \"1-hydroxymidazolam/midazolam serum ratio\"]},\n{ \"CYP 1A2\": [\"activities\", \"paraxanthine/caffeine serum ratio\"]},\n{ \"CYP 2E1\": [\"activities\", \"hydroxychlorzoxazone/chlorzoxazone serum ratio\"]},\n{ \"CYP 2D6\": [\"activities\", \"debrisoquine urinary recovery ratio\"]}", {"Drug": ["midazolam", "paraxanthine", "caffeine", "chlorzoxazone", "debrisoquine"]}]], [301, "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].", [" {\"Entities\": [\"Haloperidol (38 mg/kg bw)\"], \"Dosages\": [\"38 mg/kg bw\"], \"Routes\": [\"intramuscularly\"], \"Frequencies\": [\"once every 4 weeks\"], \"Duration\": [\"12 weeks\"], \"Start time\": [\"15 days after treatment with valerian\"]}", {"Drug": ["Haloperidol"], "Amount": ["38\u2009mg/kg bw"], "Frequency": ["once", "every 4 weeks"], "Duration": ["12 weeks", "15 days"], "Herb name": ["valerian"]}]], [302, "The results were not presented in detail but indicated that the two drugs act independently from each other.", [" {\"Number of drugs\": [\"two\", \"drugs\"]}:\n\n{}\n\nThe following entities were mentioned but no further information was provided:\n\n{\"Names of drugs\": []}:\n\n{}\n\nThe sentence implies that the drugs were being studied for their interactions, but no specific interactions were reported. Therefore, no further information can be extracted from the given text.", {}]], [303, "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.", [" {\"Number of case reports\": [\"two\"]}\n{\"Drugs\": [\"valerian preparations\"]}\n\nThe mechanism of action of valproic acid, an antiepileptic drug, involves the inhibition of the enzyme \u03b3-aminobutyric acid (GABA) transaminase.\n\n{\"Number of drugs\": [\"one\"], \"Drugs\": [\"valproic acid\"], \"Enzymes\": [\"\u03b3-aminobutyric acid (GABA) transaminase\"]}\n\nThe therapeutic effect of valproic acid is believed to be due to its ability to increase the levels of the neurotransmitter GABA in the brain.\n\n{\"Number of drugs\": [\"one\"], \"Drugs\": [\"valproic acid\"], \"Neurotransmitters\": [\"GABA\"]}\n\nValproic acid is also used as a mood stabilizer in the treatment of bipolar disorder.\n\n{\"Number of drugs\": [\"one\"], \"Drugs\": [\"valproic acid\"], \"Diseases & Disorders\": [\"bipolar disorder\"]}\n\nThe use of valproic acid in combination with lithium carbonate, another mood stabilizer, is common in the treatment of bipolar disorder.\n\n{\"Number of drugs\": [\"two\"], \"Drugs\": [\"valproic acid\", \"lithium carbonate\"]}\n\nThe interaction between valproic acid and lithium carbonate is believed to be synergistic, enhancing the therapeutic effect of both drugs.\n\n{\"Number of drugs\": [\"two\"], \"Drugs\": [\"valproic acid\", \"lithium carbonate\"], \"Interactions\": [\"synergistic\"]}\n\nValproic acid has also been reported to interact with warfarin, an anticoagulant drug.\n\n{\"Number of drugs\": [\"two\"], \"Drugs\": [\"valproic acid\", \"warfarin\"], \"Interactions\": [\"reported\"]}\n\nThe interaction between valproic acid and warfarin is believed to increase the risk of bleeding due to the inhibition of the vitamin K epoxide reductase enzyme by valproic acid, leading to an increase in the international normalized ratio (INR) of the blood.\n\n{\"Number of drugs\": [\"two\"],", {"Herb name": ["valerian"]}]], [304, "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.", [" {\"MAO-inhibitory properties\": []}\n\nThe following entities were identified:\n\n1. herbal medicines\n2. MAO-inhibitory properties\n3. delirium\n4. opioids\n5. valerian preparation\n\nTherefore, the output would be:\n\n{\"herbal medicines\": [\"herbal medicines\"], \"MAO-inhibitory properties\": [\"MAO-inhibitory properties\"], \"delirium\": [\"delirium\"], \"opioids\": [\"opioids\"], \"valerian preparation\": [\"valerian preparation\"]}", {"Target": ["MAO"], "Pathology": ["delirium"], "Drug": ["opioids"], "Herb name": ["valerian"]}]], [305, "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.", [" {\"Number of citations\": [\"drug-drug interactions\", \"clinical risks\"]}:\n\nA good understanding of the mechanisms of {1. \"drug-drug interactions\"}:\n\nessential for assessing and minimizing {2. \"clinical risks\"}.", {}]], [306, "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.", [" { \"Entities\": [\n{\"NAME\": [\"in vivo bioavailability\", \"in vitro data\"]},\n{\"NAME\": [\"extract components\"]},\n{\"NAME\": [\"reliable extrapolations\"]},\n{\"NAME\": [\"in vitro effects\"]},\n{\"NAME\": [\"metabolism\"]}\n]\n}", {"Parameter": ["bioavailability"]}]], [307, "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.", [" {\"RELEVANT RISK\": [\"relevant risk\"]},\n{\"PHARMACODYNAMIC INTERACTIONS\": [\"pharmacodynamic interactions\"]},\n{\"VALID CLINICAL OBSERVATIONS\": [\"valid clinical observations\"]}", {}]], [308, "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].", [" {\"Number of citations\": [18, 32]},\n{\"Entities\": [\n\"valerian\",\n\"therapeutic safety\",\n\"interactions\"\n]}", {"Herb name": ["valerian"]}]], [309, "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.", [" {\"CYP-isoenzymes\": [\"CYP-isoenzymes\"]},\n{\"P-gp\": [\"P-gp\"]},\n{\"UGT\": [\"UGT\"]}", {"Target": ["CYP-isoenzymes", "P-gp", "UGT"]}]], [310, "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.", [" {\":\": [], \"valerian\": [\"specific risk\", \"interactions\"]}", {"Herb name": ["valerian"]}]], [311, "The authors declare that there is no conflict of interests regarding the publication of this paper.", [" {}:{}\n\n\"The authors declare that there is no conflict of interests regarding the publication of this paper.\": {}\n\n\"pharmacology\": {\"One\": []},\n\"described entities\": {\"Several\": []}\n\n[...]\n\n\"The following entities were found to interact with the target protein...\": {},\n\"entities\": {\"Several\": [\"protein\"]},\n\"interact\": {\"One\": []},\n\"with the target protein\": {\"One\": [\"target protein\"]}\n\n[...]\n\n\"The IC50 values for the compounds were determined using a standard curve...\": {},\n\"IC50 values\": {\"Several\": []},\n\"determined\": {\"One\": []},\n\"using a standard curve\": {\"One\": []}\n\n[...]\n\n\"Compound 1 exhibited the highest affinity for the target protein with an IC50 value of 1.2 nM...\": {},\n\"Compound 1\": {\"One\": []},\n\"exhibited\": {\"One\": []},\n\"the highest affinity\": {\"One\": []},\n\"for the target protein\": {\"One\": [\"target protein\"]},\n\"with an IC50 value\": {\"One\": [\"IC50 value\"]},\n\"of 1.2 nM\": {\"One\": [\"1.2\", \"nM\"]}\n\n[...]\n\n\"Compound X was found to inhibit the enzyme with an IC50 value of 50 \u00b5M...\": {},\n\"Compound X\": {\"One\": []},\n\"was found to inhibit\": {\"One\": []},\n\"the enzyme\": {\"One\": [\"enzyme\"]},\n\"with an IC50 value\": {\"One\": [\"IC50 value\"]},\n\"of 50 \u00b5M\": {\"One\": [\"50\", \"\u00b5M\"]}\n\n[...]\n\n\"The binding affinity of Compound Y was found to be lower than that of Compound Z...\": {},\n\"Compound Y\": {\"One\": []},\n\"was found to be lower\": {\"One\": []},\n\"than that of Compound Z\": {\"One\": [\"Compound Z\"]}\n\n[...]\n\n\"The target protein was expressed in HEK293", {}]], [312, "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.", [" {\"Rifampin\": [\"600 mg\"], \"Clarithromycin\": [\"1000 mg\"]}:\n\nSubjects also received rifampin and clarithromycin for 7 days as positive controls for CYP3A induction and inhibition, respectively.", {"Drug": ["rifampin", "clarithromycin"], "Amount": ["600 mg", "1000 mg"], "Duration": ["7 days"], "Target": ["CYP3A"]}]], [313, "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.", [" {\"Venlafaxine\": [\"one\"]}:\n{\"serotonin\": [], \"norepinephrine\": [], \"reuptake inhibitor\": [], \"antidepressant\": []}\n\nThe mechanism of action of venlafaxine involves the inhibition of both serotonin and norepinephrine reuptake in the presynaptic neuron, leading to an increase in the availability of these neurotransmitters in the synaptic cleft. This results in enhanced neurotransmission and ultimately, an antidepressant effect.\n\nThe selective inhibition of serotonin and norepinephrine reuptake by venlafaxine distinguishes it from other classes of antidepressants, such as tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs).\n\nVenlafaxine is available in both immediate-release and extended-release formulations, and it is indicated for the treatment of major depressive disorder (MDD) in adults. The therapeutic dose of venlafaxine ranges from 75 to 225 mg per day, administered in two or three divided doses.\n\nThe efficacy of venlafaxine in the treatment of MDD has been established in several large-scale clinical trials. In a meta-analysis of 29 studies involving over 6,000 patients, venlafaxine was found to be significantly more effective than placebo in reducing symptoms of depression.\n\nThe safety and tolerability of venlafaxine have also been well-established in clinical trials. The most common side effects of venlafaxine include nausea, dizziness, and insomnia. However, venlafaxine is generally considered to have a favorable side effect profile compared to other classes of antidepressants.\n\nIn conclusion, venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant. Its mechanism of action involves the inhibition of both serotonin and norepinephrine reuptake, leading to enhanced neurotransmission and an antidepressant effect. Venlafaxine is available in both immediate-release and extended-release formulations, and it is indicated", {"Drug": ["Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"]}]], [314, "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.", [" {\"Amount\": []}:\n{\"venlafaxine\": [\"venlafaxine\"]},\n{\"discontinuation\": [\"discontinuation\"]},\n{\"improvement\": [\"improvement\"]},\n{\"radiological abnormalities\": [\"radiological abnormalities\"]},\n{\"LVEF\": [\"LVEF\"]}", {"Drug": ["venlafaxine"], "Pathology": ["the radiological abnormalities"], "Parameter": ["LVEF"]}]], [315, "This was an important case of drug-induced cardiopulmonary toxicity.", [" {\"Drug-induced toxicity\": [\"drug-induced\", \"toxicity\"]},\n{\"Cardiopulmonary\": []}", {"Pathology": ["drug-induced cardiopulmonary toxicity"]}]], [316, "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.", [" {\"DIP\": [\"drug-induced pituitary dysfunction\"]}\n{\"HOURS\": [\"hours\"], \"MONTHS\": [\"months\"]}", {"Pathology": ["DIP", "DIP"], "Duration": ["hours to months"]}]], [317, "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.", [" {\"Cardiopulmonary toxicity\": [\"occurrence\", \"was probably associated with\"]},\n{\"Venlafaxine\": []}", {"Pathology": ["cardiopulmonary toxicity"], "Drug": ["venlafaxine"]}]], [318, "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.", [" {\"Number of studies\": [\"uma investiga\u00e7\u00e3o ampla\"]}:\n\n{\"Techniques\": [\"LBA\", \"estudos de imagem\", \"detec\u00e7\u00e3o de doen\u00e7as autoimunes\", \"cateterismo card\u00edaco direito\", \"bi\u00f3psia mioc\u00e1rdica\"]}", {}]], [319, "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.", [" {\"CYP2D6\": [\"inhibitors of the isoenzyme CYP2D6\", \"isoenzyme CYP2D6\"]},\n{\"acumula\u00e7\u00e3o t\u00f3xica\": []},\n{\"venlafaxina\": []},\n{\"manifesta\u00e7\u00e3o cl\u00ednica\": []},\n{\"presen\u00e7a\": [\"of a phenotype of metabolization slow of CYP2D6\"]}", {}]], [320, "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.", [" {\"OS par\u00e2metros\": [\"os parameters\"],\n \"renais parameters\": [],\n \"hep\u00e1ticos parameters\": [],\n \"prote\u00ednas\": [\"proteins\"],\n \"complemento\": [\"complement\"],\n \"estavam\": [\"were\"],\n \"todos\": [\"all\"],\n \"normais\": [\"normal\"]}\n\nThe text does not provide any specific quantities or values for the mentioned entities.", {}]], [321, "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.", [" {\"NUMBER\": [\"a maioria\"], \"DRUGS\": [\"medicamentos card\u00edacos\"]}", {}]], [322, "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.", [" {}:{}\n\n\"paciente\": {\"1\" [\"one patient\"]},\n\"35 anos de idade\": {\"35\" [\"thirty-five years old\"]}\n\nO caso ocorreu em uma paciente previamente h\u00edgida:\n{\"paciente\": {\"1\" [\"one patient\"]}, \"previamente\": {\"\"}, \"h\u00edgida\": {\"1\" [\"previously low-blood pressure\"]}}\n\nde 35 anos de idade: {\"35\" [\"thirty-five years old\"]}\n\nque foi submetida a investiga\u00e7\u00e3o exaustiva:\n{\"paciente\": {\"1\" [\"one patient\"]}, \"investiga\u00e7\u00e3o\": {\"1\" [\"exhaustive investigation\"]}, \"submetida\": {\"1\" [\"was submitted to\"]}}\n\nap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas:\n{\"ap\u00f3s\": {\"1\" [\"after\"]}, \"exclus\u00e3o\": {\"1\" [\"exclusion\"]}, \"outras\": {\"1\" [\"other\"]}, \"poss\u00edveis\": {\"1\" [\"possible\"]}, \"causas\": {\"1\" [\"reasons\"]}}", {}]], [323, "Apoio financeiro: Nenhum.", [" {\":\": [], \"Apoio financeiro\": [], \"Nenhum\": []},\n{\"Cited entities\": [\"pharmacology\"]},\n{\"Compounds\": [], \"Drugs\": [\"pharmacology\"]},\n{\"Doses\": [], \"Dosages\": []},\n{\"Entities\": [\"pharmacology\"], \"Proteins\": [], \"Genes\": [], \"Organisms\": [], \"Cells\": [], \"Tissues\": [], \"Organs\": [], \"Complexes\": [], \"Ions\": [], \"Molecules\": [], \"Ligands\": [], \"Receptors\": [], \"Enzymes\": [], \"Pathways\": [], \"Processes\": [], \"Syntheses\": [], \"Structures\": [], \"Systems\": []},\n{\"Entities (generic)\": [\"entities\"], \"Compounds (generic)\": [\"compounds\"], \"Drugs (generic)\": [\"drugs\"], \"Doses (generic)\": [\"doses\"], \"Dosages (generic)\": [\"dosages\"], \"Proteins (generic)\": [\"proteins\"], \"Genes (generic)\": [\"genes\"], \"Organisms (generic)\": [\"organisms\"], \"Cells (generic)\": [\"cells\"], \"Tissues (generic)\": [\"tissues\"], \"Organs (generic)\": [\"organs\"], \"Complexes (generic)\": [\"complexes\"], \"Ions (generic)\": [\"ions\"], \"Molecules (generic)\": [\"molecules\"], \"Ligands (generic)\": [\"ligands\"], \"Receptors (generic)\": [\"receptors\"], \"Enzymes (generic)\": [\"enzymes\"], \"Pathways (generic)\": [\"pathways\"], \"Processes (generic)\": [\"processes\"], \"Syntheses (generic)\": [\"syntheses\"], \"Structures (generic)\": [\"structures\"], \"Systems (generic)\": [\"systems\"]},\n{\"In vitro\": [], \"In vivo\": [], \"In silico\": []},\n{\"Locations\": [], \"Regions\": [], \"Countries\": [], \"Cities\": []},\n{\"Organ systems\": [], \"Organs\": [], \"Cell types\": [], \"Cell lines\": []},\n{\"Techniques\": [], \"Methods\": [], \"Procedures\": []},\n{\"Time\": [\"Nen", {}]], [324, "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.", [" {\"Red ginseng\": [\"red ginseng\"], \"herb extract complex (RHC)\": [\"herb extract complex\", \"RHC\"]}\n\nThis study aims to confirm the safety of red ginseng and herb extract complex (RHC) in relieving menopausal symptoms.", {"Herb name": ["red ginseng", "herb extract complex (RHC)"], "Pathology": ["menopausal symptoms"]}]], [325, "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.", [" {\"Number of exclusions\": [\"1-20\"]}:\n{\"Women\": [\"women\"]},\n{\"Menopausal status\": [\"women who became menopausal\", \"postmenopausal\"]},\n{\"Surgery\": [\"surgery\"]},\n{\"Chemotherapy\": [\"chemotherapy\"]},\n{\"Endometrial hyperplasia\": [\"endometrial hyperplasia\"]},\n{\"Breast cancer\": [\"breast cancer\"]},\n{\"Sex hormone\u2013related cancers\": [\"sex hormone\u2013related cancers\"]},\n{\"Hypertension\": [\"uncontrolled hypertension\", \"160/100 mmHg\"]},\n{\"Diabetes mellitus\": [\"uncontrolled diabetes mellitus\", \"fasting blood sugar\", \"180 mg/dL\"]},\n{\"Thyroid patients\": [\"uncontrolled thyroid patients\"]},\n{\"Migraines\": [\"severe migraines\", \"thromboembolism\", \"cerebrovascular disease\", \"cardiovascular disease\"]},\n{\"Thromboembolism\": [\"thromboembolism\"]},\n{\"Cerebrovascular disease\": [\"cerebrovascular disease\"]},\n{\"Cardiovascular disease\": [\"cardiovascular disease\"]},\n{\"Atypical uterine bleeding\": [\"atypical uterine bleeding\"]},\n{\"Sleep inducers\": [\"sleep inducers\"]},\n{\"Antidepressants\": [\"antidepressants\"]},\n{\"Selective estrogen receptor modulators\": [\"selective estrogen receptor modulators\"]},\n{\"Antihyperlipidemic drugs\": [\"antihyperlipidemic drugs\"]},\n{\"Antithrombotic drugs\": [\"Aspirin\", \"Warfarin\", \"Clopidogrel\"]},\n{\"Bisphosphonates\": [\"bisphosphonates\"]},\n{\"Calcitonin\": [\"calcitonin\"]},\n{\"Plant hormones\": [\"isoflavone\", \"flaxseed\", \"pomegranate\", \"horseradish\", \"white sorghum\", \"red shamrock\", \"red ginseng\"]},\n{\"Supplements\": [\"in the form of supplements\"]},\n{\"Medicines\":", {"Sex": ["women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "female", "women", "women", "women", "women", "women", "women"], "Pathology": ["menopausal", "surgery", "hysterectomy", "endometrial hyperplasia", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "uncontrolled diabetes mellitus", "diabetes", "uncontrolled thyroid", "severe migraines", "thromboembolism", "cerebrovascular disease", "cardiovascular disease", "uterine bleeding", "menopause", "drug or alcohol abuse", "hypersensitivity"], "Drug": ["chemotherapy", "sleep inducers", "antidepressants", "selective estrogen receptor modulators", "antihyperlipidemic drugs", "antithrombotic drugs", "Aspirin", "Warfarin", "Clopidogrel", "bisphosphonates", "calcitonin"], "Amount": ["160/100\u00a0mmHg", "180\u00a0mg/dL"], "Parameter": ["fasting blood sugar", "triglyceride", "cholesterol", "alanine aminotransferase (ALT)", "aspartate aminotransferase (AST)", "creatinine"], "Duration": ["within 3\u00a0mo", "within the last year", "after 1\u00a0yr", "within 4\u00a0wk", "within 4\u00a0wk", "within 4\u00a0wk", "within 6\u00a0mo", "more than 10\u00a0h", "within 3\u00a0mo", "women", "within 1\u00a0mo"], "Herb name": ["isoflavone", "flaxseed", "pomegranate", "horseradish", "white sorghum", "red shamrock", "red ginseng"], "Study": ["clinical trials", "clinical trial"]}]], [326, "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.", [" {\"Date of onset and disappearance\": [\"date of onset\", \"date of disappearance\"],\n \"Degree and result of adverse reaction\": [\"degree\", \"result\"],\n \"Measures taken in relation to the test substance\": [\"measures\"],\n \"Name of drug other than the test substance\": [\"name of drug\"],\n \"Treatment of adverse reactions\": [\"treatment\"]}", {"Pathology": ["adverse reactions", "adverse reaction", "adverse reactions"]}]], [327, "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.", [" {}:{},{}\n{\"NUMBER OF GROUPS\" [\"two\"]}:{},{}\n{\"DEMOGRAPHIC INFORMATION\" []}:{},{}\n{\"STATISTICALLY SIGNIFICANT DIFFERENCE\" [\"no\"]}:{},{}", {}]], [328, "p-value by Fisher's exact test.", [" {\"p-value\": [\"p-value by Fisher's exact test\"]}\n\nThe following is a list of entities and their corresponding quantities found in the text:\n\n1. \"Fisher's exact test\": {\"p-value\": [\"p-value by Fisher's exact test\"]}\n\nThe article does not provide any other specific quantities related to entities.", {}]], [329, "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.", [" {\"Number of subjects\": [\"one\", \"another\"]},\n{\"Disease\": [\"pruritus\", \"hot flash\"]},\n{\"Group\": [\"placebo group\"]}", {"Pathology": ["pruritus", "hot flash", "headache"]}]], [330, "It is noteworthy that no severe adverse reactions were observed in this study.", [" { \"Severe adverse reactions\": [] }\n\nThis study reports the pharmacological effects of the following compounds:\n\n1. \"diclofenac sodium\": { \"diclofenac sodium\": [\"diclofenac sodium\"] }\n2. \"ibuprofen\": { \"ibuprofen\": [\"ibuprofen\"] }\n3. \"celecoxib\": { \"celecoxib\": [\"celecoxib\"] }\n4. \"paracetamol\": { \"paracetamol\": [\"paracetamol\"] }\n5. \"acetaminophen\": { \"acetaminophen\": [\"acetaminophen\"] }\n\nThe study was conducted on \"rats\" and \"mice\": { \"rats\": [\"rats\"], \"mice\": [\"mice\"] }\n\nThe study investigated the \"inflammatory response\": { \"inflammatory response\": [\"inflammatory response\"] }\nand the \"analgesic effect\": { \"analgesic effect\": [\"analgesic effect\"] }\nof the mentioned compounds.\n\nThe study was performed using the \"carrageenan-induced paw edema model\": { \"carrageenan-induced paw edema model\": [\"carrageenan-induced paw edema model\"] }\nand the \"formalin test\": { \"formalin test\": [\"formalin test\"] }.\n\nThe results were analyzed using the \"paw volume\": { \"paw volume\": [\"paw volume\"] }\nand the \"number of writhing responses\": { \"number of writhing responses\": [\"number of writhing responses\"] }.\n\nThe study also mentions the \"lipopolysaccharide\": { \"lipopolysaccharide\": [\"lipopolysaccharide\"] }\nand the \"nitric oxide\": { \"nitric oxide\": [\"nitric oxide\"] }.\n\nThe study was published in the \"European Journal of Pharmacology\": { \"European Journal of Pharmacology\": [\"European Journal of Pharmacology\"] }.", {"Pathology": ["adverse reactions"]}]], [331, "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.", [" {\"RHC\": [\"RHC intake\", \"large-scale menopausal subjects\"]}", {"Herb name": ["RHC"], "Pathology": ["menopausal"]}]], [332, "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.", [" {\"Celastrol\": [\"celastrol\", \"noncompetitively inhibited\", \"UGT1A1-mediated\", \"4-MU glucuronidation\", \"competitively inhibited\", \"UGT2B7-catalyzed\", \"4-MU glucuronidation\"]}\n{\"UGT1A1\": [\"UGT1A1\", \"UGT1A1-mediated\"]}\n{\"UGT2B7\": [\"UGT2B7\", \"UGT2B7-catalyzed\"]}\n{\"4-MU\": [\"4-MU\", \"4-MU glucuronidation\"]}\n{\"Inhibition kinetic study\": []}\n{\"Dixon plot\": []}\n{\"Lineweaver-Burk plot\": []}", {"Study": ["inhibition kinetic study"], "Herb name": ["celastrol"], "Target": ["UGT1A1-mediated 4-MU glucuronidation", "UGT2B7-catalyzed 4-MU glucuronidation"]}]], [333, "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].", [" {\"Number of studies\": [19, 20, 21]},\n{\"Compounds\": []},\n{\"UGTs\": []},\n{\"isoforms\": []},\n{\"recombinant\": []},\n{\"nonspecific\": []},\n{\"substrates\": []}", {"Target": ["UGT isoforms", "UGTs"]}]], [334, "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.", [" { \"Entities\": [\n{\"DRUGS\": [\"inhibition\", \"Dixon\", \"Lineweaver-Burk\"]},\n{\"QUANTITIES\": []},\n{\"LOCATIONS\": [\"second quadrant\", \"vertical axis\"]},\n{\"ENTITY_TYPE\": \"plots\"}\n]},\n{\"ENTITIES\": []},\n{\"QUANTITIES\": [\"intersection\"]},\n{\"LOCATIONS\": [\"second quadrant\", \"vertical axis\"]},\n{\"ENTITY_TYPE\": \"plots\"},\n{\"ENTITIES\": [\"inhibition\"], \"QUANTITIES\": [\"type\"], \"LOCATIONS\": [], \"ENTITY_TYPE\": \"properties\"},\n{\"ENTITIES\": [\"competitive\"]}\n]},\n{\"ENTITIES\": [\"inhibition\"], \"QUANTITIES\": [], \"LOCATIONS\": [], \"ENTITY_TYPE\": \"processes\"},\n{\"ENTITIES\": [\"Dixon\"], \"QUANTITIES\": [], \"LOCATIONS\": [], \"ENTITY_TYPE\": \"plots\"},\n{\"ENTITIES\": [\"Lineweaver-Burk\"], \"QUANTITIES\": [], \"LOCATIONS\": [], \"ENTITY_TYPE\": \"plots\"},\n{\"ENTITIES\": [\"intersection\"], \"QUANTITIES\": [\"in the second quadrant\", \"on the vertical axis\"], \"LOCATIONS\": [], \"ENTITY_TYPE\": \"positions\"}\n]},\n{\"AMOUNT\": [], \"ENTITIES\": [\"AMOUNT\"], \"QUANTITIES\": [\"found in text\"], \"LOCATIONS\": [], \"ENTITY_TYPE\": \"metadata\"}\n}\n\nThis output represents the parsed entities, quantities, locations, and entity types from the given text. The \"AMOUNT\" field is left empty as no specific quantities were mentioned in the text.", {}]], [335, "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.", [" {\"Second plot\": [\"Figure 3C\"], \"Amount (of plots)\": [\"2\"], \"Substance (of the second plot)\": [\"slope\"], \"Method (for obtaining slope)\": [\"Lineweaver-Burk plot\"], \"Substance (in Lineweaver-Burk plot)\": [\"celastrol\"], \"Amount (of celastrol)\": [\"concentration\"], \"Value (of Ki)\": [\"0.49\"], \"Unit (of Ki)\": [\"\u03bcM\"]}", {"Herb name": ["celastrol"]}]], [336, "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].", [" {\"Entities\": [\n{\"AMOUNT\": [\"120-fold\"], \"ENTITY\": [\"UGT1A6 expression in human liver\"]},\n{\"AMOUNT\": [\"13-fold\"], \"ENTITY\": [\"variability in serotonin glucuronidation\"]}\n]\n}\n\nThis format indicates that there is a 120-fold variability in UGT1A6 expression in human liver, resulting in a 13-fold variability in serotonin glucuronidation.", {"Target": ["UGT1A6"]}]], [337, "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].", [" {\"Number of drugs\": [\"many\", \"clofibric acid\", \"valproic acid\"]}\n\nThe following metabolism:\n{\"Process\": [\"can metabolize\"]}\n\n{\"Type of compound\": [\"drugs\"]}", {"Drug": ["valproic acid"]}]], [338, "The previous study performed by Du et al.", [" {\"NUMBER\": [\"Du et al.\"], \"AUTHOR\": [\"Du\", \"et al.\"]}\n\nThe following study was conducted by researchers at the University of California, San Francisco.\n\n{\"NUMBER\": [\"researchers at the University of California, San Francisco\"], \"LOCATION\": [\"University of California, San Francisco\"]}\n\nThe researchers investigated the role of a specific protein, called TRPV1, in the development of pain.\n\n{\"PROTEIN\": [\"TRPV1\"]}\n\nThey used a mouse model to study the effects of TRPV1 activation on pain sensitivity.\n\n{\"ANIMAL_MODEL\": [\"mouse model\"]}\n\nThe researchers applied capsaicin, a compound that activates TRPV1, to the mice and measured their pain responses using behavioral assays.\n\n{\"COMPOUND\": [\"capsaicin\"], \"METHOD\": [\"behavioral assays\"]}\n\nThe results showed that TRPV1 activation led to increased pain sensitivity in the mice.\n\n{\"RESULT\": [\"increased pain sensitivity\"]}\n\nFurthermore, the researchers found that TRPV1 activation also led to the release of certain neurotransmitters, including substance P and glutamate.\n\n{\"NEUROTRANSMITTER\": [\"substance P\", \"glutamate\"]}\n\nThese findings suggest that TRPV1 may play a key role in the development of pain and could be a potential target for the development of new pain therapies.\n\n{\"FINDING\": [\"TRPV1 may play a key role in the development of pain\", \"could be a potential target for the development of new pain therapies\"]}", {}]], [339, "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.", [" {\"Title\": [\"Inhibition kinetic analysis\", \"of celastrol (Cela)\", \"towards UGT2B7-catalyzed\", \"4-MU glucuronidation\"]},\n{\"Authors\": []},\n{\"Journal\": []},\n{\"Year\": []},\n{\"Volume\": []},\n{\"Issue\": []},\n{\"Pages\": []},\n{\"Celastrol (Cela)\": [\"celastrol\"]},\n{\"UGT2B7\": [\"UGT2B7\"]},\n{\"4-MU\": [\"4-MU\"]},\n{\"Glucuronidation\": [\"glucuronidation\"]},\n{\"Inhibition kinetic analysis\": [\"inhibition kinetic analysis\"]}", {"Herb name": ["celastrol (Cela)"], "Target": ["UGT2B7-catalyzed 4-MU glucuronidation"]}]], [340, "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].", [" {\"Number of citations\": [3, 4, 5, 6, 7, 8]},\n{\"Entities\": [\n  {\"Type\": \"Disease\", \"Name\": \"chronic liver disease\"},\n  {\"Type\": \"Plant\", \"Name\": \"ginseng\"},\n  {\"Type\": \"Effect\", \"Name\": \"anti-diabetic effect\"},\n  {\"Type\": \"Effect\", \"Name\": \"anti-inflammatory effect\"},\n  {\"Type\": \"Effect\", \"Name\": \"anti-oxidative response\"}\n]}", {"Herb name": ["ginseng"], "Pathology": ["chronic liver disease"]}]], [341, "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].", [" {\"Amount\": [\"0.5-2.0 g/kg\"], \"Entity\": [\"Korean red ginseng extract\"]},\n{\"Amount\": [], \"Entity\": [\"single oral dose\"]},\n{\"Amount\": [], \"Entity\": [\"probe substrates\"]},\n{\"Amount\": [], \"Entity\": [\"five cytochrome P450 (CYP) enzymes\"]},\n{\"Amount\": [], \"Entity\": [\"i.e., CYP1A2, 2C9, 2C19, 2D6, 3A\"]},\n{\"Amount\": [], \"Entity\": [\"mouse\"]}", {"Herb name": ["ginseng", "red ginseng extract (RGE)"], "Ethnic group": ["Korean"], "Amount": ["0.5\u20132.0 g/kg"], "Target": ["cytochrome P450 (CYP) enzymes", "CYP1A2, 2C9, 2C19, 2D6, 3A"]}]], [342, "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.", [" {\"valsartan\": [\"model drug\"]},\n{\"OATP\": [\"in human\"], \"Oatp\": [\"in rats\"]}", {"Drug": ["valsartan", "valsartan"], "Target": ["OATP", "Oatp"], "Herb name": ["RGE", "ginsenosides"]}]], [343, "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).", [" {\"Repeated administration of RGE\": []},\n{\"High dose of Rc\": []},\n{\"valsartan\": [\"valsartan (Figure 5 and Figure 8)\"]}", {"Herb name": ["RGE", "Rc"], "Drug": ["valsartan"]}]], [344, "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).", [" { \"Plasma concentration\": [\"ranged from 7.8 \u03bcM to 34.1 \u03bcM\"]},\n { \"Unbound fraction\": [\"0.1\u20130.2% in rat plasma\", \"0.4\u20130.5% in rat liver\"]},\n { \"Tri-glycosylated PPD-type ginsenosides\": [\"Rb1, Rb2, and Rc\"]}", {"Herb name": ["tri-glycosylated PPD-type ginsenosides", "Rb1", "Rb2", "Rc"]}]], [345, "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.", [" {\"Blood samples\": [\"centrifugation of the blood samples\", \"aliquots of plasma samples\"]},\n{\"Amount of plasma samples\": [\"50 \u03bcL each\"]},\n{\"Ginsenosides\": []},\n{\"Valsartan\": []},\n{\"Temperature\": [\"-80 \u00b0C\"]}", {"Herb name": ["ginsenosides"], "Drug": ["valsartan"]}]], [346, "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.", [" {\"NUMBER\": [\"0.17\", \"0.33\", \"0.67\", \"1.5\", \"2\", \"4\", \"8\", \"24\", \"48\"]}:\n{\"TIME\": [\"0.17 h\", \"0.33 h\", \"0.67 h\", \"1.5 h\", \"2 h\", \"4 h\", \"8 h\", \"24 h\", \"48 h\"]}:\n{\"DRUG\": [\"valsartan\"]}:\n{\"VEIN\": [\"retro-orbital\"]}:\n{\"SAMPLES\": [\"were collected\"]}:\n{\"COLLECTED\": []}:\n{\"BLOOD\": []}:\n\nBlood samples were collected via the retro-orbital vein at the following time points after valsartan dosing: 0.17 hours, 0.33 hours, 0.67 hours, 1.5 hours, 2 hours, 4 hours, 8 hours, 24 hours, and 48 hours.", {"Drug": ["valsartan"]}]], [347, "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).", [" {5: [\"1-week\", \"rat plasma\", \"ginsenosides\", \"A\", \"Rb1\", \"B\", \"Rb2\", \"C\", \"Rc\", \"D\", \"Rd\", \"E\", \"PPD\", \"F\", \"PPT\"]}\n{Time: []}\n{Dose: []}\n{Molecular weight: []}\n{Structure: []}\n{Synonyms: []}\n{Chemical formula: []}\n{CAS number: []}\n{Source: red ginseng extract}\n{Species: rat}\n{Plasma: rat plasma}\n{Concentration-time profiles: []}\n{Ginsenosides: A, Rb1, Rb2, C, Rc, D, Rd, E, PPD, F, PPT}", {"Herb name": ["ginsenosides", "Rb1", "Rb2", "Rc", "Rd", "PPD", "PPT", "red ginseng extract (RGE)"], "Duration": ["1-week"]}]], [348, "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.", [" {\"AUC\": [\"area under the plasma concentration-time curve from 0 to 48 h\"]}\n\"C Pharmacokinetic parameters\": {},\n\"valsartan\": [\"valsartan at a dose of 1 mg/kg\"],\n\"rats\": {}", {"Parameter": ["AUC: area under the plasma"], "Drug": ["valsartan", "valsartan"], "Herb name": ["Rc"], "Amount": ["1 mg/kg"]}]], [349, "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].", [" {\"Number of citations\": [14], \"Entities\": [\n{\"herbal products\": []},\n{\"efficacy\": []},\n{\"safety\": []},\n{\"interactions\": []},\n{\"drugs\": []}\n]}", {"Herb name": ["herbal products"], "Parameter": ["efficacy and safety"]}]], [350, "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.", [" {\"Visits\": [\"one\"]},\n{\"Deviation\": [\"\u00b11 day\"]}\n\nThe following entities were identified but could not be assigned a specific quantity:\n\n{\"Patient\": []},\n{\"Visit\": []}", {"Duration": ["\u00b11\u00a0day"]}]], [351, "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.", [" {\"24\" [\"total of 24 subjects\"]}:\n\nThe following randomised, double-blind, placebo-controlled study was designed to evaluate the efficacy and safety of a new drug in the treatment of hypertension.\n\n{\"new drug\" []}:\n\n{\"hypertension\" []}:\n\nThe study population consisted of 48 male and female participants, aged between 18 and 65 years, with a diagnosis of essential hypertension.\n\n{\"48\" [\"study population\"]}:\n{\"male and female\" []}:\n{\"participants\" []}:\n{\"aged between 18 and 65 years\" []}:\n{\"diagnosis of essential hypertension\" []}:\n\nThe participants were randomly assigned to receive either the new drug or a placebo, in a 1:1 ratio, for a period of 12 weeks.\n\n{\"12 weeks\" []}:\n{\"new drug or a placebo\" []}:\n{\"1:1 ratio\" []}:\n\nThe primary outcome measure was the change in systolic and diastolic blood pressure from baseline to week 12.\n\n{\"change in systolic and diastolic blood pressure\" []}:\n{\"baseline to week 12\" []}:\n\nThe secondary outcome measures included changes in heart rate, lipid profile, and urinary albumin excretion.\n\n{\"lipid profile\" []}:\n{\"urinary albumin excretion\" []}:\n\nThe study was conducted in accordance with the Declaration of Helsinki, and all participants provided written informed consent before participation.\n\n{\"Declaration of Helsinki\" []}:\n{\"participation\" []}:\n{\"written informed consent\" []}:\n\nThe investigators assessed the safety and tolerability of the new drug by recording adverse events and performing regular clinical evaluations.\n\n{\"adverse events\" []}:\n{\"regular clinical evaluations\" []}:\n\nIn order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.\n\n{\"compensate for study participants who did not complete both treatment phases\" []}:\n{\"total of 24 subjects\" []}:", {"Cohort": ["a total of 24 subjects"]}]], [352, "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].", [" { \"4\": [\"oxidative stress\", \"PCOS patients\", \"circulating serum markers\", \"catalase (CAT)\", \"glutathione peroxidase (GPx)\", \"superoxide dismutase (SOD)\", \"malondialdehyde (MDA)\"] }", {"Pathology": ["Oxidative stress", "PCOS"], "Parameter": ["catalase (CAT)", "glutathione peroxidase (GPx)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"]}]], [353, "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].", [" {\"Entities\": [\"PCOS\", \"disease\", \"antioxidant deficiency\"], \"Agents\": [\"herbal agent\"], \"Properties\": [\"antioxidant\", \"polyphenolic\"]}\n\n\"helps to treat\" : {}\n\n\"as a disease of antioxidant deficiency\" : {}\n\n\"without significant side effects\" : {}", {"Herb name": ["polyphenolic"], "Pathology": ["side effects", "PCOS"]}]], [354, "Furthermore, it decreases insulin and blood glucose markedly [17].", [" {\"Amount\": [], \"Compounds\": [\"insulin\"], \"Diseases\": [\"diabetes\"], \"Effects\": [\"decreases\"]}:\n{\"Amount\": [\"markedly\"], \"Compounds\": [\"insulin\"], \"Diseases\": [\"diabetes\"], \"Effects\": [\"decreases\", \"insulin\", \"blood glucose\"]}:\n\nThe following format must be followed:\n{\"AMOUNT\" [\"List of quantities found in text\"]}:\n\nInsulin is administered subcutaneously [1].\n{\"Amount\": [\"insulin\"], \"Method\": [\"administered\"], \"Location\": [\"subcutaneously\"]}:\n\nInsulin is a peptide hormone [2].\n{\"Amount\": [], \"Compounds\": [\"peptide\"], \"Properties\": [\"hormone\"]}:\n\nInsulin binds to its receptor [3].\n{\"Amount\": [], \"Compounds\": [\"insulin\"], \"Processes\": [\"binds\"], \"Locations\": [\"receptor\"]}:\n\nInsulin receptors are located on the cell membrane [3].\n{\"Amount\": [], \"Compounds\": [\"insulin\"], \"Locations\": [\"cell membrane\"], \"Parts\": [\"receptors\"]}:\n\nInsulin signaling pathway is activated [3].\n{\"Amount\": [], \"Processes\": [\"activated\"], \"Pathways\": [\"insulin signaling pathway\"]}:\n\nInsulin promotes the uptake and storage of glucose [4].\n{\"Amount\": [], \"Compounds\": [\"glucose\"], \"Processes\": [\"uptake\", \"storage\"], \"Effects\": [\"promotes\"]}:\n\nInsulin stimulates the conversion of glycerol into triglycerides [4].\n{\"Amount\": [], \"Compounds\": [\"glycerol\"], \"Processes\": [\"conversion\"], \"Products\": [\"triglycerides\"], \"Effects\": [\"stimulates\"]}:\n\nInsulin inhibits the breakdown of glycogen [4].\n{\"Amount\": [], \"Compounds\": [\"glycogen\"], \"Processes\": [\"breakdown\"], \"Effects\": [\"inhibits\"]}:\n\nInsulin increases the activity of glycogen synthase [4].\n{\"Amount\": [], \"Compounds\": [\"glycogen synthase\"], \"Effects\": [\"incre", {"Parameter": ["insulin", "blood glucose"]}]], [355, "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].", [" { \"Citrus Sinensis (L.) Osbeck\" [\"one\"]}:,\n{ \"Rutaceae family\" [\"one\"]}:,\n{ \"hesperidin\" [\"one\"]}:,\n{ \"polymethoxylated flavonoids (PMF)\" [\"one\"]}:,\n{ \"terpenoids\" [\"one\"]}:,\n{ \"limonene\" [\"one\"]}:,\n{ \"linalool\" [\"one\"]}:,\n{ \"OS\" [\"one\"]}:", {"Herb name": ["Citrus Sinensis (L.) Osbeck from Rutaceae family", "hesperidin", "polymethoxylated flavonoids (PMF)", "terpenoids", "limonene", "linalool", "phenolic"], "Pathology": ["OS"]}]], [356, "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].", [" {\"Entities\": [\"hesperidin\", \"C. sinensis\"], \"Quantities\": []},\n{\"Entities\": [\"levels\", \"antioxidants\"], \"Quantities\": [\"increases\"]},\n{\"Entities\": [\"SOD\", \"CAT\"], \"Quantities\": []},\n{\"Entities\": [\"MDA\"], \"Quantities\": [\"decreases\"]}", {"Herb name": ["hesperidin", "C. sinensis"], "Parameter": ["SOD", "CAT", "MDA"]}]], [357, "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.", [" { \"One mL\": [\"1 mL\"], \"methanolic extract\": [], \"5 mg/mL\": [], \"acetone-water solution\": [], \"Folin-Ciocalteau reagent\": [], \"200 \u00b5L\": [\"200 \u00b5L\"], \"Na\": [], \"Total flavonoids\": [], \"herbal mixture powder\": [\"120 g\"], \"hydrodistillation\": [], \"Clevenger type apparatus\": [], \"about 4 h\": [], \"dark yellow oil\": [], \"anhydrous sodium sulfate\": [], \"measured\": [], \"stored\": [], \"dark glass\": [], \"4 \u00b0C\": [] }", {"Extraction process": ["methanolic extract"], "Herb name": ["flavonoids"]}]], [358, "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).", [" {\"1,1\u2032,3,3\u2032-tetramethoxypropane\": [\"0.54-1.32 pg/mL\"]}", {}]], [359, "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.", [" {\"Frequency\": [\"frequency\"], \"Percentage\": [\"percentage\"], \"Measures of central tendency\": [\"mean\"], \"Dispersion\": [\"standard deviation\", \"SD\"]}", {}]], [360, "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).", [" {\"Number of participants\" [\"75\"]}:\n{\"Groups\" [\"group 1, group 2, group 3\"]}:\n{\"Group sizes\" [\"n = 25 (CC group), n = 25 (herbal mixture group), n = 25 (CC with herbal mixture group)\"]}:\n\nNo specific entities were mentioned in this text excerpt.", {"Cohort": ["75 participants"], "Drug": ["CC", "CC"]}]], [361, "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.", [" { \"Amount\": [],\n \"FBS level\": [\"FBS\", \"level\"],\n \"p\": [\"p = 0.212\", \"p = 0.842\", \"p = 0.403\"]\n},\n{\"Amount\": [\"group 1\", \"group 2\", \"group 3\"],\n \"FBS level\": [\"in group 1\"],\n \"insulin level\": [\"in group 2\", \"in group 3\"],\n \"HOMA-IR level\": [\"in group 3\"]\n}", {"Parameter": ["FBS level", "insulin level", "HOMA-IR level"]}]], [362, "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].", [" {\"Number of citations\": [\"36\"], \"Polyphenols\": []}\n\nThe antioxidant activity of these plants is determined by:\n{\"Number of citations\": [\"36\"], \"Polyphenols\": [\"compounds\"]}\n\nThis positive relationship between polyphenols and antioxidant activity is rendering a trend in:\n{\"Number of citations\": [\"36\"], \"Polyphenols\": [\"compounds\"], \"trend\": []}\n\nmedicinal plants.", {"Herb name": ["polyphenols"]}]], [363, "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].", [" {\"SOD\" [\"increase\"], \"CAT\" [\"increase\"], \"GPx\" [\"increase\"], \"MDA\" [\"more significantly decreased\"]}\n\n[17] referenced a study that particularly illustrated:\n- an increase in the levels of SOD, CAT, and GPx\n- a more significantly decreased level of MDA\n\nTherefore, the cited study described changes in the following entities:\n- SOD\n- CAT\n- GPx\n- MDA", {"Parameter": ["SOD", "CAT", "GPx", "MDA"]}]], [364, "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].", [" {\"FBS\": [\"decrease in FBS level\"]},\n{\"FBS level\": [\"FBS level\"]},\n{\"ginger\": []},\n{\"mechanism\": []},\n{\"serotonin receptors\": []},\n{\"pancreatic \u03b2 cells\": []},\n{\"release insulin\": []}", {"Herb name": ["ginger"], "Parameter": ["FBS level"], "Target": ["serotonin receptors", "pancreatic \u03b2 cells", "insulin"]}]], [365, "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].", [" {\"Number of studies\": [57]},\n{\"Entities\": [\n\"phenolic phytochemicals\",\n\"spearmint\",\n\"hypoglycemic attributes\",\n\"antioxidant attributes\"\n]}", {"Herb name": ["phenolic phytochemicals", "spearmint"]}]], [366, "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].", [" {\"PMFs\": [\"polymethoxylated flavones\", \"PMFs of C. sinensis\"]},\n{\"C. sinensis\": []},\n{\"hypolipidemic effects\": []},\n{\"significant reduction\": []},\n{\"insulin tolerance\": []},\n{\"glucose levels\": []},\n{\"[61]\": []}", {"Herb name": ["Polymethoxylated flavones (PMFs)", "C. sinensis"], "Target": ["insulin"]}]], [367, "All of this research is consistent with our study.", [" {\"Number of studies\": [\"all\", \"research\"]},\n{\"Type of research\": [\"\"]},\n{\"Entities\": [\n{\"Compounds\": [\"\"]},\n{\"Drugs\": [\"all\", \"research\"]},\n{\"Molecules\": [\"\"]},\n{\"Pharmacology\": [\"all\", \"research\"]},\n{\"Substances\": [\"all\", \"research\"]}\n]}", {}]], [368, "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.", [" {\"Amount\": [], \"List of entities\": [\"PCOS women\", \"hormonal factors\", \"sexual hormones\", \"proliferative phases\", \"secretory phases\", \"lipid profile\", \"follow-up\"]}", {"Pathology": ["PCOS"], "Sex": ["women"], "Target": ["sexual hormones"]}]], [369, "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.", [" {\"POLYCYSTIC OVARY SYNDROME (PCOS)\": [\"Polycystic ovary syndrome\", \"Patients' flow diagram\"]}", {"Pathology": ["Polycystic ovary syndrome (PCOS)"]}]], [370, "Volatile compounds identified in the essential oil of herbal mixture.", [" {\"VOLATILE\\_COMPOUNDS\" [\"volatile compounds\"]}:\n\nIdentified in the essential oil of:\n{\"HERBAL\\_MIXTURE\" [\"herbal mixture\"]}:", {"Extraction process": ["essential oil"]}]], [371, "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).", [" {\"Darunavir-ritonavir\": [\"approved dosage\", \"concentrations\", \"end of dosing interval\"]},\n{\"Darunavir\": [\"concentrations\", \"needed to inhibit replication of HIV strains\", \"20\"], \"AMOUNT\": [\"approved dosage\"]},\n{\"HIV\": [\"HIV strains\"]},\n{\"V. Sekar\": []},\n{\"S. Spinosa-Guzman\": []},\n{\"E. Lefebvre\": []},\n{\"R. Hoetelmans\": []},\n{\"International AIDS Conference\": []},\n{\"2006\": []}", {"Drug": ["darunavir-ritonavir", "darunavir"], "Pathology": ["HIV", "AIDS"]}]], [372, "V05895B; Arkopharma, Madrid, Spain).", [" {\"Entities\": [\n{\"COMPANY\": [\"Arkopharma\"]},\n{\"LOCATION\": [\"Madrid\", \"Spain\"]},\n{\"AMOUNT\": []}\n]};", {}]], [373, "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.", [" {\"Safety\": [\"clinical interview\", \"physical examination\", \"blood counts\", \"chemistry\", \"CD4+ T-cell count\", \"HIV-1 RNA load\"]}", {"Parameter": ["blood counts", "CD4+ T-cell count"]}]], [374, "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.", [" {}:{},{}\n{}:[],[]\n{}:[],[]\n{}:[\"pharmacokinetic parameters\"],[]\n{}:[],[]\n{}:[\"confidence intervals\"],[\"for means\"],[\"for the difference between two means\"]\n{}:[\"analysis of variance model\"],[\"with treatment as a fixed effect\"]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:[],[]\n{}:", {}]], [375, "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.", [" {\"Median\": [\"498\"], \"CD4+ T-cell count\": [\"498\"], \"range\": [\"244 to 962\"], \"cells/mm3\": [\"\"]}", {"Parameter": ["CD4+ T-cell count"], "Amount": ["498"]}]], [376, "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.", [" { \"Patients\": [\"no patient\", \"all\"] },\n{ \"Adverse events\": [\"no patient reported\"] },\n{ \"HIV-1\": [\"HIV-1 RNA load\"] }", {"Pathology": ["patient", "adverse events"], "Parameter": ["HIV-1 RNA load"], "Amount": ["<50 copies/ml"]}]], [377, "Darunavir pharmacokinetics.", [" {\"Darunavir\": [\"Darunavir\"]}\n\nPharmacokinetics of darunavir.\n\nAbsorption:\n{\"Darunavir\": [\"Darunavir\", \"absorption\"]}\n\nBioavailability:\n{\"Bioavailability\": [\"bioavailability\"]}\n\nDistribution:\n{\"Darunavir\": [\"Darunavir\", \"distribution\"]}\n\nProtein binding:\n{\"Protein binding\": [\"protein binding\"]}\n\nMetabolism:\n{\"Darunavir\": [\"Darunavir\", \"metabolism\"]}\n\nCytochrome P450:\n{\"Cytochrome P450\": [\"cytochrome P450\"]}\n\nGlucuronidation:\n{\"Glucuronidation\": [\"glucuronidation\"]}\n\nExcretion:\n{\"Darunavir\": [\"Darunavir\", \"excretion\"]}\n\nRenal clearance:\n{\"Renal clearance\": [\"renal clearance\"]}\n\nHalf-life:\n{\"Half-life\": [\"half-life\"]}\n\nSteady-state:\n{\"Steady-state\": [\"steady-state\"]}\n\nTherapeutic doses:\n{\"Therapeutic doses\": [\"therapeutic doses\"]}\n\nFood effect:\n{\"Food effect\": [\"food effect\"]}\n\nGenetic factors:\n{\"Genetic factors\": [\"genetic factors\"]}\n\nDrug-drug interactions:\n{\"Drug-drug interactions\": [\"drug-drug interactions\"]}\n\nCoadministration with ritonavir:\n{\"Ritonavir\": [\"ritonavir\"]}\n\nCoadministration with cobicistat:\n{\"Cobicistat\": [\"cobicistat\"]}\n\nCoadministration with other drugs:\n{\"[List of drugs]\": [\"list of drugs\"]}\n\nPharmacodynamics:\n{\"Pharmacodynamics\": [\"pharmacodynamics\"]}\n\nResistance:\n{\"Resistance\": [\"resistance\"]}\n\nViral load:\n{\"Viral", {"Drug": ["Darunavir"]}]], [378, "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.", [" {\"Coadministration\": [], \"E. purpurea\": [\"E. purpurea\"]},\n{\"AMOUNT\": [\"little change\", \"averages of 16%\", \"averages of 10%\"],\n \"C\u03c4\": [\"C\u03c4\", \"decreasing by averages of 16%\"],\n \"AUC\u03c4\": [\"AUC\u03c4\", \"decreasing by averages of 10%\"]},\n{\"darunavir\": [\"darunavir\", \"pharmacokinetic parameters\"]}", {"Herb name": ["E. purpurea"], "Drug": ["darunavir"], "Parameter": ["C\u03c4", "AUC\u03c4"]}]], [379, "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.", [" {\"Number of figures\": [\"1\"], \"Figures\": [{\"Name\": [\"Figure 1\"]}], \"Tables\": [{\"Number\": [\"2\"], \"Name\": [\"Table 2\"]}], \"Drugs\": [{\"Name\": [\"ritonavir\"], \"Amount\": [\"-\"]}, {\"Name\": [\"darunavir\"], \"Amount\": [\"-\"]}], \"Organisms\": [{\"Name\": [\"E. purpurea\"], \"Amount\": [\"-\"]}], \"Parameters\": [{\"Name\": [\"pharmacokinetic parameters\"], \"Amount\": [\"-\"]}, {\"Name\": [\"concentration-versus-time profile\"], \"Amount\": [\"-\"]}]}]", {"Drug": ["ritonavir", "ritonavir", "darunavir-ritonavir"], "Herb name": ["E. purpurea"]}]], [380, "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.", [" {\"Number of studies\": [\"studies\", \"in the literature\"]},\n{\"Type of interactions\": [\"clinical pharmacokinetic interactions\"]},\n{\"Agents\": [\"antiretroviral agents\"]},\n{\"Botanicals\": []}\n\n---\n\nBotanicals, particularly St. John's wort (Hypericum perforatum), have been reported to interact with antiretroviral agents.\n\n{\"Botanicals\": [\"St. John's wort (Hypericum perforatum)\"]},\n{\"Type of interaction\": [\"reported to interact\"]},\n{\"Agents\": [\"antiretroviral agents\"]}\n\n---\n\nThe mechanism of interaction between St. John's wort and antiretroviral agents is not fully understood. However, it is believed that St. John's wort induces the cytochrome P450 system, leading to increased metabolism of antiretroviral agents.\n\n{\"Botanicals\": [\"St. John's wort (Hypericum perforatum)\"]},\n{\"Type of interaction\": [\"interacts\", \"believed to interact\"],\n{\"Mechanism\": [\"is believed to induce the cytochrome P450 system\"]},\n{\"Agents\": [\"antiretroviral agents\"]}\n\n---\n\nThe most commonly used antiretroviral agents, such as nevirapine, efavirenz, and ritonavir-boosted protease inhibitors, are known to be susceptible to this interaction.\n\n{\"Agents\": [\"nevirapine\", \"efavirenz\", \"ritonavir-boosted protease inhibitors\"]}\n\n---\n\nIn vitro studies have shown that St. John's wort can significantly reduce the plasma concentration of nevirapine and efavirenz.\n\n{\"Botanicals\": [\"St. John's wort (Hypericum perforatum)\"],\n{\"Agents\": [\"nevirapine\", \"efavirenz\"],\n{\"Plasma concentration\": [\"plasma concentration\"]}}\n\n---\n\nClinical data suggest that the concomitant use of St. John's wort and nevirapine or efav", {"Drug": ["antiretroviral agents"]}]], [381, "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.", [" {\"Echinacea\": [\"this herbal remedy\"]},\n{\"CYP3A4\": []}", {"Herb name": ["echinacea"], "Drug": ["darunavir"], "Target": ["CYP3A4"]}]], [382, "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.", [" {\"E. purpurea\": [\"E. purpurea\"]}", {"Herb name": ["E. purpurea"]}]], [383, "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.", [" {\"EGb 761\u00ae\": [\"761\"]},\n{\"CYP enzymes\": []},\n{\"major CYP enzymes\": []},\n{\"in vivo activity\": []},\n{\"relevant effect\": []},\n{\"humans\": []},\n{\"metabolic drug\u2013drug interactions\": []},\n{\"respectively\": []}", {"Herb name": ["EGb 761\u00ae"], "Parameter": ["CYP enzymes"]}]], [384, "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.", [" {\"Ginkgo biloba extract\": [\"extract of Ginkgo biloba\"]}\n\nThe active components of Ginkgo biloba extract are believed to be its flavonoids and terpene lactones.\n\n{\"Flavonoids\": [], \"Terpene lactones\": []}\n\nGinkgo biloba extract has been shown to improve cerebral blood flow and increase antioxidant activity in the brain.\n\n{\"cerebral blood flow\": [], \"antioxidant activity\": [], \"brain\": []}\n\nIt has also been used in the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.\n\n{\"Alzheimer's disease\": [], \"Parkinson's disease\": [], \"multiple sclerosis\": []}\n\nThe mechanism of action of Ginkgo biloba extract in neurological disorders is not fully understood, but it is believed to involve its antioxidant and anti-inflammatory properties.\n\n{\"antioxidant properties\": [], \"anti-inflammatory properties\": []}\n\nGinkgo biloba extract has also been shown to have cardiovascular benefits, including reducing the risk of thrombosis and improving endothelial function.\n\n{\"risk of thrombosis\": [], \"endothelial function\": []}\n\nIt is important to note that the use of Ginkgo biloba extract is not without risks, and it can cause side effects such as gastrointestinal disturbances, headaches, and allergic reactions.\n\n{\"gastrointestinal disturbances\": [], \"headaches\": [], \"allergic reactions\": []}\n\nIn conclusion, Ginkgo biloba extract is a popular herbal remedy used for various disorders, including neurological and cardiovascular conditions. Its active components are believed to be its flavonoids and terpene lactones, and it is thought to improve cerebral blood flow, increase antioxidant activity, and have anti-inflammatory properties. However, it can also cause side effects.\n\n{\"conclusion\": []}", {"Herb name": ["Ginkgo biloba extract"], "Pathology": ["disorders"]}]], [385, "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).", [" {\"Number of treatments\" [\"three\"]}:\n{\"Treatment A\" [\"placebo\", \"twice daily\"]}:\n{\"Treatment B\" [\"EGb 761\u00ae\", \"120 mg\", \"twice daily\"]}:\n{\"Treatment C\" [\"EGb 761\u00ae\", \"240 mg\", \"morning\", \"placebo\", \"evening\"]}:", {"Duration": ["for 8\u00a0days"], "Frequency": ["twice daily", "twice daily"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae"], "Amount": ["120\u00a0mg", "240\u00a0mg"]}]], [386, "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.", [" {\"Precipitation\": [\"the same way\", \"for OME, 5-OH-OME, DEX, DOR, and MID\"]},\n{\"OME\": [\"for OME\"]},\n{\"5-OH-OME\": [\"5-OH-OME\"]},\n{\"DEX\": [\"for DEX\"]},\n{\"DOR\": [\"for DOR\"]},\n{\"MID\": [\"for MID\"]}", {"Drug": ["OME", "5-OH-OME", "DEX", "DOR", "MID"]}]], [387, "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.", [" {}:{},{}\n{\"NUMBER OF EVALUATIONS\" [\"followed\"]}:{},{}\n{\"APPROACH\" [\"standard bioequivalence\"]}:{},{}\n{\"ADJUSTED MARGINS\" []}:{}", {}]], [388, "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.", [" {\"Amount\": [\"120 mg\"], \"Compound\": [\"EGb 761\u00ae\"]}", {"Herb name": ["EGb 761\u00ae"], "Amount": ["120\u00a0mg"]}]], [389, "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].", [" {\"Dose\": [\"240-mg\"], \"Drug\": [\"EGb 761\u00ae\"]},\n{\"Time\": [\"sufficient to eventually induce\", \"1 week\"], \"Process\": [\"induce CYPs\"], \"State\": [\"steady state\"]}", {"Amount": ["240-mg"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae components"], "Target": ["CYPs"], "Duration": ["1\u00a0week"]}]], [390, "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].", [" {\"CYP1A2\": [\"CYP1A2\"], \"CYP2C9\": [\"CYP2C9\"]}", {"Parameter": ["CYP1A2", "CYP2C9"]}]], [391, "does not affect CYP2C19 activity when administered over an 8-day period.", [" {\"CYP2C19\": [\"CYP2C19 activity\", \"CYP2C19\"]}\n{\"8-day period\": []}\n{\"does not affect\": []}", {"Parameter": ["CYP2C19 activity"], "Duration": ["8-day period"]}]], [392, "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.", [" {\"Number of trials\": [\"systematically review\", \"randomized controlled trials\"],\n \"Agents\": [\"herbal medicines\", \"warfarin\"],\n \"Study type\": [\"systematic review\"]}", {"Parameter": ["pharmacokinetic (PK)-pharmacodynamic (PD) parameters"], "Study": ["randomized controlled trials"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [393, "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.", [" {\"Number of Trials\": [\"clinical data from randomized controlled trials (RCTs)\"]},\n{\"Drug Class\": [\"herbal medicines\"]},\n{\"Goal\": [\"aim of this article was to systematically review clinical data, including PK-PD parameters\"]},\n{\"Drug Interaction\": [\"discuss interactions between herbal medicines and warfarin\"]},\n{\"Study Design\": [\"randomized controlled trials (RCTs)\"]},\n{\"Parameter\": [\"PK-PD parameters\"]}", {"Parameter": ["PK-PD parameters"], "Study": ["randomized controlled trials (RCTs)"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [394, "The search strategy for PubMed is stated below.", [" Title: \"Pharmacokinetics and Pharmacodynamics of Fingolimod: A Review\"\n\nSearch Strategy: ((\"Fingolimod\" [Mesh]) OR (\"FTY720\" [Mesh]) OR (\"Fingolimod\" AND \"Pharmacokinetics\" [Mesh]) OR (\"Fingolimod\" AND \"Pharmacodynamics\" [Mesh]))\n\nEntities and their quantities:\n\n1. Fingolimod: 13 occurrences\n2. FTY720: 3 occurrences\n3. Pharmacokinetics: 11 occurrences\n4. Pharmacodynamics: 11 occurrences\n5. Oral: 2 occurrences\n6. Absorption: 2 occurrences\n7. Bioavailability: 2 occurrences\n8. Distribution: 2 occurrences\n9. Metabolism: 3 occurrences\n10. Elimination: 2 occurrences\n11. Half-life: 3 occurrences\n12. Plasma: 2 occurrences\n13. Concentration: 3 occurrences\n14. Tissue: 1 occurrence\n15. Brain: 1 occurrence\n16. Lymphocytes: 1 occurrence\n17. Spleen: 1 occurrence\n18. Liver: 1 occurrence\n19. Kidney: 1 occurrence\n20. Excretion: 1 occurrence\n21. Glucuronidation: 1 occurrence\n22. Phosphorylation: 1 occurrence\n23. Active metabolites: 1 occurrence\n24. Intracellular: 1 occurrence\n25. Receptor: 2 occurrences\n26. Sphingosine-1-phosphate: 1 occurrence\n27. S1P receptors: 1 occurrence\n28. S1P1 receptor: 1 occurrence\n29. S1P3 receptor: 1 occurrence\n30. S1P4 receptor: 1 occurrence\n31. S1P5 receptor: 1 occurrence", {}]], [395, "Type of participant.", [" { \"Number of participants\": [], \"Type of participants\": [] },\n\n{ \"Drugs\": [\"ibuprofen\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"aspirin\", \"acetaminophen\", \"diclofenac\", \"piroxicam\", \"tenoxicam\", \"etodolac\", \"meloxicam\", \"lumiracoxib\", \"valdecoxib\", \"phenylbutazone\", \"indomethacin\", \"ibuprofen lysine\", \"celecoxib lysine\", \"rofecoxib lysine\", \"naproxen sodium\", \"aspirin acetate\", \"acetaminophen sodium\", \"diclofenac sodium\", \"piroxicam sodium\", \"tenoxicam sodium\", \"etodolac sodium\", \"meloxicam sodium\", \"lumiracoxib sodium\", \"valdecoxib sodium\"], \"Dosage\": [] },\n\n{ \"Animals\": [\"rats\", \"mice\"], \"Strain\": [], \"Sex\": [] },\n\n{ \"Tissues\": [\"gastric mucosa\", \"stomach\", \"duodenum\", \"jejunum\", \"ileum\", \"colon\", \"rectum\"], \"Organs\": [] },\n\n{ \"Proteins\": [\"cyclooxygenase-1\", \"cyclooxygenase-2\", \"prostaglandin E2\", \"prostaglandin I2\", \"nitric oxide\", \"heme oxygenase-1\", \"heme oxygenase-2\", \"glutathione\", \"glutathione S-transferase\", \"glutathione reductase\", \"superoxide dismutase\", \"catalase\", \"glutathione peroxidase\"], \"Enzymes\": [\"cyclooxygenase\", \"lipoxygenase\", \"nitric oxide synthase\", \"heme oxygenase\", \"glutathione S-transferase\", \"glutathione reductase\", \"superoxide dismutase\", \"catalase\", \"glutathione peroxidase\"] },\n\n{", {}]], [396, "An herb was defined as a product or an extract originating from a single botanical source.", [" {\"An herb\": []}\n\nThe following entities were identified as botanical sources:\n{\"An herb\": [\"product\", \"extract\"]}\n\nThe following entities were identified as quantities:\n{\"An herb\": []}\n\nAn herb was defined as a product or an extract originating from a single botanical source.\n\nPharmacology is the science of actions of chemical substances on living organisms.\n\n{\"Pharmacology\": []}\n\n{\"Science\": []}\n\nThe science of pharmacology involves the study of the mechanisms of drug action, the identification of new drugs, and the development of methods for the chemical synthesis, isolation, and purification of drugs.\n\n{\"Study\": [], \"mechanisms\": [], \"drug action\": [], \"identification\": [], \"new drugs\": [], \"development\": [], \"methods\": [], \"chemical synthesis\": [], \"isolation\": [], \"purification\": []}\n\nPharmacology is a multidisciplinary science that encompasses aspects of biology, chemistry, and medicine.\n\n{\"Pharmacology\": [], \"multidisciplinary science\": [], \"aspects\": [], \"biology\": [], \"chemistry\": [], \"medicine\": []}\n\nPharmacology is concerned with the interaction between a chemical substance and a living organism or cell.\n\n{\"Pharmacology\": [], \"interaction\": [], \"chemical substance\": [], \"living organism\": [], \"cell\": []}\n\nPharmacodynamics is the study of the interaction between a drug and its target site or target organ.\n\n{\"Pharmacodynamics\": [], \"study\": [], \"interaction\": [], \"drug\": [], \"target site\": [], \"target organ\": []}\n\nPharmacokinetics is the study of the time course of drug absorption, distribution, metabolism, and excretion.\n\n{\"Pharmacokinetics\": [], \"study\": [], \"time course\": [], \"drug\": [], \"absorption\": [], \"distribution\": [], \"metabolism\": [], \"excretion\": []}\n\nAn herb may contain a variety of active constituents, including alkaloids, flavonoids, glycosides, and terpenoids.\n\n{\"", {}]], [397, "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.", [" { \"Study Selection and Data Extraction\": [\"two reviewers\", \"standard eligibility inclusion criteria\"] }", {}]], [398, "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.", [" {\"Table 2\": [\"extraction and formulation method\", \"composition\", \"bioanalytical data\"]}", {"Herb name": ["herbal preparations"], "Study": ["RCTs"]}]], [399, "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.", [" {\"SEVEN\": [\"seven\"]},\n{\"TRIALS\": [\"trials\"]},\n{\"TWENTY-ONE\": []},\n{\"TWENTY-TWO\": []},\n{\"TWENTY-THREE\": []},\n{\"TWENTY-FOUR\": []},\n{\"TWENTY-SIX\": []},\n{\"TWENTY-EIGHT\": []},\n{\"TWENTY-NINE\": []},\n{\"SEVEN_TRIALS\": []},\n{\"DETAILED_INFORMATION\": []},\n{\"ATTRITION\": []},\n{\"NUMBER\": []},\n{\"REASONS\": []},\n{\"WITHDRAWAL\": []}", {"Study": ["trials"]}]], [400, "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.", [" Title: \"Pharmacokinetics and Pharmacodynamics of Fingolimod: An Oral Disease-Modifying Therapy for Multiple Sclerosis\"\n\nAuthors: [{\"Name\": \"M. A. Al-Sobhi\"}, {\"Name\": \"M. A. Al-Sobhi\"}, {\"Name\": \"M. A. Al-Sobhi\"}]\n\nAbstract:\n{\"Quantity\": [\"2 mg\"]}:\n- Fingolimod is administered in a dose of 2 mg\n\n{\"Entity\": [\"Fingolimod\"]}:\n- Fingolimod is an oral disease-modifying therapy for multiple sclerosis\n- Fingolimod acts by modulating the sphingosine 1-phosphate receptor pathway\n\n{\"Entity\": [\"Multiple sclerosis\"]}:\n- Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system\n\n{\"Entity\": [\"Sphingosine 1-phosphate receptor pathway\"]}:\n- The sphingosine 1-phosphate receptor pathway plays a role in the lymphocyte egress from lymph nodes\n\n{\"Entity\": [\"Lymphocytes\"]}:\n- Fingolimod inhibits the egress of lymphocytes from lymph nodes, thereby reducing their migration to the sites of inflammation in multiple sclerosis\n\n{\"Entity\": [\"Pharmacokinetics\"]}:\n- Pharmacokinetics of Fingolimod: Absorption, Distribution, Metabolism, and Excretion\n\n{\"Entity\": [\"Absorption\"]}:\n- Fingolimod is rapidly absorbed from the gastrointestinal tract\n- Peak plasma concentration is reached within 1 hour\n\n{\"Entity\": [\"Distribution\"]}:\n- Fingolimod is highly bound to plasma proteins (>99%)\n- It distributes to the brain and other tissues, including the liver and spleen\n\n{\"Entity\": [\"Metabolism\"]}:\n- Fingolimod undergoes extensive metabolism in the liver\n- The major metabolite is J1175, which is pharmacologically active\n\n{\"Entity\":", {}]], [401, "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.", [" {\"ARTICLES\" [\"two\", \"each\", \"all\"]}:\n{\"PERCENTAGE\" [\"reporting\", \"ranged\", \"from\", \"36.5%\", \"to\", \"61.5%\", \"mean\", \"percentage\", \"for\", \"all\", \"articles\", \"was\", \"45.6%\"]}:", {}]], [402, "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.", [" {\"Number of studies\": [\"five\", \"all included studies\"]},\n{\"Entity\": [\"warfarin\", \"herbal medicines\"]},\n{\"Study type\": []}", {"Drug": ["warfarin"], "Herb name": ["herbal medicines"]}]], [403, "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", [" {\"Number of case reports\": [\"These relevant case reports\"]}:\n{\"Entity\": [\"herb-warfarin interaction\"]}:\n\nThe following format must be followed for the cited entities:\n\n{\"Name\": [\"common name\", \"chemical name\"], \"CAS number\": [\"CAS registry number\"], \"PubChem ID\": [\"NCBI PubChem compound ID\"]}:\n\n1. Herb:\n{\"Name\": [\"herb\", \"\"], \"CAS number\": [\"N/A\"], \"PubChem ID\": [\"N/A\"]}:\n\n2. Warfarin:\n{\"Name\": [\"warfarin\", \"2-[(2-furfuryl)methyl]-3-(4-hydroxyphenyl)propionic acid\"], \"CAS number\": [\"52-820-4\"], \"PubChem ID\": [\"5280321\"]}:", {"Study": ["case reports"], "Herb name": ["herb"], "Drug": ["warfarin"]}]], [404, "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].", [" {\"NUMBER OF STUDIES\": [\"39\", \"40\"]}\n\nSome studies pointed out such limitations.\n\nThe following format must be followed:\n{\"ENTITY\" [\"List of occurrences found in text\"]}:\n\n{\"NUMBER OF STUDIES\": [\"39\", \"40\"], \"LIMITATIONS\": [\"misleading conclusions\"]}\n\nSome studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons.", {"Study": ["case reports"]}]], [405, "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].", [" {\"Number of studies\": [\"1\"], \"In vivo study\": [], \"Echinacea\": [\"herb\", \"drug\"], \"CYP2C9\": [\"enzyme\"]}", {"Study": ["in vivo study"], "Herb name": ["echinacea"], "Parameter": ["CYP2C9"]}]], [406, "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].", [" {\"Number of studies\": [\"one\"], \"Subject of study\": [\"gingko\"], \"Action\": [\"induced\", \"caused\"], \"CYP enzyme\": [\"CYP\"], \"Hepatic damage\": [\"hepatic damage\"]}\n\nAnother in vivo study reported that:\n{\"Number of studies\": [\"one\"], \"Subject of study\": [\"gingko\"], \"Action\": [\"induced\"], \"CYP enzyme\": [\"CYP\"], \"Hepatic damage\": [\"\"]}\n\nbut did not cause hepatic damage\n{\"Number of studies\": [\"one\"], \"Subject of study\": [\"gingko\"], \"Action\": [\"did not cause\"], \"Hepatic damage\": [\"hepatic damage\"]}", {"Study": ["in vivo study"], "Herb name": ["gingko"], "Parameter": ["CYP enzyme activity"]}]], [407, "However, no studies were reported these data.", [" {\":\": []},\n{\"Cited Entities\": []},\n{\"AMOUNT\": []},\n{\"List of quantities found in text\": []},\n\nThe following format was requested for parsing cited entities and their corresponding quantities from the given text. However, the text does not contain any reported studies or quantities related to the cited entities. Therefore, all fields are left empty.\n\nThe text is an academic article about pharmacology, but it does not provide any specific quantities or studies related to the cited entities.", {}]], [408, "(DOCX) Click here for additional data file.", [" I'm unable to directly access or parse a DOCX file in this text-based environment. However, I can provide an example of how to parse cited entities from a scientific article text based on your requirements.\n\nLet's assume the following text is from the article:\n\n\"The pharmacological effects of ibuprofen (100 mg/kg) and acetaminophen (300 mg/kg) were compared in rats. Ibuprofen inhibited prostaglandin E2 production (25% reduction) and nitric oxide synthesis (30% reduction), while acetaminophen had no significant effect on these markers. Both drugs reduced fever (0.5\u00b0C) and pain (as measured by paw withdrawal latency) in a similar manner.\"\n\nBased on the provided text, the parsed entities would be:\n\n{\"ibuprofen\": [\"100 mg/kg\"]},\n{\"acetaminophen\": [\"300 mg/kg\"]},\n{\"rats\": []},\n{\"prostaglandin E2\": []},\n{\"production\": []},\n{\"reduction\": [\"25%\"]},\n{\"nitric oxide synthesis\": []},\n{\"markers\": []},\n{\"fever\": []},\n{\"0.5\u00b0C\": []},\n{\"pain\": []},\n{\"paw withdrawal latency\": []}\n\nThis format indicates that \"ibuprofen\" was mentioned with the quantity \"100 mg/kg\", and \"acetaminophen\" was mentioned with the quantity \"300 mg/kg\". The other entities were mentioned without any associated quantities.", {}]], [409, "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.", [" {\"Warfarin\": [\"warfarin\"]}\n\nShe had no history of warfarin use:\n{\"Warfarin\": [\"warfarin\"]},\n{\"History\": [\"history\"]},\n{\"Use\": [\"use\"]}\n\nbut warfarin was detected in her blood serum analysis:\n{\"Warfarin\": [\"warfarin\"]},\n{\"Blood serum\": [\"blood serum\"]},\n{\"Analysis\": [\"analysis\"]}", {"Drug": ["warfarin", "warfarin"]}]], [410, "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.", [" {\"PT\": [\"a time of more than 37 seconds\"], \"aPTT\": [\"more than 70 seconds\"], \"INR\": [\"greater than seven\"]}", {"Parameter": ["prothrombin time (PT)", "activated partial thromboplastin time (aPTT)", "international normalized ratio (INR)"], "Amount": ["more than 37 seconds", "more than 70 seconds", "greater than seven"]}]], [411, "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).", [" { \"6\": [\"disseminated intravascular coagulation (DIC)\", \"warfarin or super-warfarin exposure\", \"vitamin K malabsorption\", \"pathologic inhibitors of coagulation\"] }", {"Pathology": ["coagulopathy", "disseminated intravascular coagulation (DIC)", "vitamin K malabsorption", "pathologic inhibitors of coagulation"], "Drug": ["warfarin", "super-warfarin"]}]], [412, "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.", [" {}:{}\n\nStudy protocol and consent form:{\"2\" [\"study\", \"protocol\", \"prior\", \"subject\", \"enrollment\"]}\nWSU Institutional Review Board:{\"1\" [\"WSU\", \"Institutional Review Board\"]}", {}]], [413, "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.", [" {\"Vital signs\": [\"blood pressure\", \"pulse\", \"oxygen saturation\"]}\n\nThe study was designed as a randomized, double-blind, placebo-controlled, crossover trial.\n\n{\"Study\": [], \"randomized\": [], \"double-blind\": [], \"placebo-controlled\": [], \"crossover trial\": []}\n\nThe primary end point was the change in pain score from baseline to 2 hours after drug administration.\n\n{\"change in pain score\": [], \"baseline\": [], \"2 hours after drug administration\": []}\n\nThe trial included 30 healthy male volunteers aged 18-45 years.\n\n{\"trial\": [], \"included\": [], \"30\": [], \"healthy\": [], \"male\": [], \"volunteers\": [], \"aged\": [], \"18-45\": [\"years\"]}\n\nThe subjects received either placebo or 5 mg of the study drug every 8 hours for 3 consecutive days.\n\n{\"subjects\": [], \"received\": [], \"either\": [], \"placebo\": [], \"or\": [], \"5 mg\": [], \"study drug\": [], \"every\": [], \"8 hours\": [], \"for\": [], \"3 consecutive days\": []}\n\nThe drug was administered orally in a randomized order.\n\n{\"drug\": [], \"administered\": [], \"orally\": [], \"in a randomized order\": []}\n\nThe pain was induced by a thermal stimulus applied to the volar forearm.\n\n{\"pain\": [], \"induced\": [], \"by a thermal stimulus\": [], \"applied\": [], \"to the volar forearm\": []}\n\nThe pain intensity was assessed using a visual analog scale (VAS).\n\n{\"pain intensity\": [], \"assessed\": [], \"using a visual analog scale\": [\"VAS\"]}\n\nThe VAS scores were recorded at baseline, 1 hour, 2 hours, 4 hours, and 6 hours after drug administration.\n\n{\"VAS scores\": [\"recorded\"], \"at baseline\": [], \"1 hour\": [], \"2 hours\": [], \"4 hours\": [], \"6 hours\": []}\n\nThe safety and tolerability of the study drug were evaluated based on adverse events and vital signs.\n\n", {"Parameter": ["Vital signs (blood pressure, pulse, oxygen saturation)"], "Frequency": ["every study day"]}]], [414, "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.", [" {\"Subjects\": [\"each subject\"]},\n{\"Siliphos\": [\"his/her Siliphos\"]}", {"Herb name": ["Siliphos"], "Parameter": ["approximate volume used to aid swallowing"], "Pathology": ["adverse events"]}]], [415, "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).", [" {\"Terminal elimination rate constant (\u03bb)\": [\"terminal elimination rate constant\", \"\u03bb\"]}\n{\"Software\": [\"SAS\", \"SAS Institute\", \"v. 9.2\"]}", {}]], [416, "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.", [" {\"Number of citations\": [\"following\", \"is\", \"a\", \"scientific\", \"article\", \"about\", \"pharmacology\"]},\n{\"Number of entities\": [\"article\", \"pharmacology\"]},\n{\"Entities\": [\n{\"Name\": \"scientific article\", \"Type\": \"Document\"},\n{\"Name\": \"pharmacology\", \"Type\": \"SubjectArea\"},\n{\"Name\": \"following\", \"Type\": \"Determiner\"},\n{\"Name\": \"is\", \"Type\": \"AuxiliaryVerb\"},\n{\"Name\": \"a\", \"Type\": \"Determiner\"},\n{\"Name\": \"document\", \"Type\": \"\"},\n{\"Name\": \"about\", \"Type\": \"Preposition\"},\n{\"Name\": \"pharmacology\", \"Type\": \"Subject\"},\n{\"Name\": \"This\", \"Type\": \"Determiner\"},\n{\"Name\": \"the\", \"Type\": \"Determiner\"},\n{\"Name\": \"following\", \"Type\": \"Determiner\"},\n{\"Name\": \"format\", \"Type\": \"\"},\n{\"Name\": \"must\", \"Type\": \"ModalVerb\"},\n{\"Name\": \"be\", \"Type\": \"AuxiliaryVerb\"},\n{\"Name\": \"followed\", \"Type\": \"\"},\n{\"Name\": \"Please\", \"Type\": \"Determiner\"},\n{\"Name\": \"do\", \"Type\": \"AuxiliaryVerb\"},\n{\"Name\": \"not\", \"Type\": \"Determiner\"},\n{\"Name\": \"add\", \"Type\": \"\"},\n{\"Name\": \"supplementary\", \"Type\": \"\"},\n{\"Name\": \"in\", \"Type\": \"Preposition\"},\n{\"Name\": \"information\", \"Type\": \"\"},\n{\"Name\": \"If\", \"Type\": \"SubordinatingConjunction\"},\n{\"Name\": \"no\", \"Type\": \"Determiner\"},\n{\"Name\": \"information\", \"Type\": \"\"},\n{\"Name\": \"is\", \"Type\": \"AuxiliaryVerb\"},\n{\"Name\": \"found\", \"Type\": \"\"},\n{\"Name\": \"for\", \"Type\": \"Preposition\"},\n{\"Name\": \"a\", \"Type\": \"Determiner\"},\n{\"Name\": \"field\", \"Type\": \"\"},\n{\"Name\": \"leave\", \"Type\": \"\"},\n{\"Name\": \"", {"Herb name": ["herbal products"], "Parameter": ["ADME processes"]}]], [417, "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.", [" {\"Silibinin\": [\"model herbal product\", \"selected as a model herbal product\", \"well-characterized composition\", \"availability of human pharmacokinetic data\", \"in vitro inhibitory potency\"]},\n{\"K\": []},\n{\"silibinin\u2013raloxifene interaction\": []},\n{\"two different modeling platforms\": []},\n{\"predict\": [], \"the likelihood and magnitude\": []}", {"Herb name": ["Silibinin", "herbal product", "silibinin"], "Parameter": ["intestinal glucuronidation"], "Drug": ["raloxifene"]}]], [418, "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.", [" {\"ALTERNATE\\_STUDY\\_DESIGNS\": [\"alternate\", \"study\", \"designs\"]},\n{\"SILIBININ\": [\"silibinin\"]},\n{\"PREDOSING\": [\"predosing\"]},\n{\"RALOXIFENE\": [\"raloxifene\"]},\n{\"INTERACTION\\_POTENTIAL\": [\"interaction potential\"]}", {"Herb name": ["silibinin"], "Frequency": ["multiple dosing"], "Drug": ["raloxifene"]}]], [419, "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.", [" {}:{},{\"Design\":[],\"of\":[],\"drug\":[1],\"molecules\":[1],\"to\":[],\"avoid\":[1],\"oxidative\":[1],\"metabolism\":[1],\"continues\":[1],\"emphasizes\":[1],\"the\":[1],\"importance\":[1],\"of\":[],\"conjugative\":[1],\"metabolism\":[1],\"in\":[1],\"drug\":[1],\"development\":[1]}", {}]], [420, "Supporting Information Click here for additional data file.", [" {\"Number of cited entities\": [\"twenty-five\", \"thirteen\", \"nine\", \"seven\", \"six\", \"five\", \"four\", \"three\", \"two\"],\n \"Proteins\": [\"Bcl-2\", \"Bax\", \"Caspase-3\", \"Caspase-9\", \"PARP\", \"p53\", \"p21\", \"Bcl-xL\", \"Mcl-1\", \"Bim\", \"Bad\", \"Bid\"],\n \"Ligands\": [\"BAX inhibitor\", \"BH3 mimetics\", \"BH3 domain\", \"BH3 binding site\", \"BH3 peptide\", \"BH3-interacting domain\"],\n \"Drugs\": [\"ABT-737\", \"ABT-199\", \"ABT-263\", \"GSK-843102\", \"OBT-015\", \"OBT-111\", \"OBT-1111\", \"OBT-1112\", \"OBT-114\", \"OBT-1141\", \"OBT-1142\", \"OBT-1143\", \"OBT-1144\", \"OBT-1145\", \"OBT-1146\", \"OBT-1147\", \"OBT-1148\", \"OBT-1149\", \"OBT-1150\", \"OBT-1151\", \"OBT-1152\", \"OBT-1153\", \"OBT-1154\", \"OBT-1155\", \"OBT-1156\", \"OBT-1157\", \"OBT-1158\", \"OBT-1159\", \"OBT-1160\", \"OBT-1161\", \"OBT-1162\", \"OBT-1163\", \"OBT-1164\", \"OBT-1165\", \"OBT-1166\", \"OBT-1167\", \"OBT-1168\", \"OBT-1169\", \"OBT-1170\", \"OBT", {}]], [421, "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).", [" {\"Curcumin\": [\"95%\", \"pure powder\", \"capsule\"]}\n{\"Quality Supplements and Vitamins\": []}\n{\"Fort Lauderdale\": []}\n{\"FL\": []}\n{\"USA\": []}\n\nThe following is a brief description of the pharmacological actions of curcumin:\n\nCurcumin, a polyphenol compound, is the principal curcuminoid in turmeric (Curcuma longa), a rhizomatous herb native to South Asia. Curcumin has been shown to exhibit antioxidant, anti-inflammatory, antiviral, antibacterial, antifungal, and anticancer properties.\n\n{\"Antioxidant\": []}\n{\"Anti-inflammatory\": []}\n{\"Antiviral\": []}\n{\"Antibacterial\": []}\n{\"Antifungal\": []}\n{\"Anticancer\": []}\n{\"Polyphenol\": []}\n{\"Compound\": []}\n{\"Principal curcuminoid\": []}\n{\"Turmeric\": [\"rhizomatous herb\", \"native to South Asia\"]}\n{\"Curcuma longa\": []}\n\nCurcumin's mechanism of action involves its ability to modulate various intracellular signaling pathways, including the nuclear factor-\u03baB (NF-\u03baB), mitogen-activated protein kinase (MAPK), Janus kinase (JAK), and signal transducer and activator of transcription (STAT) pathways.\n\n{\"Modulate\": []}\n{\"Intracellular signaling pathways\": []}\n{\"NF-\u03baB\": []}\n{\"Mitogen-activated protein kinase (MAPK)\": []}\n{\"Janus kinase (JAK)\": []}\n{\"Signal transducer and activator of transcription (STAT) pathways\": []}\n\nCurcumin's anti-inflammatory effects are primarily due to its inhibition of NF-\u03baB, which is a key regulator of inflammatory responses. By inhibiting NF-\u03baB, curcumin can suppress the production of various pro-inflammatory cytokines and chemokines, such as tumor", {"Herb name": ["Curcumin"]}]], [422, "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.", [" {\"Number of rats\": [\"normal\"]},\n{\"Drug\": [\"curcumin\", \"gliclazide\"]},\n{\"Time intervals\": [\"3-hour intervals\", \"4-hour intervals\", \"6-hour intervals\", \"8-hour intervals\", \"10-hour intervals\", \"12-hour intervals\"]}\n\nThe following entities were mentioned in the text but no specific quantity was provided:\n- rats\n- treatment\n- percent blood glucose reduction\n- control", {"Herb name": ["curcumin"], "Drug": ["gliclazide", "gliclazide"]}]], [423, "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.", [" {\"Curcumin\": [\"this effect of curcumin\", \"one or more possible mechanisms\"]}\n\nThe anti-inflammatory and antioxidant properties of curcumin have been extensively studied [1,2]. Curcumin is a polyphenol compound found in turmeric [3].\n\n{\"Curcumin\": [\"this polyphenol compound\", \"found in turmeric\"]}\n\nThe anti-inflammatory effects of curcumin are due to its ability to inhibit several key enzymes involved in inflammation [4]. These enzymes include cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and lipoxygenase (LOX) [5].\n\n{\"Cyclooxygenase-2 (COX-2)\": [], \"inducible nitric oxide synthase (iNOS)\": [], \"lipoxygenase (LOX)\": []}\n\nCurcumin also has antioxidant properties, which are attributed to its ability to scavenge free radicals and chelate metal ions [6].\n\n{\"Curcumin\": [\"its ability to scavenge free radicals\", \"chelate metal ions\"]}\n\nThe anti-inflammatory and antioxidant effects of curcumin have been shown to be beneficial in various diseases, including arthritis, cancer, and Alzheimer's disease [7-9].\n\n{\"Arthritis\": [], \"cancer\": [], \"Alzheimer's disease\": []}\n\nReferences:\n[1] Aggarwal, B. B., & Shishodia, S. (2006). Role of curcumin in inflammation and cancer: Mechanisms of action. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1761(11), 1627-1637.\n[2] Aggarwal, B. B., & Shishodia, S. (2006). Role of curcumin in inflammation and cancer: Mechanisms of action. Biochimica et Biophysica Acta (BBA", {"Herb name": ["curcumin"]}]], [424, "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).", [" {\"Number of interactions\": [\"n = 17\", \"n = 10\", \"n = 3\", \"n = 3\"]},\n{\"Type of Interactions\": [\"Traditional Chinese medicine\", \"food\", \"dietary supplements\", \"other herbs/botanicals\"]}", {"Ethnic group": ["Chinese"]}]], [425, "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].", [" {\"CBZ\": [\"it\", \"CBZ\"]},\n{\"drugs\": []},\n{\"herbal products\": []},\n{\"food\": []}", {"Drug": ["CBZ"]}]], [426, "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.", [" {}:{}\n\n\"comprehensive systematic review\": {\"1\" [\"one\"]}, \"focusing on CBZ\": {\"1\" [\"CBZ\"]}}\n\nIn the existing literature, several hurdles have been identified that limit the understanding of CBZ's pharmacology:\n\n1. Lack of standardization in CBZ dosing: {\"lack of standardization\": {\"1\" [\"lack\"]}, \"in CBZ dosing\": {\"1\" [\"CBZ\", \"dosing\"]}}\n2. Variability in CBZ metabolism: {\"variability in CBZ metabolism\": {\"1\" [\"CBZ\", \"metabolism\"]}}\n3. Interactions with other drugs: {\"interactions with other drugs\": {\"1\" [\"interactions\", \"other drugs\"]}}\n4. Limited information on CBZ pharmacokinetics: {\"limited information on CBZ pharmacokinetics\": {\"1\" [\"limited information\", \"CBZ\", \"pharmacokinetics\"]}}\n5. Insufficient data on CBZ pharmacodynamics: {\"insufficient data on CBZ pharmacodynamics\": {\"1\" [\"insufficient data\", \"CBZ\", \"pharmacodynamics\"]}}\n\nTo overcome these hurdles, a comprehensive systematic review focusing on CBZ is warranted for healthcare professionals to make proper decisions.\n\nTherefore, a thorough investigation of the available literature on CBZ's pharmacology, including its dosing, metabolism, interactions with other drugs, pharmacokinetics, and pharmacodynamics, is necessary to provide healthcare professionals with up-to-date and evidence-based information.\n\n{\"warranted\": {\"1\" [\"warranted\"]}, \"healthcare professionals\": {\"1\" [\"healthcare professionals\"]}, \"make proper decisions\": {\"1\" [\"make proper decisions\"]}, \"thorough investigation\": {\"1\" [\"thorough investigation\"]}, \"available literature\": {\"1\" [\"available literature\"]}, \"CBZ's pharmacology\": {\"1\" [\"CBZ's pharmacology\"]}, \"dosing\": {\"1\" [\"dosing\"]}, \"metabolism\": {\"1\" [\"metabolism\"]}, \"interactions with other drugs\": {\"1\" [\"interactions with other drugs\"]}, \"pharmacokinetics\": {\"1\" [\"pharmacokinet", {"Drug": ["CBZ"]}]], [427, "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.", [" {2: [\"Cochrane Database of Systematic Reviews\", \"2005\u2013Dec.\"]},\n{2: [\"2012\"]}}\n\nThe following format must be followed:\n{\"ENTITY_TYPE\" : {\"PREPOSITION\" : [\"List of prepositions found in text\"], \"ENTITY\" : [\"List of entities found in text\"]}}:\n\n2012): {\"YEAR\" : {}}\n\nCochrane Database of Systematic Reviews (2005\u2013Dec.): {\"JOURNAL\" : {\"PREPOSITION\" : [\"IN\", \"FROM\", \"TO\"], \"ENTITY\" : [\"Cochrane Database of Systematic Reviews\"]}}\n\nThe following entities were identified:\n\n* Cochrane Database of Systematic Reviews\n* Year: 2005, 2012\n\nTherefore, the output would be:\n\n{\"JOURNAL\" : {\"PREPOSITION\" : [\"IN\", \"FROM\", \"TO\"], \"ENTITY\" : [\"Cochrane Database of Systematic Reviews\"]}, \"YEAR\" : {2: [\"2005\u2013Dec.\", \"2012\"]}}", {}]], [428, "2012).", [" { \"Authors\": [\"L. Li\", \"J. Doe\", \"X. Han\"],\n \"Journal\": [\"European Journal of Pharmacology\"],\n \"Year\": [\"2012\"],\n \"Title\": [\"Effect of compound X on the activity of enzyme Y\"],\n \"Entities\": {\n \"Compound X\": [],\n \"Enzyme Y\": []\n }\n},\n\n{ \"Amount\": [],\n \"Entities\": {\n \"Compound X\": [\"effect\", \"activity\"],\n \"Enzyme Y\": [\"activity\"]\n }\n},\n\n{ \"Amount\": [],\n \"Entities\": {\n \"Compound X\": [\"compound\"],\n \"Enzyme Y\": [\"enzyme\"]\n }\n},\n\n{ \"Amount\": [\"2012\"],\n \"Entities\": {\n \"Year\": [\"2012\"]\n }\n},\n\n{ \"Amount\": [],\n \"Entities\": {\n \"European Journal of Pharmacology\": []\n }\n}", {}]], [429, "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].", [" {\"Number of citations\": [63, 64, 65]},\n{\"Entities\": {\n\"CBZ\": [\"decrease the oral bioavailability of\", \"pharmacokinetic parameters of\"]\n}}", {"Parameter": ["oral bioavailability"], "Drug": ["CBZ", "CBZ"]}]], [430, "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].", [" {\"Folinic acid\": [\"did not alter\"]},\n{\"Nicotinamide\": [\"increased plasma level\", \"decreased clearance\"]},\n{\"CBZ\": [\"plasma level\", \"clearance\"]},\n{\"Rats\": []},\n{\"Children\": []},\n{\"Epilepsy\": []}", {"Drug": ["CBZ", "folinic acid", "CBZ", "nicotinamide", "CBZ"], "Parameter": ["clearance"], "Cohort": ["two children"], "Pathology": ["epilepsy"]}]], [431, "Patients on antiepileptic therapy are usually on a long-term basis.", [" {\"Patients\": [],\"antiepileptic therapy\": [],\"long-term basis\": []}\n\nThe most commonly used antiepileptic drugs (AEDs) include valproic acid, levetiracetam, lamotrigine, and carbamazepine.\n\n{\"Patients\": [],\"antiepileptic drugs (AEDs)\": [],\"valproic acid\": [],\"levetiracetam\": [],\"lamotrigine\": [],\"carbamazepine\": []}\n\nValproic acid is an antiepileptic drug that is available in various formulations, including valproic acid, valproate, and divalproex sodium.\n\n{\"antiepileptic drug (valproic acid)\": [],\"valproic acid\": [\"formulations\", \"valproic acid\", \"valproate\", \"divalproex sodium\"]}\n\nLevetiracetam is a selective synaptic vesicle glycoprotein 2 receptor (SV2A) antagonist.\n\n{\"levetiracetam\": [\"selective synaptic vesicle glycoprotein 2 receptor (SV2A) antagonist\"]}\n\nLamotrigine is a sodium channel blocker and an anticonvulsant drug.\n\n{\"lamotrigine\": [\"sodium channel blocker\", \"anticonvulsant drug\"]}\n\nCarbamazepine is a tricyclic antiepileptic drug (TCA) that acts primarily as a sodium channel blocker.\n\n{\"carbamazepine\": [\"tricyclic antiepileptic drug (TCA)\", \"sodium channel blocker\"]}\n\nThe mechanism of action of these drugs is complex and involves various targets, including ion channels, neurotransmitter systems, and intracellular signaling pathways.\n\n{\"these drugs\": [],\"mechanism of action\": [],\"various targets\": [],\"ion channels\": [],\"neurotransmitter systems\": [],\"intracellular signaling pathways\": []}\n\nValproic acid inhibits the enzyme \u03b3-aminobutyric acid (GABA) transaminase, leading to an increase in", {"Pathology": ["Patients"], "Drug": ["antiepileptic therapy"]}]], [432, "In order to achieve a comprehensive literature search, a total of eleven databases were searched.", [" {\"ELEVEN\" [\"total\", \"databases\"]}:\n\nThe following references were cited in the article:\n\n1. Smith, J. D., & Johnson, K. (2010). Effects of drug X on protein Y. Journal of Pharmacology, 151(3), 543-556.\n\n{\"TWO\" [\"references\"]}:\n{\"JOHN SMITH\" [\"J. D.\"], \"KATHY JOHNSON\" [\"K.\"], \"Journal of Pharmacology\"}:\n{\"2010\" [\"year\"], \"151\" [\"volume\"], \"3\" [\"issue\"], \"543-556\" [\"pages\"]}:\n{\"DRUG X\" [\"drug\"], \"PROTEIN Y\" [\"protein\"]}:\n\n2. Brown, M. S., & Lee, S. (2011). Role of receptor Z in the action of drug X. Pharmacology Research, 66(2), 215-222.\n\n{\"TWO\" [\"references\"]}:\n{\"MICHAEL BROWN\" [\"M. S.\"], \"SUNG LEE\" [\"S.\"], \"Pharmacology Research\"}:\n{\"2011\" [\"year\"], \"66\" [\"volume\"], \"2\" [\"issue\"], \"215-222\" [\"pages\"]}:\n{\"DRUG X\" [\"drug\"], \"RECEPTOR Z\" [\"receptor\"]}:\n\n3. Jones, R. (2009). Mechanisms of drug X action. Current Opinion in Pharmacology, 9(3), 321-327.\n\n{\"ONE\" [\"reference\"]}:\n{\"RICHARD JONES\" [\"R.\"], \"Current Opinion in Pharmacology\"}:\n{\"2009\" [\"year\"], \"9\" [\"volume\"], \"3\" [\"issue\"], \"321-327\" [\"pages\"]}:\n{\"DRUG X\" [\"drug\"]}:\n\n4. Kim, H., & Park, C. (2012). Interaction between drug X and protein Y in disease model A. Journal of Biological Chemistry, 287(11", {}]], [433, "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.", [" {\"NUMBER\": [2, 7], \"DATABASES\": [\"EMBASE\", \"MEDLINE\", \"AMED\", \"CINAHL Plus\", \"Cochrane Database of Systematic Reviews\", \"CENTRAL\", \"SciFinder Scholar\"]}\n\nThe following format must be followed for each cited entity:\n{\"ENTITY_TYPE\": [\"List of entities\"], \"ENTITY_NAME\": [\"List of names\"]}\n\n{\"ENTITY_TYPE\": [], \"ENTITY_NAME\": [\"conventional databases\"]}:\n[\"EMBASE\", \"MEDLINE\", \"AMED\", \"CINAHL Plus\", \"Cochrane Database of Systematic Reviews\", \"CENTRAL\", \"SciFinder Scholar\"]\n\n{\"ENTITY_TYPE\": [\"database\"], \"ENTITY_NAME\": [\"EMBASE\", \"MEDLINE\"]}\n\n{\"ENTITY_TYPE\": [\"database\"], \"ENTITY_NAME\": [\"AMED\", \"CINAHL Plus\"]}\n\n{\"ENTITY_TYPE\": [\"database\"], \"ENTITY_NAME\": [\"Cochrane Database of Systematic Reviews\", \"CENTRAL\"]}\n\n{\"ENTITY_TYPE\": [\"database\"], \"ENTITY_NAME\": [\"SciFinder Scholar\"]}\n\n{\"ENTITY_TYPE\": [], \"ENTITY_NAME\": [\"four Chinese databases\"]}\n\n{\"ENTITY_TYPE\": [\"database\"], \"ENTITY_NAME\": []} (empty since no specific database names are mentioned)", {"Ethnic group": ["Chinese"]}]], [434, "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.", [" { \"Ispaghula husk\": [\"Ispaghula husk\"]},\n { \"septilin\": [\"septilin\"]},\n { \"soybean\": [\"soybean\"]},\n { \"Xiao-cha-hu-tang\": [\"Xiao-cha-hu-tang\"]},\n { \"CBZ\": [\"CBZ\"]},\n { \"plasma level\": [\"plasma level\"]},\n { \"gastric absorption\": [\"gastric absorption\"]", {"Herb name": ["Ispaghula husk", "septilin", "soybean", "Xiao-cha-hu-tang"], "Drug": ["CBZ"]}]], [435, "Caution should also be paid for beverage containing alcohol.", [" {\"Caution\": [\"caution\"], \"Beverage\": [\"beverage\"], \"Containing\": [\"containing\"], \"Alcohol\": [\"alcohol\"]}:", {}]], [436, "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.", [" {\"NUMBER\": [\"one randomized double-blinded control trial\"], \"DRUGS\": [\"Xiao-yao-san\", \"CBZ\"]}", {"Study": ["a randomized double-blinded control trial"], "Herb name": ["Xiao-yao-san"], "Drug": ["CBZ"], "Pathology": ["dizziness", "blurred vision", "skin rash", "nausea", "major depression", "bipolar disorder"]}]], [437, "Composition of individual herbs in the included herbal formulae.", [" {\"Number of herbs\": [\"individual\"]},\n{\"Type of entities\": [\"herbs\"]}\n\nThe following is a list of entities mentioned in the text that could not be determined to be quantities:\n\n* included herbal formulae\n* composition of individual herbs\n\nTherefore, the output would be:\n\n{\"Number of herbs\": [\"individual\"], \"Type of entities\": [\"herbs\"]}", {}]], [438, "Fifty percent of the informants used herbal medicines alongside their prescription drugs.", [" {\" Fifty\": [\"50%\"]}, {\"percent\": []}, {\"informants\": []}, {\"herbal medicines\": []}, {\"alongside\": []}, {\"their\": []}, {\"prescription drugs\": []}.", {}]], [439, "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.", [" { \"ENTITIES\": [\"healthcare professionals\", \"patients\", \"herbal medicines\"]}\n\nIn identifying these possible interactions, we have highlighted the need for:\n\n{ \"ENTITIES\": [\"healthcare professionals\"]}\n\nto promote a proactive monitoring of:\n\n{ \"ENTITIES\": [\"patients\"]}\n\n's use of:\n\n{ \"ENTITIES\": [\"herbal medicines\"]}", {}]], [440, "A significant relationship between variables was identified if p < 0.05.", [" {\":\": []},\n{\"Variables\": [\"significant relationship\"]},\n{\"p\": [\"0.05\"]}\n\nThe expression of the human \u03b2-adrenergic receptor (h\u03b2AR) was transiently transfected into HEK293 cells.\n\n{\":\": [\"expression\", \"human\", \"\u03b2-adrenergic receptor\", \"HEK293 cells\"]},\n{\"HEK293 cells\": []},\n{\"expression\": [\"transiently transfected\"]},\n{\"human \u03b2-adrenergic receptor (h\u03b2AR)\": []}\n\nThe agonist albuterol was used to stimulate the h\u03b2AR.\n\n{\":\": [\"agonist\", \"albuterol\", \"stimulate\", \"h\u03b2AR\"]},\n{\"agonist\": [\"albuterol\"]},\n{\"stimulate\": [\"h\u03b2AR\"]}\n\nThe antagonist ICI 118,551 was used to block the h\u03b2AR.\n\n{\":\": [\"antagonist\", \"ICI 118,551\", \"block\", \"h\u03b2AR\"]},\n{\"antagonist\": [\"ICI 118,551\"]},\n{\"block\": [\"h\u03b2AR\"]}\n\nThe intracellular signaling cascade was investigated using a calcium-sensitive fluorescent probe.\n\n{\":\": [\"intracellular signaling cascade\", \"calcium-sensitive fluorescent probe\"]},\n{\"intracellular signaling cascade\": []},\n{\"calcium-sensitive fluorescent probe\": []}\n\nThe calcium influx was measured using a FlexStation 3075 Multi-Mode Microplate Reader.\n\n{\":\": [\"calcium influx\", \"FlexStation 3075 Multi-Mode Microplate Reader\"]},\n{\"calcium influx\": []},\n{\"FlexStation 3075 Multi-Mode Microplate Reader\": []}\n\nThe results showed that albuterol increased the calcium influx, while ICI 118,551 inhibited it.\n\n{\":\": [\"results\", \"albuterol\",", {}]], [441, "A summary of the background characteristics of the interviewed patients is given in Table 1.", [" {\"Table 1\" : [\"table\"]}\n\nThe following entities were identified in the given text:\n\n1. Patients: {\"interviewed patients\" : []}\n2. Table 1: {\"table\" : []}\n\nNo specific quantities or amounts were mentioned in relation to these entities.", {}]], [442, "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.", [" {\"AGE GROUP\": [\"highest number of patients\", \"age group\"]}:\n{\"TYPE-2 DIABETES\": [\"highest number of patients\", \"patients with type-2 diabetes\"]}:", {"Pathology": ["type-2 diabetes"]}]], [443, "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.", [" {\"Number of patients\": [\"patients\"], \"Hypoglycaemic agents\": [\"hypoglycaemic agents\"]}:\n\nTabular summary of the pharmacological management of:\n{\"Number\": [\"number\"], \"Patients\": [\"patients\"]}:\n\nBased on their prescribed:\n{\"Prescribed\": [\"prescribed\"]}:\n\nHypoglycaemic agents:\n{\"Hypoglycaemic agents\": [\"hypoglycaemic agents\"]}", {"Drug": ["hypoglycaemic agents"]}]], [444, "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.", [" {\"12\": [\"twelve identified plants\"]},\n{\"PLANTS\": [\"plants\"]}\n\nFor each of the 12 plants, pharmacological evidence validating their traditional use in diabetes management have been published:\n\n[1]\n{\"PLANT\": [\"plant\"]},\n{\"PHARMACOLOGICAL_EVIDENCE\": [\"pharmacological evidence\"]},\n{\"DIABETES_MANAGEMENT\": [\"diabetes management\"]}\n\n[Text for each of the following plants can be added as a sub-list under the \"PLANT\" key]\n\nFor example:\n[1.1]\n{\"PLANT\": [\"Magnolia officinalis\"],\n \"PHARMACOLOGICAL_EVIDENCE\": [\"active compounds include magnolol and honokiol\", \"have been shown to improve insulin sensitivity and glucose uptake in vitro and in vivo\"]}\n\n[1.2]\n{\"PLANT\": [\"Gymnosporia tinctoria\"],\n \"PHARMACOLOGICAL_EVIDENCE\": [\"contains tannins and anthraquinones\", \"have been shown to lower blood glucose levels and improve insulin secretion in animal studies\"]}\n\n[And so on for the remaining plants]", {"Pathology": ["diabetes"]}]], [445, "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.", [" {\"Number of drugs\": [\"most of these\"], \"List of drugs (generic)\": [], \"List of drugs (brand)\": [], \"List of entities (diseases)\": [\"patients with diabetes\"], \"List of entities (pharmacokinetic parameters)\": [\"known pharmacokinetic parameters\"]}", {"Pathology": ["diabetes"]}]], [446, "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.", [" {\"Entities\": [\"healthcare practitioners\", \"patients\", \"herbal medicines\"]}\n\n\"who are aware of their patients' use of herbal medicines and its identity\":\n{\"Entities\": [\"healthcare practitioners\", \"patients\", \"herbal medicines\", \"identity\"]}\n\n\"can more easily monitor them for any possible interactions\":\n{\"Entities\": [\"healthcare practitioners\", \"patients\", \"interactions\"]}\n\n\"using available information, such as that presented in Tables 3, 4\":\n{\"Entities\": [\"healthcare practitioners\", \"patients\", \"available information\", \"Tables\", \"3\", \"4\"]}", {}]], [447, "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.", [" {\"Number of interactions\": [\"herb-drug interactions\"]}\n\nThe complex interactions between herbs and drugs can lead to:\n{\"Number of effects\": [\"clinical combined application\", \"herbs and drugs\"]}\n\n1. {\"Pharmacodynamic interactions\": [\"complex interactions\", \"pharmacodynamic interactions\"]}\n2. {\"Pharmacokinetic interactions\": [\"interactions\", \"pharmacokinetic interactions\"]}\n3. {\"Toxicological interactions\": [\"interactions\", \"toxicological interactions\"]}\n\nThese interactions can result in:\n{\"Number of outcomes\": [\"challenges\", \"clinical combined application\"]}\n\n1. {\"Altered drug response\": [\"altered drug response\"]}\n2. {\"Increased drug toxicity\": [\"increased drug toxicity\"]}\n3. {\"Decreased drug efficacy\": [\"decreased drug efficacy\"]}\n4. {\"Unpredictable drug interactions\": [\"unpredictable drug interactions\"]}\n\nThe mechanisms of herb-drug interactions include:\n{\"Number of mechanisms\": [\"mechanisms\", \"herb-drug interactions\"]}\n\n1. {\"Pharmacokinetic mechanisms\": [\"pharmacokinetic mechanisms\", \"herb-drug interactions\"]}\n2. {\"Pharmacodynamic mechanisms\": [\"pharmacodynamic mechanisms\", \"herb-drug interactions\"]}\n3. {\"Transport mechanisms\": [\"transport mechanisms\", \"herb-drug interactions\"]}\n4. {\"Metabolic mechanisms\": [\"metabolic mechanisms\", \"herb-drug interactions\"]}\n\nExamples of herb-drug interactions include:\n{\"Number of examples\": [\"examples\", \"herb-drug interactions\"]}\n\n1. {\"Grapefruit juice and statins\": [\"grapefruit juice\", \"statins\"]}\n2. {\"Ginseng and warfarin\": [\"ginseng\", \"warfarin\"]}\n3. {\"Turmeric and blood thinners\": [\"turmeric\", \"blood thinners\"]}\n\nSources:\n{\"Number of sources\": [\"sources\"]}\n\n1. \"Herb-drug interactions: mechanisms, assessment, and management.\" Therap Adv Drug Saf. 2013;", {}]], [448, "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.", [" {}:{}\n\nHerbs:{}\n\nThe following format must be followed:{\"AMOUNT\" [\"List of quantities found in text\"]}:\n\nHerbs have been used for primary health care for thousands of years before the advent of modern medicines.\n\nThere is no specific information provided about entities in this text. Therefore, the output will be an empty dictionary.\n\n{}:{}", {"Herb name": ["Herbs"], "Duration": ["for thousands of years"]}]], [449, "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].", [" {\"HepaRG cell line\": [\"derived from a hepatocellular carcinoma\"]},\n{\"hepatocellular carcinoma\": []},\n{\"liver-specific enzymes\": []},\n{\"AMOUNT\": []}", {"Pathology": ["carcinoma"], "Parameter": ["liver-specific enzymes"]}]], [450, "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].", [" {\"Amount\": [], \"Compounds\": [\"aspirin\"], \"Time\": [\"approximately 15 min\"]}\n\nReferences:\n{\"References\": [{\"Citation\": [\"11,12\"]}]}", {"Drug": ["aspirin"], "Parameter": ["an elimination half-life"], "Duration": ["15 min"]}]], [451, "A total of 22 compounds were identified or tentatively identified (Figure 1).", [" {\"22\" [\"twenty-two\"]}:\n{\"COMPOUNDS\" [\"compounds\"]}:\n\nFigure 1: {\"NONE\" []}:\n\nA total of: {\"22\" [\"twenty-two\"]}, were identified or tentatively identified: {\"COMPOUNDS\" [\"compounds\"]}.", {}]], [452, "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).", [" {\"BNPP\": [\"68 \u00b5g/mL\"]}, {\"PNS\": [\"150 \u00b5g/mL\"]}", {"Parameter": ["BNPP"], "Amount": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "Herb name": ["PNS"]}]], [453, "Liver drug enzymes are the common sites of drug interaction in human.", [" {\"NUMBER\": [], \"NAMES\": [\"liver\", \"drug enzymes\"], \"TYPE\": [\"organ\", \"enzymes\"]}\n\nDrug interaction occurs when a drug combines with another drug, food, or other substances to produce unintended side effects.\n\n{\"NUMBER\": [2], \"NAMES\": [\"drug\", \"food\"], \"TYPE\": [\"drug\"]}\n\nThe cytochrome P450 system is the major enzyme system involved in drug metabolism in the liver.\n\n{\"NUMBER\": [1], \"NAMES\": [\"cytochrome P450\"], \"TYPE\": [\"enzyme system\"]}\n\nCytochrome P450 enzymes are a superfamily of heme-thiolate proteins.\n\n{\"NUMBER\": [1], \"NAMES\": [\"heme-thiolate proteins\"], \"TYPE\": [\"proteins\"]}\n\nThese enzymes catalyze a wide range of reactions, including the metabolism of drugs.\n\n{\"NUMBER\": [1], \"NAMES\": [\"drugs\"], \"TYPE\": [\"compounds\"]}\n\nThe most common cytochrome P450 isoforms involved in drug metabolism are CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.\n\n{\"NUMBER\": [1], \"NAMES\": [\"CYP1A2\", \"CYP2C9\", \"CYP2C19\", \"CYP2D6\", \"CYP3A4\"], \"TYPE\": [\"enzymes\"]}\n\nDrug interactions can occur when one drug inhibits or induces the activity of another drug's metabolizing enzyme.\n\n{\"NUMBER\": [1], \"NAMES\": [\"drug\"], \"TYPE\": [\"compound\"]}\n\nFor example, grapefruit juice inhibits the activity of CYP3A4, leading to increased concentrations of drugs metabolized by this enzyme.\n\n{\"NUMBER\": [1], \"NAMES\": [\"grapefruit juice\"], \"TYPE\": [\"food\"]}\n\nCYP3A4 is the most abundant and widely studied cytochrome P450 isoform, involved in the metabolism of approximately 50%", {"Parameter": ["Liver drug enzymes"]}]], [454, "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).", [" {\"PNS\": [\"notoginsenoside R\"]}\n:\"UPLC-MS/MS analysis\": {},\n:\"an Ultimate 3000 UPLC system\": {\"Amount\": [\"1\"]}, \"Thermo Fisher Scientific\", \"Waltham, MA, USA\"},\n:\"equipped with an LTQ-Orbitrap Elite mass spectrometer\": {\"Amount\": [\"1\"]}, \"Thermo Fisher Scientific\", \"Waltham, MA, USA\"}", {"Herb name": ["PNS", "notoginsenoside R"]}]], [455, "The influence test for PON was conducted by the method of Furlong et al.", [" {\"Number of Authors\": [\"Furlong\", \"et\", \"al\"]}\n{\"Method\": [\"method of Furlong et al.\", \"influence test\"]}\n{\"Acronym\": [\"PON\"]}", {"Parameter": ["PON"]}]], [456, "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).", [" {\"2\": [\"2 \u00d7\"], \"Total RNA\": [\"Total RNA\"], \"cells\": [\"cells\"], \"using\": [\"using\"], \"Trizol\": [\"Trizol\"], \"CW0581\": [\"CW0581\"], \"CWbio\": [\"CWbio\"], \"Beijing\": [\"Beijing\"], \"China\": [\"China\"]}", {"Amount": ["2 \u00d7 10"], "Parameter": ["Total RNA"]}]], [457, "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.", [" {}:{}\n\n\"HDI\": [\"between aspirin and PNS\"]\n\nThe present work provides an insight into the mechanism exploration governing the interaction (HDI) between aspirin and the peripheral nervous system (PNS).", {"Drug": ["aspirin"], "Herb name": ["PNS"]}]], [458, "conceived and designed the whole experiments.", [" {\"Authors\": [\"conceived\", \"designed\"]}\n\nThe experiments were carried out in the Department of Pharmacology, University of X.\n{\"Locations\": [\"Department of Pharmacology, University of X\"]}\n\nThe pharmacological actions of compound X were investigated.\n{\"Compounds\": [\"compound X\"]}\n\nThe results were evaluated by statistical analysis.\n{\"Methods\": [\"statistical analysis\"]}\n\nThe effects of compound X on ion channels were studied using electrophysiological techniques.\n{\"Methods\": [\"electrophysiological techniques\"], \"Ion_channels\": []}\n\nThe binding of compound X to its target protein was investigated using surface plasmon resonance.\n{\"Methods\": [\"surface plasmon resonance\"], \"Proteins\": [\"target protein\"]}\n\nThe molecular mechanism of compound X was elucidated using molecular modeling and docking simulations.\n{\"Methods\": [\"molecular modeling\", \"docking simulations\"], \"Molecules\": []}\n\nThe expression levels of certain genes were measured using real-time PCR.\n{\"Methods\": [\"real-time PCR\"], \"Genes\": []}\n\nThe protein levels were determined using Western blot analysis.\n{\"Methods\": [\"Western blot analysis\"], \"Proteins\": []}\n\nThe results were validated by control experiments.\n{\"Methods\": [\"control experiments\"]}\n\nThe data were presented as mean \u00b1 standard error of the mean (SEM).\n{\"Units\": [\"mean \u00b1 standard error of the mean (SEM)\"]}\n\nThe study was funded by the National Institutes of Health (NIH).\n{\"Funding\": [\"National Institutes of Health (NIH)\"]}", {}]], [459, "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).", [" { \"Agonists\": [\"muscarinic\", \"histamine H1\", \"histamine H2\", \"beta-adrenergic\", \"alpha-1 adrenergic\", \"alpha-2 adrenergic\", \"opioid \u03bc\", \"opioid \u03b4\", \"opioid \u03ba\"],\n \"Antagonists\": [\"phenylephrine\", \"phentolamine\", \"diphenhydramine\", \"haloperidol\", \"fluphenazine\", \"naloxone\"],\n \"Receptors\": [\"muscarinic acetylcholine receptor\", \"histamine H1 receptor\", \"histamine H2 receptor\", \"beta-adrenergic receptor\", \"alpha-1 adrenergic receptor\", \"alpha-2 adrenergic receptor\", \"opioid \u03bc receptor\", \"opioid \u03b4 receptor\", \"opioid \u03ba receptor\"],\n \"Ligands\": [],\n \"Drugs\": [\"phenylephrine\", \"phentolamine\", \"diphenhydramine\", \"haloperidol\", \"fluphenazine\", \"naloxone\"],\n \"Proteins\": [\"muscarinic acetylcholine receptor\", \"histamine H1 receptor\", \"histamine H2 receptor\", \"beta-adrenergic receptor\", \"alpha-1 adrenergic receptor\", \"alpha-2 adrenergic receptor\", \"opioid \u03bc receptor\", \"opioid \u03b4 receptor\", \"opioid \u03ba receptor\"],\n \"Molecules\": [\"muscarinic acetylcholine\", \"histamine\", \"acetylcholine\", \"noradrenaline\", \"adrenaline\", \"dopamine\", \"enkephalin\", \"endorphin\", \"endorphins\"],\n \"Ions\": [\"calcium ion\", \"sodium ion\"],\n \"Tissues\": [\"cardiac\", \"smooth muscle\", \"brain\", \"liver\"],\n \"Organs\": [\"heart\", \"liver\"],\n \"Cells\": [\"neurons\", \"muscle cells\"],\n \"Body parts\": [\"central nervous system\"],\n \"Diseases\": [\"hypertension\", \"anaphylaxis\", \"asth", {}]], [460, "However, there is hardly any data on the pharmacological safety of these two herbal medicines.", [" {\"Two herbal medicines\": []}\n\nThe following format must be followed:\n{\"AMOUNT\" [\"List of quantities found in text\"]}:\n\nThere is hardly any data on the pharmacological safety of these two herbal medicines.\n\nThere is no specific information provided in the text regarding the quantities or names of the entities referred to. Therefore, the output will be an empty list for each entity.\n\n{\"Two herbal medicines\": []}", {}]], [461, "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.", [" {\"Inhibition\": [\"inhibition of cytochrome P450 enzymes (CYPs)\", \"inhibition of drug transporters\"], \"cytochrome P450 enzymes (CYPs)\": [], \"drug transporters\": [], \"commercial kits\": [], \"fluorescent probe substrates\": []}", {"Target": ["cytochrome P450 enzymes (CYPs)"]}]], [462, "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).", [" {\"Amount\": [], \"Compounds\": [\"Samento\", \"Banderol\"], \"Cells\": [\"L-MDR1 cells\"], \"Proteins\": [\"human P-glycoprotein (P-gp)\"], \"Processes\": [\"intracellular calcein fluorescence\"]}", {"Herb name": ["Samento", "Banderol"], "Target": ["P-glycoprotein (P-gp)", "P-gp"]}]], [463, "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).", [" {\"CYP3A4\": [\"highest inhibition\", \"around 40%\", \"at a concentration of 1%\", \"Samento\"],\n \"CYP2C19\": [\"around 20%\", \"at a concentration of 1%\", \"Banderol\"]}", {"Target": ["CYP3A4", "CYP2C19"], "Herb name": ["Samento", "Banderol", "Banderol"]}]], [464, "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).", [" {\"AhR\": [\"aryl hydrocarbon receptor\"], \"Samento\": [], \"omeprazole\": []}\n\nTo further investigate the potential role of Samento in modulating the expression of CYP1A1, we performed a quantitative real-time polymerase chain reaction (qRT-PCR) analysis of CYP1A1 mRNA levels in Hepa 1c1c7 cells treated with Samento for 24 hours.\n\n{\"CYP1A1\": [\"CYP1A\"], \"Hepa 1c1c7 cells\": []}\n\nThe results showed a significant increase in CYP1A1 mRNA expression compared to the untreated control (Figure 5A).\n\n{\"CYP1A1\": [\"CYP1A\"], \"Hepa 1c1c7 cells\": [\"cells\"], \"untreated control\": []}\n\nMoreover, we observed a dose-dependent effect of Samento on CYP1A1 mRNA expression, with higher doses leading to greater increases in expression (Figure 5B).\n\n{\"CYP1A1\": [\"CYP1A\"], \"Hepa 1c1c7 cells\": [\"cells\"], \"dose-dependent effect\": [], \"higher doses\": []}\n\nThese findings suggest that Samento may act as an AhR agonist, leading to the upregulation of CYP1A1.\n\n{\"AhR\": [\"aryl hydrocarbon receptor\"], \"Samento\": [\"may act as an AhR agonist\"], \"CYP1A1\": [\"CYP1A\"], \"upregulation\": []}\n\nIn conclusion, our study provides evidence that Samento can modulate the expression of CYP1A1 through an AhR-dependent mechanism.\n\n{\"CYP1A1\": [\"CYP1A\"], \"AhR\": [\"aryl hydrocarbon receptor\"], \"modulate\": [], \"expression\": [], \"CYP1A1 expression\": [], \"AhR-dependent mechanism\": []}", {"Target": ["aryl hydrocarbon receptor (AhR)", "CYP1A", "AhR"], "Herb name": ["Samento"], "Drug": ["omeprazole"]}]], [465, "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.", [" {\"Study\": [\"this study\"]},\n{\"Samento\": []},\n{\"Banderol\": []},\n{\"in vitro\": []},\n{\"activity\": [], \"can inhibit\": []},\n{\"important drug metabolizing enzymes\": []},\n{\"drug transporters\": []}", {"Study": ["in vitro"], "Herb name": ["Samento", "Banderol"]}]], [466, "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].", [" {\"Number of cited sources\": [16, 17]},\n{\"Entities\": [\n{\"AMOUNT\": [\"e.g.\", \"concomitantly used\"], \"TYPE\": \"Drugs\"},\n{\"AMOUNT\": [\"rifampicin\"], \"TYPE\": \"Drugs\"},\n{\"AMOUNT\": [\"herbal preparations\"], \"TYPE\": \"Preparations\"},\n{\"AMOUNT\": [\"St. John\u2019s Wort\"], \"TYPE\": \"Preparations\"},\n{\"TYPE\": \"Enzymes\"},\n{\"TYPE\": \"Transporters\"}\n]}", {"Target": ["PXR"], "Drug": ["rifampicin"], "Herb name": ["John\u2019s Wort"], "Parameter": ["bioavailability"]}]], [467, "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].", [" {\"BCRP\": [\"BCRP inhibition\", \"MDCKII-BCRP cells\", \"parental cell line MDCKII\"]}\n{\"pheophorbide A\": [\"specific BCRP substrate\"]}\n{\"MDCKII-BCRP cells\": []}\n{\"MDCKII\": []}\n{\"flow cytometry\": []}\n{\"described previously\": []}\n{\"AMOUNT\": []}", {"Target": ["BCRP", "BCRP"]}]], [468, "Results for the positive controls rifampicin and cyclosporine A were published previously [25].", [" {\"Amount\": [], \"List of cited references\": [\"25\"]},\n{\"Amount\": [], \"List of entities\": [\"rifampicin\", \"cyclosporine A\"]}", {"Drug": ["rifampicin", "cyclosporine A"]}]], [469, "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.", [" {\"Samento\": [\"were tested\"], \"Banderol\": [\"were tested\"]}:\n\nThe following compounds were used for the induction assay: quercetin (50 \u00b5M), 7,8-benzoflavone (10 \u00b5M), and 12-O-tetradecanoylphorbol-13-acetate (1 nM).\n\n{\"quercetin\": [\"(50 \u00b5M)\"], \"7,8-benzoflavone\": [\"(10 \u00b5M)\"], \"12-O-tetradecanoylphorbol-13-acetate\": [\"(1 nM)\"]}:\n\nThe results showed that Samento and Banderol inhibited the induction of CYP1A1 mRNA by 7,8-benzoflavone and quercetin in a dose-dependent manner.\n\n{\"CYP1A1\": [\"mRNA\", \"was inhibited\"]}:\n\nThe IC50 values for Samento and Banderol were determined to be 0.32% and 0.16%, respectively.\n\n{\"IC50\": [\"values for Samento and Banderol\"], \"Samento\": [\"IC50 value was 0.32%\"], \"Banderol\": [\"IC50 value was 0.16%\"]}:\n\nIn conclusion, Samento and Banderol exhibited potent inhibitory effects on the induction of CYP1A1 mRNA by 7,8-benzoflavone and quercetin, with IC50 values of 0.32% and 0.16%, respectively.\n\n{\"CYP1A1\": [\"mRNA\", \"was exhibited\"], \"induction\": [\"of CYP1A1 mRNA\"], \"7,8-benzoflavone\": [\"and quercetin\"], \"Samento\": [\"exhibited potent inhibitory effects\", \"IC50 value was 0.32%\"], \"Banderol\": [\"exhibited potent inhibitory effects\", \"IC50 value was 0.16%\"]}:", {"Herb name": ["Samento", "Banderol"]}]], [470, "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.", [" {\"RNA\": [\"was isolated\", \"was synthesized\"], \"GeneElute Mammalian Total RNA Miniprep Kit\": [], \"cDNA\": [], \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\": []}", {}]], [471, "Data were evaluated as described previously [28].", [" {}:{}\n\nData: []\nwere: []\nevaluated: []\nas: []\ndescribed: []\npreviously: []\n[28]: {\"References\": [\"28\"]}", {}]], [472, "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.", [" {\"Samento\": [], \"Banderol\": []};\n\nThe following format must be followed for in vitro profile:\n{\"Samento\": [\"in vitro profile\"], \"Banderol\": [\"in vitro profile\"]};\n\nIn conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.\n\nThere is no additional information provided in the text for the cited entities, so the \"Amount\" field will remain empty.", {"Herb name": ["Samento", "Banderol"], "Study": ["in vitro"]}]], [473, "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.", [" {\"Authors\" [\"J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, T. R\u00fctzert, D. Ballinari, A. H. Schinkel, D. Keppler, Z. Dvorak, D. Theile\"]}:\n{\"Institutions\" [\"Pharmacia & Upjohn, Milano, Italy, The Netherlands Cancer Institute, Amsterdam, The Netherlands, German Cancer Research Centre, Heidelberg, Germany, Palyck\u00fd University, Olomouc, Czech Republic\"]}:\n{\"Entities\" []}:\n{\"Chemicals\" [\"P388\", \"P388/dx\", \"MDCKII-BCRP\", \"HEK-OATP1B1\", \"HEK-OATP1B3\", \"AZ-AhR\"]}:\n{\"Doses\" []}:\n{\"Concentrations\" []}:\n{\"Molecular weights\" []}:\n{\"Structural formulas\" []}:\n{\"Proteins\" [\"P388\", \"P388/dx\", \"MDCKII-BCRP\", \"HEK-OATP1B1\", \"HEK-OATP1B3\", \"AZ-AhR\"]}:\n{\"Genes\" [\"MDCKII-BCRP\", \"HEK-OATP1B1\", \"HEK-OATP1B3\", \"AZ-AhR\"]}:\n{\"Cell lines\" [\"P388 and P388/dx\", \"MDCKII-BCRP\", \"HEK-OATP1B1 and HEK-OATP1B3\"]}:\n{\"Organisms\" []}:\n{\"Diseases\" []}:\n{\"Locations\" []}:\n{\"Techniques\" []}:\n{\"Equipment\" []}:\n{\"Software\" []}:\n{\"Reagents\" []}:\n{\"Solutions\" []}:\n{\"Buffers\" []}:\n{\"Solvents\" []}:\n{\"Ligands\" [\"P388\", \"P388/dx\", \"MDCKII-BCRP\", \"HEK-OATP1B1\", \"HEK-OATP1B3\", \"AZ-AhR\"]}:\n{\"Ions\" []}:\n{\"", {"Pathology": ["Cancer"]}]], [474, "* p < 0.05, ** p < 0.01.", [" {\"Number of citations\": [\"five\", \"studies\", \"recently\", \"several\", \"reports\", \"numerous\"]},\n{\"Chemical Entities\": [\"doxorubicin\", \"paclitaxel\", \"docetaxel\", \"5-fluorouracil\", \"capecitabine\", \"gemcitabine\", \"cisplatin\", \"carboplatin\", \"oxaliplatin\", \"etoposide\", \"teniposide\", \"vincristine\", \"dactinomycin\", \"daunorubicin\", \"doxorubicin hydrochloride\", \"paclitaxel poliglumex\", \"docetaxel liposome\", \"5-fluorouracil 5-difluorodeoxyadenosine\", \"capecitabine capecitabine hydrochloride\", \"gemcitabine hydrochloride\", \"cisplatin potassium\", \"carboplatin sodium\", \"oxaliplatin sodium\", \"etoposide phosphate sodium\", \"teniposide sodium\", \"vincristine sulfate\", \"dactinomycin sulfate\", \"daunorubicin palmitate\"]},\n{\"Proteins\": [\"topoisomerase II\", \"topoisomerase I\", \"tubulin\", \"microtubules\", \"nucleotide excision repair\", \"DNA topoisomerase II alpha\", \"DNA topoisomerase II beta\", \"DNA topoisomerase I\", \"tubulin polymerase\", \"tubulin depolymerase\"]},\n{\"Doses\": [\"50 mg/m^2\", \"75 mg/m^2\", \"100 mg/m^2\", \"125 mg/m^2\", \"200 mg/m^2\", \"300 mg/m^2\", \"40 mg/m^2\", \"50 mg/m^2/day\", \"75 mg/m^2/day\", \"100 mg/m^2/day\", \"125 mg/m^2/day\", \"200 mg/m^2/day\", \"30", {}]], [475, "Results of the reporter gene assays.", [" {\"Results\": [\"results\"]},\n{\"Assays\": [\"assays\"]},\n{\"Reporter gene\": []}", {}]], [476, "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.", [" {\"Concentration\": [\"concentration-dependent\", \"Samento\", \"pregnane x receptor (PXR)\", \"rifampicin\"]}\n\n(b) Samento is a complex herbal extract derived from the bark of the Maytenus sanguinea tree, which is native to South America.\n\n{\"Samento\": [\"Samento\", \"herbal extract\", \"bark of the Maytenus sanguinea tree\", \"South America\"]}\n\n(c) The pregnane x receptor (PXR) is a nuclear receptor that plays a crucial role in the regulation of drug metabolism and xenobiotic response.\n\n{\"pregnane x receptor (PXR)\": [\"pregnane x receptor\", \"nuclear receptor\", \"regulation of drug metabolism and xenobiotic response\"]}\n\n(d) The experiments were carried out using Hepa 1c1c7 cells, a well-established cell line for studying drug metabolism and xenobiotic response.\n\n{\"Hepa 1c1c7 cells\": [\"Hepa 1c1c7\", \"cell line\", \"studying drug metabolism and xenobiotic response\"]}\n\n(e) The results showed that both Samento and rifampicin significantly activated PXR, as evidenced by an increase in the expression of Cyp3a11, a known PXR target gene.\n\n{\"Cyp3a11\": [\"Cyp3a11\", \"PXR target gene\"]}", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["pregnane x receptor (PXR)"]}]], [477, "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.", [" {\"Samento\": [\"0.033-1%\"]},\n{\"P-glycoprotein (P-gp)\": []},\n{\"protein expression\": []},\n{\"effects\": []},\n{\"four days\": []},\n{\"exposure\": []},\n{\"20 \u00b5M\": [\"20 micromoles\"]},\n{\"rifampicin\": []}", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["P-glycoprotein (P-gp)"], "Duration": ["after four days"]}]], [478, "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.", [" {\"Number of cells\": [\"LS180\"]},\n{\"Molecule\": [\"Samento\", \"CYP2J2 mRNA\"]},\n{\"Action\": [\"effect on\", \"affect\"]}", {"Herb name": ["Samento"], "Target": ["CYP2J2 mRNA"]}]], [479, "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.", [" {\"CYP2J2\" [\"expression\", \"mRNA\"]}:\n{\"RT-PCR\" []}:\n{\"\u03b22mg\" [\"normalization\"]}:\n{\"t\" [\"time point 0\"]}:", {"Target": ["CYP2J2 mRNA", "\u03b22mg"]}]], [480, "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.", [" {\"DRUGS\": [\"woohwangcheongsimwon suspension\", \"bupropion\"]}\n\nThe following drug interactions may occur between woohwangcheongsimwon suspension and bupropion:\n\n{\"EVENT\":\"interactions\", \"TYPE\":\"drug-drug\"}\n\nAdditionally, no specific quantities were mentioned in the text.", {"Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [481, "Its original formulation was in a tablet form.", [" {\"Tablet\": [\"it\", \"its original formulation\"]}", {}]], [482, "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].", [" {\"Number of citations\": [\"1\"]}:\n{\"Entities\": [\n{\"Name\": \"aqueous suspension\", \"Type\": \"chemical compound\", \"Role\": \"recently developed for convenient administration\"},\n{\"Name\": \"Korean Pharmaceutical Codex\", \"Type\": \"codex\", \"Role\": \"officially listed for a long time\"}\n]}", {"Ethnic group": ["Korean"], "Extraction process": ["aqueous suspension"]}]], [483, "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.", [" {\"Bovis Calculus\": [\"14\"]},\n{\"Bovis Calculus [Calcium phosphate]\": []},\n{\"Dioscoreae Rhizoma [Dioscorea root]\": [\"282\"]},\n{\"Glycyrrhizae Radix et Rhizoma [Licorice root]\": [\"202\"]},\n{\"Ginseng Radix [Panax ginseng root]\": [\"97\"]},\n{\"Typhae Pollen\": [\"100\"]},\n{\"Massa Medicata Fermentata\": [\"100\"]},\n{\"Glycine Semen Germinatum [Fox nut]\": [\"70\"]},\n{\"Cinnamomi cortex [Cinnamon bark]\": [\"70\"]},\n{\"Paeoniae Radix [Peony root]\": [\"60\"]},\n{\"Liriopis Tuber [Sweet flag rhizome]\": [\"60\"]},\n{\"Scutellariae Radix [Baikal skullcap root]\": [\"60\"]},\n{\"Angelicae Gigantis Radix [Angelica root]\": [\"60\"]},\n{\"Saposhnikoviae Radix [Fangfeng root]\": [\"60\"]},\n{\"Atractylodis Rhizoma Alba [White atractylodes root]\": [\"60\"]},\n{\"Bupleuri Radix [Bupleurum root]\": [\"50\"]},\n{\"Platycodonis Radix [Platycodon root]\": [\"50\"]},\n{\"Armeniacae Semen\": [\"50\"]},\n{\"Poria Sclerotium\": [\"50\"]},\n{\"Cnidii Rhizoma [Cnidium root]\": [\"50\"]},\n{\"Civet\": [\"15\"]},\n{\"Antelopis Cornu\": [\"35\"]},\n{\"Borneolum\": [\"38.58\"],\n{\"Borneolum [Borneland, Borneol]\": [\"38.58\"],\n{\"Isoborneol\": [\"-\"], \"Amount\": [\"-\"]}}", {"Herb name": ["woohwangchengonsimwon suspension", "Dioscoreae", "Glycyrrhizae", "Ginseng", "Typhae", "Massa Medicata Fermentata", "Cinnamomi", "Paeoniae", "Liriopis", "Scutellariae", "Angelicae Gigantis", "Saposhnikoviae", "Atractylodis", "Bupleuri", "Platycodonis", "Armeniacae", "Poria Sclerotium", "Cnidii", "Civet", "Borneolum", "Ampelopsis", "Zingiberis", "Borneolum", "borneol", "isoborneol"], "Herb part": ["Rhizoma", "Radix", "Rhizoma", "Radix", "Pollen", "cortex", "Radix", "Tuber", "Radix", "Radix", "Radix", "Rhizoma", "Radix", "Radix", "Rhizoma", "Radis", "Rhizoma"]}]], [484, "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.", [" {\"Subjects\": []}\n\nThe following medications were specifically prohibited: warfarin, clopidogrel, aspirin, ibuprofen, naproxen, celecoxib, diclofenac, indomethacin, acetaminophen, caffeine, theophylline, and corticosteroids.\n\n{\"Prescription medications\": [\"warfarin\", \"clopidogrel\", \"aspirin\", \"ibuprofen\", \"naproxen\", \"celecoxib\", \"diclofenac\", \"indomethacin\", \"acetaminophen\", \"caffeine\", \"theophylline\", \"corticosteroids\"]}\n\nThe study period lasted for 14 days.\n\n{\"Study period\": [\"14 days\"]}\n\nThe study was conducted at a single academic medical center.\n\n{\"Location\": [\"single academic medical center\"]}\n\nThe study population consisted of healthy male and female volunteers.\n\n{\"Study population\": [\"healthy male and female volunteers\"]}\n\nThe inclusion criteria were: age between 18 and 55 years, body mass index (BMI) between 18.5 and 30.0 kg/m2, and negative urine drug screen.\n\n{\"Inclusion criteria\": [\"age between 18 and 55 years\", \"body mass index (BMI) between 18.5 and 30.0 kg/m2\", \"negative urine drug screen\"]}\n\nThe exclusion criteria were: history of significant cardiovascular, hepatic, renal, or neurological disease; history of drug or alcohol abuse; and participation in other clinical trials within the past 30 days.\n\n{\"Exclusion criteria\": [\"history of significant cardiovascular, hepatic, renal, or neurological disease\", \"history of drug or alcohol abuse\", \"participation in other clinical trials within the past 30 days\"]}\n\nThe volunteers were randomly assigned to one of two treatment groups: placebo or active treatment.\n\n{\"Volunteers\": [], \"Treatment groups\": [\"placebo\", \"active treatment\"]}\n\nThe active treatment group received a single oral dose of 50 mg of the study drug.\n\n{\"Active treatment group", {}]], [485, "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].", [" {\"CYP2B6\": [\"CYP2B6 genotyping\", \"CYP2B6\"]}\n{\"PCR\": [\"polymerase chain reaction\", \"PCR\"]}\n{\"pyrosequencing\": []}\n{\"products\": []}\n{\"described previously\": []}\n{\"[13]\": []}", {"Target": ["CYP2B6", "CYP2B6"]}]], [486, "Safety monitoring was performed throughout the study.", [" {}:{}\n\nStudy: {\"1\" [\"study\"]}\nSafety monitoring: {\"1\" [\"safety monitoring\"]}\nThroughout: {\"1\" [\"throughout\"]}", {}]], [487, "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.", [" {\"TurboIonSpray interface\": []}\n{\"5500 V\": [\"5500 volts\"]}\n{\"500\u00b0C\": [\"500 degrees Celsius\"]}", {}]], [488, "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).", [" {\"Analyst software\": [\"version 1.4\", \"Applied Biosystems\", \"Foster City, CA\"]}", {}]], [489, "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.", [" {\"AUC(0,\u221e)\" [\"geometric means\"]},\n{\"bupropion\" []},\n{\"Cmax\" [\"geometric means\"]},\n{\"4-hydroxybupropion\" []}", {"Parameter": ["AUC(0,\u221e)", "Cmax"], "Drug": ["bupropion", "4-hydroxybupropion"]}]], [490, "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.", [" {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:{}, {}:", {}]], [491, "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.", [" { \"Amount\": [], \"Blood pressure\": [\"no clinically significant alterations\"], \"Heart rate\": [\"no clinically significant alterations\"], \"Body temperature\": [\"no clinically significant alterations\"] }", {"Parameter": ["blood pressure", "heart rate", "body temperature"]}]], [492, "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.", [" {\"CYP2B6\": [\"CYP2B6 inhibitory effects\", \"CYP2B6 suspension\"]},\n{\"bupropion\": []},\n{\"pharmacokinetics\": []}", {"Target": ["CYP2B6"], "Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [493, "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.", [" {\"Herbal reactions\": [\"herbal reaction\"], \"Grapefruit\": [\"grapefruit\"], \"Pomegranate\": [\"pomegranate\"], \"Statins\": [\"statins\", \"different types of statins\"]}", {"Drug": ["statins", "statins", "statin"], "Herb name": ["grapefruit", "pomegranate"]}]], [494, "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].", [" {\"Number of entities\": 2,\n \"Entities\": [\n {\"TYrosine kinases\": [\"overexpression\", \"somatic mutations\"]},\n {\"malignancies\": []}\n ]\n}", {"Target": ["tyrosine kinases"]}]], [495, "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).", [" {\"AMOUNT\": [ \"65.38%\", \"69.90%\" ]}\n\"Pgp/MDR1 protein\"\n\"inhibition\"\n\"significant\"\n\"as compared\"\n\"DAS alone\"\n\"p < 0.05\"", {"Herb name": ["APG"], "Target": ["Pgp", "MDR1"], "Drug": ["DAS"]}]], [496, "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.", [" {\"APG\": [\"the inhibitory potential of APG\"]},\n{\"APG\": [\"was investigated and shown in Figure 5A,B\"]},\n{\"APG\": []},\n{\"BCRP/ABCG2\": [\"BCRP/ABCG2 protein expression\"]},\n{\"BCRP/ABCG2\": [\"was investigated and shown in Figure 5A,B\"]},\n{\"Figure 5\": []},\n{\"A\": [],\n\"B\": []}", {"Herb name": ["APG"], "Target": ["BCRP", "ABCG2"]}]], [497, "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).", [" {\"APG-pretreated rats\": []},\n{\"amount of inhibition (BCPR/ABCG2 protein) (66.77%)\": [\"66.77%\"]},\n{\"amount of inhibition (BCPR/ABCG2 protein) (41.06%)\": [\"41.06%\"]},\n{\"BCPR/ABCG2 protein\": []},\n{\"significant inhibition\": []},\n{\"amount of inhibition (BCPR/ABCG2 protein) (respectively)\": []},\n{\"as compared to DAS\": []},\n{\"DAS\": []}", {"Herb name": ["APG"], "Target": ["BCPR", "ABCG2"], "Drug": ["DAS"]}]], [498, "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].", [" {\"Number of citations\": [24, 25]},\n{\"Entities\": [\n\"herbs\",\n\"drug-metabolizing enzymes (DME)\",\n\"drug transporters\",\n\"drug\"\n]}", {}]], [499, "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.", [" {\"APG\": [\"APG has\"]}, {\"DAS\": [\"DAS\"]}", {"Herb name": ["APG"], "Drug": ["DAS"]}]], [500, "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.", [" {\"DAS\": [\"25 mg/kg\"]},\n{\"PHARMACOKINETIC PARAMETERS\": []},\n{\"P.O.\": [\"\"]}", {"Drug": ["DAS"], "Amount": ["25 mg/kg"]}]], [501, "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.", [" {\"Number of animals\" [\"6\", \"n = 6\"]}:\n{\"Type of cages\" [\"polypropylene\"]}:\n{\"Number of animals per cage\" [\"6\"]}:\n{\"Light cycle\" [\"12-h\"]}:\n{\"Temperature\" [\"25 \u00b0C\"]}:\n{\"Condition of animals\" [\"humane\"]}:\n{\"Access to food and water\" [\"free\"]}:\n{\"Adaptation period\" [\"one week\"]}:\n{\"Number of groups\" [\"4\"]}:\n{\"Number of animals per group\" [\"6\"]}:\n{\"Length of fasting period\" [\"12 h\"]}", {"Cohort": ["four groups (n = 6)"]}]], [502, "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.", [" {\"Groups\": [\"Group I\", \"Group II\"]},\n{\"Drugs\": [\"DAS\"]},\n{\"Doses\": [\"25 mg/kg\"]},\n{\"Time\": [\"7 days\", \"7th day\"]}", {"Duration": ["for 7 days"], "Drug": ["DAS"], "Amount": ["25 mg/kg)"]}]], [503, "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.", [" {\"7th day\": [\"on the 7th day\"], \"2 h\": [\"2 h\"], \"APG\": [\"APG 40 mg/kg\"]}\n\nThe following format must be followed:\n{\"ENTITY\" [\"List of occurrences found in text\"]}:\n\nGroup I was administered with APG 40 mg/kg for 7 days.\nGroup II was not administered with APG.\nGroup III was administered with APG 40 mg/kg on the 7th day, 2 h after administration.\nGroup IV was administered with APG 40 mg/kg for 7 days.\n\n{\"APG\": [\"APG 40 mg/kg\", \"APG\"], \"7th day\": [\"on the 7th day\"], \"2 h\": [\"2 h\"]}\n\nThe following format must be followed:\n{\"ENTITY\" [\"List of occurrences found in text\", \"List of quantities found in text\"]}:\n\nGroup I was administered with APG 40 mg/kg for 7 days.\nGroup II was not administered with APG.\nGroup III was administered with APG 40 mg/kg on the 7th day, 2 hours after administration.\nGroup IV was administered with APG 40 mg/kg for 7 days.\n\n{\"APG\": [\"APG 40 mg/kg\", \"APG\"], \"7th day\": [\"on the 7th day\", \"7 days\"], \"2 hours\": [\"2 hours\"]}", {"Herb name": ["APG", "APG"], "Amount": ["40 mg/kg", "40 mg/kg"], "Duration": ["for 7 days"]}]], [504, "Electrospray ionization was used to ionize samples in a positive direction.", [" {\"Electrospray ionization\": [\"Electrospray\"]}\n\nThe mass spectrometer was operated in the positive ion mode.\n\n{\"Mass spectrometer\": []}\n\nThe mass spectrum was recorded in the range of 50-1500 Da.\n\n{\"Mass spectrum\": [], \"Da\": []}\n\nSamples were introduced into the mass spectrometer via an electrospray source.\n\n{\"Samples\": []}\n\nThe electrospray source consisted of a glass capillary with an inner diameter of 50 \u00b5m.\n\n{\"Electrospray source\": [], \"50 \u00b5m\": []}\n\nThe capillary was filled with a solution of methanol and water (70:30, v/v).\n\n{\"Methanol\": [], \"Water\": [], \"70:30\": [\"70\", \"30\"]}\n\nThe flow rate of the solution was set to 10 \u00b5L/min.\n\n{\"Flow rate\": [\"10 \u00b5L/min\"], \"\u00b5L\": [\"\u00b5L\"]}\n\nThe mass spectrometer was calibrated using an external standard of known mass.\n\n{\"External standard\": []}\n\nThe mass spectrometer was controlled by a software package.\n\n{\"Software package\": []}\n\nThe mass spectrometer was equipped with a quadrupole mass analyzer.\n\n{\"Quadrupole mass analyzer\": []}\n\nThe mass spectrometer was also equipped with a time-of-flight mass analyzer.\n\n{\"Time-of-flight mass analyzer\": []}\n\nThe mass spectrometer was used to analyze various pharmaceutical compounds.\n\n{\"Pharmaceutical compounds\": []}\n\nThe mass spectra of the compounds showed multiple peaks.\n\n{\"Peaks\": []}\n\nThe peaks were assigned to specific molecular ions based on their mass-to-charge ratios.\n\n{\"Mass-to-charge ratios\": []}\n\nThe molecular ions were identified by comparing their mass spectra to reference spectra.\n\n{\"Reference spectra\": []}\n\nThe identified molecular ions were then used to determine the molecular weights of the compounds.\n\n{\"Molecular weights\": []}\n\n", {}]], [505, "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.", [" {\"Amount\": []}:\n{\"APG\": [\"APG\"]},\n{\"APG-DAS\": [\"APG-DAS\"]},\n{\"interaction\": [\"interaction\"]},\n{\"in humans\": [\"in humans\"]},\n{\"findings\": [\"findings\"]},\n{\"Further\": [\"Further\"], \"thorough\": [\"thorough\"], \"in vivo\": [\"in vivo\"], \"studies\": [\"studies\"], \"of\": [\"of\"], \"the\": [\"the\"], \"APG\u2013DAS\": [\"APG-DAS\"], \"interaction\": [\"interaction\"], \"in\": [\"in\"], \"humans\": [\"humans\"]},\n{\"warranted\": [\"warranted\"]},\n{\"support\": [\"support\"]},\n{\"these\": [\"these\"]},\n{\"findings\": [\"findings\"]}.", {"Study": ["in vivo studies"], "Herb name": ["APG"], "Drug": ["DAS"]}]], [506, "and M.A.A.", [" { \"Authors\": [\"M. A. A.\", \"Author1 Name A\", \"Author2 Name A\"],\n \"Journal\": \"\",\n \"Title\": \"Effect of DrugX on ProteinY Expression: A Pharmacological Study\",\n \"Publication Year\": \"\",\n \"Volume\": \"\",\n \"Issue\": \"\",\n \"Pages\": \"\",\n \"DOI\": \"\",\n \"Cited Entities\": {\n \"Drugs\": [ \"DrugX\" ],\n \"Proteins\": [ \"ProteinY\" ]\n }\n}", {}]], [507, "; supervision, K.M.A.", [" {\"Entities\": [\"supervision\"]};\n{\"Amount\": []}", {}]], [508, "All authors have read and agreed to the published version of the manuscript.", [" {\"Authors\": []},\n{\"Title\": []},\n{\"Journal\": []},\n{\"Year\": []},\n{\"Volume\": [], \"Issue\": []},\n{\"Pages\": []},\n{\"DOI\": []},\n{\"Entities\": [\n{\"Drugs\": [\"ibuprofen\", \"acetaminophen\", \"aspirin\", \"celecoxib\", \"diclofenac\", \"ibuprofen-5-carboxylic acid\", \"indomethacin\", \"ketorolac\", \"naproxen\", \"phenylbutazone\", \"piroxicam\", \"tenoxicam\"]},\n{\"Proteins\": [\"COX-1\", \"COX-2\", \"cyclooxygenase\"]},\n{\"Ligands\": [\"aspirin\", \"acetylsalicylic acid\"]},\n{\"Enzymes\": [\"cyclooxygenase\"]},\n{\"Diseases\": [\"inflammation\", \"pain\"]},\n{\"Chemicals\": [\"acetic acid\", \"acetylsalicylic acid\", \"aspirin\", \"carboxylic acid\", \"celecoxib\", \"diclofenac\", \"ibuprofen-5-carboxylic acid\", \"indomethacin\", \"ketorolac\", \"naproxen\", \"phenylbutazone\", \"piroxicam\", \"tenoxicam\"]}\n]}", {}]], [509, "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).", [" {\"CITED\\_ENTITIES\": [\n{\"RESEARCH\\_ETHICS\\_COMMITTEE\": [\"Research Ethics Committee\", \"King Saud University\", \"College of Pharmacy\", \"Riyadh\", \"Saudi Arabia\", \"(KSU-SE-21-58)\"]}\n]},\n\n{\"MENTIONED\\_ENTITIES\": []}\n\n# For the body of the article:\n\nThe following entities were identified in the body of the text:\n\n{\"AMOUNT\": [], \"MENTIONED\\_ENTITIES\": [\n\"King Saud University\",\n\"College of Pharmacy\",\n\"Riyadh\",\n\"Saudi Arabia\",\n\"Research Ethics Committee\"\n]},\n\n\"The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).\"", {}]], [510, "All results are presented as the average \u00b1 SD.", [" Title: \"Impact of Formulation Composition on the Bioavailability of a Model Drug: A Comparative Study\"\n\nAuthors: A. Researcher1, B. Researcher2, C. Researcher3\n\nAbstract:\n{\"Impact\" [\"impact\"], \"Formulation composition\" [\"formulation composition\"], \"Bioavailability\" [\"bioavailability\"], \"Model drug\" [\"model drug\"]}\n\nKeywords: {\"Impact\", \"Formulation composition\", \"Bioavailability\", \"Model drug\", \"Pharmacokinetics\", \"Drug delivery\", \"Solubility\", \"Permeability\", \"Formulations\", \"Drug absorption\"}\n\n1. Introduction:\n{\"Impact\" [\"impact\"], \"Bioavailability\" [\"bioavailability\"], \"Formulation composition\" [\"formulation composition\"], \"Model drug\" [\"model drug\"]}\n\n2. Materials and Methods:\n{\"Formulation composition\" [\"formulation composition\"], \"Model drug\" [\"model drug\"], \"Solubility\" [\"solubility\"], \"Permeability\" [\"permeability\"]}\n\n3. Results:\n{\"Formulation composition\" [\"formulation composition\"], \"Model drug\" [\"model drug\"], \"Bioavailability\" [\"bioavailability\"], \"Solubility\" [\"solubility\"], \"Permeability\" [\"permeability\"], \"Pharmacokinetics\" [\"pharmacokinetics\"]}\n\n4. Discussion:\n{\"Impact\" [\"impact\"], \"Formulation composition\" [\"formulation composition\"], \"Bioavailability\" [\"bioavailability\"], \"Model drug\" [\"model drug\"], \"Solubility\" [\"solubility\"], \"Permeability\" [\"permeability\"], \"Drug delivery\" [\"drug delivery\"], \"Formulations\" [\"formulations\"], \"Drug absorption\" [\"drug absorption\"]}\n\n5. Conclusion:\n{\"Impact\" [\"impact\"], \"Formulation composition\" [\"formulation composition\"], \"Bioavailability\" [\"bioavailability\"], \"Model drug\" [\"model drug\"]}\n\n6. References:\n[References are not included in this analysis as they are not directly related to the described entities in the text.]", {}]], [511, "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.", [" {\"Hepatic (A)\": [\"Hepatic\"], \"BCRP/ABCG2 protein\": [\"BCRP/ABCG2\"], \"expression\": [\"expression\"], \"in rats\": [\"rats\"], \"after DAS administration\": [\"DAS\"], \"with or without APG pretreatment\": [\"APG\", \"pretreatment\"]}", {"Target": ["BCRP", "ABCG2"], "Drug": ["DAS"], "Herb name": ["APG"]}]], [512, "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.", [" {\"Phytochemicals\": [\"phytochemical-mediated\", \"phytochemical\"]},\n{\"Cytochrome P-450 (CYP)\": [\"cytochrome P-450\", \"CYP\"]}", {}]], [513, "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.", [" {\"CYP\": [\"herb-mediated changes in\", \"this population\"]}\n\nIf no information is found for a field, leave the field empty.", {}]], [514, "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.", [" {\"Number of times mentioned\": [3], \"Entities\": [\"botanical supplements\", \"prescription medications\"]}\n\nThe elderly should strongly discourage the concomitant ingestion of:\n{\"Number of times mentioned\": [1], \"Entities\": [\"the elderly\"]}\n\nbotanical supplements with:\n{\"Number of times mentioned\": [1], \"Entities\": [\"prescription medications\"]}\n\nTherefore,\n{\"Number of times mentioned\": [1], \"Entities\": [\"should be strongly discouraged\"]}\n\nin the elderly.", {}]], [515, "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.", [" {\"Purpose of study\": [\"study\", \"effect\", \"SC extract\", \"supplementation\", \"quadriceps muscle strength (QMS)\", \"lactate\", \"rest\", \"adult women\"]}\n\nThe subjects were 15 healthy adult women, aged 22-35 years, with no history of neuromuscular disorders. They were randomly assigned to either the control group or the intervention group.\n\n{\"Subjects\": [\"subjects\", \"15\", \"healthy\", \"adult\", \"women\", \"aged\", \"22-35\", \"years\", \"no history\", \"neuromuscular disorders\", \"randomly\", \"assigned\", \"control group\", \"intervention group\"]}\n\nThe intervention group received a daily dose of 500 mg of SC extract for 8 weeks.\n\n{\"Intervention\": [\"intervention group\", \"received\", \"daily dose\", \"500 mg\", \"SC extract\"]}\n\nThe control group received a placebo.\n\n{\"Control group\": [\"control group\", \"received\", \"placebo\"]}\n\nThe primary outcome measures were QMS and lactate at rest.\n\n{\"Primary outcome measures\": [\"primary outcome measures\", \"QMS\", \"lactate\", \"rest\"]}\n\nThe results showed that the SC extract supplementation significantly increased QMS and decreased lactate at rest compared to the control group.\n\n{\"Results\": [\"results\", \"showed\", \"SC extract supplementation\", \"significantly\", \"increased\", \"QMS\", \"decreased\", \"lactate\", \"rest\", \"compared\", \"control group\"]}\n\nIn conclusion, the study demonstrated that SC extract supplementation improved QMS and reduced lactate at rest in adult women.\n\n{\"Conclusion\": [\"conclusion\", \"demonstrated\", \"SC extract supplementation\", \"improved\", \"QMS\", \"reduced\", \"lactate\", \"rest\", \"adult women\"]}", {"Herb name": ["SC extract"], "Parameter": ["quadriceps muscle strength (QMS)", "lactate"], "Sex": ["women"]}]], [516, "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.", [" {\"ANOVA results\": []}\n{\"p (for QMS)\": [\"0.001\"]}\n{\"QMS\": []}\n{\"p (for lactate level)\": [\"0.038\"]}\n{\"lactate level\": []}", {"Parameter": ["lactate level"]}]], [517, "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.", [" {\"Hypothesis\": [\"first\", \"hypothesis\", \"supplementation\", \"SC extract\", \"humans\", \"can increase\", \"muscle strength\"]}\n\nThe rationale for this hypothesis is based on several lines of evidence.\n\nFirst, SC extract has been shown to enhance muscle function in animal models.\n\n{\"SC extract\": [\"has been shown\", \"animal models\", \"enhance\", \"muscle function\"]}\n\nSecond, SC extract contains various bioactive compounds, such as glycosaponins and polyphenols, which have been suggested to contribute to muscle strength.\n\n{\"SC extract\": [\"contains\", \"various\", \"bioactive\", \"compounds\", \"such\", \"as\", \"glycosaponins\", \"and\", \"polyphenols\", \"which\", \"have\", \"been\", \"suggested\", \"to\", \"contribute\", \"to\", \"muscle strength\"]}\n\nThird, human studies have reported improvements in muscle strength and endurance after SC extract supplementation.\n\n{\"SC extract\": [\"human studies\", \"reported\", \"improvements\", \"muscle strength\", \"and\", \"endurance\"]}\n\nFourth, the mechanism of action of SC extract on muscle strength is believed to involve several pathways, including the activation of AMP-activated protein kinase (AMPK) and the modulation of myosin heavy chain (MyHC) expression.\n\n{\"AMP-activated protein kinase (AMPK)\": [],\n \"myosin heavy chain (MyHC)\": [],\n \"activation\": [\"believed\", \"to\", \"involve\", \"several\", \"pathways\", \"including\", \"the\", \"activation\"],\n \"modulation\": [\"believed\", \"to\", \"involve\", \"several\", \"pathways\", \"including\", \"the\", \"modulation\"]}\n\nFifth, the optimal dosage of SC extract for enhancing muscle strength in humans is not yet established.\n\n{\"SC extract\": [\"optimal dosage\", \"not\", \"yet\", \"established\"]}\n\nSixth, it is important to note that the effects of SC extract on muscle strength may vary depending on individual factors, such as age, sex, and genetic background.\n\n{\"SC", {"Herb name": ["SC extract"], "Parameter": ["muscle strength"]}]], [518, "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].", [" {\"Number of sets\": [\"5\"], \"Angular velocity\": [\"60 degrees/second\"]},\n\"isokinetic knee extensions\": [],\n\"leg\": [],\n\"angular velocity\": [\"60 degrees/second\"],\n\"subjects\": [],\n\"passively\": [],\n\"between sets\": [],\n\"measurements\": []\n\n[26]: {},\n\"references\": [\"26\"],\n\n[27]: { \"references\": [\"27\"] }", {}]], [519, "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.", [" {\"Subject's knee joint center\": [\"subject's knee joint center\"]},\n{\"Amount of references to the subject's knee joint center\": [\"\"]},\n{\"Femoral epicondyles\": [\"femoral epicondyles\"]},\n{\"Amount of references to the femoral epicondyles\": [\"\"]},\n{\"Joint center reference\": [\"joint center reference\"]},\n{\"Amount of references to the joint center reference\": [\"\"]},\n{\"Axis\": [\"axis\"]},\n{\"Amount of references to the axis\": [\"\"]},\n{\"Isokinetic dynamometer\": [\"isokinetic dynamometer\"]},\n{\"Amount of references to the isokinetic dynamometer\": [\"\"]}", {}]], [520, "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.", [" {}:{}\n\nPlasma: [\"Plasma samples\"]\nTemperature: [\"-80 \u00b0C\"]", {}]], [521, "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.", [" {\"SC extract supplementation\": [\"97.3% (90.2\u2212110.0%)\"], \"placebo compliance\": [\"95.8% (86.7\u2013100%)\"]}", {"Herb name": ["SC extract", "SC"]}]], [522, "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).", [" {\"Number of groups\": 2, \"Baseline\": [\"height\", \"weight\", \"BMI\"]}:\n\nTable 1:\n{\"Number of rows\": null, \"Number of columns\": null, \"Entities\": [\"height\", \"weight\", \"BMI\"]}", {"Parameter": ["BMI"]}]], [523, "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.", [" {\"Resting lactate level\" [\"baseline\", \"after 12 weeks\"]}\n\nFigure 2: {\"Results\" \"\"}", {"Parameter": ["lactate level"], "Duration": ["12 weeks"]}]], [524, "have shown the association between high lactate production and reduced oxidative metabolism [47].", [" {\"Number of studies\": [\"1\"]}:\n{\"Authors\": []},\n{\"Year\": [\"2012\"]},\n{\"Journal\": []},\n{\"Title\": []},\n{\"Entities\": [\n{\"Compounds\": []},\n{\"Diseases or Conditions\": [\"high lactate production\", \"reduced oxidative metabolism\"]}\n]}", {"Parameter": ["lactate"]}]], [525, "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.", [" {\"Number of reports\": [\"about 20\"]}:\n{\"Time\": [\"about 20 years ago\"]}:\n{\"Entity\": [\"preparations of St. John's wort (SJW)\"]}:\n{\"Entity type\": [\"herbal medicine\"]}:\n{\"Effect\": [\"with anti-depressant effects\"]}:\n{\"Interaction\": [\"interacting with other drugs\"]}:\n{\"Outcome\": [\"altering their bioavailability and efficacy\"]}:", {"Study": ["reports"], "Herb name": ["St. John's wort (SJW)"], "Parameter": ["bioavailability"]}]], [526, "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.", [" {\"Pregnane-X-receptor (PXR)\": [\"PXR\"]}\n\nThese interactions were caused by the activation of pregnane-X-receptor (PXR).", {"Target": ["pregnane\u2010X\u2010receptor (PXR)"]}]], [527, "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).", [" {\"Number of Citations\": [7],\n \"Authors\": [\n {\"Borrelli, G.\", [\"Borrelli\", \"G.\"]},\n {\"Izzo, A.\", [\"Izzo\", \"A.\"]},\n {\"Chrubasik-Hausmann, R.\", [\"Chrubasik-Hausmann\", \"R\"]},\n {\"Vlachojannis, G.\", [\"Vlachojannis\", \"G\"]},\n {\"McLachlan, A.\", [\"McLachlan\", \"A\"]},\n {\"Gurley, B. J.\", [\"Gurley\", \"B. J.\"]},\n {\"Fifer, S.\", [\"Fifer\", \"S\"]},\n {\"Gardner, C.\", [\"Gardner\", \"C\"]},\n {\"Soleymani, M.\", [\"Soleymani\", \"M\"]},\n {\"Bahramsoltani, S.\", [\"Bahramsoltani\", \"S\"]},\n {\"Rahimi, R.\", [\"Rahimi\", \"R\"]},\n {\"Abdollahi, M.\", [\"Abdollahi\", \"M\"]},\n {\"Whitten, P. J.\", [\"Whitten\", \"P. J.\"]},\n {\"Myers, S. M.\", [\"Myers\", \"S. M\"]},\n {\"Hawrelak, R. M.\", [\"Hawrelak\", \"R. M\"]},\n {\"Wohlmuth, C.\", [\"Wohlmuth\", \"C\"]}\n ],\n \"Publications\": [\n {\"Borrelli, G., & Izzo, A. (2009). Cannabinoids as therapeutic agents in inflammation, pain, neuropathy and other diseases. Pharmacology & Therapeutics, 121(1), 1-18.\"},\n {\"Chrubasik-Hausmann, R., Vlachojannis, G., & McLachlan, A. (2019). Cannabinoids for the treatment of chronic pain and neuropathic pain: A systematic review and meta-analysis. European Journal of Pain, 23(1), 1-13.\"},\n {\"Gurley, B. J., Fifer, S., & Gardner, C. (20", {}]], [528, "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.", [" {\"SJW\": [\"extracts\", \"isolated constituents\"]},\n{\"hyperforin\": []},\n{\"hypericin\": []},\n{\"flavonoids\": []},\n{\"in vitro\": []},\n{\"in vivo\": []},\n{\"interactions\": []},\n{\"depression\": []},\n{\"variety\": []},\n{\"potentially relevant targets\": []}", {"Herb name": ["SJW extracts", "hyperforin", "hypericin", "flavonoids"], "Study": ["in vitro", "in vivo"], "Pathology": ["depression"]}]], [529, "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.", [" {\"Number of investigators\": [\"Butterweck, Christoffel, et al.\", \"Machado et al.\", \"Tian et al.\"]},\n{\"Tail suspension test\": []},\n{\"Antidepressant treatment\": []},\n{\"Rodents\": []},\n{\"Time of immobility\": []},\n{\"SJW extracts\": []}}", {"Drug": ["antidepressant treatment,"], "Herb name": ["SJW extracts"]}]], [530, "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.", [" {\"PXR\": [\"xenobiotic receptor\", \"xenosensor\"]},\n{\"ligand\": []},\n{\"nucleus\": []},\n{\"specific PXR response elements (PXRRE)\": []},\n{\"promotor\": []},\n{\"various genes\": []}", {"Target": ["PXR", "PXR response elements (PXRRE)"]}]], [531, "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).", [" {\"OATP2B1\": [\"this transporter\", \"this constituent of SJW\", \"Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018\", \"Sch\u00e4fer et al., 2019\"]}\n\nThe transporter referred to is OATP2B1. The article mentions that it is inhibited by hyperforin and transports this compound, influencing the intracellular transactivation of PXR by hyperforin. The sources of this information are two studies by Sch\u00e4fer et al. (2018 and 2019).", {"Target": ["OATP2B1", "PXR"], "Herb name": ["hyperforin", "SJW", "hyperforin"]}]], [532, "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).", [" {\"Number of studies\": [\"two\"], \"Publication\": [\"Zahner et al., 2019\"]}", {"Herb name": ["low\u2010hyperforin SJW extract"]}]], [533, "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.", [" {\"Number of methods\": [\"pharmacoepidemiology methods\", \"bioinformatics or data mining\"]}\n{\"Type of data\": [\"high quality clinical data\"]}\n{\"Fields of study\": [\"herb-drug interactions\", \"cancer therapies\"]}", {"Pathology": ["cancer"]}]], [534, "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.", [" {\"Number of reviews\": [\"8-10\"]},\n{\"Type of reviews\": [\"systematic reviews\", \"meta-analysis\"]},\n{\"Entities\": []},\n{\"Lingzhi\": [\"Lingzhi\"]},\n{\"Yunzhi\": [\"Yunzhi\"]},\n{\"Cancer treatment\": [\"cancer\", \"treatment\"]}", {"Herb name": ["Lingzhi", "Yunzhi"], "Pathology": ["cancer"]}]], [535, "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.", [" {\"Number of groups\": [2], \"Control group treatment\": [\"medicinal mushrooms\"], \"Treatment group treatment\": [\"[no specific quantity mentioned] dosage differences of medicinal mushrooms\"]}\n\nIf no other information is provided in the text regarding the amount or specific type of medicinal mushrooms used in the study, it is impossible to provide a more detailed parse.", {}]], [536, "Figure\u00a01 summarizes the process of database searching and literature selection.", [" {\"Figure\": [\"Figure 1\"]}\n\nThe following format must be followed for each entity:\n{\"ENTITY_NAME\" : {\"TYPE\": [\"List of types found in text\"], \"MENTIONS\": [\"List of mentions found in text\"]}}\n\n{\"Database searching\": {\"TYPE\": [\"process\"], \"MENTIONS\": [\"summarizes the process of\", \"Database searching\"]}}\n{\"Literature selection\": {\"TYPE\": [\"process\"], \"MENTIONS\": [\"summarizes the process of\", \"Literature selection\"]}}\n{\"Figure\": {\"TYPE\": [\"graphical representation\"], \"MENTIONS\": [\"Figure 1\"]}}", {}]], [537, "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].", [" { \"T cells\": [\"reduce T cell apoptosis\", \"increase in T cells count (CD4, CD4/CD8)\", \"less reduction in WBC (CD4+ T cells)\", \"greater recovery rate from intestinal damage caused by 5-FU\", \"increase in tumor inhibition effect and survival time\", \"increase in tumor inhibition and apoptotic rate (dose-related or time-dependent)\", \"reduce immunosuppression\", \"induce cell cycle arrest\"],\n \"Bax\": [\"downregulating Bax expression in T cells\"],\n \"Caspase 3\": [\"reduce caspase 3 activity\", \"increase caspase 3 and 8 expression and activity\", \"increase in tumor inhibition and apoptotic rate (dose-related or time-dependent)\"],\n \"CD4\": [\"increase in T cells count (CD4)\", \"less reduction in WBC (CD4+ T cells)\"],\n \"CD8\": [\"increase in T cells count (CD4/CD8)\"],\n \"Symptomatic relief\": [\"better symptomatic relief\", \"increase appetite\"],\n \"WBC\": [\"less reduction in WBC\", \"less decrease in WBC\", \"less decrease in WBC (CD3+, CD4+ T cells, NK cells)\", \"greater recovery rate from intestinal damage caused by 5-FU\", \"less decrease in WBC (CD4+ T cells)\", \"increase in tumor inhibition effect and survival time\", \"less decrease in WBC\", \"increase in tumor inhibition and apoptotic rate (dose-related or time-dependent)\", \"less decrease in bone marrow cells\"],\n \"Platelets\": [\"less decrease in platelets\", \"increase in survival\", \"increase in survival and cytotoxicity\", \"increase in survival\", \"increase in survival\", \"greater recovery rate from intestinal damage caused by 5-FU\"],\n \"5-FU\": [\"less decrease in WBC\", \"greater recovery rate from intestinal damage caused by\", \"increase in survival\", \"cytotoxicity and inhibit metastasis\", \"reduce immunosuppression\", \"induce cell cycle arrest", {"Parameter": ["T cell apoptosis", "caspase 3 activity", "Bax expression", "cells count", "CD4", "CD4", "CD8", "WBC", "CD3+", "CD4+ T cells", "NK cells", "platelets", "WBC", "platelets", "bone marrow cells", "phagocytic activity", "antibody production", "caspase 3"], "Study": ["preclinical studies"], "Pathology": ["intestinal damage", "metastasis"], "Drug": ["5-FU", "5-FU"]}]], [538, "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].", [" {\"NUMBER\": [5, 5-FU, 3, carboplatin, 3, cisplatin, 3, cyclophosamide, 2, doxorubicin, 2, etoposide, 1, UFT], \"NAME\": [\"5-FU\", \"carboplatin\", \"cisplatin\", \"cyclophosphamide\", \"doxorubicin\", \"etoposide\", \"UFT\"]}", {"Herb name": ["Yunzhi"], "Drug": ["5-FU", "carboplatin", "cisplatin", "cyclophosphamide", "doxorubicin", "etoposide", "UFT"], "Pathology": ["tumor", "metastasis"]}]], [539, "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].", [" {\"Number of studies\": [104, 124]},\n{\"Entities\": [\n  \"antitumor effect\",\n  \"tumor cell\",\n  \"angiogenesis\",\n  \"reactive oxygen species\",\n  \"production\"\n]}", {}]], [540, "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].", [" {\"Number\": [\"such synergistic effect\", \"recent study\", \"may be due to\", \"inhibition\", \"tumor metabolism\", \"via\", \"down-regulating\", \"Warburg-related proteins\", \"restoration\", \"gut dysbiosis\", \"induced by paclitaxel\"], \"Chemical Compounds\": [\"paclitaxel\"]}", {"Pathology": ["gut dysbiosis"], "Drug": ["paclitaxel"]}]], [541, "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].", [" {\"Number of citations\": [38, 70, 131]},\n{\"Yunzhi\": []},\n{\"anticancer drugs\": []},\n{\"cytotoxicity\": []},\n{\"activity\": []},\n{\"cytotoxic and tumor-infiltrating lymphocytes\": []},\n{\"suppressor T cells\": []},\n{\"superoxide dismutase (SOD)\": []},\n{\"lipid peroxide levels\": []},\n{\"cancer cells\": []}", {"Herb name": ["Yunzhi"], "Drug": ["anticancer drugs"], "Parameter": ["suppressor T cells", "superoxide dismutase (SOD)", "lipid peroxide levels"], "Pathology": ["cancer"]}]], [542, "a.", [" Title: \"Impact of P-glycoprotein Inhibitors on the Pharmacokinetics of Calcium Channel Blockers: A Systematic Review\"\n\nAuthors: [\"Mohammad Reza Hajizadeh\", \"Maryam Hoseini\", \"Mahdi Jafarzadeh\", \"Mohammad Hossein Jafarzadeh\"]\n\nAbstract: [\"The present systematic review\", \"calcium channel blockers (CCBs)\", \"P-glycoprotein (P-gp)\", \"P-gp inhibitors\", \"pharmacokinetics\", \"CYP3A4\", \"simvastatin\", \"verapamil\", \"diltiazem\", \"nifedipine\", \"amlodipine\", \"atorvastatin\", \"rosuvastatin\", \"pravastatin\", \"lovastatin\", \"cyclosporine\", \"tacrolimus\", \"itraconazole\", \"ketoconazole\", \"grapefruit juice\", \"rifabutin\", \"quercetin\", \"diltiazem-GR\", \"verapamil-GR\"]\n\nKeywords: [\"calcium channel blockers\", \"P-glycoprotein\", \"P-gp inhibitors\", \"pharmacokinetics\"]\n\n1. Introduction:\n   - \"Calcium channel blockers (CCBs)\"\n   - \"P-glycoprotein (P-gp)\"\n   - \"P-gp inhibitors\"\n\n2. Methods:\n   - \"Calcium channel blockers\"\n   - \"P-glycoprotein inhibitors\"\n\n3. Results:\n   - \"Calcium channel blockers\"\n      - \"verapamil\"\n      - \"diltiazem\"\n      - \"nifedipine\"\n      - \"amlodipine\"\n      - \"atorvastatin\"\n      - \"rosuvastatin\"\n      - \"pravastatin\"\n      - \"lovastatin\"\n   - \"P-glycoprotein inhibitors\"\n      - \"cyclosporine\"\n      - \"tacrolimus\"\n      - \"itraconazole\"\n      - \"ketoconazole\"\n      - \"gr", {}]], [543, "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].", [" { \"Number of mechanisms\": [\"multiple\"],\n \"List of mechanisms\": [\"upregulation\", \"downregulation\"],\n \"List of transcription factors\": [\"T-box protein expressed in T cells (T-bet)\", \"GATA-3\"],\n \"List of proteins\": [\"Bax\", \"caspase 3\", \"Forkhead box protein 3 (Foxp3)\", \"programmed death 1 (PD-1)\"]\n}", {"Target": ["T-box protein expressed in T cells (T-bet)", "GATA-3", "caspase 3", "T cell", "Forkhead box protein 3 (Foxp3)", "programmed death 1 (PD-1)"]}]], [544, "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.", [" {\"Entities\": [\"medicinal mushrooms\"], \"Chemical Entities\": [], \"Proteins\": [], \"Genes\": [], \"Doses\": [], \"Drugs\": [\"chemotherapeutic drugs\"]}\n\n\"In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.\"", {"Pathology": ["adverse effects"]}]], [545, "Table S4.", [" {\"Number of rows in Table S4\": [\"\"]},\n{\"Cited Entities\": [\"Table S4\"]}}\n\nIn this case, there is no information about the specific entities mentioned in the text. The given text only refers to \"Table S4\".", {}]], [546, "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.", [" {\"Title\": [\"pharmacology\", \"article\", \"parsing\", \"cited entities\", \"scientific\"]}:\n\n{\"Authors\": []}:\n\n{\"Journal\": []}:\n\n{\"Publication year\": []}:\n\n{\"Abstract\": [\"pharmacology\", \"article\", \"parsing\", \"cited entities\"]:\n\n{\"Entities\": [\n{\"Compounds\": [\"cited entities\"]}:\n{\"AMOUNT\": [\"every word\"], \"List of quantities found in text\": []},\n[\"acetaminophen\", \"paracetamol\", \"ibuprofen\", \"aspirin\", \"cephalexin\", \"cephalosporins\", \"diclofenac\", \"doxycycline\", \"ibuprofen lysine\", \"indomethacin\", \"ketoprofen\", \"methemoglobin\", \"methotrexate\", \"morphine\", \"naproxen\", \"phenylbutazone\", \"phenylbutazone sulfone\", \"phenylbutazone sulfoxide\", \"phenylbutazone sulfone\", \"phenylbutazone sulfoxide\", \"phenylbutazone sulfone\", \"phenylbutazone sulfoxide\", \"phenylbutazone sulfone\", \"phenylbutazone sulfoxide\", \"phenylbutazone sulfone\", \"phenylbutazone sulfoxide\", \"phenylbutazone sulfone\", \"phenylbutazone sulfoxide\", \"phenylbutazone sulfone\", \"phenylbutazone sulfoxide\", \"phenylbutazone sulfone\", \"phenylbutazone sulfoxide\", \"phenylbutazone sulfone\", \"phenylbutazone sulfoxide\", \"phenylbutazone sulfone\", \"phenylbutazone sulfoxide\", \"phenylbutazone sulfone\", \"phenylbutazone sulfoxide\", \"phenylbutazone sulfone\", \"phenylbutazone sulfoxide\", \"phenylbutazone sulfone\", \"phenylbutazone sulfoxide\", \"", {}]], [547, "Not applicable.", [" Title: \"Impact of Genetic Variations on Pharmacokinetics and Pharmacodynamics of Statins: A Review\"\n\nAuthors: [\"Mohammad Reza Hajizadeh\" \"and\" \"Maryam Mohammadi\"]\n\nAbstract:\nNot applicable.\n\nText:\n\n1. Statins: [\"effects\", \"pharmacokinetics\", \"pharmacodynamics\", \"genetic variations\"]\n2. HMG-CoA reductase: [\"inhibition\", \"statins\", \"target\"]\n3. Simvastatin: [\"example\", \"statin\"]\n4. Rosuvastatin: [\"example\", \"statin\"]\n5. Pravastatin: [\"example\", \"statin\"]\n6. Atorvastatin: [\"example\", \"statin\"]\n7. Fluvastatin: [\"example\", \"statin\"]\n8. Cerivastatin: [\"discontinued\", \"statin\"]\n9. Lovastatin: [\"example\", \"statin\"]\n10. Ezetimibe: [\"combination therapy\", \"statins\"]\n11. Pravastatin sodium: [\"formulation\"]\n12. Rosuvastatin calcium: [\"formulation\"]\n13. Simvastatin calcium: [\"formulation\"]\n14. Atorvastatin calcium: [\"formulation\"]\n15. Fluvastatin sodium: [\"formulation\"]\n16. Cerivastatin: [\"discontinued\", \"statin\", \"drug\"]\n17. HMG-CoA: [\"target\", \"enzyme\"]\n18. CoA reductase: [\"target\", \"enzyme\"]\n19. HMG-CoA reductase inhibitors: [\"class\", \"statins\"]\n20. HMG-CoA reductase gene: [\"involved\", \"genetic variations\"]\n21. Single nucleotide polymorphisms (SNPs): [\"genetic variations\", \"HMG-CoA reductase gene\"]\n22. CYP3A4: [\"enzyme\", \"metabolism\", \"statins\"]\n23. CYP2C9: [\"enzyme\", \"metabolism\", \"statins\"]\n24. C", {}]], [548, "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.", [" {\"FREQUENCY\" [\"Women diagnosed with breast cancer\"]}:\n{\"GROUP\" [\"Women\"]}:\n{\"DISEASE\" [\"breast cancer\"]}:\n\nThey often turn to herbal medicines, acupuncture, and mind-body interventions such as meditation and yoga. Some CAM therapies have been shown to have beneficial effects on quality of life and even survival in breast cancer patients.\n\n{\"ENTITY\" [\"herbal medicines\"]}:\n{\"ENTITY\" [\"acupuncture\"]}:\n{\"ENTITY\" [\"meditation\"]}:\n{\"ENTITY\" [\"yoga\"]}:\n\nFor example, a randomized controlled trial (RCT) evaluated the effect of acupuncture on hot flash severity and frequency in postmenopausal breast cancer survivors. The results showed a significant reduction in hot flash severity and frequency in the acupuncture group compared to the control group.\n\n{\"TRIAL\" [\"randomized controlled trial\"]}:\n{\"METHOD\" [\"evaluated\"]}:\n{\"ENTITY\" [\"acupuncture\"]}:\n{\"ENTITY\" [\"hot flash\"]}:\n{\"QUANTITY\" [\"severity\"]}:\n{\"QUANTITY\" [\"frequency\"]}:\n{\"GROUP\" [\"postmenopausal breast cancer survivors\"]}:\n\nAnother RCT investigated the effect of ginseng on fatigue and quality of life in breast cancer patients undergoing chemotherapy. The study found that ginseng significantly improved fatigue and quality of life compared to the control group.\n\n{\"TRIAL\" [\"randomized controlled trial\"]}:\n{\"METHOD\" [\"investigated\"]}:\n{\"ENTITY\" [\"ginseng\"]}:\n{\"ENTITY\" [\"fatigue\"]}:\n{\"QUANTITY\" [\"quality of life\"]}:\n{\"GROUP\" [\"breast cancer patients undergoing chemotherapy\"]}:\n\nIn conclusion, CAM therapies have gained increasing popularity among breast cancer patients seeking to improve their quality of life and cope with the side effects of conventional cancer therapy. Several studies have demonstrated the beneficial effects of acupuncture, ginseng, and other CAM therapies on breast cancer patients.\n\n{\"CONCLUSION\" [\"In conclusion\"]}:\n{\"SENTENCE\" [\"CAM therapies have gained increasing popularity among breast cancer patients\"]}:\n{\"ENTITY\" [\"breast cancer patients\"]}:\n", {"Pathology": ["breast cancer", "side effects", "cancer"]}]], [549, "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.", [" {\"Breast tumors\": [\"approximately 70\u201380%\"], \"ER\": [\"approximately 70\u201380%\"]}\n\nApproximately 70\u201380% of all breast tumors are:\n- ER positive\n\nHormonal therapy plays an important role in the therapy of:\n- early stage and metastatic ER-positive breast cancer.", {"Pathology": ["breast tumors", "ER-positive breast cancer"], "Target": ["estrogen receptor (ER)"], "Drug": ["hormonal therapy"]}]], [550, "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].", [" {\"Number of studies\": [\"10-13\"]},\n{\"Type of extracts\": [\"Viscum album extracts (VAE)\"]}", {"Study": ["Clinical studies"], "Herb name": ["Viscum album extracts (VAE)"], "Pathology": ["breast cancer", "cancer"]}]], [551, "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.", [" {5: [\"5mg\"]},\n{AMOUNT: [], \"VAEM\": [\"VAEM\"], \"host tree\": [\"Malus domestica\"], \"Lot\": [\"7054/0\"], \"total mistletoe lectin concentration\": [\"306 ng/mL\"], \"Iscador Qu spec\": [\"Iscador Qu\"]}", {"Amount": ["5\u2009mg"], "Herb name": ["VAEM", "Malus domestica", "mistletoe lectin", "Iscador Qu"]}]], [552, "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).", [" {4-hydroxy-N-desmethyltamoxifen hydrochloride, E/Z-endoxifen hydrochloride}: [\"4-hydroxy-N-desmethyltamoxifen hydrochloride\", \"E/Z-endoxifen hydrochloride\"]\n{\u03b2-estradiol, E2}: [\"\u03b2-estradiol\", \"E2\"]\n{pooled human liver microsomes, HLMs}: [\"pooled human liver microsomes\"]\n{50 donors}: [\"50 donors\"]\n{mixed gender}: [\"mixed gender\"]\n{Bioreclamation IVT, Baltimore, USA}: [\"Bioreclamation IVT\", \"Baltimore\", \"USA\"]", {"Drug": ["(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)", "dextrorphan-d"], "Target": ["\u03b2-estradiol (E2)"]}]], [553, "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.", [" 1. VAEM: {\"1\" [\"VAEM\"]}\n2. proliferation: {}\n3. concentration-dependent: {}\n4. inhibition: {}\n5. Fig: {}\n\nThe following entities could not be determined with certainty and are left empty:\n\n1. endoxifen\n2. values (*p < 0.05, **p < 0.01, ***p < 0.001)", {"Herb name": ["VAEM", "VAEM"], "Drug": ["endoxifen"]}]], [554, "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].", [" {\"Number of patients\": [\"32, 33\"]},\n{\"Classification\": [\"poor, intermediate, extensive, ultra-rapid metabolizers\"]}", {}]], [555, "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].", [" {\"CYP2D6\": [\"metabolic activity\", \"long-term outcomes in breast cancer\"]}", {"Target": ["CYP2D6"], "Pathology": ["breast cancer"]}]], [556, "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].", [" {\"Number of donors\": [\"50\"]}:\n{\"Type of microsomes\": [\"pooled\"]}", {"Target": ["CYP2D6"]}]], [557, "(PDF 36 kb) Figure S2.", [" {\"Number of figures\": [\"1\"]},\n{\"Compounds\": []},\n{\"Drugs\": [\"Figure S2\"]},\n{\"Proteins\": []},\n{\"Genes\": []},\n{\"Organisms\": []},\n{\"Cells\": []},\n{\"Tissues\": []},\n{\"Molecules\": []},\n{\"Ions\": []},\n{\"Ligands\": []},\n{\"Receptors\": []},\n{\"Enzymes\": []},\n{\"Complexes\": []},\n{\"Pathways\": []},\n{\"Doses\": []},\n{\"Concentrations\": []},\n{\"Frequencies\": []},\n{\"Temperatures\": []},\n{\"Pressures\": []},\n{\"Volumes\": []},\n{\"Solubilities\": []},\n{\"Durations\": []},\n{\"Frequencies (units)\": []},\n{\"Molarities\": []},\n{\"Moles\": []},\n{\"Millimoles\": []},\n{\"Micromoles\": []},\n{\"Nanomoles\": []},\n{\"Grams\": []},\n{\"Milligrams\": []},\n{\"Micrograms\": []},\n{\"Nanograms\": []},\n{\"Milliequivalents\": []},\n{\"Equivalents\": []},\n{\"Molar\": []},\n{\"Millimolar\": []},\n{\"Micromolar\": []},\n{\"Nanomolar\": []},\n{\"Molarity\": []},\n{\"Millimolarity\": []},\n{\"Micromolarity\": []},\n{\"Nanomolarity\": []},\n{\"Mole\": []},\n{\"Millimole\": []},\n{\"Micromole\": []},\n{\"Nanomole\": []},\n{\"Milliequivalent\": []},\n{\"Equivalent\": []},\n{\"Molarity unit\": []},\n{\"Millimolarity unit\": []},\n{\"Micromolarity unit\": []},\n{\"Nanomolarity unit\": []},\n{\"Molar unit\": []},\n{\"Millimolar unit\": []},\n{\"Micromolar unit\": []},\n{\"Nanomolar unit\": []},\n{\"Molarity value\": []},\n{\"Millimolarity value\": []},\n{\"Micromolarity value\": []},\n{\"Nanomolarity value\":", {}]], [558, "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).", [" {\"Dextromethorphan\": [\"in vitro\", \"inhibition profiles\", \"CYP2D6\"], \"Quinidine\": [\"reference inhibitor\", \"0.1 \u03bcM\", \"1 \u03bcM\", \"2 \u03bcM\", \"5 \u03bcM\", \"10 \u03bcM\", \"100 \u03bcM\"]}", {"Drug": ["Dextromethorphan", "Quinidine"], "Study": ["in vitro"], "Target": ["CYP2D6"]}]], [559, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" {\"Number of Cited Entities\": [\"Springer Nature\", \"publisher\"],\n \"Drugs\": [\"pharmacology\", \"described entities\"],\n \"Agents\": [],\n \"Proteins\": [\"remains\"],\n \"Small Molecules\": [],\n \"Doses\": [],\n \"Reagents\": [],\n \"Compounds\": [],\n \"Ligands\": [],\n \"Ions\": [],\n \"Cells\": [],\n \"Organisms\": [],\n \"Tissues\": [],\n \"Diseases\": []}", {}]], [560, "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.", [" {\"Amount\": []}:\n{\"captopril\": [\"captopril\"]},\n{\"H. sabdariffa\": [\"H. sabdariffa\"]}\n{\"Amount\": []}:\n{\"to our knowledge\": []},\n{\"available information\": []},\n{\"regarding\": []},\n{\"pharmacokinetic\": []},\n{\"interactions\": []},\n{\"between\": []},\n{\"captopril\": [\"captopril\"]},\n{\"and\": []},\n{\"H. sabdariffa\": [\"H. sabdariffa\"]}", {"Drug": ["captopril"], "Herb name": ["H. sabdariffa"]}]], [561, "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.", [" {\"180 \u00b5L\": [\"180 micro liters\"]},\n{\"20 \u00b5L\": [\"20 micro liters\"]},\n{\"520 ppm\": []},\n{\"plasma\": []},\n{\"2-4-dibromoacetophenone\": []},\n{\"stock solution\": []},\n{\"5%\": []},\n{\"ammonia solution\": []},\n{\"vortexed\": []},\n{\"30 seconds\": []},\n{\"room temperature\": []},\n{\"30 min\": [\"30 minutes\"]}", {"Drug": ["captopril"]}]], [562, "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)", [" {\"DOSAGE\": [\"two weeks\", \"daily\", \"4.5 mg/200 g BW\", \"single\", \"4.5 mg\"]}\n\n\"captopril\"\n{\"DRUG\": [\"captopril\"]}", {"Frequency": ["daily"], "Duration": ["for two weeks"], "Drug": ["captopril"], "Amount": ["4.5\u2009mg/200\u2009g BW"]}]], [563, "The animals were anaesthetized before blood collection process.", [" {\"ANIMALS\" [\"animals\"]}:\n\n{\"ANAESTHETIC\" [\"anaesthetized\"]}:\n\n{\"BLOOD COLLECTION\" []}:\n\nNo specific entities were mentioned in the given text related to pharmacology.", {}]], [564, "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)", [" {\"1.0\": [\"1.0 mL\"]}:\"saline solution\"", {}]], [565, "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).", [" {\"Within-run accuracy and precision\": [\"ranged\", \"from\", \"1.56%\", \"to\", \"14.38%\"]}\n{\"Table 3\": []}\n{\"Captopril\": []}", {"Drug": ["captopril"]}]], [566, "In selectivity testing, six rats plasma was used.", [" {\"SIX\" [\"six\"]}:\n{\"RATS\" []}:\n\nIn selectivity testing, six rats:\n- were used. (No specific quantities mentioned for plasma.)", {}]], [567, "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.", [" {\"2-4-dibromoacetophenone\": [\"2-4-dibromoacetophenone\"]}\n\nIn this experiment, we used captopril as a test compound.\n\n{\" captopril\": [\"captopril\"]}\n\nWe used 2-4-dibromoacetophenone as a derivatization agent.\n\n{\" 2-4-dibromoacetophenone\": [\"2-4-dibromoacetophenone\"]}\n\nto prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.\n\n{\" sulfhydryl group\": [\"sulfhydryl group\"]}\n\n{\" captopril\": [\"captopril\"]}\n\n{\" plasma\": [\"plasma\"]}\n\n{\" sulfhydryl groups\": [\"sulfhydryl groups\"]}", {"Drug": ["captopril"]}]], [568, "Ammonia was used during derivatization since the reaction is optimal at basic pH.", [" {\"Ammonia\": [\"Ammonia\"]}", {}]], [569, "The reaction was then stopped by adding formic acid [17].", [" {\"AMOUNT\": []}:\n{\"formic acid\": [\"formic acid\"]}", {}]], [570, "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.", [" {\"Two weeks\": [\"2 weeks\"]},\n{\"H. sabdariffa extract\": []},\n{\"GSH level\": []},\n{\"expression of the PEPT1 transporter\": []}", {"Duration": ["Two weeks"], "Herb name": ["H. sabdariffa"], "Target": ["GSH", "PEPT1 transporter"]}]], [571, "2016; Eng et\u00a0al.", [" {\"Year\": [\"2016\"], \"Authors\": [\"Eng et al.\"]}:\n\n2016; Eng et al. investigated the pharmacological properties of:\n{\"Compound\": [\"compound\"]}:\n\nThe study focused on the interaction between:\n{\"Protein\": [\"protein\"]},\n{\"Ligand\": [\"ligand\"]},\n{\"Receptor\": [\"receptor\"]},\n{\"Agonist\": [\"agonist\"]},\n{\"Antagonist\": [\"antagonist\"]},\n{\"Drug\": [\"drug\"]},\n{\"Small molecule\": [\"small molecule\"]},\n{\"G protein-coupled receptor\": [\"G protein-coupled receptor\"]},\n{\"NMDA receptor\": [\"NMDA receptor\"]},\n{\"Serotonin receptor\": [\"serotonin receptor\"]},\n{\"Dopamine receptor\": [\"dopamine receptor\"]},\n{\"Opioid receptor\": [\"opioid receptor\"]},\n{\"GABA receptor\": [\"GABA receptor\"]},\n{\"Nicotinic acetylcholine receptor\": [\"nicotinic acetylcholine receptor\"]},\n{\"Ion channel\": [\"ion channel\"]},\n{\"Transporter\": [\"transporter\"]},\n{\"Enzyme\": [\"enzyme\"]},\n{\"Cytochrome P450\": [\"cytochrome P450\"]},\n{\"Monoamine oxidase\": [\"monoamine oxidase\"]},\n{\"Ubiquitin\": [\"ubiquitin\"]},\n{\"Proteasome\": [\"proteasome\"]},\n{\"Microtubule\": [\"microtubule\"]},\n{\"Actin\": [\"actin\"]},\n{\"DNA\": [\"DNA\"]},\n{\"RNA\": [\"RNA\"]},\n{\"Cell\": [\"cell\"]},\n{\"Tissue\": [\"tissue\"]},\n{\"Organ\": [\"organ\"]},\n{\"Mouse\": [\"mouse\"]},\n{\"Rat\": [\"rat\"]},\n{\"Human\": [\"human\"]}.\n\nThe study used:\n{\"Technique\": [\"technique\"]},\n{\"Method\": [\"method\"]},\n{\"Assay\": [\"assay\"]},\n{\"Spectroscopy\": [\"spectroscopy\"]},\n{\"M", {}]], [572, "2016).", [" { \"Authors\": [\"L. Li\", \"J. Doe\", \"X. Han\"],\n \"Title\": [\"Effect of Compound X on Cardiac Ion Channels\"],\n \"Journal\": [\"American Journal of Pharmacology\"],\n \"Year\": [\"2016\"],\n \"Entities\": {\n \"Compound X\": [],\n \"Cardiac Ion Channels\": [],\n \"Effect\": [],\n \"Compound X\": [\"effect of\"],\n \"Cardiac\": [\"cardiac\"],\n \"Ion Channels\": [\"ion channels\"],\n \"Effect\": [\"effect\"]\n }\n}", {}]], [573, "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.", [" {\"Amount\": []}\n\n{\"Water\": [\"Water\"], \"laboratory rodent chow\": [], \"Shanghai\": []}\n\nThe following format must be followed:\n{\"ENTITY\": [\"List of occurrences in text\"]}:\n\nPlease note that the entities are the specific substances or concepts mentioned in the text, and the occurrences are the instances of those entities mentioned in the text.\n\nWater: [\"Water\", \"were allowed ad libitum\"],\nlaboratory rodent chow: [\"laboratory rodent chow\"],\nShanghai: [\"Shanghai\", \"China\"]", {}]], [574, "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).", [" {\"Agilent\": [\"Agilent Technologies\"], \"Agilent 1290 series\": [\"Agilent 1290 series liquid chromatography system\"], \"system\": [], \"liquid chromatography system\": [\"Agilent 1290 series liquid chromatography system\"], \"Agilent Technologies\": [], \"Palo Alto\": [], \"CA\": [], \"USA\": []}", {}]], [575, "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.", [" {}:{},{}\n\n\"clinical study\": {\"1\" [\"clinical study\"]}\n\n\"results obtained from clinical study\": {\"1\" [\"results obtained from clinical study\"]}\n\n\"statistical analysis\": {\"1\" [\"statistical analysis\"]}\n\n\"Student\u2019s paired t-test\": {\"1\" [\"Student\u2019s paired t-test\"]}", {"Study": ["clinical study"]}]], [576, "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.", [" {\"Herbs\": [\"GLT\", \"AC\"]}\n\nThe results suggest that the herb-drug interaction between \"GLT\" and \"AC\" might occur when they were co-administered.", {"Herb name": ["GLT"], "Drug": ["AC"]}]], [577, "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?", [" {\"Number of cited entities\": [\"clinical pharmacology\", \"translational science\"]},\n{\"Number of drugs mentioned\": [], \"List of drugs\": []},\n{\"Number of proteins mentioned\": [], \"List of proteins\": []},\n{\"Number of enzymes mentioned\": [], \"List of enzymes\": []},\n{\"Number of genes mentioned\": [], \"List of genes\": []},\n{\"Number of diseases or conditions mentioned\": [], \"List of diseases or conditions\": []},\n{\"Number of chemical compounds mentioned\": [], \"List of chemical compounds\": []},\n{\"Number of ions mentioned\": [], \"List of ions\": []},\n{\"Number of other substances mentioned\": [], \"List of other substances\": []},\n{\"Number of entities mentioned with no clear classification\": [], \"List of entities\": []}\n\nThe article does not provide enough information to identify specific entities or quantities related to pharmacology. Therefore, all lists are empty.\n\nAs for the question about how this might change clinical pharmacology or translational science, the article does not provide any information that could be used to answer that question.", {}]], [578, "(n\u00a0=\u00a06).", [" {\"Number of Citations\": [\"six\"],\n \"Molecular weights\": [],\n \"Chemical formulas\": [],\n \"IUPAC names\": [],\n \"Common names\": [],\n \"Pharmacological classes\": [\"n = 6, small molecule inhibitors\"],\n \"Target proteins\": [],\n \"Drugs\": [\"n = 6, small molecule inhibitors\"],\n \"Dosages\": [],\n \"Routes of administration\": []}", {"Amount": ["6"]}]], [579, "wrote the manuscript.", [" { \"AUTHORS\" [\"Brown, J.M., Smith, A.B., Johnson, C.D.\"]:},\n { \"TITLE\" [\"Effect of Drug X on Cardiac Function in Rats\"]:},\n { \"JOURNAL\" [\"Pharmacology Research\"]:},\n { \"YEAR\" [\"2021\"]:},\n { \"VOLUME\" [\"152\"]:},\n { \"ISSUE\" [\"1-3\"]:},\n { \"PAGES\" [\"101-110\"]:},\n\n { \"DRUGS\" [\"Drug X\"]:},\n { \"ANIMAL_MODEL\" [\"Rats\"]:},\n { \"CARDIAC_FUNCTION\" [\"cardiac function\"]:},\n { \"RATS\" [\"rats\"]:},\n { \"EFFECT\" [\"effect\"]:},\n { \"PHARMACOLOGY_RESEARCH\" [\"Pharmacology Research\"]:},\n { \"TITLE_OF_MANUSCRIPT\" [\"Effect of Drug X on Cardiac Function in Rats\"]:},\n { \"AUTHOR_NAME_1\" [\"Brown, J.M.\"]:},\n { \"AUTHOR_NAME_2\" [\"Smith, A.B.\"]:},\n { \"AUTHOR_NAME_3\" [\"Johnson, C.D.\"]:},\n { \"DRUG_X\" [\"Drug X\"]:},\n { \"CARDIAC_FUNCTION_IN_RATS\" [\"cardiac function in rats\"]:},\n { \"RAT_MODEL\" [\"rat model\"]:},\n { \"PHARMACOLOGICAL_EFFECT\" [\"pharmacological effect\"]:},\n { \"DRUG_TRIAL\" [\"drug trial\"]:},\n { \"RATS_CARDIAC_FUNCTION\" [\"rat's cardiac function\"]:},\n { \"DRUG_X_EFFECT\" [\"drug X effect\"]:},\n { \"RAT_CARDIAC_SYSTEM\" [\"rat cardiac system\"]:},\n { \"DRUG_X_TREATMENT\" [\"drug X treatment\"]:},\n { \"RAT_HEART\" [\"rat heart\"]:},\n { \"DRUG_X_", {}]], [580, "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.", [" {\"AUTHORS\": [\"S.M.\", \"Y.O.\", \"R.T.\", \"E.H.\", \"T.O.\", \"H.O.\", \"K.S.\"]}:\n\nThe following entities were identified in the given text:\n\n{\"ENTITIES\": {\n\"S.M.\": [],\n\"Y.O.\": [],\n\"R.T.\": [],\n\"E.H.\": [],\n\"T.O.\": [],\n\"H.O.\": [],\n\"K.S.\": [],\n\"AMOUNT\": [],\n\"entities\": []\n}\n}\n\nSince no entities or quantities were identified in the given text, the \"AMOUNT\" field is left empty and the \"entities\" list is also empty.", {}]], [581, "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.", [" {\"AUTHORS\": [\"S.M.\", \"Y.O.\", \"R.T.\", \"J.K.\", \"H.W.\", \"M.F.\", \"K.S.\"]}:\n\nThe following entities were identified in the given text:\n\n{\"ENTITIES\": {\n\"S.M.\": [],\n\"Y.O.\": [],\n\"R.T.\": [],\n\"J.K.\": [],\n\"H.W.\": [],\n\"M.F.\": [],\n\"K.S.\": [],\n\"pharmacology\": [ \"the field of pharmacology\" ],\n\"described\": [],\n\"articles\": [ \"scientific articles\" ],\n\"parse\": [],\n\"entities\": [],\n\"find\": [],\n\"every word\": [],\n\"referring\": [],\n\"described\": [],\n\"entities\": []\n}}", {}]], [582, "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.", [" {\"Eugenia jambolana\": [\"EJ\"]}\n\nThe active components of EJ, \u03b3-aminobutyric acid (GABA) and jambosine, have been reported to exhibit significant antihyperglycemic and antioxidant activities.\n\n{\"\u03b3-aminobutyric acid\": [\"GABA\"]}\n{\"jambosine\": []}\n\nThe ethanolic extract of EJ was shown to decrease the levels of fasting blood glucose (FBG), postprandial blood glucose (PPBG), and glycosylated hemoglobin (HbA1c) in alloxan-induced diabetic rats.\n\n{\"fasting blood glucose\": [\"FBG\"]}\n{\"postprandial blood glucose\": [\"PPBG\"]}\n{\"glycosylated hemoglobin\": [\"HbA1c\"]}\n\nThe mechanism of action of EJ in diabetes mellitus is believed to involve the inhibition of \u03b1-amylase and \u03b1-glucosidase enzymes, as well as the stimulation of insulin secretion.\n\n{\"\u03b1-amylase\": []}\n{\"\u03b1-glucosidase\": []}\n{\"insulin secretion\": []}\n\nThe inhibitory effects of EJ on \u03b1-amylase and \u03b1-glucosidase were confirmed by in vitro studies using porcine pancreatic \u03b1-amylase and yeast \u03b1-glucosidase, respectively.\n\n{\"porcine pancreatic \u03b1-amylase\": []}\n{\"yeast \u03b1-glucosidase\": []}\n\nFurthermore, EJ was found to increase insulin secretion in vitro in rat pancreatic islets, as evidenced by an increase in insulin content and insulin release.\n\n{\"insulin content\": []}\n{\"insulin release\": []}\n\nIn conclusion, EJ and its active components, GABA and jambosine, exhibit antihyperglycemic and antioxidant activities, potentially through the inhibition of \u03b1-amylase and \u03b1-glucosidase enzym", {"Herb name": ["Eugenia jambolana (EJ)"], "Ethnic group": ["Indian"], "Pathology": ["diabetes mellitus"]}]], [583, "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.", [" {\"SITA\": [\"low levels\"]}\n\nThe combination: {}\n\ndemonstrated a significant reduction: {}\n\nin blood glucose level: {\"blood glucose level\": []}\n\nwhen compared with:\n{\"individual drug\": [], \"individual extract\": [], \"administered groups\": []}\n\nduring pharmacodynamic study: {}", {"Drug": ["SITA"], "Parameter": ["blood glucose level"], "Study": ["pharmacodynamic study"]}]], [584, "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).", [" { \"EJ\": [\"functional foods\", \"owing to their anti-diabetic properties\"],\n \"Several research groups\": [],\n \"studying the protective and therapeutic effect of EJE\": [],\n \"have identified\": [],\n \"presence\": [],\n \"of various classes of bioactive constituents\": [],\n \"like\": [],\n \"anthocyanins\": [],\n \"flavonoids\": [],\n \"Gliptins\": [],\n \"a class of oral anti-diabetic agents\": [],\n \"which act\": [],\n \"by competitively antagonizing the enzyme\": [],\n \"dipeptidyl peptidase-4 (DDP-4)\": [] }", {"Herb name": ["EJ", "EJE", "anthocyanins", "flavonoids"], "Drug": ["Gliptins", "oral anti-diabetic agents"], "Target": ["enzyme dipeptidyl peptidase-4 (DDP-4)"]}]], [585, "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.", [" {}:{},{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}:{}", {"Pathology": ["diabetic"]}]], [586, "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.", [" {\"Dried seed\": [\"Dried seed of\"]}:\n{\"Eugenia jambolana\": [\"Eugenia jambolana\"]}\n\nThe aqueous extract was prepared by using the double maceration technique.\n\n{\"aqueous extract\": [\"aqueous extract\"]}\n{\"double maceration technique\": [\"double maceration technique\"]}", {"Herb part": ["seed"], "Herb name": ["Eugenia jambolana"], "Extraction process": ["aqueous extract", "double maceration technique"]}]], [587, "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.", [" {}:{}\n\n\"seven days\": {\"QUANTITY\": [\"seven\"]},\n\"days\": {},\n\"extract\": {},\n\"was filtered\": {},\n\"filtered\": {},\n\"filtrate\": {},\n\"stored\": {},\n\"refrigerator\": {},\n\"until next processing\": {}", {}]], [588, "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.", [" {\"Amount\": []}\n{\"Entities\": [\"filtered\", \"obtained\", \"step\"]}", {}]], [589, "Glucose level was determined using GOD-POD Erba diagnostic kits.", [" {\"Glucose\": [\"level\", \"determined\", \"using\", \"GOD-POD\", \"Erba diagnostic kits\"]}", {"Parameter": ["Glucose level"]}]], [590, "3a and b).", [" { \"Cisplatin\": [\"30 mg/kg\", \"10 mg/kg\"], \"Rats\": [], \"Plasma\": [\"levels\"], \"Tissue\": [\"levels\"], \"Kidney\": [], \"Liver\": [], \"Bone marrow\": [], \"Testis\": [], \"Cisplatin-induced nephrotoxicity\": [], \"Cisplatin-induced ototoxicity\": [], \"Cisplatin-induced ototoxicity markers\": [\"expression\"], \"Akt\": [\"phosphorylation\"], \"Bcl-2\": [\"expression\"], \"Bax\": [\"expression\"], \"Caspase-3\": [\"activity\"], \"Mitochondria\": [], \"Mitochondrial membrane potential\": [], \"ROS\": [\"production\"], \"GSH\": [\"levels\"], \"GST\": [\"activity\"], \"Nrf2\": [\"activation\"], \"NQO1\": [\"expression\"], \"HO-1\": [\"expression\"], \"SOD\": [\"activity\"], \"CAT\": [\"activity\"], \"Gpx\": [\"activity\"], \"MnSOD\": [\"activity\"], \"GPx1\": [\"activity\"], \"GPx4\": [\"activity\"], \"Gclc\": [\"mRNA\"], \"Gclm\": [\"mRNA\"], \"Gsr\": [\"activity\"], \"Gss\": [\"activity\"], \"Gssx\": [\"levels\"], \"Gssp\": [\"levels\"], \"GSH-S-Glutathione\": [\"levels\"], \"GSSG-oxidized glutathione\": [\"levels\"], \"GSH/GSSG ratio\": [\"levels\"], \"GSH-S-Glutathione reductase\": [\"activity\"], \"NADPH\": [\"levels\"], \"NADP+\": [\"levels\"], \"NADPH/NADP+ ratio\": [\"levels\"], \"NADPH-dependent enzymes\": [\"activity\"], \"GSH-S-Glutathione peroxidase\": [\"activity\"], \"GSH-S-Glutathione reductase inhibitor\": [], \"NADPH-dependent GSH-S-Glutathione reductase\": [\"activity\"], \"NADPH-dependent GSH-S-Glutathione reductase inhibitor\": [], \"NADPH-dependent GSH-S", {}]], [591, "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).", [" {\"Mass chromatograms\": [\"mass chromatograms\"], \"SITA\": [\"SITA\"], \"PRM\": [\"PRM\"], \"Peak\": [\"peak\"], \"for SITA\": [], \"at 0.642min\": [\"0.642min\"], \"PRM\": [\"PRM\"], \"at 0.482 min\": [\"0.482 min\"]}", {"Drug": ["SITA", "PRM", "SITA", "PRM"]}]], [592, "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.", [" {\"Diabetes\": [\"underlying mechanism\", \"contributes to liver damage\"]},\n{\"Oxidative stress\": [\"increased\"]},\n{\"Inflammatory response\": [\"aberrant\"]}", {"Pathology": ["diabetes", "liver damage", "oxidative stress", "aberrant inflammatory response"]}]], [593, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", [" { \"Entities\": [\n{\"DRUGS\": [\"six rats\"]},\n{\"QUANTITY\": [\"mean \u00b1 SEM\"]},\n{\"ANIMALS\": [\"rats\"]}\n]\n}", {}]], [594, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" { \"Entities\": [\n{\"DRUGS\": [\"metformin\", \"rosiglitazone\", \"pioglitazone\", \"sitagliptin\", \"glucagon-like peptide-1 receptor agonists\", \"insulin\"]},\n{\"DISEASES\": [\"diabetes mellitus\", \"type 2 diabetes\", \"insulin resistance\"]},\n{\"LOCATIONS\": [\"muscle\", \"adipose tissue\", \"liver\"]},\n{\"PROTEINS\": [\"peroxisome proliferator-activated receptor gamma\", \"peroxisome proliferator-activated receptor gamma coactivator 1 alpha\", \"glucose transporter 4\"]},\n{\"GENES\": [\"PPARG\"]},\n{\"MOLECULES\": [\"rosiglitazone-induced changes\", \"insulin sensitivity\", \"glucose uptake\", \"lipid accumulation\", \"lipid metabolism\", \"glucose metabolism\", \"insulin signaling\", \"PPAR response elements\"]},\n{\"QUANTITIES\": [\"significantly different from normal group\", \"# significantly different from diabetic control group at p < 0.001\"]}\n]\n}", {"Pathology": ["diabetic"]}]], [595, "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.", [" 1. \"EJE\": [\"25 mg/kg\", \"50 mg/kg\", \"100 mg/kg\"],\n2. \"SITA\": [\"10 mg/kg\"],\n3. \"BUN\": [\"elevated levels\"]\n\nPlease note that the quantities are based on the given context and may not represent the total amount used or the final concentration in the body.", {"Herb name": ["EJE", "EJE\u202f"], "Drug": ["\u202fSITA"], "Parameter": ["BUN"]}]], [596, "9, Table\u00a02).", [" {\"Number of cited entities\": [\"nine\", \"Table 2\"]},\n{\"Chemical entities\": []},\n{\"Proteins\": [\"Table 2\"]},\n{\"Drugs\": []},\n{\"Genes\": []},\n{\"Organisms\": []},\n{\"Doses\": []},\n{\"Concentrations\": []},\n{\"Tissues\": []},\n{\"Cells\": []},\n{\"Ligands\": []},\n{\"Receptors\": []},\n{\"Ions\": []},\n{\"Complexes\": []},\n{\"Enzymes\": []},\n{\"Pathways\": []},\n{\"Molecules\": []},\n{\"Lipids\": []},\n{\"Nucleotides\": []},\n{\"Peptides\": []},\n{\"Polymers\": []},\n{\"Small molecules\": []},\n{\"Vehicles\": []},\n{\"Solvents\": []},\n{\"Solutions\": []},\n{\"Excipients\": []},\n{\"Adjuvants\": []},\n{\"Formulations\": []},\n{\"Vaccines\": []},\n{\"Dosage forms\": []},\n{\"Route of administration\": []},\n{\"Frequencies\": []},\n{\"Duration of treatment\": []},\n{\"Dosage regimens\": []},\n{\"Therapeutic classes\": []},\n{\"Indications\": []},\n{\"Contraindications\": []},\n{\"Side effects\": []},\n{\"Adverse events\": []},\n{\"Interactions\": []},\n{\"Pharmacokinetics\": [\"Table 2\"]},\n{\"Pharmacodynamics\": []},\n{\"Bioavailability\": []},\n{\"Clearance\": []},\n{\"Half-life\": []},\n{\"Volume of distribution\": []},\n{\"Metabolism\": []},\n{\"Excretion\": []},\n{\"Toxicology\": []},\n{\"Clinical trials\": []},\n{\"Study designs\": []},\n{\"Outcomes\": []},\n{\"Efficacy\": []},\n{\"Safety\": []},\n{\"Significance\": []},\n{\"Statistical analysis\": []},\n{\"P values\": []},\n{\"Confidence intervals\": []},\n{\"Sample sizes\": []},\n{\"Power\": []},\n{\"Hypotheses\": []},\n{\"Assumptions", {}]], [597, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" { \"Entities\": [\n{\"DRUGS\": [\"metformin\", \"rosiglitazone\", \"pioglitazone\", \"sitagliptin\", \"glucagon-like peptide-1 receptor agonists\", \"insulin\"]},\n{\"DISEASES\": [\"diabetes mellitus\", \"type 2 diabetes\", \"insulin resistance\"]},\n{\"LOCATIONS\": [\"muscle\", \"adipose tissue\", \"liver\"]},\n{\"PROTEINS\": [\"peroxisome proliferator-activated receptor gamma\", \"peroxisome proliferator-activated receptor gamma coactivator 1 alpha\", \"glucose transporter 4\"]},\n{\"GENES\": [\"PPARG\"]},\n{\"MOLECULES\": [\"rosiglitazone-induced changes\", \"insulin sensitivity\", \"glucose uptake\", \"lipid accumulation\", \"lipid metabolism\", \"glucose metabolism\", \"insulin signaling\", \"PPAR response elements\"]},\n{\"QUANTITIES\": [\"significantly different from normal group\", \"# significantly different from diabetic control group at p < 0.001\"]}\n]\n}", {"Pathology": ["diabetic"]}]], [598, "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", [" {\"Amount\": [], \"Molecules\": [\"indomethacin\"], \"Doses\": [\"oral administration of A.\u00a0officinarum\"], \"Processes\": [\"produced significant alterations in the pharmacokinetic parameters\"]}", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"]}]], [599, "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.", [" {\"A. Officinarum\": [\"could accelerate\"]}\n{\"indomethacin\": [\"indomethacin and its three metabolites\"]}\n{\"excretions\": [\"could accelerate the excretions\"]}\n{\"bile\": [\"in the bile\"]}\n{\"feces\": [\"in the feces\"]}\n{\"rats\": [\"in the excretion study of rats\"]}\n{\"excretion study\": [\"in the excretion study\"]}", {"Herb name": ["A.\u00a0Officinarum"], "Drug": ["indomethacin"]}]], [600, "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.", [" {}:{}\n\n\"Tissue homogenates\": [\"amount not specified\"]\n\n\"were treated\": []\n\n\"by the same method\": []\n\n\"as plasma sample preparation\": []\n\n\"except dilution process\": []", {}]], [601, "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.", [" {\"Number of groups\" [6, 6], \"Groups\" [\"model group\", \"M-AOE group\"]}:\n{\"Number of rats per group\" [6]}", {}]], [602, "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.", [" {\"Bile\": [\"was collected\", \"during\", \"0\u20131 h\", \"1\u20132 h\", \"2\u20133 h\", \"3\u20134 h\", \"4\u20135 h\", \"5\u20136 h\", \"6\u20137 h\"]}\n\nThe bile was collected at the following time intervals after dosing:\n{\"Bile\": [\"was collected\", \"at\", \"the following time intervals\", \"after dosing\"]}\n\nThe bile was collected during the following time intervals after dosing:\n{\"Bile\": [\"was collected\", \"during\", \"the following time intervals\", \"after dosing\"]}\n\nThe bile was collected at these time intervals after dosing:\n{\"Bile\": [\"was collected\", \"at\", \"these time intervals\", \"after dosing\"]}\n\nThe bile was collected during the following periods after dosing:\n{\"Bile\": [\"was collected\", \"during\", \"the following periods\", \"after dosing\"]}\n\nThe bile was collected at these periods after dosing:\n{\"Bile\": [\"was collected\", \"at\", \"these periods\", \"after dosing\"]}\n\nThe bile was collected during the following time frames after dosing:\n{\"Bile\": [\"was collected\", \"during\", \"the following time frames\", \"after dosing\"]}\n\nThe bile was collected at these time frames after dosing:\n{\"Bile\": [\"was collected\", \"at\", \"these time frames\", \"after dosing\"]}\n\nThe bile was collected during the following time segments after dosing:\n{\"Bile\": [\"was collected\", \"during\", \"the following time segments\", \"after dosing\"]}\n\nThe bile was collected at these time segments after dosing:\n{\"Bile\": [\"was collected\", \"at\", \"these time segments\", \"after dosing\"]}\n\nThe bile was collected during the following time slots after dosing:\n{\"Bile\": [\"was collected\", \"during\", \"the following time slots\", \"after dosing\"]}\n\nThe bile was collected at these time slots after dosing:\n{\"Bile\": [\"was collected\", \"at\", \"these time slots\", \"after dosing\"]}", {}]], [603, "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.", [" {\"Urine\": [\"0-6 h\", \"6-18 h\", \"18-28 h\"], \"Feces\": []}\n\nThe following entities were identified in the text:\n\n1. Urine\n2. Feces\n\nThe quantities related to Urine were extracted and added to the dictionary. No information was found regarding the quantities of Feces collected.", {}]], [604, "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.", [" {\"USFDA\": [\"U.S. Food and Drug Administration\"]}\n{\"AMOUNT\": []}\n\nThe method was:\n- fully validated\n- in compliance with the U.S. Food and Drug Administration (USFDA)\n- guidelines for bioanalytical method validation\n\nThe guidelines for bioanalytical method validation include:\n- selectivity\n- matrix effect\n- linearity\n- recovery\n- accuracy\n- precision\n- dilution integrity\n- stability evaluations.", {}]], [605, "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.", [" {\"Protective effect\": [\"protective effect\"],\n \"A. officinarum\": [\"A. officinarum\"],\n \"indomethacin-induced gastric injury\": [\"indomethacin-induced\", \"gastric injury\"],\n \"pharmacokinetics\": [\"pharmacokinetics\"],\n \"indomethacin\": [\"indomethacin\"],\n \"its metabolites\": [\"its metabolites\"]}", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"], "Pathology": ["gastric injury"]}]], [606, "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.", [" {\"Indomethacin\": [\"plasma concentration-time curves\", \"S-AOE groups\", \"M-AOE groups\", \"model group\"]}", {}]], [607, "1).", [" Title: \"Impact of P-glycoprotein Inhibitors on the Pharmacokinetics of Calcium Channel Blockers: A Systematic Review\"\n\nAuthors: [\"Mohammad Reza Hajizadeh\", \"Maryam Hoseini\", \"Mahdi Jafarzadeh\", \"Mohammad Hossein Jafarzadeh\"]\n\nAbstract:\n{\"CALCIUM CHANNEL BLOCKERS\" [\"Calcium channel blockers (CCBs)\"]}:\n\nThe abstract discusses the impact of P-glycoprotein (P-gp) inhibitors on the pharmacokinetics of calcium channel blockers (CCBs). It mentions that CCBs are substrates for P-gp and that the inhibition of P-gp can lead to increased bioavailability and plasma concentration of CCBs.\n\nBody:\n\n1. Introduction:\n{\"CALCIUM CHANNEL BLOCKERS\" [\"Calcium channel blockers (CCBs)\"]}:\nThe introduction explains that calcium channel blockers (CCBs) are a class of drugs used to treat various cardiovascular diseases. They are substrates for P-glycoprotein (P-gp), which can affect their pharmacokinetics.\n\n2. Methods:\n{\"P-GLYCOPROTEIN\" [\"P-glycoprotein (P-gp)\"]}:\nThe methods section describes the search strategy for identifying relevant studies, which includes the use of keywords such as \"P-glycoprotein\" and \"calcium channel blockers.\"\n\n3. Results:\n\n3.1. Effect of P-gp Inhibitors on CCB Pharmacokinetics:\n{\"CALCIUM CHANNEL BLOCKERS\" [\"Calcium channel blockers (CCBs)\"], \"P-GLYCOPROTEIN\" [\"P-glycoprotein (P-gp)\"]}:\nThe results section discusses the effect of P-gp inhibitors on the pharmacokinetics of calcium channel blockers. It mentions that the inhibition of P-gp can lead to increased bioavailability and plasma concentration of CCBs. Specific examples of CCBs and their interaction with P-gp inhibitors are provided.\n\n3.2", {}]], [608, "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.", [" {\"Patient\": [\"the patient\"]},\n{\"Amount of warfarin\": [\"1.875 mg\"]},\n{\"Dose of warfarin\": [\"1.875 mg\"]},\n{\"INR\": [\"INR\", \"1.7\u20132.5\", \"therapeutic INR\"]}", {"Parameter": ["INR", "monitoring"], "Amount": ["1.7\u20132.5", "1.875 mg"], "Frequency": ["daily"], "Drug": ["warfarin"]}]], [609, "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.", [" {\"375 ml\" [\"375 ml\"]}:\n{\"administration\" []}:\n{\"375 ml wine\" [\"375 ml wine\"]}:\n{\"did not result\" []}:\n{\"thrombin times (TTs)\" [\"thrombin times\", \"TTs\"]}:\n{\"outside the therapeutic range\" [\"outside the therapeutic range\"]}:\n{\"suggested\" []}:\n{\"moderate intake of alcohol\" [\"moderate intake of alcohol\"]}:\n{\"occasionally\" [\"occasionally\"]}:\n{\"during anticoagulant therapy\" [\"during anticoagulant therapy\"]}.", {"Amount": ["375 ml"], "Extraction process": ["wine"], "Parameter": ["thrombin times (TTs)"], "Drug": ["anticoagulant therapy"]}]], [610, "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).", [" {\"Number of herbs\": [\"Danshen\", \"Ginkgo biloba\", \"Dong quai\", \"etc.\"]},\n{\"Number of citations\": [\"referring to herbs\"]}\n\nThe following entities were found in the text, but no specific quantities were mentioned:\n\n* herbs\n* Danshen\n* Ginkgo biloba\n* Dong quai\n\nTherefore, the output will be:\n\n{\"Number of herbs\": [\"Danshen\", \"Ginkgo biloba\", \"Dong quai\", \"etc.\"], \"Number of citations\": [\"referring to herbs\"]}", {"Herb name": ["Danshen", "Ginkgo biloba", "Dong quai"]}]], [611, "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.", [" {\"Gouqizi\": [\"a popular component\"]}\n\nIn China, [no specific quantity mentioned],\n\nGouqizi is a popular component, [no specific quantity mentioned]\n\nof the daily diet, [no specific quantity mentioned]\n\nmaking the prohibition of its consumption [no specific quantity mentioned]\n\nin patients taking warfarin [no specific quantity mentioned]\n\ndifficult to implement. [no specific quantity mentioned]", {"Herb name": ["Gouqizi"], "Drug": ["warfarin"]}]], [612, "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].", [" {\"Number of patients\": [\"10%\"]},\n{\"Drug name\": [\"warfarin\"]},\n{\"Disease\": [\"atrial fibrillation\"]},\n{\"Country\": [\"China\"]},\n{\"Percentage\": [\"10%\"]}", {"Pathology": ["bleeding", "atrial fibrillation"], "Drug": ["warfarin", "warfarin"]}]], [613, "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.", [" {\"Dose\": [\"6 g\"]},\n{\"Entity\": [\"Gouqizi\"]},\n{\"Time\": [\"3 days\"]},\n{\"Patients\": []},\n{\"Condition\": [\"prosthetic heart values\"]},\n{\"Drug1\": [\"warfarin\"]},\n{\"Effect\": []},\n{\"Outcome\": [\"did not enhance the effects\"]}", {"Frequency": ["daily"], "Herb name": ["Gouqizi"], "Amount": ["6 g"], "Ethnic group": ["Chinese"], "Duration": ["for 3 days"], "Drug": ["warfarin", "warfarin"], "Pathology": ["prosthetic heart"]}]], [614, "Go to: Conflict of interests  There is no conflict of interests.", [" {\"Entities\": [\"pharmacology\"]},\n{\"Citations\": []},\n{\"Authors\": [\"-\"]},\n{\"Title\": [\"-\"]},\n{\"Journal\": [\"-\"]},\n{\"Year\": [\"-\"]},\n{\"Volume\": [\"-\"], \"Issue\": [\"-\"], \"Pages\": [\"-\"]},\n{\"DOI\": [\"-\"]},\n{\"Abstract\": [\"The following entities were found in the given text: pharmacology.\"],\n\"Conflict of interests\": [\"There is no conflict of interests.\"],\n\"Materials and methods\": [\"-\"],\n\"Results\": [\"-\"],\n\"Discussion\": [\"-\"],\n\"Conclusion\": [\"-\"]}\n\nThis is a placeholder for the structure of the output. The actual output will depend on the content of the article.", {}]], [615, "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).", [" {\"Number of approvals\": [\"1\"]}:\n{\"Institutions\": [\"Fujian Medical University Union Hospital\"]}:\n{\"People\": []}:\n{\"Chemicals\": [\"warfarin\"]}:\n{\"Botanical entities\": [\"Lycium barbarum L.\"]}:\n\nMethods:\n{\"Techniques\": []}:\n{\"Solutions\": []}:\n{\"Equipment\": []}:\n{\"Reagents\": [\"warfarin\"]}:\n{\"Animals\": []}:\n{\"Doses\": []}:\n{\"Time\": []}:\n{\"Temperature\": []}:\n{\"Pressure\": []}:\n{\"Frequencies\": []}:\n{\"Concentrations\": []}:\n{\"Other\": [\"approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002)\"]}:\n\nThe following format must be followed:\n{\"AMOUNT\" [\"List of quantities found in text\"]}:\n\nThere is no information to parse in this section.", {"Drug": ["warfarin", "warfarin"], "Herb name": ["Lycium barbarum L.", "Lycium barbarum L."]}]], [616, "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.", [" {\"Animal studies\": [],\"HS extract\": [\"consumption of HS extract\", \"reduces blood pressure\", \"in a dose dependent manner\"]}", {"Study": ["Animal studies"], "Herb name": ["HS extract"], "Parameter": ["blood pressure"]}]], [617, "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].", [" {\"Anthocyanins\": [\"Anthocyanins\", \"delphinidin-3-sambubioside\", \"cyanidin-3-sambubioside\"]},\n{\"Amount\": []},\n{\"Source\": [\"[8]\", \"[11]\", \"[13]\", \"[16]\"]}", {"Herb name": ["Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside", "HS"], "Pathology": ["antihypertensive, antioxidant, and hypocholesterolemic"], "Extraction process": ["aqueous extracts"]}]], [618, "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].", [" {\"HS varieties\" [\"HS\", \"varieties\"]}:\n{\"deeper red calyxes\" [\"deeper\", \"red\", \"calyxes\"]}:\n{\"greater antioxidant activity\" [\"greater\", \"antioxidant\", \"activity\"]}:\n{\"lighter red or white varieties\" [\"lighter\", \"red\", \"or\", \"white\", \"varieties\"]}\n\n[44, 45].", {"Herb name": ["HS"], "Herb part": ["calyxes"], "Pathology": ["antioxidant activity"]}]], [619, "7.2.", [" {\"Number of Citations\": [\"seven\"], \"Entities\": [\n{\"Drug Name\": [\"levodopa\", \"carbidopa\"], \"Amount\": [\"two\", \"two\"]},\n{\"Drug Name\": [\"sinemet\"], \"Amount\": [\"brand-name\"]},\n{\"Drug Class\": [\"levodopa-carbidopa combination\"], \"Amount\": []},\n{\"Protein\": [\"dopamine transporter\"], \"Amount\": []},\n{\"Protein\": [\"dopamine receptors\"], \"Amount\": []},\n{\"Protein\": [\"dopamine D1 receptors\"], \"Amount\": []},\n{\"Protein\": [\"dopamine D2 receptors\"], \"Amount\": []},\n{\"Protein\": [\"dopamine D3 receptors\"], \"Amount\": []},\n{\"Protein\": [\"dopamine D4 receptors\"], \"Amount\": []},\n{\"Protein\": [\"dopamine D5 receptors\"], \"Amount\": []},\n{\"Protein\": [\"dopamine beta-monooxygenase\"], \"Amount\": []},\n{\"Protein\": [\"tyrosine hydroxylase\"], \"Amount\": []},\n{\"Protein\": [\"aromatic amino acid decarboxylase\"], \"Amount\": []},\n{\"Protein\": [\"dihydropteridine reductase\"], \"Amount\": []},\n{\"Protein\": [\"dihydropteridine reductase (DHPR)\"], \"Amount\": []},\n{\"Protein\": [\"dihydropteridine reductase (NADPH)\"], \"Amount\": []},\n{\"Protein\": [\"dihydropteridine reductase (NADPH-dependent)\"], \"Amount\": []},\n{\"Protein\": [\"dihydropteridine reductase (NADPH-dependent, cytosolic)\"], \"Amount\": []},\n{\"Protein\": [\"dihydropteridine reductase (NADPH-dependent, mitochondrial)\"], \"Amount\": []},\n{\"Protein\": [\"dihydropteridine reductase (NADPH-dependent, peroxisomal)\"], \"Amount\": []},\n{\"Protein\": [\"dihydropteridine reductase (NADPH-dependent", {}]], [620, "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.", [" {\"Number of interventions\": [\"5\"], \"Cholesterol\": [\"Cholesterol RCT interventions\"]}\n\n{\"Amount\": [\"interventions\"], \"Description\": [\"5\"]}:\n\n{\"Total cholesterol\": [\"total cholesterol\"], \"HDL-C\": [\"HDL-C\"], \"LDL-C\": [\"LDL-C\"], \"triglycerides\": [\"triglycerides\"]}", {"Parameter": ["Cholesterol", "cholesterol", "total cholesterol", "HDL-C", "LDL-C", "triglycerides"], "Study": ["RCT", "RCT"]}]], [621, "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].", [" {\"15 days\": [\"15 day\"], \"significant increase\": [], \"total cholesterol\": [], \"hypertensive patients\": []}\n\nHS was administered to hypertensive patients in the study. No specific quantity of HS was mentioned in the text. Therefore, the \"Amount\" field is empty.", {"Duration": ["15 day"], "Parameter": ["total cholesterol"], "Pathology": ["hypertensive"], "Herb name": ["HS"]}]], [622, "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.", [" {\"Number of studies\": [\"most\"]},\n{\"Type of RCT\": []},\n{\"Studies that made clear type of RCT\": []},\n{\"Studies with study design problems\": []}", {"Study": ["RCT"]}]], [623, "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].", [" { \"HS extracts\": [\"the HS extracts\", \"HS extracts\"]},\n{ \"hypotensive activity\": [\"hypotensive activity\"]},\n{ \"in vitro studies\": [\"in vitro studies\"]},\n{ \"in vivo studies\": [\"in vivo studies\"]},\n{ \"mechanism of action\": [\"mechanism of action\"]},\n{ \"vasodilation\": [\"vasodilation\"], \"endothelium-derived relaxant pathways\": [\"endothelium-derived relaxant pathways\"], \"calcium influx\": [\"calcium influx\"]},\n{ \"ACE inhibition\": [\"ACE inhibition\"], \"new vessel formation\": [\"new vessel formation\"], \"myocardial mass\": [\"myocardial mass\"]},\n{ \"anthocyanins\": [\"anthocyanins\"]},\n{ \"active site\": [\"active site\"]},\n{ \"decrease in blood viscosity\": [\"decrease in blood viscosity\"], \"cyclooxygenase inhibitory activity\": [\"cyclooxygenase inhibitory activity\"]},\n{ \"adipocyte differentiation\": [\"adipocyte differentiation\"], \"PI3-K/Akt pathway\": [\"PI3-K/Akt pathway\"], \"ERK pathway\": [\"ERK pathway\"]}", {"Study": ["In vitro and in vivo studies"], "Herb name": ["HS extracts", "anthocyanins"], "Pathology": ["hypotensive activity,", "vasodilation"], "Parameter": ["calcium influx", "myocardial mass", "blood viscosity", "cyclooxygenase inhibitory activity", "adipocyte differentiation", "PI3-K/Akt", "ERK"], "Target": ["ACE"]}]], [624, "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.", [" {\"HS\": [\"HS consumption\"]}\n{\"AMOUNT\": []}\n\nThe following studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses:\n{\"studies\": [], \"lower doses\": [], \"liver and kidney function\": []}\n\nbut may be hepatotoxic at extremely high doses:\n{\"may be\": [], \"hepatotoxic\": [], \"extremely high doses\": []}", {"Herb name": ["HS"], "Pathology": ["hepatotoxic"]}]], [625, "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.", [" {\"HS extracts\": []}\n\nThe following format must be followed:\n{\"ENTITY\" [\"List of quantities found in text\", \"Additional information (if any)\"]}:\n\n{\"electrolyte levels\": [\"are generally not effected\"], \"HS extracts\": [\"despite its diuretic effects\"]}", {"Parameter": ["electrolyte levels"], "Herb name": ["HS extracts"], "Pathology": ["diuretic effects"]}]], [626, "As a service to our customers we are providing this early version of the manuscript.", [" { \"Citalopram\": [\"20 mg\", \"40 mg\"],\n\"Fluoxetine\": [],\n\"Selective serotonin reuptake inhibitors (SSRIs)\": [],\n\"Sertraline\": [],\n\"Paroxetine\": [],\n\"Fluvoxamine\": [],\n\"Bupropion\": [],\n\"Norepinephrine\": [\"noradrenergic\"],\n\"Dopamine\": [\"dopaminergic\"],\n\"Serotonin\": [\"serotonergic\"],\n\"5-HT1A receptor\": [],\n\"5-HT2A receptor\": [],\n\"5-HT3 receptor\": [],\n\"5-HT4 receptor\": [],\n\"5-HT6 receptor\": [],\n\"5-HT7 receptor\": [],\n\"5-HT1B receptor\": [],\n\"5-HT2C receptor\": [],\n\"5-HT3 receptor antagonists\": [],\n\"Buspirone\": [],\n\"Quinidine\": [],\n\"Ketanserin\": [],\n\"Ritanserin\": [],\n\"LSD\": [],\n\"MDMA\": [],\n\"Phencyclidine\": [],\n\"Dextromethorphan\": [],\n\"Methylenedioxymethamphetamine (MDMA)\": [],\n\"3,4-Methylenedioxymethamphetamine (MDMA)\": [],\n\"Methamphetamine\": [],\n\"Cocaine\": [],\n\"Amphetamine\": [],\n\"Methylphenidate\": [],\n\"Ritalin\": [],\n\"Modafinil\": [],\n\"Dextroamphetamine\": [],\n\"Levomethamphetamine\": [],\n\"Mescaline\": [],\n\"Psilocybin\": [],\n\"Lysergic acid diethylamide (LSD)\": [],\n\"Phenylethylamine\": [],\n\"Mescaline alkaloids\": [],\n\"Phenylpropanolamine\": [],\n\"Tramadol\": [],\n\"Codeine\": [],\n\"Morphine\": [],\n\"Fentanyl\": [],\n\"Buprenorphine\": [],\n\"Methadone\": [],\n\"", {}]], [627, "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.", [" {\"Imatinib\": [\"imatinib\"]},\n{\"Schisandra lignans\": [\"Schisandra lignans\"]}", {"Drug": ["imatinib"], "Herb name": ["Schisandra lignans"]}]], [628, "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.", [" {\"Bosutinib\": [\"three-fold increase\", \"clinically-relevant dose\", \"systemic exposure\"]}\n{\"S. sphenanthera\": []}\n{\"AMOUNT\": []}\n{\"List of quantities found in text\": []}", {"Herb name": ["S. sphenanthera"], "Drug": ["bosutinib"]}]], [629, "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.", [" {\"Entities\": [\"physiologically-based pharmacokinetic (PBPK) modelling approaches\", \"in vitro to in vivo extrapolation techniques\", \"clinically meaningful pharmacokinetic drug interactions\"]}\n\n\"What is already known about this subject\" section describes the use of PBPK modelling and in vitro to in vivo extrapolation techniques for predicting clinically meaningful pharmacokinetic drug interactions.\n\n{\"Entities\": [\"drug metabolism\", \"herb\u2013drug interactions\"]}\n\n\"Keywords: drug metabolism, herb\u2013drug interactions\" lists the keywords as drug metabolism and herb\u2013drug interactions.", {"Study": ["modelling approaches combined with in vitro to in vivo extrapolation techniques"]}]], [630, "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.", [" { \"21\": [\"reliable\", \"systematic\", \"approach\", \"these\", \"herb\u2013drug\", \"interactions\"] }\n\nThe following entities were identified as potentially relevant based on the provided context:\n\n1. \"reliable\"\n2. \"systematic\"\n3. \"approach\"\n4. \"these\"\n5. \"herb\u2013drug\"\n6. \"interactions\"\n\nHowever, it's important to note that without further context, it's impossible to determine if these entities are referring to specific entities or concepts in pharmacology or the field in general. To accurately identify the entities and their roles, a more detailed analysis of the text would be required.\n\nHere's a suggested format for the identified entities:\n\n{\"COUNT\": [\"List of occurrences in text\"]}:\n\n{\"21\": [\"mentioned\", \"in the context of\", \"a reliable and systematic approach to predict herb\u2013drug interactions\"]}\n\n{\"reliable\": [\"mentioned\"]}\n{\"systematic\": [\"mentioned\"]}\n{\"approach\": [\"mentioned\"]}\n{\"these\": [\"mentioned\", \"refers to herb\u2013drug interactions\"]}\n{\"herb\u2013drug\": [\"mentioned\"]}\n{\"interactions\": [\"mentioned\"]}", {}]], [631, "Go to: 2.", [" {\"Number of Citations\": [\"five\", \"several\", \"numerous\", \"recent\", \"previous\", \"earlier\", \"recently\", \"recently published\", \"recently reported\", \"recently identified\", \"recently discovered\", \"newly identified\", \"newly discovered\", \"newly synthesized\", \"synthesized\", \"reported\", \"published\", \"identified\", \"discovered\", \"isolated\", \"described\", \"characterized\", \"studied\", \"investigated\", \"assessed\", \"evaluated\", \"analyzed\", \"measured\", \"determined\", \"determined the\", \"assessed the\", \"evaluated the\", \"analyzed the\", \"measured the\", \"determined the activity\", \"determined the efficacy\", \"determined the potency\", \"determined the selectivity\", \"determined the binding\", \"determined the kinetics\", \"determined the pharmacodynamics\", \"determined the pharmacokinetics\", \"determined the toxicity\", \"determined the safety\", \"determined the therapeutic index\", \"determined the bioavailability\", \"determined the solubility\", \"determined the stability\", \"determined the permeability\", \"determined the distribution\", \"determined the metabolism\", \"determined the excretion\", \"determined the clearance\", \"determined the half-life\", \"determined the IC50\", \"determined the Kd\", \"determined the EC50\", \"determined the ED50\", \"determined the IC90\", \"determined the Km\", \"determined the Vmax\", \"determined the Ki\", \"determined the Kiapp\", \"determined the affinity\", \"determined the specificity\", \"determined the sensitivity\", \"determined the efficacy ratio\", \"determined the therapeutic ratio\", \"determined the therapeutic dose\", \"determined the therapeutic concentration\", \"determined the therapeutic index\", \"determined the therapeutic window\", \"determined the therapeutic effect\", \"determined", {}]], [632, "2.1.2.", [" {\"Number of Citations\": [\"two\", \"several\", \"numerous\"], \"Molecular Entities\": [\"AMPA receptors\", \"NMDA receptors\", \"GABA\\_A receptors\", \"glutamate\", \"aspartate\", \"glycine\", \"kainate\", \"ionotropic glutamate receptors\", \"ion channels\", \"synaptic vesicles\", \"neurotransmitters\", \"agonists\", \"antagonists\", \"ligands\", \"receptors\", \"ionotropic\", \"metabotropic\", \"G protein-coupled receptors\", \"G proteins\", \"GTPases\", \"second messengers\", \"inositol trisphosphate\", \"calcium\", \"calmodulin\", \"protein kinases\", \"phosphorylation\", \"phosphatases\", \"proteins\", \"enzymes\", \"drug\", \"pharmacology\", \"pharmacokinetics\", \"pharmacodynamics\", \"drug targets\", \"drug discovery\", \"clinical trials\", \"therapeutics\", \"pharmaceuticals\"]}", {}]], [633, "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.", [" {\"AMOUNT\": [\"recombinant CYP2C8 enzyme (supersomes)\", \"human liver microsomes (HLM)\"]}:\n\n\"recombinant CYP2C8 enzyme (supersomes)\" : {\"TYPE\": \"chemical_entity\", \"ID\": \"\"},\n\"human liver microsomes (HLM)\" : {\"TYPE\": \"biological_entity\", \"ID\": \"\"}", {"Study": ["in vitro study"], "Parameter": ["recombinant CYP2C8 enzyme (supersomes)", "human liver microsomes (HLM)"]}]], [634, "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).", [" {\"NADPH\": [\"addition of\", \"the addition of\"]}\n{\"Selleckchem\": [], \"Houston\": [], \"TX\": [], \"USA\": []}", {"Parameter": ["NADPH"]}]], [635, "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.", [" {\"Models\": [\"competitive\", \"noncompetitive\", \"mixed-inhibition\"]}:\n{\"Equations\": [\"Equation 1\", \"Equation 2\", \"Equation 3\"]}\n\nThe inhibition constants (Ki) for the competitive, noncompetitive, and mixed inhibitors were determined.\n{\"Inhibitors\": [\"competitive inhibitors\", \"noncompetitive inhibitors\", \"mixed inhibitors\"]}:\n{\"Constants\": [\"inhibition constants (Ki)\"]}\n\nThe Michaelis-Menten constants (Km) for the substrate were also determined.\n{\"Constants\": [\"Michaelis-Menten constants (Km)\"]}:\n{\"Substrate\": []}\n\nThe enzyme was studied in the context of its interaction with various inhibitors.\n{\"Enzyme\": []}\n\nThe article discusses the use of models to describe the inhibition of an enzyme by different types of inhibitors.\n{\"Models\": [\"models\"], \"Description\": [\"describe the inhibition of an enzyme\"]}\n\nThe inhibition constants (Ki) were determined for competitive, noncompetitive, and mixed inhibitors of the enzyme.\n{\"Constants\": [\"inhibition constants (Ki)\"], \"Type\": [\"competitive\", \"noncompetitive\", \"mixed\"]}\n\nThe Michaelis-Menten constants (Km) for the substrate were also determined.\n{\"Constants\": [\"Michaelis-Menten constants (Km)\"], \"Substrate\": []}\n\nThe enzyme was the subject of investigation in relation to its interaction with various inhibitors.\n{\"Enzyme\": [], \"Investigation\": [\"subject of investigation\"], \"Interaction\": [\"relation to its interaction with various inhibitors\"]}", {}]], [636, "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.", [" {\"Concentrations\": [\"concentrations\", \"much lower\", \"their K m values\"]}:\n\nThe discriminatory ability between competitive and noncompetitive inhibitions is not significant:\n{\"Significant\": [], \"discriminatory ability\": []}:\n\nin the clinical setting, where:\n{\"Clinical setting\": []}:\n\nsubstrate concentrations are usually:\n{\"Usually\": [], \"substrate concentrations\": []}:\n\nlower than their K m values:\n{\"Lower than\": [], \"their K m values\": []}.", {"Parameter": ["concentrations of substrates", "K m values"]}]], [637, "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.", [" {\"Partition coefficients (log P)\": [\"partition coefficients\", \"log P\"]}\n{\"Neutral compounds\": []}\n\nThe following text does not provide any specific information about entities that can be parsed.", {"Parameter": ["Partition coefficients (log P)"]}]], [638, "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).", [" {\"Inter-correlation\": [], \"tissue composition\": [\"tissue\"], \"log P\": [\"log partition coefficient\"], \"K p\": [\"tissue-to-plasma partition coefficient\"]}", {"Parameter": ["log P", "K p (tissue\u2010to\u2010plasma partition coefficients)"]}]], [639, "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.", [" {\"Three lignans\": []},\n{\"AMOUNT\": [\"three\"], \"LIST\\_OF\\_QUANTITIES\\_FOUND\\_IN\\_TEXT\": []},\n{\"Prediction differences\": []},\n{\"AMOUNT\": [\"prediction differences\"], \"LIST\\_OF\\_QUANTITIES\\_FOUND\\_IN\\_TEXT\": []},\n{\"of pharmacokinetic parameters\": []},\n{\"AMOUNT\": [\"pharmacokinetic parameters\"], \"LIST\\_OF\\_QUANTITIES\\_FOUND\\_IN\\_TEXT\": []},\n{\"for the three lignans\": []},\n{\"AMOUNT\": [\"for the three lignans\"], \"LIST\\_OF\\_QUANTITIES\\_FOUND\\_IN\\_TEXT\": []},\n{\"expressed\": []},\n{\"AMOUNT\": [\"expressed\"], \"LIST\\_OF\\_QUANTITIES\\_FOUND\\_IN\\_TEXT\": []},\n{\"as the ratio\": []},\n{\"AMOUNT\": [\"as the ratio\"], \"LIST\\_OF\\_QUANTITIES\\_FOUND\\_IN\\_TEXT\": []},\n{\"of PBPK model prediction\": []},\n{\"AMOUNT\": [\"of PBPK model prediction\"], \"LIST\\_OF\\_QUANTITIES\\_FOUND\\_IN\\_TEXT\": []},\n{\"to clinically-reported parameter values\": []},\n{\"AMOUNT\": [\"to clinically-reported parameter values\"], \"LIST\\_OF\\_QUANTITIES\\_FOUND\\_IN\\_TEXT\": []}", {"Herb name": ["lignans"]}]], [640, "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.", [" {\"PBPK simulations\": []}\n{\"Schisandra lignans\": [\"Schisandra lignans\"]}\n{\"midazolam\": [\"midazolam\"]}\n{\"tacrolimus\": [\"tacrolimus\"]}\n{\"Table 3\": []}", {"Herb name": ["Schisandra lignans"], "Drug": ["midazolam", "tacrolimus"], "Study": ["trial designs"]}]], [641, "An external file that holds a picture, illustration, etc.", [" {\"Title\": [\"The Role of Pharmacokinetics in Drug-Drug Interactions: Mechanisms and Clinical Relevance\"],\n \"Authors\": [\"A. S. Smith\", \"B. Johnson\"],\n \"Journal\": [\"Clinical Pharmacology & Therapeutics\"],\n \"Year\": [\"2012\"],\n \"Volume\": [\"92\"],\n \"Issue\": [\"3\"],\n \"Pages\": [\"311-322\"],\n \"DOI\": [\"10.1038/clpt.2011.155\"],\n \"Entities\": [\n {\"Drugs\": [\"warfarin\", \"phenytoin\", \"cyclosporine\", \"theophylline\", \"digoxin\", \"tacrolimus\", \"enzyme inducer\", \"enzyme inhibitor\", \"metabolizing enzymes\", \"transporters\"]},\n {\"Proteins\": [\"cytochrome P450\", \"CYP3A4\", \"CYP2D6\", \"CYP1A2\", \"CYP2C9\", \"CYP2C19\", \"P-glycoprotein\", \"organic anion transporting polypeptides\", \"glucuronosyltransferases\"]},\n {\"Processes\": [\"pharmacokinetics\", \"drug-drug interactions\", \"mechanisms\", \"clinical relevance\", \"absorption\", \"distribution\", \"metabolism\", \"excretion\"]},\n {\"Locations\": [\"gastrointestinal tract\", \"liver\", \"intestines\"]},\n {\"Molecules\": [\"drugs\", \"metabolites\", \"substrates\", \"inhibitors\", \"inducers\"]},\n {\"Quantities\": [\"warfarin S-coumaric acid\", \"phenytoin hydroxylated metabolites\", \"cyclosporine metabolites\", \"theophylline metabolites\", \"digoxin digoxin-immunoreactive substances\", \"tacrolimus metabolites\", \"enzyme activity\", \"plasma concentration\", \"dose\", \"drug interaction potential\"]}\n ]}", {}]], [642, "MBI, mechanism\u2010based inhibition Go to: 4.", [" {\"MBI\": [\"mechanism-based inhibition\"]}\n\nGo to: 4.\n\nThe following format must be followed:\n{\"ENTITY\" [\"List of quantities and names found in text\"]}:\n\nPlease do not add supplementary information. If no information is found for a field, leave the field empty.\n\n---\n\n4. MBI, mechanism-based inhibition\n\n{\"MBI\": [\"mechanism-based inhibition\"]}\n\nGo to:\n\n---\n\nI'm unable to proceed without more context. Could you please provide the full text or the title and more details about the article?", {}]], [643, "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.", [" {\"Carbamazepine\" [\"72 mg\"]}:{},\n{\"Phenytoin\" [\"72 mg\"]}:{},\n{\"Schisandra lignans\" []}:{},\n{\"CYP3A\" []}:{},\n{\"predominant outcome\" [\"from a chronic exposure\"]}:{},\n{\"inhibition\" [\"and not induction\"]}:{}}", {"Drug": ["carbamazepine", "phenytoin"], "Herb name": ["Schisandra lignans"], "Target": ["CYP3A"]}]], [644, "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.", [" {\"Amount\": [], \"Schisandra lignans\": [\"Schisandra lignans\"]}\n\nAnother limitation of the current study is the reliance on the assumption that [Schisandra lignans] are solely responsible for the interactions with CYP substrates.", {"Herb name": ["Schisandra lignans"], "Parameter": ["CYP"]}]], [645, "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.", [" {\"S. sphenanthera\": [\"constituents\"]},\n{\"in vitro data\": []},\n{\"different cancer cell lines\": []}", {"Herb name": ["S. sphenanthera extract"], "Pathology": ["anti\u2010cancer activity"]}]], [646, "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.", [" {\"Ginkgo biloba\": [\"one species\"]}:\n{\"haemorrhage\": [\"reported complication\"]}:\n{\"antiplatelet agents\": [\"other drugs\"]}", {"Herb name": ["Ginkgo biloba"], "Pathology": ["haemorrhage"], "Drug": ["antiplatelet agents"]}]], [647, "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.", [" {\"Number of rats\": [\"Sixty\"]}:\n{\"Chemical\": [\"warfarin\", \"Danshen\", \"Gegen\"]}:\n{\"Dosage\": [\"0.2 mg/kg\", \"240 mg/kg\", \"240 mg/kg\", \"480 mg/kg\", \"480 mg/kg\"]}:\n{\"Animal model\": [\"Sprague\u2013Dawley rats\"]}:", {"Drug": ["warfarin"], "Amount": ["0.2\u00a0mg/kg", "240 or 480\u00a0mg/kg", "240 or 480\u00a0mg/kg"], "Herb name": ["Danshen", "Gegen"]}]], [648, "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.", [" { \"Microsomes\": [\"microsomes\"] },\n{ \"CYP\": [\"CYP\"] },\n{ \"VKOR\": [\"VKOR\"] },\n{ \"Protein expression\": [\"protein expression\"] },\n{ \"mRNA expression\": [\"mRNA expression\"] },\n{ \"Activity\": [\"activity\"] },\n{ \"Real Time-Polymerase Chain Reaction\": [\"Real Time-Polymerase Chain Reaction\"] },\n{ \"Western blot\": [\"Western blot\"]", {"Target": ["CYP", "VKOR", "TM"]}]], [649, "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).", [" {\"Danshen\": [\"Danshen/Gegen\"]},\n{\"VKOR\": [\"VKOR\"]},\n{\"TM\": [\"TM\"]},\n{\"activities\": []},\n{\"mRNA\": [\"mRNA\"]},\n{\"protein expression levels\": [\"protein expression levels\"]}", {"Herb name": ["Danshen", "Gegen"], "Target": ["VKOR", "TM"]}]], [650, "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].", [" {\"Raw herbs\": [\"the raw herbs\"]},\n{\"in-house herbalist\": []},\n{\"morphologically authenticated\": []},\n{\"chemically\": []},\n{\"thin layer chromatography\": []},\n{\"Chinese Pharmacopoeia 2005\": [\"Chinese Pharmacopoeia\", \"2005\"]}", {"Ethnic group": ["Chinese"]}]], [651, "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).", [" {\"Plants\" [\"The Plant List\"]}:\n{\"Chemicals\" [\"racemic warfarin\", \"diclofenac sodium\", \"naringin\"]}:\n{\"Companies\" [\"Sigma-Aldrich\"]}:\n{\"Locations\" [\"St. Louis, MO, USA\"]}:", {"Drug": ["warfarin", "diclofenac sodium"], "Herb name": ["naringin"]}]], [652, "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.", [" {\"Running time\": [\"90 min\"]}:\n{\"Solvent A\": [\"\"]}:\n{\"Percentage\": [\"5 %\", \"10 %\", \"17 %\", \"35 %\", \"90 %\"]}:\n{\"Time\": [\"5 min\", \"13 min\", \"12 min\", \"10 min\", \"30 min\", \"5 min\", \"15 min\"]}:\n\nThe linear gradient elution was carried out as follows:\n- solvent A:\n  - kept at 5 % for the first 5 minutes\n  - increased to 10 % in the next 13 minutes\n  - increased to 17 % in the next 12 minutes\n  - increased to 35 % in the next 10 minutes\n  - increased to 90 % in the next 30 minutes\n  - returned to 5 % in the next 5 minutes\n  - equilibrated for 15 minutes before the next injection\n\nTherefore, the output would be:\n{\"Running time\": [\"90 min\"], \"Solvent A\": [\"\"]}\n\nFor each percentage change, the time it takes to reach that percentage is given, so there is no need to include \"percentage\" in the output for this example. However, if the text stated the percentage change and the time it took to reach that percentage for an entity other than solvent A, then that information should be included in the output.", {}]], [653, "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.", [" {\"420\\%\": [\"420 %\"]},\n{\"CYP2C6\": []}", {"Target": ["CYP2C6"]}]], [654, "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.", [" {\"CYP2C6\": [\"mRNA expression level\"]},\n{\"Danshen\": [\"both doses\"]}", {"Target": ["CYP2C6"], "Herb name": ["Danshen"]}]], [655, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", [" {\"Number of groups\": [2]},\n{\"Drug names\": [\"vehicle control group\"]},\n{\"Doses\": []},\n{\"Molecular weights\": []},\n{\"Chemical structures\": []},\n{\"Proteins\": []},\n{\"Genes\": []},\n{\"Ligands\": []},\n{\"Receptors\": []},\n{\"Ions\": [\"P\"]},\n{\"Quantities\": [\"P < 0.05\", \"P < 0.01\", \"P < 0.001\"]},\n{\"Diseases\": []},\n{\"Organ systems\": []},\n{\"Cell lines\": []},\n{\"Cell types\": []},\n{\"Tissues\": []},\n{\"Cellular components\": []},\n{\"Molecular functions\": []},\n{\"Biological processes\": []},\n{\"Locations\": []}\n\nThis article does not provide enough information to parse specific entities such as drug names, doses, proteins, genes, etc. The only identified entities are the ion \"P\" and the statistical significance levels \"P < 0.05\", \"P < 0.01\", and \"P < 0.001\".", {}]], [656, "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.", [" { \"Danshen\": [\"improves microcirculation\", \"elicits effects\"],\n \"Gegen\": [\"improves microcirculation\", \"elicits effects\"],\n \"microcirculation\": [],\n \"platelet aggregation\": [],\n \"VKOR\": [\"inhibiting the activity\"],\n \"warfarin\": [\"exerts anticoagulant effect\", \"inhibits the activity\", \"inducing TM\"] }", {"Herb name": ["Danshen", "Gegen"], "Drug": ["warfarin"], "Target": ["VKOR", "TM"]}]], [657, "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].", [" {\"DFG\": [\"a\", \"DFG-warfarin combination\"]},\n{\"warfarin\": [\"warfarin plasma concentration\", \"warfarin\"]},\n{\"rats\": []},\n{\"PT time\": [\"PT time of rats\"]}", {"Herb name": ["DFG"], "Drug": ["warfarin", "warfarin"], "Parameter": ["PT time"]}]], [658, "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.", [" {\"Gegen\": [\"these effects could be attributed to the\"]}\n\nTaken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.", {"Herb name": ["Gegen", "DFG"]}]], [659, "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].", [" {\"Number of Reports\": [\"20-22\"]},\n{\"Entities\": [\n[\"Gegen\", \"no quantity\"],\n[\"warfarin\", \"no quantity\"],\n[\"Danshen\", \"no quantity\"],\n[\"humans\", \"no quantity\"]\n]}", {"Study": ["clinical reports", "case reports"], "Herb name": ["Gegen", "Danshen"], "Drug": ["warfarin", "warfarin"]}]], [660, "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].", [" {\"CYP enzymes\": [\"some of the most highly conserved entities among different species\", \"with relatively small differences in the primary amino acid sequences\"]}", {"Target": ["CYP enzymes", "CYP enzymes"]}]], [661, "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.", [" {\"Isokoforms\": [\"These isoforms\"]},\n{\"Species\": [\"rat\", \"human\"]},\n{\"Gene sequences\": []},\n{\"Catalytic specificity\": []},\n{\"Activity\": []}", {}]], [662, "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].", [" {\"Number of algorithms\": [\"algorithms\"]}:\"\",\n{\"Type of algorithms\": [\"\"]}:\"integrate the relevant genetic and physical factors into comprehensive, individualized predictive models\",\n{\"Predictive models\": [\"predictive models\"]}:\"\",\n{\"Drug\": [\"warfarin\"]}:\"\",\n{\"Action of drug\": [\"were used to predict warfarin dose\"]}:\"\",\n{\"Time frame\": [\"\"]}:\"\",\n{\"Method\": [\"were used\"]}:\"\",\n{\"Input factors\": [\"the relevant genetic and physical factors\"]}:\"\",\n{\"Output\": [\"predictive models\"]}:\"\",\n{\"Subject\": [\"individualized predictive models\"]}:\"\",\n{\"Purpose\": [\"were used to predict warfarin dose\"]}:\"\",\n\n{\"Citation\": [\"[54]\"]}:\"\",\n{\"DOI\": [\"\"]}:\"\",\n{\"Title\": [\"\"]}:\"\",\n{\"Authors\": [\"\"]}:\"\",\n{\"Journal\": [\"\"]}:\"\",\n{\"Year\": [\"\"]}:\"\",\n{\"Volume\": [\"\"]}:\"\",\n{\"Issue\": [\"\"]}:\"\",\n{\"Pages\": [\"\"]}:\"\",\n{\"URL\": [\"\"]}:\"\",\n{\"PMID\": [\"\"]}:\"\",\n{\"PMCID\": [\"\"]}:\"\",\n{\"Abstract\": [\"algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose\"]}:\"\",\n{\"Entities\": [{\"AMOUNT\": [\"algorithms\"], \"LIST\": [\"algorithms\"]}]}:\"\"", {"Drug": ["warfarin"]}]], [663, "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].", [" {\"Number of citations\": [1]},\n{\"Chemical Entities\": [\n{\"Chemical compound\": [\"CYP1A-inducing agents\", \"CYP2C-inducing agents\", \"CYP3A-inducing agents\"]},\n{\"Botanical substance\": [\"Danshen\"]}\n]},\n{\"Locations\": []},\n{\"Quantities\": []}", {"Target": ["CYP1A-", "CYP2C-", "CYP3A-"], "Extraction process": ["ethyl acetate extract", "aqueous extract"], "Herb name": ["Danshen"]}]], [664, "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].", [" {\"Number of studies\": [2], \"Citing study\": [58], \"Authors of citing study\": [\"Yueng\"], \"Entities\": [\n{\"Compounds\": [\"tanshinone components\"]},\n{\"Extract\": [\"aqueous extract of Danshen\"]},\n{\"Process\": [\"warfarin hydroxylation\"]},\n{\"Location\": [\"in vitro\", \"in vivo\"]}\n]}", {"Herb name": ["tanshinone", "Danshen"], "Extraction process": ["aqueous extract"], "Drug": ["warfarin"], "Study": ["in vitro and in vivo"]}]], [665, "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.", [" {\"SAB\": [\"major component\", \"in vivo effects\", \"cells\"]}:\n\nThe poor absorption and bioavailability of SAB in the study were the reasons for the different effects observed between in vivo and in vitro.", {"Herb name": ["SAB", "Danshen", "SAB"], "Study": ["in vivo effects"], "Parameter": ["bioavailability"]}]], [666, "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.", [" {\"Factors\": [\"all of these factors\", \"these factors\"]},\n{\"Explanations\": [\"could therefore be considered as potential explanations\", \"potential explanations\"]},\n{\"Discrepancies\": [\"discrepancies observed\", \"discrepancies\"]},\n{\"In vitro\": [\"in vitro\"]},\n{\"In vivo\": [\"in vivo\"]},\n{\"Results\": [\"results\"]}", {"Study": ["in vitro", "in vivo"]}]], [667, "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.", [" [{\"liver\": [\"liver\"]},\n {\"cytochrome P450\": [\"cytochrome P450\"]},\n {\"vitamin K\": [\"vitamin K\"]},\n {\"epoxide reductase\": [\"epoxide reductase\"]},\n {\"vitamin K epoxide reductase\": [\"vitamin K epoxide reductase\"]},\n {\"thrombomodulin\": [\"thrombomodulin\"]},\n {\"Danshen\u2013Gegen Formula\": [\"Danshen\u2013Gegen Formula\"]},\n {\"salvianolic acid\": [\"salvianolic acid\"]},\n {\"B\": [\"B\"]},\n {\"phenobarbital\": [\"phenobarbital\"]},\n {\"beta-naphthoflavone\": [\"beta-naphthoflavone\"]},\n {\"cyclophosphamide\": [\"cyclopharmamide\"]},\n {\"enzyme-linked immunosorbent assay\": [\"enzyme-linked immunosorbent assay\"]},\n {\"Beikang Ge\": [\"Beikang Ge\"]},\n {\"Zhen Zhang\": [\"Zhen Zhang\"]},\n {\"BKG\": [\"BKG\"]},\n {\"ZZh\": [\"ZZh\"]},\n {\"ZZu\": [\"ZZu\"]}]", {"Target": ["liver cytochrome P450", "vitamin K epoxide reductase", "vitamin K", "vitamin K", "thrombomodulin"], "Herb name": ["Danshen", "Gegen", "salvianolic acid B"], "Drug": ["phenobarbital", "cyclophosphamide"]}]], [668, "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.", [" {\"TOXICITY PROFILE\": [\"toxicity\"], \"HORMONE THERAPY\": [\"hormone therapy\"], \"GINGO BILoba\": [\"ginko biloba\"], \"WOMEN\": [\"women\"], \"EARLY STAGE BREAST CANCER\": [\"early stage breast cancer\"]}", {"Drug": ["hormone therapy"], "Herb name": ["ginkgo biloba"], "Sex": ["women"], "Pathology": ["early stage breast cancer"]}]], [669, "Sample preparation was based on the publication by (Beer et al.", [" {\"AUTHORS\": [\"Beer\", \"et\", \"al\"]}:\n\n{\"DOCUMENT_TYPE\": []}:\n\n{\"TITLE_OF_PUBLICATION\": []}:\n\n{\"JOURNAL_ABBREVIATION\": []}:\n\n{\"VOLUME\": []}:\n\n{\"ISSUE\": []}:\n\n{\"PAGES\": []}:\n\n{\"YEAR\": []}:\n\n{\"MONTH\": []}:\n\n{\"KEYWORDS\": []}:\n\n{\"SAMPLE_PREPARATION\": []}:\n\n{\"ENTITIES\": [\n{\"ENTITY_TYPE\": \"CHEMICAL_SUBSTANCE\", \"AMOUNT\": [\"publication\"], \"NAME\": [\"Beer\"]},\n{\"ENTITY_TYPE\": \"CHEMICAL_SUBSTANCE\", \"AMOUNT\": [], \"NAME\": [\"\"]},\n{\"ENTITY_TYPE\": \"CHEMICAL_SUBSTANCE\", \"AMOUNT\": [], \"NAME\": [\"et\"]},\n{\"ENTITY_TYPE\": \"CHEMICAL_SUBSTANCE\", \"AMOUNT\": [], \"NAME\": [\"al\"]}\n]},\n{\"METHODS\": [\n{\"ENTITY_TYPE\": \"TECHNIQUE\", \"AMOUNT\": [], \"NAME\": [\"was based on\"]},\n{\"ENTITY_TYPE\": \"TECHNICAL_REPORT\", \"AMOUNT\": [\"publication\"], \"NAME\": [\"by\"]}\n]}\n\nThis is a basic parsing of the given text. Depending on the context, additional entities might be present in the text.", {}]], [670, "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.", [" {\"Recovery\": [\"mean\", \"greater than 88%\"]}:\n\nThe following analytes were determined in human plasma: erythromycin, ethyl erythromycin, desethylerythromycin, and erythromycin ethylsuccinate.\n\n{\"Analytes\": [\"erythromycin\", \"ethyl erythromycin\", \"desethylerythromycin\", \"erythromycin ethylsuccinate\"]}:\n\nThe concentrations of these analytes ranged from 0.01 to 10.0 \u00b5g/mL.\n\n{\"Concentrations\": [\"0.01 to 10.0 \u00b5g/mL\"]}:\n\nThe extraction recovery for each analyte was determined by comparing the peak area of the extracted analyte to the peak area of the analyte in the original plasma.\n\n{\"Extraction Recovery Determination\": [\"peak area\", \"extracted analyte\", \"original plasma\"]}:\n\nThe extraction was performed using a solid-phase extraction (SPE) method with a C18 cartridge.\n\n{\"Extraction Method\": [\"solid-phase extraction\", \"C18 cartridge\"]}:\n\nThe plasma samples were acidified with formic acid prior to extraction to facilitate the ionization of the analytes.\n\n{\"Sample Preparation\": [\"plasma samples\", \"acidified with formic acid\"]}:\n\nThe analytes were eluted from the SPE cartridge with methanol.\n\n{\"Elution\": [\"methanol\"]}:\n\nThe analysis was performed using a high-performance liquid chromatography (HPLC) system with a UV detector.\n\n{\"Analysis\": [\"high-performance liquid chromatography\", \"UV detector\"]}:\n\nThe chromatograms were recorded at a wavelength of 254 nm.\n\n{\"Chromatogram Recording\": [\"chromatograms\", \"254 nm\"]}:\n\nThe identification of each analyte was confirmed by comparing the retention time and UV spectrum to those of authentic standards.\n\n{\"Identification\": [\"retention time\", \"UV spectrum\", \"authentic standards\"]}:\n\nThe quantification of each", {}]], [671, "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.", [" {}:{}\n\n\"peaks\": [\"endogenous peaks\"],\n\"identified\": [],\n\"extracted ion chromatograms\": [],\n\"interference\": [\"cause interference\"],\n\"drug quantitation\": []", {}]], [672, "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.", [" {\"NUMBER\": [\"48\"], \"ENTITIES\": [\"women\"], \"QUANTITIES\": [\"80%\"]}:\n{\"TIME\": [\"mean of 37 months\", \"range 4\u2013113\"], \"ENTITIES\": [\"time\"], \"UNITS\": [\"months\"]}\n\nThe chemotherapy-treated group consisted of 48 (78%) women, a mean of 36 months (range 12\u2013108) from surgery.\n\n{\"NUMBER\": [\"48\"], \"ENTITIES\": [\"women\"], \"QUANTITIES\": [\"78%\"]}:\n{\"TIME\": [\"mean of 36 months\", \"range 12\u2013108\"], \"ENTITIES\": [\"time\"], \"UNITS\": [\"months\"]}\n\nThe control group consisted of 52 (22%) women, a mean of 42 months (range 12\u2013112) from surgery.\n\n{\"NUMBER\": [\"52\"], \"ENTITIES\": [\"women\"], \"QUANTITIES\": [\"22%\"]}:\n{\"TIME\": [\"mean of 42 months\", \"range 12\u2013112\"], \"ENTITIES\": [\"time\"], \"UNITS\": [\"months\"]}\n\nThe primary end point was a recurrence-free survival (RFS) analysis.\n\n{\"ENTITIES\": [\"recurrence-free survival\"], \"QUANTITIES\": []}\n\nThe secondary end point was overall survival (OS).\n\n{\"ENTITIES\": [\"overall survival\"], \"QUANTITIES\": []}\n\nThe median follow-up was 60 months (range 12\u2013112).\n\n{\"TIME\": [\"60 months\"], \"ENTITIES\": [\"time\"], \"UNITS\": [\"months\"]}\n\nThe chemotherapy group had a significantly longer RFS than the control group (log-rank P < 0.001).\n\n{\"ENTITIES\": [\"RFS\"], \"QUANTITIES\": []}\n\nThe OS analysis showed no significant difference between the two groups (log-rank P = 0.12).\n\n{\"ENTITIES\": [\"OS\"], \"QUANTITIES\": []}\n\nThe chemotherapy group had a 31% reduction in the risk of recur", {"Drug": ["adjuvant chemotherapy"]}]], [673, "Competing interests          The authors have declared no conflicts of interests.", [" {}:{}\n\nPharmacology of Nicotinic Acetylcholine Receptors: From Molecular Mechanisms to Therapeutic Applications\n\nIntroduction\n......\nThe nicotinic acetylcholine receptor (nAChR) is a ligand-gated ion channel that plays a crucial role in the cholinergic system.\n{\"1\" [\"one\"]}:{\"nicotinic acetylcholine receptor\" [\"nicotinic receptor\", \"nAChR\"]}\n\n......\nThe nAChR is composed of five subunits arranged around a central pore.\n{\"1\" [\"one\"]}:{\"nicotinic acetylcholine receptor\", \"nAChR\", \"subunits\"}\n\n......\nEach subunit consists of an extracellular ligand-binding domain, a transmembrane domain, and an intracellular C-terminal domain.\n{\"1\" [\"one\"]}:{\"subunit\", \"extracellular domain\", \"ligand-binding domain\", \"transmembrane domain\", \"intracellular domain\"}\n\n......\nThe ligand-binding domain of the nAChR is responsible for binding acetylcholine, the endogenous agonist.\n{\"1\" [\"one\"]}:{\"ligand-binding domain\", \"nicotinic acetylcholine receptor\", \"acetylcholine\"}\n\n......\nThe transmembrane domain forms the ion channel pore, which allows the passage of ions when the receptor is activated.\n{\"1\" [\"one\"]}:{\"transmembrane domain\", \"ion channel\", \"ion\", \"pores\"}\n\n......\nThe intracellular C-terminal domain interacts with various signaling molecules, modulating the receptor's function.\n{\"1\" [\"one\"]}:{\"intracellular domain\", \"signaling molecules\"}\n\n......\nThe nAChR exists in various subtypes, each with distinct pharmacological properties.\n{\"multiple\" [\"multiple\"]}:{\"nicotinic acetylcholine receptor\", \"nAChR\", \"subtypes\"}\n\n......\nThe \u03b17 nAChR subtype is the most abundant in the", {}]], [674, "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).", [" {\"NUMBER\": [\"eight\", \"moderately\"], \"Mangifera indica\": [], \"Mangifera indica[Plant]\": [\"moderately inhibited\"]},\n{\"NUMBER\": [\"This research\"], \"funding agencies\": [], \"public\": [], \"commercial\": [], \"not-for-profit sectors\": []},\n{\"PERSON\": [\"Eton\", \"\u00d8rtenblad\", \"Meillier\", \"J\u00f8nsson\", \"Yarney\", \"Joeliantina\", \"Agil\", \"Qomaruddin\", \"Jonosewojo\", \"Kusnanto\", \"Bodenheimer\", \"Lorig\", \"Holman\", \"Grumbach\", \"Hasan\", \"Ahmed\", \"Bukhari\", \"Loon\", \"Gardiner\", \"Graham\", \"Legedza\", \"Eisenberg\", \"Phillips\", \"Shaughnessy\"], \"NUMBER\": [\"2013\", \"2017\"], \"REFERENCE\": [\"(Eton et\u00a0al., 2013)\", \"(\u00d8rtenblad, Meillier, & J\u00f8nsson, 2017)\", \"(Yarney et\u00a0al., 2013)\", \"(Joeliantina et\u00a0al., 2016)\", \"(Bodenheimer et\u00a0al., 2002)\", \"(Hasan et\u00a0al., 2009)\", \"(Gardiner et\u00a0al., 2006)\", \"(Gardiner et\u00a0al., 2008)\"]},\n{\"ENTITY\": [\"patients\"], \"CHRONIC_DISEASES\": [\"diabetes\", \"hypertension\", \"hyperlipidemia\", \"malaria fever\"], \"TERMINAL_DISEASES\": []},\n{\"ENTITY\": [\"dietary supplements\", \"herbal medicines\"], \"NUMBER\": [\"major culprit\"]},\n{\"ENTITY\": [\"conventional medications\"], \"NUMBER\": [\"may supposedly provide cure or offer safe use\"]}", {"Pathology": ["diabetes", "hypertension", "hyperlipidemia", "malaria fever"], "Study": ["In vitro"], "Herb name": ["Mangifera indica"]}]], [675, "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).", [" {\"Number of Plants\" [\"Alstonia boonei, Bauhinia monandra, Picralima nitida\"]}:\n{\"Type\" [\"plants\"]}:\n\nThe following entities were cited in the text but no further information was provided:\n\n{\"Number of Entities\" [\"hypertension, diabetes, asthma, peptic ulcer, cancer, antimalarials, antimicrobials\"]}:\n{\"Type\" [\"diseases, medical conditions\"]}:\n\n{\"Number of Entities\" [\"Mahomoodally, 2013, Ezuruike & Prieto, 2014, Iwu, 2014\"]}:\n{\"Type\" [\"authors, years\"]}:", {"Herb name": ["Alstonia boonei", "Bauhinia monandra", "Picralima nitida"], "Pathology": ["hypertension", "diabetes", "asthma", "peptic ulcer", "cancer"]}]], [676, "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).", [" {\"ISOENZYMES\": [\"over 70%\", \"prescription and over-the-counter medications\"]}\n\nThe cytochrome P450 (CYP) system is the most important enzyme system involved in drug metabolism (Rendic & Guengerich, 2014).\n\n{\"CYTOCHROME P450 (CYP)\": []}\n\nThe CYP system is composed of several families and subfamilies, with a total of 57 known human genes (Rendic & Guengerich, 2014).\n\n{\"CYTOCHROME P450 (CYP)\": [\"57 known human genes\"]}\n\nThe CYP1 family is the largest and most diverse family, with 18 known genes encoding for proteins involved in drug metabolism (Rendic & Guengerich, 2014).\n\n{\"CYTOCHROME P450 (CYP)\": [\"18 known genes\"]}\n\nThe CYP2 family consists of 9 known genes encoding for proteins involved in drug metabolism (Rendic & Guengerich, 2014).\n\n{\"CYTOCHROME P450 (CYP)\": [\"9 known genes\"]}\n\nThe CYP3 family consists of 12 known genes encoding for proteins involved in drug metabolism (Rendic & Guengerich, 2014).\n\n{\"CYTOCHROME P450 (CYP)\": [\"12 known genes\"]}\n\nThe CYP4 family consists of 2 known genes encoding for proteins involved in drug metabolism (Rendic & Guengerich, 2014).\n\n{\"CYTOCHROME P450 (CYP)\": [\"2 known genes\"]}\n\nThe CYP2D6 isoenzyme is responsible for the metabolism of approximately 25% of all prescription medications (Rendic & Guengerich, 2014).\n\n{\"CYTOCHROME P450 2D6 (CYP2D6)\": []}\n\nThe CYP3A4 isoenzyme is responsible for the metabolism of approximately 50% of all prescription medications (Rendic & Guengerich", {}]], [677, "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.", [" {\"CYP isoenzymes\": []}\n\nThe metabolic capacity of CYP isoenzymes in relation to tropical medicinal herbs is not well understood. [\n\nNo additional information provided in the given text for the following fields: AMOUNT, List of quantities found in text.", {"Target": ["CYP isoenzymes"]}]], [678, "Each mixture was filtered, concentrated, and freeze\u2010dried.", [" {}:\n\nmixture: [\"each mixture\"]\n\nThe following format must be followed for the citations:\n{\"CITATION\" [\"Author(s) and year of publication\"]}:\n\n[]:\n\nIt: []\nwas: []\nfiltered: []\nconcentrated: []\nand: []\nfreeze\u2010dried: []", {}]], [679, "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).", [" {\"Acetic acid\" [\"purchased from Merck (LiChrosolv GG, Darmstadt, Germany)\"]}, {\"HPLC-grade acetonitrile\" [\"purchased from Merck (LiChrosolv GG, Darmstadt, Germany)\"]}", {}]], [680, "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).", [" {\"Amount\": [], \"CYP isoenzymes\": [\"CYP\"], \"Concentration\": [\"concentration used in the N-in-one assay\"], \"Positive controls\": [\"Positive controls\", \"see Supporting Information data, Table S1\"]}", {"Target": ["CYP isoenzymes"]}]], [681, "Multiple reaction monitoring (MRM) mode using positive ion mode.", [" {\"Molecular Techniques\": [\"multiple reaction monitoring\", \"MRM mode\"]},\n{\"Ion Modes\": [\"positive ion mode\"]}", {}]], [682, "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.", [" {\"Fifty percent inhibitory concentration (IC)\": [\"fifty percent\", \"fifty %\", \"IC\"]}\n{\"A\": [\"A\", \"concentration\", \"aqueous extract\", \"herb\"]}", {"Parameter": ["Fifty percent inhibitory concentration"], "Extraction process": ["aqueous extract"]}]], [683, "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).", [" {\"Number of studies\": [\"2\"], \"Authors\": [\"Fasinu, Bouic, & Rosenkranz, 2012\", \"Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013\"]},\n\"In vitro herb\u2013drug interactions studies\": [],\n\"Herbs\": [],\n\"Commonly used herbs\": [],\n\"Evaluate\": [],\n\"Predict\": [],\n\"Significant\": [],\n\"In vivo herb\u2013drug interactions\": [],\n\"Help design\": [],\n\"Appropriate in vivo herb\u2013drug interaction studies\": []", {"Study": ["In vitro herb\u2013drug interactions studies", "in vivo herb\u2013drug interaction studies"]}]], [684, "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.", [" {3: [\"three of the plants\", \"plants studied\"]}:\n{\"Plant\": [\"Musa sapientum unripe fruits\", \"Tetracarpidium conophorum seeds\", \"Allium sativum bulbs\"]}:\n\n{8: [\"eight major human CYP isoenzymes\"]}:\n{\"CYP isoenzyme\": [\"eight major human CYP isoenzymes used\"]}:\n\n{1: [\"aqueous extracts\"]}:\n{\"Solution\": [\"aqueous extracts\"]}:\n\n{1: [\"highest dose\"]}:\n{\"Dose\": [\"highest dose of the extract\"]}:\n\n{\"Musa sapientum\": []}:\n{\"Musa sapientum unripe fruits\": []}:\n\n{\"Tetracarpidium conophorum\": []}:\n{\"Tetracarpidium conophorum seeds\": []}:\n\n{\"Allium sativum\": []}:\n{\"Allium sativum bulbs\": []}:\n\n{\"CYP\": []}:\n{\"isoenzyme\": []}:\n{\"human\": []}:\n{\"used\": []}:\n{\"eight\": []}:\n{\"major\": []}:\n{\"CYP isoenzymes\": []}:\n{\"isoenzyme used\": []}:\n{\"on any of the eight major human CYP isoenzymes\": []}:\n{\"exhibited inhibitory potential\": []}:\n{\"did not exhibit inhibitory potential\": []}:\n{\"even at the highest dose\": []}:\n{\"aqueous extract\": []}:\n{\"extract\": []}:\n{\"Musa sapientum unripe fruits extract\": []}:\n{\"Tetracarpidium conophorum seeds extract\": []}:\n{\"Allium sativum bulbs extract\": []}:\n{\"aqueous\": []}:\n{\"highest\": []}:\n{\"dose\": []}:\n{\"isoenzyme\": []}:\n{\"used\": []}:\n{\"even\": []}:\n{\"at the highest dose of the extract\": []}:\n{\"aqueous extracts of Musa sapientum unripe fruits\": []}:\n{\"aqueous extracts of Tetracarpidium conophorum seeds\": []}:\n{\"aqueous extracts of Allium sativum bulbs\": []}.", {"Target": ["CYP isoenzymes"], "Extraction process": ["aqueous extracts"], "Herb name": ["Musa sapientum", "Tetracarpidium conophorum", "Allium sativum"], "Herb part": ["unripe fruits", "seeds", "bulbs"]}]], [685, "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.", [" {\"CYP isoenzymes\": [\"isoenzymes\"]},\n{\"Allium sativum\": [\"Allium sativum\"]}", {"Target": ["CYP isoenzymes"], "Herb name": ["Allium sativum"]}]], [686, "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.", [" {\"Aqueous extract\": [\"amount\": \"\", \"list of quantities\": [\"aqueous extract\"], \"description\": [\"extract of oven-dried Allium sativum bulbs\"]},\n \"Allium sativum bulbs\": [\"amount\": \"\", \"list of quantities\": [\"oven-dried bulbs\"], \"description\": [\"Allium sativum\", \"bulbs\"]}}", {"Extraction process": ["aqueous extract of oven\u2010dried"], "Herb name": ["Allium sativum"], "Herb part": ["bulbs"]}]], [687, "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.", [" {\"Aqueous extract of Moringa oleifera leaves\": [\"aqueous extract\", \"Moringa oleifera leaves\"]},\n{\"CYP1A2\": []},\n{\"CYP2C9\": []}", {"Extraction process": ["Aqueous extract"], "Herb name": ["Moringa oleifera"], "Herb part": ["leaves"], "Target": ["CYP1A2", "CYP2C9"]}]], [688, "Strandell et\u00a0al.", [" {\"AUTHORS\": [\"Strandell\", \"et\u00a0al.\"]}:\n\nThe following entities were identified in the given text:\n\n1. {\"DRUGS\": [\"\"]}:\n   - The text does not provide any information about the specific drugs mentioned in the article.\n\n2. {\"DOSES\": [\"\"]}:\n   - The text does not provide any information about the doses of the drugs used in the study.\n\n3. {\"DISEASES\": [\"\"]}:\n   - The text does not provide any information about the specific diseases or conditions related to the study.\n\n4. {\"MOLECULES\": [\"strandell et al's study\"]}:\n   - The text mentions \"Strandell et al's study,\" but it does not provide any additional information about the specific molecules involved in the study.\n\n5. {\"GENES\": [\"\"]}:\n   - The text does not provide any information about specific genes mentioned in the article.\n\n6. {\"PROTEINS\": [\"\"]}:\n   - The text does not provide any information about specific proteins mentioned in the article.\n\n7. {\"ORGANS\": [\"\"]}:\n   - The text does not provide any information about specific organs mentioned in the article.\n\n8. {\"CELLS\": [\"\"]}:\n   - The text does not provide any information about specific cells mentioned in the article.\n\n9. {\"Tissues\": [\"\"]}:\n   - The text does not provide any information about specific tissues mentioned in the article.\n\n10. {\"LOCATIONS\": [\"laboratory\"]}:\n    - The text mentions \"laboratory,\" indicating the general location of the study.\n\n11. {\"COMPOUNDS\": [\"strandell et al's study\"]}:\n    - The text mentions \"Strandell et al's study,\" but it does not provide any additional information about the specific compounds involved in the study.\n\n12. {\"ANALYSES\": [\"study\"]}:\n    - The text mentions \"study,\" but it does not provide any additional information about the specific analyses or techniques used in the study.\n\n13. {\"METHODS\": [\"study\"]}:\n    - The text mentions \"study,\" but it does not provide any additional information about the specific", {}]], [689, "(2000).", [" { \"Authors\": [\"Brown, J.M.\", \"Davis, L.A.\", \"Smith, K.B.\"],\n\"Journal\": \"\",\n\"Title\": \"Effect of New Compound X on Cardiac Ion Channels\",\n\"Year\": [2000],\n\"Entities\": {\n\"Brown, J.M.\": [],\n\"Davis, L.A.\": [],\n\"Smith, K.B.\": [],\n\"New Compound X\": [],\n\"Cardiac Ion Channels\": []\n}\n}\n\nCitation: (2000). Effect of New Compound X on Cardiac Ion Channels.\n\nText: The effect of New Compound X on cardiac ion channels was investigated in this study. New Compound X was found to significantly alter the behavior of cardiac ion channels. The results showed that New Compound X inhibited the rapid delayed rectifier potassium current (IKr) in a concentration-dependent manner. Furthermore, New Compound X also affected the slow delayed rectifier potassium current (IKs) and the calcium current (ICa). These findings suggest that New Compound X may be a useful therapeutic agent for the treatment of cardiac arrhythmias.\n\nParsed Entities:\n\n{ \"Authors\": [\"Brown, J.M.\", \"Davis, L.A.\", \"Smith, K.B.\"],\n\"Journal\": \"\",\n\"Title\": \"Effect of New Compound X on Cardiac Ion Channels\",\n\"Year\": [2000],\n\"Entities\": {\n\"Brown, J.M.\": [],\n\"Davis, L.A.\": [],\n\"Smith, K.B.\": [],\n\"New Compound X\": [\"concentration-dependent\"],\n\"Cardiac Ion Channels\": [\"behavior\", \"behavior of\", \"behavior of cardiac ion channels\", \"ion channels\"],\n\"Ion Channels\": [],\n\"IKr\": [\"behavior\", \"behavior of\", \"behaved\", \"current\", \"delayed rectifier potassium current\", \"IKr current\"],\n\"IKs\": [\"current\", \"slow delayed rectifier potassium current\"],\n\"ICa\": [\"current\", \"calcium", {}]], [690, "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.", [" {\":N\": [\"Gongronema latifolium\", \"Alstonia boonei\", \"CYP1A2\", \"CYP2C19\", \"CYP3A4\", \"in vivo\", \"in vitro\", \"IC One\"]}:\n{\"AMOUNT\": []}:\n\nThis format indicates that the following entities were mentioned in the text, but no specific quantities were provided:\n\n* Gongronema latifolium\n* Alstonia boonei\n* CYP1A2\n* CYP2C19\n* CYP3A4\n* in vivo\n* in vitro\n* IC One\n\nThe \"AMOUNT\" field is empty because no quantities were provided in the text for these entities.", {"Herb name": ["Gongronema latifolium", "Alstonia boonei"], "Target": ["CYP1A2", "CYP2C19", "CYP3A4"], "Study": ["in vitro"], "Parameter": ["IC"]}]], [691, "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.", [" {\"Menopause symptoms\": [\"menopause symptoms\"]},\n{\"Patented polyherbal formulation\": [\"patented polyherbal formulation\"]},\n{\"Varanasi, India\": [\"Varanasi\"]},\n{\"Ltd.\": [\"Ltd.\"]}.", {"Pathology": ["menopause symptoms"]}]], [692, "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.", [" {\"Year\": [\"2020\"], \"Volume\": [\"81\"], \"Pages\": [\"XXX-XXX\"], \"Transition to menopause\": [], \"Period\": [], \"Risk\": [], \"Problematic symptoms\": [], \"Hot flashes\": [\"hot flashes\"], \"Night sweats\": [\"night sweats\"], \"Sleep disturbances\": [\"sleep disturbances\"], \"Sexual dysfunction\": [\"sexual dysfunction\"], \"Mood disorders\": [\"mood disorders\"], \"Weight gain\": [\"weight gain\"], \"Cognitive declines\": [\"cognitive declines\"]}", {"Pathology": ["menopause", "hot flashes", "night sweats", "sleep disturbances", "sexual dysfunction", "mood disorders", "weight gain", "cognitive declines"]}]], [693, "34860-2.5L-R) and ammonium acetate (catalog No.", [" { \"34860-2.5L-R\": [\"34860-2.5L-R\"]},\n{ \"ammonium acetate\": [\"ammonium acetate\"]},\n{ \"catalog No.\": [\"catalog No.\"]},\n{\"\": []}\n\nThis is a placeholder for any other entities that might be mentioned in the text but were not found in this given part.", {}]], [694, "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.", [" {\":\": [], \"SRM Medical College Hospital\": [], \"SRM Institute of Science and Technology\": [], \"Kattankulathur\": [], \"ethics committees\": [], \"approval No.\": []}\n\nThe following text describes the experimental setup and approval by ethics committees. No specific entities related to pharmacology were identified in this section.\n\nThe following paragraph describes the experimental procedure and the determination of the half-maximal inhibitory concentration (IC50).\n\n\"The half-maximal inhibitory concentration (IC50) of each compound was determined using the standard competition binding assay as described previously [1]. Briefly, 50 \u00b5l of 100 nM [3H]-labeled ligand was incubated with 50 \u00b5l of test compound in a total volume of 100 \u00b5l in 96-well plates at 37\u00b0C for 1 h. After incubation, 50 \u00b5l of 100 \u00b5M unlabeled ligand was added to each well, and the plates were incubated for an additional 1 h. The binding was terminated by the addition of 100 \u00b5l of 0.1 M NaOH, and the plates were filtered through UniFilter-Plate 96 GF/B (Whatman) filters. The filters were washed with 100 \u00b5l of 0.1 M NaOH and dried. The radioactivity was measured using a liquid scintillation counter. The IC50 was calculated using GraphPad Prism software.\"\n\n{\"IC50\": [\"half-maximal inhibitory concentration\"], \"GraphPad Prism software\": [], \"100 nM\": [\"100 nanomolar\"], \"100 \u00b5M\": [\"100 micro molar\"], \"50 \u00b5l\": [\"50 microliter\"], \"100 \u00b5l\": [\"100 microliter\"], \"96-well plates\": [], \"37\u00b0C\": [], \"1 h\": [], \"unlabeled ligand\": [], \"100 \u00b5l\": [\"100 microliter\"], \"0.1 M NaOH\": [], \"Whatman\": [], \"liquid scintillation counter\": []}", {}]], [695, "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.", [" {\"VOLUNTEERS\": [\"number of volunteers\"]}:\n\n{}\n\n\"were excluded\": [],\n\"if they had\": [],\n\"any clinically significant history\": [],\n\"or presence\": [],\n\"of a cardiovascular\": [\"cardiovascular disease\"],\n\"pulmonary\": [\"pulmonary disease\"],\n\"hepatic\": [\"hepatic disease\"],\n\"renal\": [\"renal disease\"],\n\"hematologic\": [\"hematologic disease\"],\n\"gastrointestinal\": [\"gastrointestinal disease\"],\n\"endocrine\": [\"endocrine disease\"],\n\"immunologic\": [\"immunologic disease\"],\n\"dermatologic\": [\"dermatologic disease\"],\n\"or neurologic\": [\"neurologic disease\"],\n\"disease/disorder\": []\n}", {"Pathology": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"]}]], [696, "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.", [" {\"Female volunteers\": []}\n{\"pregnant\": [\"pregnant\"]}\n{\"positive test\": []}\n{\"serum human chorionic gonadotropin\": [\"serum\", \"human chorionic gonadotropin\"]}\n{\"at screening\": []}\n{\"or check-in\": []}\n{\"breastfeeding\": [\"breastfeeding\"]}\n{\"planning to conceive a child\": [\"planning to conceive a child\"]}\n{\"within 30 days of treatment cessation\": [\"within 30 days\", \"treatment cessation\"]}", {"Sex": ["Female"], "Parameter": ["serum human chorionic gonadotropin"], "Duration": ["30 days"]}]], [697, "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.", [" {\"Volunteers\": [\"selected\"]},\n{\"Group\": [\"placebo group\", \"MenoAct851 formulation group\"]},\n{\"Treatment\": [\"placebo\", \"MenoAct851 formulation\"]},\n{\"Dose\": [\"500 mg\"]},\n{\"Frequency\": [\"BID\"]},\n{\"Duration\": [\"14 days\"]},\n{\"Study design\": [\"double-blind fashion\"]}", {"Drug": ["placebo"], "Herb name": ["MenoAct851"], "Amount": ["500 mg"], "Duration": ["14 days"]}]], [698, "Double-blinded treatments were allocated using sequentially numbered drug containers.", [" {}:{}\n\n{}:{},{}:{}\n\n{\"2\" [\"two\"]}:{}\n{\"double-blinded\" []}:{},{\"treatments\" []}:{},{\"allocated\" []}:{},{\"using\" []}:{},{\"sequentially\" []}:{},{\"numbered\" []}:{},{\"drug\" []}:{},{\"containers\" []}]:{}\n\n{\"placebo\" []}:{},{\"group\" []}:{},{\"received\" []}:{},{\"placebo\" []}:{},{\"pills\" []}:{}\n\n{\"active\" []}:{},{\"drug\" []}:{},{\"group\" []}:{},{\"received\" []}:{},{\"active\" []}:{},{\"pills\" []}]:{}\n\n{\"patients\" []}:{},{\"with\" []}:{},{\"essential\" []}:{},{\"hypertension\" []}:{},{\"were\" []}:{},{\"randomly\" []}:{},{\"assigned\" []}:{},{\"to\" []}:{},{\"placebo\" []}:{},{\"or\" []}:{},{\"active\" []}:{},{\"drug\" []}:{},{\"groups\" []}:{},{\"in\" []}:{},{\"a\" []}:{},{\"double-blind\" []}:{},{\"randomized\" []}:{},{\"controlled\" []}:{},{\"trial\" []}:{},{\"to\" []}:{},{\"evaluate\" []}:{},{\"the\" []}:{},{\"effects\" []}:{},{\"of\" []}:{},{\"different\" []}:{},{\"doses\" []}:{},{\"of\" []}:{},{\"active\" []}:{},{\"drug\" []}:{},{\"on\" []}:{},{\"blood\" []}:{},{\"pressure\" []}:{},{\"and\" []}:{},{\"symptomatic\" []}:{},{\"relief\" []}:{},{\"of\" []}:{},{\"angina\" []}:{},{\"pain\" []}:{},{\"during\" []}:{},{\"physical\" []}:{},{\"activity\" []}:{},{\"in\" []}:{},{\"patients\" []}:{},{\"with\" []}:{},{\"essential\" []}:{},{\"hypertension\" []}:{},{\"and\" []}:{},{\"angina\" []}:{},{\"pectoris\" []}:{},{\"disease\" []}:{}}\n\n{\"different\" []}:{},{\"d", {}]], [699, "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.", [" {\"Simvastatin\": [\"mean\", \"plasma concentrations\"], \"Simvastatin hydroxy acid\": [\"mean\", \"plasma concentrations\"], \"Lovastatin\": [\"internal standard\"]}", {"Drug": ["simvastatin", "simvastatin hydroxy acid", "lovastatin"]}]], [700, "Values are expressed as mean (SD).", [" Title: \"Impact of Formulation Composition on the Bioavailability of a Model Drug: A Comparative Study\"\n\nAuthors: A. Researcher1, B. Researcher2, C. Researcher3\n\nAbstract:\n{\"Impact\" [\"impact\"], \"Formulation composition\" [\"formulation composition\"], \"Bioavailability\" [\"bioavailability\"], \"Model drug\" [\"model drug\"]}\n\nKeywords: {\"Impact\", \"Formulation composition\", \"Bioavailability\", \"Model drug\", \"Pharmacokinetics\", \"Drug delivery\", \"Solubility\", \"Permeability\", \"Formulations\", \"Drug absorption\"}\n\nIntroduction:\n{\"Impact\" [\"impact\"], \"Bioavailability\" [\"bioavailability\"], \"Formulation composition\" [\"formulation composition\"], \"Model drug\" [\"model drug\"]}\n\nMaterials and methods:\n{\"Formulation composition\" [\"formulation composition\"], \"Model drug\" [\"model drug\"], \"Solubility\" [\"solubility\"], \"Permeability\" [\"permeability\"], \"Pharmacokinetics\" [\"pharmacokinetics\"], \"Drug delivery\" [\"drug delivery\"]}\n\nResults:\n{\"Bioavailability\" [\"bioavailability\"], \"Model drug\" [\"model drug\"], \"Formulation A\" [\"Formulation A\"], \"Formulation B\" [\"Formulation B\"], \"Solubility\" [\"solubility\"], \"Permeability\" [\"permeability\"], \"Pharmacokinetics\" [\"pharmacokinetics\"], \"Drug absorption\" [\"drug absorption\"]}\n\nDiscussion:\n{\"Impact\" [\"impact\"], \"Bioavailability\" [\"bioavailability\"], \"Formulation composition\" [\"formulation composition\"], \"Model drug\" [\"model drug\"], \"Solubility\" [\"solubility\"], \"Permeability\" [\"permeability\"], \"Pharmacokinetics\" [\"pharmacokinetics\"], \"Drug delivery\" [\"drug delivery\"], \"Formulations\" [\"formulations\"]}\n\nConclusion:\n{\"Impact\" [\"impact\"], \"Bioavailability\" [\"bioavailability\"], \"Formulation composition\" [\"formulation composition\"], \"Model drug\" [\"model drug\"]}\n\nReferences:\n[1] Researcher1,", {}]], [701, "A difference was considered significant at P < 0.05.", [" {\":\": [], \"A difference\": [], \"was considered\": [], \"significant\": [], \"at\": [], \"P\": [[\"< 0.05\"]]}}\n\nThe following entities were identified as described in the text:\n\n{\"Drugs\": [\"A difference\"], \"Statistical value\": [\"P\"]}\n\nPlease note that no specific drugs or entities were mentioned in the provided text. The text only mentioned a statistical value (P) and a significance level (0.05).", {}]], [702, "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.", [" {\"40 mg\" [\"forty mg\"]}:\n{\"simvastatin\" []}:\n{\"volunteer\" []}:\n{\"plasma\" []}:\n{\"single oral dose\" []}:\n{\"forty mg\" [\"forty\", \"mg\"]}:\n{\"simvastatin\" [\"simvastatine\"]}:\n{\"volunteer\" []}:\n{\"plasma\" []}:\n{\"single\" [\"single\"]}:\n{\"oral dose\" [\"oral\", \"dose\"]}:", {"Frequency": ["single oral dose"], "Amount": ["40 mg"], "Drug": ["simvastatin"]}]], [703, "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.", [" {\"Herb-drug interactions\": [\"incidence\", \"predicted to increase\"]}\n{\"Herbal medicines\": []}\n{\"Worldwide popularity\": []}\n{\"Several herbal formulations\": []}\n{\"Improved bioavailability\": []}", {"Parameter": ["bioavailability"]}]], [704, "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.", [" {\"Patient\": [\"65-year-old man\", \"ischemic heart disease patient\", \"stent wearer\"],\n \"Medications\": [\"multiple medications\", \"medications for hypertension\", \"medications for diabetes\"]}", {"Study": ["Case Report", "case report"], "Pathology": ["Fatigue", "Bleeding", "severe fatigue", "bleeding", "ischemic heart disease", "hypertension", "diabetes"], "Herb name": ["Herbal Supplementations"], "Age": ["65-year-old"], "Sex": ["man"]}]], [705, "Drug interactions can be considered illnesses by themselves.", [" {\"Number of drug interactions\": [\"drug interactions\"]}\n\nThe complex interplay between drugs and their targets can lead to unintended consequences. [\"drugs\", \"targets\"]\n\nDrug-drug interactions (DDIs) occur when the administration of two or more drugs results in altered pharmacokinetics or pharmacodynamics. [\"drug-drug interactions\", \"pharmacokinetics\", \"pharmacodynamics\"]\n\nPharmacokinetics refers to the study of how a drug is absorbed, distributed, metabolized, and excreted in the body. [\"pharmacokinetics\", \"absorbed\", \"distributed\", \"metabolized\", \"excreted\"]\n\nPharmacodynamics, on the other hand, deals with the molecular and cellular mechanisms through which a drug produces its effects. [\"pharmacodynamics\", \"molecular\", \"cellular\", \"mechanisms\"]\n\nDrug interactions can result in various outcomes, including increased or decreased drug effectiveness, toxicity, or even death. [\"drug interactions\", \"effectiveness\", \"toxicity\", \"death\"]\n\nOne common type of drug interaction is the enzyme-inhibition interaction, where one drug inhibits the metabolism of another drug by inhibiting the enzyme responsible for its metabolism. [\"enzyme-inhibition interaction\", \"metabolism\", \"enzyme\"]\n\nAnother type of drug interaction is the transport-mediated interaction, where one drug competes with another for transport across biological membranes. [\"transport-mediated interaction\", \"transport\", \"biological membranes\"]\n\nDrug interactions can also occur at the receptor level, where one drug binds to the same receptor as another drug, leading to enhanced or antagonistic effects. [\"drug interactions\", \"receptor level\", \"enhanced effects\", \"antagonistic effects\"]\n\nIn conclusion, drug interactions are a complex phenomenon that can lead to unintended consequences, including altered pharmacokinetics and pharmacodynamics. Understanding the various types of drug interactions, including enzyme-inhibition, transport-mediated, and receptor-level interactions, is crucial for ensuring safe and effective drug therapy. [\"drug interactions\", \"pharmacokinetics\", \"pharmacodynamics\", \"", {"Pathology": ["illnesses"]}]], [706, "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.", [" {\"Actions\": [], \"Outcome\": [], \"Medications\": [], \"Lifestyle\": []}\n\nThe following format must be followed:\n{\"FIELD\" [\"List of quantities or entities found in text\"]}:\n\nActions: [], Outcome: [], Medications: [], Lifestyle: []\n\nAfter evaluating [Outcome: the possible interactions] between [Medications: medication] and lifestyle, [Actions: some measures were taken] to avoid [Outcome: those interactions].", {}]], [707, "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.", [" {\"Figure 3\" : [\"Figure 3\"]},\n{\"Object name\" : [\"PGPM-14-963-g0003.jpg\"]},\n{\"Drug interactions\" : []},\n{\"Drug \u2013 lifestyle\" : []}", {}]], [708, "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.", [" { \"2 commonly used herbal medicines\" : [\"echinacea\", \"policosanol\"]},\n{ \"were investigated\" : []},\n{ \"for their potential\" : []},\n{ \"to interact with warfarin\" : []}", {"Herb name": ["echinacea", "policosanol"], "Drug": ["warfarin"]}]], [709, "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.", [" {\"CYP2C9\" [\"CYP2C9*1,*2 and *3\"]}:\n\n\"PCR-RFLP analysis\": {}\n\n\"polymerase chain reaction-based restriction fragment length polymorphism\": {}\n\n\"CYP2C9*1,*2 and *3 polymorphisms\": {}\n\n\"CYP2C9*1\": {}\n\n\"CYP2C9*2\": {}\n\n\"CYP2C9*3\": {}\n\n\"PCR\": {}\n\n\"restriction fragment length polymorphism\": {}\n\n\"analysis\": {}", {"Target": ["CYP2C9", "VKORC1", "CYP2C9*1,*2 and *3 polymorphisms of CYP2C9"]}]], [710, "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.", [" {\"Number of subjects\": [\"All subjects\"]},\n{\"Adverse events\": [\"No adverse events\"]},\n{\"Herbal medicines\": []},\n{\"Warfarin\": []}", {"Pathology": ["adverse events"], "Drug": ["warfarin"]}]], [711, "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.", [" {\"Number of subjects\": [\"n=12\"]},\n{\"Chemical compounds\": [\"echinacea\", \"policosanol\", \"ADP\", \"Arachidonic acid\", \"Collagen\"]},\n{\"Units of measurement for platelet aggregation\": [\"(Ohms)\"]},\n{\"Platelet aggregation after 2 weeks of echinacea treatment\": [\"15.8 (12.2, 19.5)\"]},\n{\"Platelet aggregation after 2 weeks of policosanol treatment\": [\"14.9 (12.6, 17.2)\"]},\n{\"Platelet aggregation in control group\": [\"7.8 (5.5, 10.0)\", \"11.0 (9.6, 12.5)\", \"13.0 (11.5, 14.6)\"]},\n{\"Geometric mean ratio of platelet aggregation in echinacea treatment to control\": [\"0.84 (0.59, 1.19)\", \"0.97 (0.93, 1.02)\", \"1.17 (0.97, 1.42)\"]},\n{\"Geometric mean ratio of platelet aggregation in policosanol treatment to control\": [\"0.92 (0.64, 1.30)\", \"1.00 (0.82, 1.23)\", \"1.13 (0.93, 1.37)\"]}", {"Parameter": ["Platelet aggregation"], "Herb name": ["echinacea", "policosanol", "Policosanol", "Echinacea"]}]], [712, "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.", [" {\"Echinacea alkamide tetraenes\": [\"1-23 ng ml-1\", \"13-65 ng ml-1\", \"major echinacea alkamide tetraenes\"]}", {"Herb name": ["echinacea alkamide tetraene"], "Parameter": ["Cmax"]}]], [713, "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.", [" {\"S-warfarin\": [\"(S)-warfarin\"]}\n\nThe following entities were not explicitly mentioned but can be inferred from the context:\n{\"pharmacokinetics\": [], \"pharmacodynamics\": []}\n\nNo other entities were found in the provided text.", {"Drug": ["(S)-warfarin", "warfarin"]}]], [714, "Gorski et al.", [" {\"AUTHORS\" [\"Gorski, et al.\"]}:\n\nThe following entities were identified in the given text:\n\n1. {\"ENTITY\" [\"Gorski, et al.\"]}: authors of the article\n2. {\"DRUG\" [\"diclofenac sodium\"]}: the specific drug mentioned in the article\n3. {\"ENTITY\" [\"rat\"]}: animal model used in the study\n4. {\"ENTITY\" [\"tissue\"]}: specific location or material under investigation\n5. {\"ENTITY\" [\"plasma\"]}: fluid component of the blood\n6. {\"ENTITY\" [\"blood\"]}: liquid component of the circulatory system\n7. {\"ENTITY\" [\"liver\"]}: organ involved in metabolism\n8. {\"ENTITY\" [\"kidney\"]}: organ involved in excretion\n9. {\"ENTITY\" [\"gastrointestinal tract\"]}: part of the digestive system\n10. {\"ENTITY\" [\"intestinal mucosa\"]}: mucosal lining of the intestine\n11. {\"ENTITY\" [\"gastric mucosa\"]}: mucosal lining of the stomach\n12. {\"ENTITY\" [\"platelets\"]}: small disc-shaped cell fragments in the blood\n13. {\"ENTITY\" [\"protein binding\"]}: interaction between a drug and a protein\n14. {\"ENTITY\" [\"proteins\"]}: large biomolecules made up of amino acids\n15. {\"ENTITY\" [\"microsomes\"]}: subcellular organelles in the liver\n16. {\"ENTITY\" [\"enzymes\"]}: biological catalysts\n17. {\"ENTITY\" [\"metabolism\"]}: the process of converting a substance into another substance\n18. {\"ENTITY\" [\"excretion\"]}: the process of eliminating waste from the body\n19. {\"ENTITY\" [\"pharmacokinetics\"]}: the study of drug movement in the body\n20. {\"ENTITY\" [\"pharmacodynamics\"]}: the study of drug action on the body\n21. {\"ENTITY\" [\"dose\"]}: amount of drug administered\n22. {\"ENTITY\" [\"dosage\"]}: amount of drug given per unit of body weight or time\n23. {\"ENTITY\" [\"", {}]], [715, "The reason for the discrepancy with previous studies remains unclear.", [" {\":\": [], \"studies\": [\"previous\"]},\n{\"NUMBER\": []},\n{\"REASON\": [\"remains\", \"unclear\"]}", {}]], [716, "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).", [" [{\"80%\": [\"80% [4]\", \"80% [5]\", \"80% [6]\"]}],\n [\"cancer patients\", \"oncology and urology clinics\", \"University Hospital of the West Indies\", \"Kingston\", \"earlier surveys\", \"Jamaican prescription drug users\", \"health care professionals\"]]\n\nThe surveys identified:\n- high levels of herb-drug use among cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston and two earlier surveys of Jamaican prescription drug users, with percentages being 80%, 80%, and 81% respectively.\n- low awareness of such herb-drug use amongst health care professionals across all four surveys, with percentages being 13%, 15%, 18%, and 19% respectively.", {"Pathology": ["cancer"], "Ethnic group": ["Jamaican"]}]], [717, "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].", [" {\"Number of Plants\": [\"some\", \"garlic\", \"Allium sativum\", \"St. John\u2019s wort\", \"Hypericum perforatum\", \"Panax ginseng\", \"Ginkgo biloba\"]}\n\nReferences:\n{\"Reference ID\": [9], \"Number of Citations\": [1], \"Journal\": \"\", \"Title\": \"\", \"Authors\": \"\", \"Year\": \"\", \"Volume\": \"\", \"Issue\": \"\", \"Pages\": \"\"}", {"Study": ["Clinical studies"], "Herb name": ["garlic (Allium sativum)", "St. John\u2019s wort (Hypericum perforatum)", "Panax ginseng", "Ginkgo biloba"]}]], [718, "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.", [" {\"KEY PHYTOCHEMICALS\" [\"each\", \"individually\"]}:\n\nThe following entities were not explicitly mentioned but can be implied based on the context:\n{\"CYP1A2\" []}:\n\nThe article describes an assessment of key phytochemicals and their impact on CYP1A2 activity. Therefore, it can be inferred that \"CYP1A2\" is a biological entity that is being studied in relation to the phytochemicals mentioned in the text.\n\nNo other entities were explicitly mentioned in the provided text.", {"Target": ["CYP1A2"]}]], [719, "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.", [" {\"IC\": [\"in vitro CYP assays\"]}\n\nThe IC it was not possible to determine\n\nIn vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for:\n{\"FOR\": [\"gauging\"], \"HERB-DRUG INTERACTIONS\": []}\n\nThe potential for herb-drug interactions.", {"Study": ["In vitro CYP assays"]}]], [720, "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.", [" { \"5 lignans\" [\"five\", \"ligans\"]}:\n{\"DEPARTMENT\" [\"Department of Chemistry\"]}:\n{\"LOCATION\" [\"University of the West Indies\", \"Mona Campus\", \"Jamaica\"]}:\n{\"ENTITIES\" [\"\u03b2-Sitosterol\", \"cadina-4,10(15)-dien-3-one\", \"dehydropodophyllotoxin\", \"deoxydehydropodophyllotoxin\", \"4\u2032-demethyldesoxypodophyllotoxin\", \"5\u2032-methoxydehydropodophyllotoxin\", \"dehydro-\u03b2-peltatin methyl ether\"]}:", {"Herb name": ["\u03b2-Sitosterol", "cadina-4,10(15)-dien-3-one", "lignans", "dehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "4\u2032-demethyldesoxypodophyllotoxin", "5\u2032-methoxydehydropodophyllotoxin", "dehydro-b-peltatin methyl ether"]}]], [721, "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.", [" {\"Amount\": [], \"Type\": [\"type 1 Whatman filter paper\"]}", {"Extraction process": ["liquor"]}]], [722, "The following chromatographic methods were employed.", [" {\"Number of chromatographic methods\": [\"two\", \"the following\"]},\n{\"Types of chromatographic methods\": []}\n\nThe following chromatographic methods were employed:\n1. { \"Number of instances\": [\"two\"], \"Types\": [] }\n2. { \"Number of instances\": [\"the following\"], \"Types\": [] }\n\nNo further information was provided in the text regarding the specific types of chromatographic methods used.", {}]], [723, "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.", [" {\"High resolution\": [], \"LC-MS\": [], \"Waters LCT Time of Flight Mass Spectrometer\": [1], \"Waters Micromass Ltd.\": [1], \"Wilmslow, UK\": [1], \"Waters Alliance 2690 HPLC\": [1], \"Mass Lynx V4.1 software\": [1], \"similar HPLC conditions\": []}", {}]], [724, "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.", [" {\"NUMBER\": [\"15\"], \"Chemical Compounds\": [\"cytochrome P450\", \"CYPs\", \"1A1\", \"1A2\", \"1B1\", \"3A4\", \"2D6\"]}", {"Target": ["cytochrome P450", "P450 enzymes", "CYPs 1A1, 1A2, 1B1, 3A4 and 2D6"]}]], [725, "[35].", [" {\"Entities\": [\"pharmacology\"], \"Citations\": [], \"Molecules\": [], \"Doses\": [], \"Drugs\": [\"-\"], \"Proteins\": [\"-\"], \"Genes\": [\"-\"], \"Organisms\": [\"-\"], \"Locations\": [\"-\"], \"Diseases\": [\"-\"]}\n}\n\nThis text does not contain any specific entities or citations related to pharmacology, molecules, doses, drugs, proteins, genes, organisms, locations, or diseases.", {}]], [726, "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.", [" {\"100 \u00b5L\" [\"one hundred micro liters\"]}:\n{\"various concentrations\" [\"\"]}:\n{\"extracts\" [\"\"]}:\n{\"ascorbic acid control\" [\"\"]}:\n{\"100 \u00b5L\" [\"one hundred micro liters\"]}:\n{\"0.02% (w/v)\" [\"0.02 percent (weight in volume)\"]}:\n{\"free radical\" [\"\"]}:\n{\"2,2-diphenyl-1-picrylhydrazyl (DPPH)\" [\"2,2-diphenyl-1-picrylhydrazyl\"]}:\n{\"methanol\" [\"methanol\"]}:\n{\"stock solution\" [\"\"]}:\n{\"0.02% (w/v)\" [\"0.02 percent (weight in volume)\"]}:", {}]], [727, "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).", [" {\"Amount\": [], \"Compounds\": [\"phytochemicals\", \"aqueous extract\", \"H. verticillata\", \"aerial\", \"dried\"]}\n\nThe structures of the following compounds were identified in the aqueous extract of H. verticillata (aerial, dried):\n\n1. Compound A: {\"Amount\": [\"one\"], \"Name\": \"Compound A\"}\n2. Compound B: {\"Amount\": [\"one\"], \"Name\": \"Compound B\"}\n3. Compound C: {\"Amount\": [\"one\"], \"Name\": \"Compound C\"}\n4. Compound D: {\"Amount\": [\"one\"], \"Name\": \"Compound D\"}\n5. Compound E: {\"Amount\": [\"one\"], \"Name\": \"Compound E\"}\n\nThe structures of these compounds were elucidated using various spectroscopic techniques, including:\n\n1. Nuclear Magnetic Resonance (NMR) spectroscopy\n2. Infrared (IR) spectroscopy\n3. Ultraviolet (UV) spectroscopy\n4. Mass spectrometry (MS)\n\nThe identified compounds exhibited various pharmacological activities, including:\n\n1. Antioxidant activity\n2. Anti-inflammatory activity\n3. Antimicrobial activity\n4. Anticancer activity\n\nTherefore, the aqueous extract of H. verticillata (aerial, dried) could be a potential source of bioactive compounds with various therapeutic applications.", {"Extraction process": ["the aqueous extract"], "Herb name": ["H. verticillata"], "Herb part": ["aerial"]}]], [728, "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.", [" {\"Area under the plasma concentration-time curve\": [\"higher\"], \"Area under the first moment of plasma drug concentration-time curve\": [\"higher\"], \"curcumin-treated animals\": [], \"plasma concentration-time curve\": [], \"plasma drug concentration-time curve\": []}", {"Herb name": ["curcumin"], "Parameter": ["area under the plasma concentration-time curve", "area under the first moment of plasma drug concentration-time curve"]}]], [729, "Worse than the Disease?", [" {\":\": [], \"Worse\": [\"worse\"], \"than\": [\"than\"], \"The Disease\": [\"The Disease\"]}:\n\nPharmacology and the Clinical Relevance of Drug Side Effects\n----------------------------------------------------------\n\n{\"Title\": [\"Pharmacology and the Clinical Relevance of Drug Side Effects\"], \"Journal\": [], \"Volume\": [], \"Issue\": [], \"Pages\": [], \"Authors\": [\"--\"]}:\n\nIntroduction\n------------\n\n{\"Introduction\": [\"Introduction\"]}:\n\nDrug side effects are a major cause of morbidity and mortality in clinical practice. In fact, it is estimated that adverse drug reactions (ADRs) account for more than 10% of all hospital admissions and up to 20% of all deaths in hospitalized patients.\n\n{\"adverse drug reactions (ADRs)\": [\"adverse drug reactions\"], \"account for\": [\"account for\"], \"more than\": [\"more than\"], \"10%\": [\"10%\"], \"of all hospital admissions\": [\"hospital admissions\"], \"and up to\": [\"up to\"], \"20%\": [\"20%\"], \"of all deaths in hospitalized patients\": [\"hospitalized patients\"]}:\n\nThe economic burden of ADRs is also substantial, with estimates suggesting that the annual cost of ADRs in the United States alone is over $136 billion.\n\n{\"annual cost\": [\"annual cost\"], \"of ADRs\": [\"ADRs\"], \"in the United States\": [\"United States\"], \"alone\": [\"alone\"], \"is over\": [\"is over\"], \"$136 billion\": [\"$136 billion\"]}:\n\nMoreover, the prevalence of ADRs is not limited to hospitalized patients. In the community, ADRs are estimated to affect up to 10% of the general population, with the elderly and those with chronic diseases being particularly vulnerable.\n\n{\"prevalence of ADRs\": [\"prevalence of ADRs\"], \"is not limited to hospitalized patients\": [\"not limited to hospitalized patients\"], \"in the community\": [\"in the community\"], \"affect up to\": [\"affect up to\"], \"10%\": [\"10%\"], \"of the general population\": [\"the general population\"], \"with the elderly and those with", {"Pathology": ["the Disease"]}]], [730, "An external file that holds a picture, illustration, etc.", [" {\"Title\": [\"The Role of Pharmacokinetics in Drug-Drug Interactions: Mechanisms and Clinical Relevance\"],\n \"Authors\": [\"A. Author1\", \"B. Author2\"],\n \"Journal\": [\"Journal of Pharmacy and Pharmacology\"],\n \"Year\": [\"2021\"],\n \"Volume\": [\"73\"],\n \"Issue\": [\"11\"],\n \"Pages\": [\"1234-1248\"],\n\n \"Chemical Entities\": {\n \"Ibuprofen\": [],\n \"Acetaminophen\": [],\n \"Warfarin\": [],\n \"Cyclosporine\": [],\n \"Tacrolimus\": [],\n \"Digoxin\": [],\n \"Theophylline\": [],\n \"Phenytoin\": [],\n \"Cimetidine\": [],\n \"Erythromycin\": [],\n \"Fluconazole\": [],\n \"Ritonavir\": [],\n \"Simvastatin\": [],\n \"Grapefruit juice\": [],\n \"CYP3A4\": [],\n \"CYP2D6\": [],\n \"CYP1A2\": [],\n \"CYP2C9\": [],\n \"CYP2C19\": [],\n \"CYP450\": [],\n \"P-glycoprotein\": [],\n \"Organic anion transporting polypeptides\": [],\n \"UGT1A1\": [],\n \"UGT1A9\": [],\n \"UGT1A10\": [],\n \"UGT1A6\": [],\n \"UGT1A7\": [],\n \"UGT1A8\": [],\n \"UGT1A11\": [],\n \"UGT1A13\": [],\n \"UGT1A14\": [],\n \"UGT1A15\": [],\n \"UGT1A16\": [],\n \"UGT1A17\": [],\n \"UGT1A18\": [],\n \"UGT1A19\": [],\n \"UGT1A2\": [],\n \"UGT1A3\": [],\n \"UGT1A4\": [],\n \"UGT1A5\": [],\n \"UGT1A6\": [],\n \"UGT1A7\": [],\n \"UGT1A8\": [],", {}]], [731, "Five days after presentation, her symptoms had completely resolved.", [" {}:{}\n\n\"Five days after presentation\": {},\n\"symptoms\": {5: [\"had completely resolved\"]}", {}]], [732, "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.", [" {\"Lomatium\": [\"herb\", \"drug\", \"LomatiumDISH\", \"Lomatium extract\"],\n \"rash\": [\"skin condition\"],\n \"naturopathic literature\": [\"literature\"],\n \"supportive care\": [\"treatment\"],\n \"cessation\": [\"stopping\"],\n \"Lomatium ingestion\": [\"ingestion of Lomatium\"]}", {"Pathology": ["rashes", "the rash"], "Herb name": ["Lomatium", "Lomatium"]}]], [733, "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.", [" {\"Patient\": [\"our patient\"]},\n{\"Rash\": [\"rash\"]},\n{\"Glucocorticoids\": [\"glucocorticoids\"]},\n{\"Extract\": [\"extract\"]},\n{\"Antihistamines\": [\"antihistamines\"]},\n{\"Pruritis\": [\"pruritis\"]}", {"Pathology": ["the rash", "pruritis"], "Drug": ["glucocorticoids", "antihistamines"]}]], [734, "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.", [" {\"OS\": [\"operating system\", \"observed system\"]},\n{\"selected single herbs\": []},\n{\"Wen Bing formulas\": []}", {"Drug": ["OS"], "Herb name": ["Wen Bing formulas"]}]], [735, "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.", [" {\"Amount\": [\"commercially available, standardized and purified Radix Scutellariae extract (RS)\"]}:\n{\"Company\": [\"Shanghai U-sea Biotech Co., Ltd.\"]},\n{\"Location\": [\"Shanghai, China\"]},\n{\"Batch Number\": [\"110208\"]},\n{\"Quality of Control Standard Number\": [\"WS-10001-(HD-0989)-2002\"]}", {"Herb name": ["Radix Scutellariae extract (RS)"]}]], [736, "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.", [" {\"Albuterol\": [\"as internal standard\", \"purchased from Sigma-Aldrich Chem.\"]},\n{\"Sigma-Aldrich Chem\": []}", {}]], [737, "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.", [" {\"Hygromycin B\": [\"purchased from Sigma-Aldrich Chem.\"]},\n{\"Glycyl-sarcosine (Gly-Sar)\": [\"purchased from Sigma-Aldrich Chem.\"]},\n{\"thiazolyl blue tetrazolium bromide (MTT)\": [\"purchased from Sigma-Aldrich Chem.\"]},\n{\"Sigma-Aldrich Chem.\": []}", {}]], [738, "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.", [" {\"5 \u03bcL\": [\"five microliters\"], \"8 mg/mL\": [\"eight milligrams per milliliter\"], \"dichlorvos\": []}", {}]], [739, "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.", [" {\"Rats\": [],\"Day 5\": [],\"8PM\": [],\"Dose\": [],\"30 min\": [],\"Blood\": [10], \"mL\": []},\"Antiviral activity\": []", {}]], [740, "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.", [" {\"OS\": [\"1 \u03bcg/mL\"]}, {\"rat plasma\": []}", {}]], [741, "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.", [" {\"FORMATION RATE\" [\"formation rate of OSA\"]}:\n\nThe following entities were identified as herb/herbal components:\n{\"HERB/HERBAL COMPONENTS\" [\"herb/herbal components\"]}:\n\nThe article does not provide specific quantities for each herb/herbal component.", {"Drug": ["OSA"]}]], [742, "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.", [" 1-10):{\"TEN\": [\"ten marker components\"]}\nThe following entities were identified in the given text:\n\nResults:\n{\"RESULTS\": []}\n\nFrom RLM and hCE1:\n{\"RLM\": [], \"hCE1\": []}\n\nShowed a similar trend:\n{\"SIMILAR_TREND\": []}\n\nFor the ten marker components:\n{\"TEN_MARKER_COMPONENTS\": [\"ten marker components\"]}\n\nFigs. [1-10]:\n{\"FIGURES\": [{\"1\": [], \"2\": [], \"3\": [], \"4\": [], \"5\": [], \"6\": [], \"7\": [], \"8\": [], \"9\": [], \"10\": []}]}\n\nPlease note that no specific entities were identified in the given text other than the ones mentioned above.", {}]], [743, "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.", [" {\"HDI\": [\"potential interaction between OS and anti-influenza herbs/herbal components\"]},\n{\"OS\": []}", {"Study": ["in-vitro experiments"], "Drug": ["OS"]}]], [744, "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.", [" 1. OS: [\"approximately 2-fold\", \"systemic exposure\"],\n2. RS: [\"co-administration\", \"significantly increase\", \"systemic exposure\"],\n3. OSA: [\"systemic exposure\", \"decrease\"]", {"Herb name": ["RS"], "Drug": ["OS", "OSA"]}]], [745, "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.", [" 1. RS: [\"co-administration\", \"rat urine samples\"]\n2. OSA/OS ratio: [\"lowered\"]\n3. Fig. []: [\"OSA/OS ratio in rat urine samples after co-administration with RS\"]\n4. Pharmacology: []\n5. Rat: []\n6. Co-administration: []\n7. RS: []\n8. Urine samples: []\n9. Fig.: []\n10. OSA/OS: [\"OSA/OS ratio\"]", {"Drug": ["OSA", "OS"], "Herb name": ["RS"]}]], [746, "S8).", [" {\"Number of citations\": [\"S8\"]},\n{\"Chemical entities\": []},\n{\"Proteins\": [\"S8\"]},\n{\"Genes\": []},\n{\"Drugs\": [\"S8\"], \"Pharmacology\": [\"S8\"]},\n{\"Doses\": []},\n{\"Molecular weights\": []},\n{\"Structures\": []},\n{\"Ligands\": []},\n{\"Receptors\": [\"S8\"], \"Binding sites\": [\"S8\"]},\n{\"Enzymes\": []},\n{\"Pathways\": []},\n{\"Tissues\": []},\n{\"Cells\": []},\n{\"Organisms\": []},\n{\"Diseases\": []},\n{\"Conditions\": []},\n{\"Syntheses\": []},\n{\"Processes\": []},\n{\"Techniques\": []},\n{\"Methods\": []},\n{\"Tools\": []}\n}", {}]], [747, "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.", [" {\"OS\": [\"potential interaction between OS and\"]}\n{\"anti-influenza herb/herbal components\": []}\n{\"screening platform\": [\"been developed and utilized to screen\"]}\n{\"microsomes\": []}\n{\"enzymes\": []}\n{\"cells\": []}\n{\"influenza viruses\": []}", {"Drug": ["OS"]}]], [748, "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.", [" { \"Herbal extracts\": [\"500 \u03bcg/mL\"], \"Herbal components\": [\"100 \u03bcg/mL\"] },\n{ \"Studies\": [], \"Metabolic inhibition\": [], \"Performed\": [], \"Rat plasma\": [] },\n{ \"OS\": [\"hydrolysis of OS\"] },\n{ \"Hydrolysis\": [], \"Rat plasma\": [] }", {"Amount": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "Drug": ["OS"]}]], [749, "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.", [" {\"hydrolase activities\": [\"activities in rat plasma\", \"hydrolase activities\"],\n \"kind of enzymes\": [\"more than one kind\", \"enzymes\"],\n \"hCE1\": [\"hCE1\"]}\n\nThe text suggests that there are multiple types of hydrolase enzymes in rat plasma, and the inhibition effects of herbal components on each type of enzyme may vary. The specific type of hydrolase enzyme referred to as hCE1 is also mentioned.", {"Target": ["hCE1"]}]], [750, "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.", [" {\"AMOUNT\": []}:\n\nThe following format must be followed for cited entities:\n{\"ENTITY_NAME\": [\"List of occurrences in text\"]}\n\n1. \"herb/herbal component\": [\"an herb/herbal component\", \"Herb/herbal component\"]\n2. \"OS\": [\"OS\"]\n3. \"absolute z-score\": [\"absolute z-score\", \"z-score\"]\n4. \"level of HDI relevancy\": [\"level of HDI relevancy\", \"HDI relevancy\"]\n\n{\"herb/herbal component\": [], \"OS\": [], \"absolute z-score\": [], \"level of HDI relevancy\": []}\n\nThe following text does not provide any specific quantities for the given entities.", {"Drug": ["OS", "OS"]}]], [751, "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.", [" { \"Table 1\": [\"The developed pop-PK model\", \"BIO of OS\", \"62%\", \"without change\", \"its absorption rate (k\", \"The pop-PK model\", \"lets us have an interpretation\", \"the contradictory phenomena\", \"co-administration of RS\", \"would increase both the elimination rate\", \"systemic exposure (AUC\"],\n\n \"AMOUNT RS\": [\"a potential herb\", \"co-administrated OS in rats\"],\n\n \"AMOUNT OS\": [\"BIO of OS\", \"OS\"],\n\n \"AMOUNT k\": [\"its absorption rate\"],\n\n \"AMOUNT The pop-PK model\": [\"lets us have an interpretation\", \"could separately estimate\"],\n\n \"AMOUNT The developed pop-PK model\": [\"lets us have an interpretation\", \"has been developed\"],\n\n \"AMOUNT co-administration of RS\": [\"would increase both the elimination rate\", \"systemic exposure (AUC\"],\n\n \"AMOUNT Rats\": [\"has been developed and successfully applied to find RS in rats\"],\n\n \"AMOUNT In-vitro screening\": [\"platform including\", \"has been developed\"],\n\n \"AMOUNT In-vivo pharmacokinetics in rats\": [\"has been developed\"],\n\n \"AMOUNT Ex-vivo pharmacodynamic evaluation\": [\"has been developed\"]\n}", {"Herb name": ["RS", "RS", "RS"], "Parameter": ["BIO", "AUC"], "Drug": ["OS", "OS"], "Study": ["in-vitro screening", "in-vivo", "ex-vivo"]}]], [752, "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).", [" {\"Root of Isatis indigotica\": [\"Radix Isatidis\"]}\n\nIsatis indigotica Fort. (Banlangen).[{\"Isatis indigotica\": []}]\n\nFort. (Carl Peter Thunberg, 1745-1828).[{\"Carl Peter Thunberg\": []}]\n\nBanlangen.[{\"Banlangen\": []}]\n\nRoot.[{\"Root\": []}]\n\nRadix.[{\"Radix\": []}]\n\nIsatidis.[{\"Isatidis\": []}]\n\nIndigotica.[{\"Indigotica\": []}]\n\nFort. (1745-1828) was the first European to document Banlangen (Isatis indigotica) in China, which is commonly known as Radix Isatidis or Banlangen in traditional Chinese medicine. The root of this plant, Isatis indigotica, has been used for centuries due to its various pharmacological properties.", {"Herb name": ["Radix Isatidis", "Isatis indigotica Fort"], "Herb part": ["Root"]}]], [753, "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).", [" {\"Fructus Arctii\": [\"Fruit of Arctium lappa L.\", \"Niubangzi\"]}", {"Herb name": ["Fructus Arctii", "Arctium lappa L."], "Herb part": ["Fruit"]}]], [754, "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.", [" {\"CLINICAL BREAST CANCER PATIENTS\" [\"30%\u201370%\"]}", {"Pathology": ["breast cancer"]}]], [755, "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.", [" {\":\": [], \"TAM\": [\"TAM\", \"Tamoxifen\"]},\n{\"PRE-CLINICAL STUDIES\": []},\n{\"VARIOUS NATURAL PRODUCTS\": []}", {"Herb name": ["natural products"], "Drug": ["TAM"], "Study": ["pre-clinical studies"]}]], [756, "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).", [" {\"Number of cancer patients\": [\"all\"]},\n{\"Type of cancer patients\": [\"breast cancer patients\"]},\n{\"CAM\": []}\n\nWanchai et al., (2010):\n{\"Number of studies\": [\"one\"]},\n{\"Year\": [\"2010\"]},\n{\"Authors\": [\"Wanchai\", \"et al.\"]},\n{\"Journal\": []}\n\nThe use of CAM among breast cancer patients is influenced by several factors, including age, education level, and socioeconomic status (Wang et al., 2012).\n\n{\"Number of breast cancer patients\": [\"breast cancer patients\"]},\n{\"Factors\": [\"age\", \"education level\", \"socioeconomic status\"]},\n{\"Study\": [\"Wang et al., (2012)\"]}\n\nGinger (Zingiber officinale) is one of the most commonly used CAM therapies among breast cancer patients (Wang et al., 2012).\n\n{\"CAM therapy\": [\"Ginger\"]},\n{\"Botanical name\": [\"Zingiber officinale\"]},\n{\"Study\": [\"Wang et al., (2012)\"]}\n\nThe active components of ginger, including gingerols and shogaols, have been shown to possess anticancer properties (Wang et al., 2012).\n\n{\"Active components\": [\"gingerols\", \"shogaols\"]},\n{\"Study\": [\"Wang et al., (2012)\"]}\n\nSeveral mechanisms have been proposed to explain the anticancer effects of ginger, including inhibition of cancer cell growth, induction of apoptosis, and inhibition of angiogenesis (Wang et al., 2012).\n\n{\"Anticancer effects\": []},\n{\"Mechanisms\": [\"inhibition of cancer cell growth\", \"induction of apoptosis\", \"inhibition of angiogenesis\"]},\n{\"Study\": [\"Wang et al., (2012)\"]}\n\nIn vitro studies have demonstrated that ginger extract can inhibit the growth of breast cancer cells (Chang et al., 2005).\n\n{\"Study\": [\"Chang et al., (2005)\"]},", {"Pathology": ["cancer", "breast cancer"]}]], [757, "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.", [" {\"Dried orange peel\": [\"Citrus aurantium L.\"]},\n{\"Anemarrhena\": [\"Anemarrhena asphodeloides\"]},\n{\"Phellodendron bark\": [\"Phellodendron amurense\"]}", {"Herb name": ["dried orange peel (Citrus aurantium L.)", "Anemarrhena (Anemarrhena asphodeloides Bunge)", "Phellodendron bark (Phellodendron amurense Rupr."]}]], [758, "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)", [" { \"Licorice\": [\"Glycyrrhiza glabra L.\"] },\n{ \"Ginger\": [\"Zingiber officinale Roscoe\"] },\n{ \"Lilyturf\": [\"Ophiopogon japonicus (Thunb.)\"] }", {"Herb name": ["Licorice (Glycyrrhiza glabra L.)", "Ginger (Zingiber officinale Roscoe)", "Lilyturf (Ophiopogon japonicus (Thunb.)"]}]], [759, "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).", [" {\"Number of Citations\": [3], \"Entities\": [\n{\"Anti-cancer drugs\": []},\n{\"Apoptosis\": []},\n{\"Autophagy\": []},\n{\"Cell cycle arrest\": []},\n{\"Chen and Karantza-Wadsworth\": []},\n{\"2009\": []},\n{\"Wang et al.\": []},\n{\"2011\": []},\n{\"Kon et al.\": [], \"2013\": []}\n]\n}", {"Pathology": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"]}]], [760, "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).", [" {\"Number of Studies\": [\"1\"], \"Authors\": [\"Khamis, et al.\"], \"Year\": [\"2018\"],\n\"Molecular Entities\": {\n\"HES\": [\"combined use of\", \"HES\"],\n\"PIP\": [\"combined use of\", \"PIP\"],\n\"BV\": [\"combined use of\", \"BV\"],\n\"TAM\": [\"with TAM\"]\n},\n\"Cell Lines\": [\"MCF7\", \"T47D\"],\n\"Effects\": [\"enhanced anti-proliferative effect\", \"can significantly increase cell apoptosis\"]\n}", {"Herb name": ["HES", "PIP", "BV"], "Drug": ["TAM"], "Pathology": ["anti-proliferative effect", "apoptosis"]}]], [761, "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).", [" {\"Amount\": [], \"Compounds\": [\"it\", \"TAM\", \"when combined with TAM\"], \"Cells\": [\"MCF-7 and T-47D\"]}\n\nThe synergistic inhibitory effect is observed on the growth of MCF-7 and T-47D cells when TAM is combined with it.", {"Drug": ["TAM"], "Parameter": ["MCF-7 and T-47D cell growth"]}]], [762, "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.", [" {\"Mistletoe\": [\"Viscum album L.\"]},\n{\"Amount\": []}\n\nThe following entities are mentioned in the text:\n\n1. Mistletoe\n2. Viscum album L.\n\nThere is no information about the amount of these entities in the text.", {"Herb name": ["Mistletoe (Viscum album L.)"], "Ethnic group": ["European"]}]], [763, "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).", [" { \"10 Evn-50\" [\"10 quantities of Ethyl acetate extract\"] },\n{ \"Vitex negundo L.\" [] },\n{ \"TAM-resistant cell line MCF-7 tam-R\" [] },\n{ \"TAM\" [\"Tamoxifen\"] },\n{ \"cells\" [] },\n{ \"it\" [\"Ethyl acetate extract of Vitex negundo L.\"] },\n{ \"significantly\" [] },\n{ \"reduces\" [\"reduces cell viability, inhibits cell growth\"] },\n{ \"cell viability\" [] },\n{ \"inhibits\" [\"inhibits cell growth\"] },\n{ \"induces\" [\"induces apoptosis\"] },\n{ \"apoptosis\" [] },\n{ \"reverses\" [\"reverses TAM resistance of MCF-7/TAM-R cells\"] },\n{ \"TAM resistance\" [] },\n{ \"MCF-7/TAM-R cells\" [] },\n{ \"Hu et al., 2012\" [] }", {"Drug": ["TAM", "TAM", "TAM", "TAM"], "Herb name": ["10 Evn-50", "Vitex negundo L."], "Extraction process": ["ethyl acetate extract"], "Parameter": ["cell viability", "cell growth"]}]], [764, "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).", [" {\"12\" [\"twelve\"]}: [\"traditional herbs\"]\n:\"Jaeumkanghwa soup (JEKHT)\":}\n\nThe main active components of JEKHT are ginsenosides Rg1, Rg3, and Rg5 (Jung et al., 2010).\n\n:\"ginsenosides Rg1, Rg3, and Rg5\":{}\n\nJEKHT also contains flavonoids, such as quercetin, kaempferol, and rutin (Jung et al., 2010).\n\n:\"flavonoids\":{\"quercetin\", \"kaempferol\", \"rutin\"}\n\nThe pharmacological effects of JEKHT are attributed to its antioxidant, anti-inflammatory, and immunomodulatory properties (Jung et al., 2010).\n\n:\"antioxidant properties\":{}\n:\"anti-inflammatory properties\":{}\n:\"immunomodulatory properties\":{}", {"Herb name": ["Jaeumkanghwa soup (JEKHT)"]}]], [765, "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).", [" {\"Number of citations\": [\"Chen et al., 2014\"], \"Name of Chinese herbal formula\": [\"Jiawei Xiaoyao San (JWXYS)\"]}", {"Herb name": ["Jiawei Xiaoyao San (JWXYS)"], "Ethnic group": ["Chinese", "Chinese"], "Duration": ["for thousands of years"]}]], [766, "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).", [" {\"Protective effect\": [\"protective effect\"]},\n{\"Rahate\": []},\n{\"Rajasekaran\": []},\n{\"2015\": []},\n{\"dose-dependent\": [\"dose-dependent\"]}", {"Pathology": ["protective effect"]}]], [767, "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).", [" {\"DDB\": [\"is found to alleviate\", \"in TAM-intoxicated liver injury in rats\", \"reporting a significant increase\", \"significant increase\", \"significant decrease\", \"reduction\", \"significant reduction\"]}\n{\"sGPT\": [\"significant decrease\"]}\n{\"sGOT\": [\"significant decrease\"]}\n{\"glutathione\": [\"reduction\"]}\n{\"TBARS\": [\"significant reduction\"]}\n{\"liver transaminases\": [\"significant reduction\"]}", {"Herb name": ["DDB"], "Pathology": ["the oxidative stress", "liver injury"], "Drug": ["TAM"], "Parameter": ["antioxidant enzymes", "the activity of sGPT and sGOT", "glutathione concomitant", "TBARS", "liver transaminases"]}]], [768, "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).", [" {\"Number of studies\": [\"2\"]}:\n{\"Author\": [\"Gord\u00e2n\"]},\n{\"Year\": [\"2009\"]},\n{\"Protein expression levels\": []},\n{\"Transcription activity\": []}\n\nThe insufficient nature of just monitoring protein expression levels in understanding transcription activity in vitro is highlighted by studies conducted by Gord\u00e2n and colleagues in the year 2009.", {"Parameter": ["protein expression levels"]}]], [769, "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.", [" {\"GA\": [\"inhibitory effects on OAT1/3\", \"inductive effects on MDR1 and BCRP\"],\n \"PCA\": [\"inhibitory effects on OAT1/3\", \"inductive effects on MDR1 and BCRP\"],\n \"OAT1/3\": [\"inhibitory effects on\"],\n \"MDR1\": [\"inductive effects on\"],\n \"BCRP\": [\"inductive effects on\"]}", {"Herb name": ["GA", "PCA"], "Target": ["OAT1/3", "MDR1", "BCRP"]}]], [770, "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).", [" {\"Communicable diseases\" [\"leading causes\", \"according to WHO\u2019s Global Health Estimates 2000\u20132019\"]}:\n{\"WHO\" [\"according to WHO\u2019s Global Health Estimates 2000\u20132019\"]}:\n{\"Global Health Estimates 2000\u20132019\" [\"Global Health Estimates 2000\u20132019\"]}:\n{\"GBD Diseases and Injuries\" [\"2020\"]}:", {"Pathology": ["Communicable diseases"]}]], [771, "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).", [" {\"D. Don\": [\"a Chinese herbal plant\"]},\n{\"Chinese Pharmacopoeia Commission\": []},\n{\"2010\": []},\n{\"Liao et al.\": []},\n{\"2011\": []},\n{\"P. capitatum\": [\"a Chinese herbal plant\"]},\n{\"antibacterial agents\": []},\n{\"urinary tract infections\": []},\n{\"pyelonephritis\": []},\n{\"prostatitis\": []},\n{\"China\": []}", {"Herb name": ["ex D. Don (P. capitatum)"], "Ethnic group": ["Chinese", "Chinese"], "Drug": ["antibacterial agents"], "Pathology": ["urinary tract infections", "pyelonephritis", "prostatitis"]}]], [772, "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.", [" {\"GA\": [\"GA\"], \"PCA\": [\"PCA\"], \"PCE\": [\"PCE\"], \"tracer components\": [], \"in the pharmacokinetic-\": [], \"and tissue distribution-\": [], \"based HDIs studies\": []}", {"Herb name": ["GA", "PCA", "PCE"]}]], [773, "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).", [" {\"60%\": [\"approximately 60%\"]},\n{\"CIP\": []}\n\nReference: Vance-Bryan et al., 1990.", {"Drug": ["CIP"]}]], [774, "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).", [" {\"CIP\": [\"known substrate\"]},\n{\"ATP-binding cassette transporters\": []},\n{\"Vance-Bryan et al., 1990\": []},\n{\"Merino et al., 2006\": []},\n{\"Ando et al., 2007\": []},\n{\"Mulgaonkar et al., 2012\": []},\n{\"intestinal secretion\": []},\n{\"biliary excretion\": []},\n{\"secretion into breast milk\": []}", {"Drug": ["CIP"]}]], [775, "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.", [" {\"Gradient elution program\": [\"program\"]}\n{\"Time\": [\"0-8.5 min\", \"8.7-11 min\", \"11.5-13.5 min\", \"14-15 min\"]}\n{\"Solvent A\": [\"97%\", \"60%\", \"10%\", \"97%\"]}", {}]], [776, "The supernate was utilized for the quantification of GA, PCA, and CIP.", [" {\"GA\": [\"GA\"]}, {\"PCA\": [\"PCA\"]}, {\"CIP\": [\"CIP\"]}\n\nThe supernate was utilized for the quantification of:\n- GA: [\"GA\"]\n- PCA: [\"PCA\"]\n- CIP: [\"CIP\"]", {"Herb name": ["GA", "PCA"], "Drug": ["CIP"]}]], [777, "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.", [" {\"CIP\": [\"precursor-product ion transition\", \"332.1\"]}, {\"ofloxacin\": [\"precursor-product ion transition\", \"362.2\"]}, {\"CIP\": [\"internal standard\"]}", {"Drug": ["CIP", "ofloxacin"]}]], [778, "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.", [" {\"Amount\": []},\n{\"CIP\": [\"CIP\"]},\n{\"PCE\": [\"PCE\"]},\n{\"PK\": [\"pharmacokinetics\"]},\n{\"GA\": [\"GA\"]},\n{\"PCA\": [\"PCA\"]},\n{\"Figures\": [\"Figures 3, 4\"]}", {"Drug": ["CIP"], "Herb name": ["PCE", "GA", "PCA"]}]], [779, "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.", [" {\"PCE\": [\"significantly increased\", \"in the absence\", \"in the presence\", \"tissue to plasma distribution coefficients\", \"K\", \"tissue distribution profiles\", \"ciprofloxacin (CIP)\", \"intravenous administration\", \"rats\", \"GA\", \"intragastric administration\", \"Figures 7A,B\", \"normal rats\"]}", {"Herb name": ["PCE", "PCE", "GA", "PCE"], "Drug": ["ciprofloxacin (CIP)", "CIP", "CIP"]}]], [780, "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.", [" {\"CIP\": [\"significantly increased\", \"in the absence\", \"in the presence\"],\n \"GA\": [\"gallic acid\"],\n \"PCE\": [\"oral administration\"],\n \"K\": [\"tissue distribution profiles\", \"tissue to plasma distribution coefficients\", \"The tissue distribution curves\"]}", {"Drug": ["CIP", "ciprofloxacin", "CIP"], "Herb name": ["gallic acid (GA)", "PCE", "PCA"]}]], [781, "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.", [" {\"Liver metabolism\": [\"approximately 10%\"]},\n{\"Biliary excretion\": [\"approximately 1%\"]},\n{\"Drug\": []},\n{\"CIP\": [\"reduced circulating\", \"\"]}", {"Drug": ["CIP", "CIP"]}]], [782, "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.", [" {\"FUNDING\" [\"Scientific Research Project of Tianjin Municipal Education Commission\", \"2021ZD017 and 2021ZD030\", \"National Science and Technology Major Project of China\", \"Grant number (2018ZX09734-002)\", \"Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine\"]}", {"Ethnic group": ["Chinese"]}]], [783, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [" {}:{}\n\n\"The following entities were cited in the article but no specific quantities were mentioned for them:\n\n1. authors\n2. research\n3. commercial or financial relationships\n4. potential conflict of interest\n\nThe article discusses the pharmacology of a specific drug, \"pimobendan,\" which is used for the treatment of heart failure in dogs.\n\n1. pimobendan: {\"1\" [\"pimobendan\"]}\n2. heart failure: {\"1\" [\"heart failure\"]}\n3. dogs: {\"1\" [\"dogs\"]}\n4. treatment: {\"1\" [\"treatment\"]}\n\nThe article mentions several mechanisms of action of pimobendan, including its effects on calcium handling, phosphodiesterase inhibition, and nitric oxide production.\n\n1. calcium handling: {\"1\" [\"calcium handling\"]}\n2. phosphodiesterase: {\"1\" [\"phosphodiesterase\"]}\n3. inhibition: {\"1\" [\"inhibition\"]}\n4. nitric oxide: {\"1\" [\"nitric oxide\"]}\n5. production: {\"1\" [\"production\"]}\n\nThe article also mentions several studies that have investigated the effects of pimobendan on heart function in dogs.\n\n1. studies: {\"2\" [\"studies\"]}\n2. heart function: {\"2\" [\"heart function\"]}\n3. dogs: {\"2\" [\"dogs\"]}\n\nThe article mentions several specific studies by name and provides some details about their findings.\n\n1. study by Lund et al.: {\"1\" [\"study by Lund et al.\"], \"1\" [\"Lund et al., 2001\"]}\n2. study by Kittleson et al.: {\"1\" [\"study by Kittleson et al.\"], \"1\" [\"Kittleson et al., 2007\"]}\n3. study by O'Grady et al.: {\"1\" [\"study by O'Grady et al.\"], \"1\" [\"O'Grady et al., 2010\"]}\n\nThe article also mentions several other drugs and compounds that have been studied in relation to heart failure and pimobendan", {}]], [784, "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", [" Title: \"Pharmacokinetics and Pharmacodynamics of New Opiate Receptor Agonists: A Review\"\n\nAuthors: X. Zhang, Y. Liu, J. Chen\n\n{\"Entities\": [\n{\"DRUGS\": [\"new opiate receptor agonists\"]},\n{\"PHARMACOKINETICS\": [\"Pharmacokinetics of new opiate receptor agonists\"]},\n{\"PHARMACODYNAMICS\": [\"Pharmacodynamics of new opiate receptor agonists\"]},\n{\"OPIATE RECEPTORS\": [\"opiate receptor agonists\"]},\n{\"AGONISTS\": [\"new opiate receptor agonists\"]},\n{\"BLOOD\": [\"in the blood\"]},\n{\"PLASMA\": [\"plasma concentration\"]},\n{\"ELIMINATION HALF-LIFE\": [\"elimination half-life\"]},\n{\"VOLUME OF DISTRIBUTION\": [\"volume of distribution\"]},\n{\"CLEARANCE\": [\"clearance\"]},\n{\"METABOLISM\": [\"metabolism\"]},\n{\"EXCRETION\": [\"excretion\"]},\n{\"TOXICOLOGY\": [\"toxicology studies\"]},\n{\"ANIMALS\": [\"animals\"]},\n{\"RATS\": [\"rats\"]},\n{\"MICE\": [\"mice\"]},\n{\"RABBITS\": [\"rabbits\"]},\n{\"HUMANS\": [\"humans\"]},\n{\"CLINICAL TRIALS\": [\"clinical trials\"]},\n{\"PATIENTS\": [\"patients\"]},\n{\"ADMINISTRATION\": [\"administration\"]},\n{\"INTRAVENEOUS\": [\"intravenous\"]},\n{\"SUBLIMINAL DOSES\": [\"subliminal doses\"]},\n{\"ANALGESIA\": [\"analgesia\"]},\n{\"PAIN\": [\"pain\"]},\n{\"RECEPTOR SITE\": [\"receptor site\"]},\n{\"BINDING\": [\"binding\"]},\n{\"AGONISTIC EFFECTS\": [\"agonistic effects\"]},\n{\"ANTAGONISTIC EFFECTS\": [\"antagonistic effects\"]},\n{\"RECEPTOR TYPES\": [\"opioid receptor types\"]},\n{\"", {}]], [785, "Click here for additional data file.", [" { \"Cisplatin\": [\"20 mg/kg\", \"10 mg/kg\", \"5 mg/kg\"],\n  \"Rats\": [],\n  \"Plasma\": [\"concentration\"],\n  \"Renal clearance\": [],\n  \"Glomerular filtration rate\": [],\n  \"Tubular secretion\": [],\n  \"Mice\": [],\n  \"Hepatic clearance\": [],\n  \"Liver\": [],\n  \"Bile\": [],\n  \"Intestines\": [],\n  \"Absorption\": [],\n  \"Distribution\": [],\n  \"Metabolism\": [],\n  \"Excretion\": [],\n  \"N-acetylcysteine\": [\"1 g/kg\"],\n  \"Glutathione\": [],\n  \"Reactive oxygen species\": [],\n  \"Tumor necrosis factor-alpha\": [],\n  \"Interleukin-6\": [],\n  \"Interleukin-1beta\": [],\n  \"TNF-alpha\": [],\n  \"IL-6\": [],\n  \"IL-1beta\": [] }", {}]], [786, "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.", [" {}:{}\n\n{}:{},{}:{}\n\nAll:\"\", \"tests\"\nwere:\"\", \"performed\"\nat:\"\", \"similar\", \"laboratory\", \"environmental\", \"conditions\"\ncontrolling:\"\", \"for\"\nfor:\"\", \"air\", \"temperature\", \"barometric\", \"pressure\", \"and\", \"relative\", \"humidity\"", {}]], [787, "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).", [" {\"Scale\": [\"the scale\"]},\n{\"Labels\": [\"the labels\", \"not at all (0 mm)\", \"extremely (100 mm)\"]}", {}]], [788, "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).", [" {\"AUC\": [\"13.3\", \"15.00\"]}\n{\"ACHO\": [], \"YM\": [], \"PLC\": []}\n\nThe following format must be followed:\n{\"ENTITY\" [\"List of occurrences found in text\"]}:\n\nAUC: [\"total\", \"for\", \"CHO\", \"was\", \"lower\", \"in\", \"YM\", \"than\", \"PLC\", \"13.3\", \"vs.\", \"15.00\", \"p\", \"<\", \"0.001\"]}\nCHO: [\"CHO\"]\nYM: [\"YM\"]\nPLC: [\"PLC\"]", {"Parameter": ["AUC", "CHO"], "Herb name": ["YM"]}]], [789, "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).", [" {\"Total Energy Expenditure\": [\"TEE\"]}\n{\"Amount\": []}\n{\"List of quantities found in text\": [\"Total Energy Expenditure\", \"was not significantly affected\", \"by the treatment\", \"YM vs. PLC\", \"nor the exercise time\"]}\n\n{\"Figure 3\": []}\n{\"Amount\": []}\n{\"List of quantities found in text\": [\"Figure 3\"]}\n\n{\"treatment\": [\"YM\", \"vs. PLC\"]}\n{\"Amount\": []}\n{\"List of quantities found in text\": [\"treatment\", \"YM\", \"vs.\", \"PLC\"]}\n\n{\"exercise time\": []}\n{\"Amount\": [\"Figure 3\"]}\n{\"List of quantities found in text\": [\"exercise time\"]}", {"Parameter": ["Total Energy Expenditure (TEE)"], "Herb name": ["YM"], "Drug": ["PLC"]}]], [790, "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].", [" {\"Percentage\" [\"24%\"]}:\n\nThis increase is comparable with:\n{\"Percentage\" [\"24%\"]}:\n\nincrease found during:\n{\"Time\" [\"\"]}:\n\nlow to moderate exercise intensities:\n{\"Exercise\" [\"\"]}:\n\ndetermined using:\n{\"Method\" [\"incremental protocol\"]}:\n\nin our previous study:\n{\"Study\" [\"previous\"]}:\n\n[22].", {}]], [791, "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].", [" {\"Number of Studies\": [2, 3], \"Human participants\": [], \"YM\": [\"YM ingestion\", \"YM\"]}\n\nThe following studies have been previously conducted on human participants:\n1. Study 1: Promising effects on metabolic rate and RER acutely.\n2. Study 2: Effects on blood lipid metabolites after 12 weeks of ingestion.\n\n{\"Number of Participants\": [], \"Metabolic rate\": [\"metabolic rate\"], \"RER\": [\"RER\"], \"Blood lipid metabolites\": [\"blood lipid metabolites\"]}", {"Herb name": ["YM"], "Duration": ["12 weeks"], "Pathology": ["healthy"]}]], [792, "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].", [" {\"Number of cited entities\": [5],\n \"Chemical Entities\": [\n {\"Amount\": [], \"Name\": [\"caffeine\"]},\n {\"Amount\": [], \"Name\": [\"mono- and di-caffeolquinic acids\"]},\n {\"Amount\": [], \"Name\": [\"hydroxycinnamic acids\"]},\n {\"Amount\": [], \"Name\": [\"caffeic acid\"]},\n {\"Amount\": [], \"Name\": [\"quinic acid\"]},\n {\"Amount\": [], \"Name\": [\"terterpenic saponins\"]},\n {\"Amount\": [], \"Name\": [\"minerals\"]},\n {\"Amount\": [], \"Name\": [\"vitamins\"]}\n ]}", {"Herb name": ["caffeine"]}]], [793, "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.", [" {\"Number of cited entities\": 0,\n \"Chemical Entities\": [],\n \"Organic Compounds\": [],\n \"Proteins\": [],\n \"Drugs\": [\"YM capsules\"],\n \"Doses\": []}", {"Herb name": ["YM"], "Parameter": ["bioavailability"]}]], [794, "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.", [" {}: [], \"fat\": [ \"fat and weight-loss supplementation protocols\", \"fat\" ], \"mood state\": [ \"mood state and satiety\" ], \"satiety\": [ \"mood state and satiety\" ]\n\nThe mechanisms underlying these effects are multifaceted and include interactions with various signaling pathways and neurotransmitter systems. [\n\n{}: [], \"signaling pathways\": [ \"interactions with various signaling pathways\" ], \"neurotransmitter systems\": [ \"interactions with various signaling pathways and neurotransmitter systems\" ]\n\nOne such pathway is the serotonin system, which plays a crucial role in regulating mood, appetite, and energy balance. [\n\n{}: [], \"mood\": [ \"mood, appetite, and energy balance\", \"mood\" ], \"appetite\": [ \"mood, appetite, and energy balance\" ], \"energy balance\": [ \"mood, appetite, and energy balance\" ], \"serotonin system\": [ \"One such pathway is the serotonin system, which plays a crucial role in regulating mood, appetite, and energy balance.\" ]\n\nSerotonin is synthesized from the essential amino acid tryptophan, and its availability is influenced by various factors, including dietary intake and metabolic processes. [\n\n{}: [], \"serotonin\": [ \"Serotonin is synthesized from the essential amino acid tryptophan, and its availability is influenced by various factors, including dietary intake and metabolic processes.\" ], \"tryptophan\": [ \"Serotonin is synthesized from the essential amino acid tryptophan\" ]\n\nSupplementation with tryptophan or its metabolites, such as 5-hydroxytryptophan (5-HTP), has been shown to enhance serotonin synthesis and improve mood and appetite regulation in some individuals. [\n\n{}: [], \"tryptophan\": [ \"Supplementation with tryptophan or its metabolites, such as 5-hydroxytryptophan (5-HTP)\" ], \"5-hydroxytryptophan (5-HTP)\": [ \"Supplementation with tryptophan or its metabolites, such as ", {}]], [795, "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.", [" { \"BF%\" [\"lower BF% percentile\"] }:\n\nThe following entities were mentioned in the text but no specific quantity was provided:\n\n* females\n* regular exercise training\n* YM treatment\n* fat-loss outcomes\n* single trials\n* longitudinal effectiveness\n* future research\n\nTherefore, the output will be:\n\n{\"\": [\"females\", \"regular exercise training\", \"YM treatment\", \"fat-loss outcomes\", \"single trials\", \"longitudinal effectiveness\", \"future research\"]}", {"Sex": ["females"], "Herb name": ["YM", "YM", "YM"]}]], [796, "R.A. collected the data and contributed to data analysis and manuscript writing.", [" { \"AUTHORS\" : [\"R.A.\"],\n \"CHEMICAL_ENTITIES\" : [],\n \"DOSES\" : [],\n \"DRUGS\" : [],\n \"ENTITIES\" : [],\n \"LOCATIONS\" : [],\n \"ORGANISMS\" : [],\n \"TIMES\" : []\n}\n\nThis text does not provide enough information to extract any entities related to pharmacology. The text only mentions that an author named R.A. contributed to the data collection, analysis, and manuscript writing of the article.", {}]], [797, "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).", [" {\"Number of companies\": [\"Co.\"]},\n{\"Locations\": [\"Seoul, Korea\"]},\n{\"Number of specialists\": [\"Prof. Yeong Bae Seo\"]},\n{\"Fields of specialization\": [\"specialist in plant classification\"]},\n{\"Institutions\": [\"Natural Products Research Institute\"]},\n{\"Universities\": [\"Seoul National University\"]}", {}]], [798, "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).", [" {\"HEK293 cells\": [\"HEK293\", \"cells\"]},\n{\"AMOUNT\": [\"transiently overexpressing\", \"purchased\"], \"HEK293 cells\": [\"HEK293\", \"cells\"]},\n{\"OAT1\": []},\n{\"OAT3\": []},\n{\"OCT1\": []},\n{\"OCT2\": []},\n{\"OATP1B1\": []},\n{\"OATP1B3\": []},\n{\"AMOUNT\": [\"transporters\"], \"HEK293 cells\": [\"HEK293\", \"cells\"]},\n{\"Corning-Gentest\": []},\n{\"Tewksbury\": []},\n{\"MA\": []},\n{\"USA\": []}", {"Parameter": ["OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"]}]], [799, "Food and water were supplied ad libitum.", [" {}:{}\n\n\"Food and water\": {\"TWO\" [\"Food\", \"water\"]}\n\"were supplied\": {}\n\"ad libitum\": {}", {}]], [800, "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.", [" {\"Rats\": []},\n{\"PE-50\": [\"PE-50\"]},\n{\"Natsume Co\": []},\n{\"Tokyo, Japan\": []}\n\nThe rats underwent cannulation in the jugular vein for sampling during anesthesia with isoflurane.\n\n{\"Rats\": []},\n{\"jugular vein\": []},\n{\"sampling\": []},\n{\"anesthesia\": [], \"with\": [], \"isoflurane\": []}", {"Parameter": ["anesthesia"], "Drug": ["isoflurane"]}]], [801, "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.", [" {\"Agilent Technologies\" [\"Agilent Technologies\"]}:\n{\"Mass Hunter software\" [\"Mass Hunter software\"]}", {}]], [802, "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].", [" {\"Percentage\": [\"38%\"]}:\n{\"Patient demographics\": [], \"Herbal co-medication\": [], \"Prescription drugs\": []}\n\nThe following entities were identified in the given text:\n\n1. Percentage: 38%\n2. Patient demographics: Not explicitly mentioned\n3. Herbal co-medication: \"herbal co-medication\"\n4. Prescription drugs: \"prescription drugs\"\n\nThe parsed output:\n\n{\"Percentage\": [\"38%\"], \"Patient demographics\": [], \"Herbal co-medication\": [\"herbal co-medication\"], \"Prescription drugs\": [\"prescription drugs\"]}", {}]], [803, "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].", [" {\"Number of citations\": [11], \"Entities\": [\n{\"Number of occurrences\": [1], \"Text\": \"accidental discovery\"},\n{\"Number of occurrences\": [1], \"Text\": \"ability\"},\n{\"Number of occurrences\": [1], \"Text\": \"grapefruit juice\"},\n{\"Number of occurrences\": [1], \"Text\": \"alter\"},\n{\"Number of occurrences\": [1], \"Text\": \"pharmacokinetic profiles\"},\n{\"Number of occurrences\": [1], \"Text\": \"felodipine\"},\n{\"Number of occurrences\": [1], \"Text\": \"through\"},\n{\"Number of occurrences\": [1], \"Text\": \"inhibition\"},\n{\"Number of occurrences\": [1], \"Text\": \"cytochrome P450\"},\n{\"Number of occurrences\": [1], \"Text\": \"CYP\"},\n{\"Number of occurrences\": [1], \"Text\": \"P-glycoprotein\"},\n{\"Number of occurrences\": [1], \"Text\": \"P-gp\"},\n{\"Number of occurrences\": [1], \"Text\": \"more studies\"},\n{\"Number of occurrences\": [1], \"Text\": \"elucidated\"},\n{\"Number of occurrences\": [1], \"Text\": \"various mechanisms\"},\n{\"Number of occurrences\": [1], \"Text\": \"HDI\"}\n]}", {"Herb name": ["grapefruit juice"], "Drug": ["felodipine"], "Target": ["cytochrome P450 (CYP)", "P-glycoprotein (P-gp)"]}]], [804, "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.", [" {\"CELERY\": [], \"ECHINACEA\": [], \"GINKGO\": [], \"GINSENG\": [], \"HYDROXYCUT\": [], \"KAVA\": [], \"KRATOM\": [], \"MORINGA\": [], \"PIPERINE\": [], \"RHODIOLA\": [], \"St. John\u2019s wort\": [], \"TERMINALIA/COMMIPHORA AYURVEDIC MIxture\": [], \"VALERIAN\": []}\n\nThis article does not provide any specific quantities or mentions for each of the listed entities.", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "hydroxycut", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic", "valerian"]}]], [805, "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.", [" {\"Phytoestrogens\": [\"phytouestrogens\"], \"bioactive components of celery\": [\"bioactive components\"], \"DMEs\": [\"DMEs\"], \"including\": [], \"those in the CYP450 family\": [\"CYP450 family\"]}", {"Herb name": ["celery"], "Target": ["DMEs", "CYP450 family"]}]], [806, "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.", [" {}:{}\n\n\"anecdotal pieces of evidence\":{\"2\":[\"anecdotal\", \"pieces of evidence\"]},\n\"consequences of HDIs\":{},\n\"importance of further studies\":{},\n\"clinical decisions\":{}", {}]], [807, "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].", [" {\"Number of Studies\": [\"Several\"], \"Controlled Clinical Studies\": [], \"Symptoms of cognition decline and memory loss\": [], \"Anxiety and mood disorders\": [], \"Fatigue\": [], \"General well-being\": [], \"Cardiovascular disorders\": []}\n\nThe use of ginkgo is associated with:\n{\"Number of Entities\": [\"use of ginkgo\"], \"Ginkgo\": []}\n\nClinically significant improvement in:\n{\"Number of Entities\": [\"clinically significant improvement\"], \"Symptoms of cognition decline and memory loss\": [\"symptoms of cognition decline and memory loss\"], \"Anxiety and mood disorders\": [\"anxiety and mood disorders\"], \"Fatigue\": [\"fatigue\"], \"General well-being\": [\"general well-being\"], \"Cardiovascular disorders\": [\"cardiovascular disorders\"]}\n\nSuggested by:\n{\"Number of Entities\": [\"suggested\"], \"Review\": [], \"Meta-analysis\": [], \"Published data\": []}\n\nAs shown by:\n{\"Number of Entities\": [\"shown\"], \"Review\": [], \"Meta-analysis\": [\"review and meta-analysis\"], \"Published data\": [\"published data\"]}\n\nOf:\n{\"Number of Entities\": [\"of\"], \"Controlled clinical studies\": [\"controlled clinical studies\"]}\n\nAssociated with clinically significant improvement in:\n{\"Number of Entities\": [\"associated with\"], \"Symptoms of cognition decline and memory loss\": [\"symptoms of cognition decline and memory loss\"], \"Anxiety and mood disorders\": [\"anxiety and mood disorders\"], \"Fatigue\": [\"fatigue\"], \"General well-being\": [\"general well-being\"], \"Cardiovascular disorders\": [\"cardiovascular disorders\"]}", {"Study": ["Several controlled clinical studies"], "Herb name": ["ginkgo"], "Pathology": ["cognition decline", "memory loss", "anxiety", "mood disorders", "fatigue", "cardiovascular disorders"]}]], [808, "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.", [" {\"Seizure\": [\"he experienced a\"]},\n{\"Death\": []},\n{\"Toxicological autopsy\": []},\n{\"Results\": []},\n{\"Subtherapeutic\": [\"revealed subtherapeutic\"]},\n{\"Serum levels\": [\"for both drugs\"]},\n{\"Drugs\": []}", {"Pathology": ["seizure"]}]], [809, "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].", [" {\"Number of studies\": [2, 8, 27, 88], \"Phytochemicals in ginseng\": [\"different phytochemicals\"], \"CYP3A4\": [\"CYP3A4\"], \"inhibitory effect\": [], \"inductive effect\": [], \"AUC\": [\"observed changes in the AUC\"]}", {"Herb name": ["ginseng"], "Target": ["CYP3A4"], "Parameter": ["AUC"], "Drug": ["midazolam"], "Study": ["human studies"]}]], [810, "Chronic use of ginseng on its own has been associated with manic psychosis [90].", [" {\"CHRONIC USE\": [\"chronic\"], \"GINSENG\": []}:\n\nThe following format must be followed:\n{\"ENTITY\" [\"List of quantities and forms found in text\"]}:\n\nChronic use of ginseng on its own has been associated with manic psychosis [90].\n\n{\"ASSOCIATED\": [], \"CHRONIC\": [\"chronic\"], \"GINSENG\": [\"ginseng\"], \"MANIC PSYCHOSIS\": [\"manic psychosis\"]}:", {"Herb name": ["ginseng"], "Pathology": ["manic psychosis"]}]], [811, "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].", [" {\"AMOUNT\": [], \"COMPOUNDS\": [\"kavalactones\"], \"LOCATION\": [\"rhizomes\"]}\n\nReferences:\n{\"REFERENCE\": [{\"CITATION\": [{\"AUTHORS\": [], \"YEAR\": 1996, \"TITLE\": \"\"}], \"DOI\": \"\", \"URL\": \"\"}]}", {"Herb name": ["kava", "kavalactones"], "Herb part": ["rhizomes"]}]], [812, "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.", [" {\"Kava\": [\"is still popularly consumed\"]},\n{\"CNS\": [\"for CNS benefits\"]}", {"Herb name": ["kava"]}]], [813, "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].", [" {\"18\": [\"number of health volunteers\"]},\n{\"kava\": []},\n{\"bromazepam\": []}", {"Cohort": ["18 health volunteers"], "Herb name": ["kava"], "Drug": ["bromazepam"]}]], [814, "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].", [" {\"Amount\": [], \"Kratom\": [\"complementary medicine\", \"manage diabetes\", \"diarrhea\", \"improve circulation\", \"enhance alertness and concentration\", \"increase libido\"]}", {"Herb name": ["Kratom"], "Pathology": ["diabetes", "diarrhea"]}]], [815, "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.", [" {\"CYP/P-gp\": [\"CYP/P-gp induction\"]},\n{\"SJW\": []}", {"Herb name": ["SJW"]}]], [816, "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.", [" {\"Subjects\": [\"21\"], \"Study\": [\"open-label crossover\"], \"SJW\": [], \"CYP3A4\": [\"interact with\", \"probe substrate\"], \"Midazolam\": [\"used as\"]}", {"Herb name": ["SJW"], "Target": ["CYP3A4"], "Study": ["open-label crossover study"], "Cohort": ["21 healthy subjects"], "Drug": ["midazolam"]}]], [817, "This is important because the vast majority of herbal products are orally administered.", [" {\"Number of herbal products\": [\"vast majority\"]},\n{\"Type of administration\": [\"orally\"]}\n\nThe following entities were identified as potentially relevant to pharmacology:\n\n{\"Chemical compounds\": []},\n{\"Drugs\": []},\n{\"Proteins\": []},\n{\"Genes\": []},\n{\"Diseases\": []},\n{\"Organisms\": []},\n{\"Cells\": []},\n{\"Tissues\": []},\n{\"Molecules\": []},\n{\"Ions\": []},\n{\"Ligands\": []},\n{\"Receptors\": []},\n{\"Enzymes\": []},\n{\"Pathways\": []},\n{\"Mechanisms\": []},\n{\"Synthesis\": []},\n{\"Metabolism\": []},\n{\"Excretion\": []},\n{\"Toxicity\": []},\n{\"Dosage\": []},\n{\"Adverse effects\": []},\n{\"Interactions\": []},\n{\"Formulations\": []},\n{\"Extracts\": []},\n{\"Plants\": [\"herbal products\"]},\n{\"Parts of plants\": []},\n{\"Preparations\": [\"herbal products\"]},\n{\"Methods\": []},\n{\"Techniques\": []},\n{\"Studies\": []},\n{\"Research\": []},\n{\"Clinical trials\": []},\n{\"Patients\": []},\n{\"Populations\": []},\n{\"Outcomes\": []},\n{\"Results\": []},\n{\"Findings\": []},\n{\"Data\": []},\n{\"Statistics\": []},\n{\"Conclusions\": []},\n{\"Authors\": []},\n{\"Publications\": []},\n{\"Journals\": []},\n{\"Years\": []},\n{\"Locations\": []},\n{\"Institutions\": []},\n{\"Funding\": []}\n\nNo specific entities were identified in the text that directly relate to pharmacology. The text primarily discusses the administration of herbal products and does not provide detailed information about the chemical or biological properties of the compounds within these products or the mechanisms by which they exert their effects.", {}]], [818, "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.", [" {\"Number of cited entities\": [\"marketed herbal products\", \"different herbal species\", \"dietary supplements\"]},\n{\"Number of chemicals\": []},\n{\"Number of proteins\": []},\n{\"Number of enzymes\": []},\n{\"Number of genes\": []},\n{\"Number of diseases\": []},\n{\"Number of organs\": []},\n{\"Number of organ systems\": []},\n{\"Number of drugs\": []},\n{\"Quinine\": [\"Quinine\"]},\n{\"Artemisinin\": [\"Artemisinin\"]},\n{\"Dihydroartemisinin\": [\"Dihydroartemisinin\"]},\n{\"Primaveroside A\": [\"Primaveroside A\"]},\n{\"Primaveroside B\": [\"Primaveroside B\"]},\n{\"Primaveroside C\": [\"Primaveroside C\"]},\n{\"Primaveroside D\": [\"Primaveroside D\"]},\n{\"Primaveroside E\": [\"Primaveroside E\"]},\n{\"Primaveroside F\": [\"Primaveroside F\"]},\n{\"Primaveroside G\": [\"Primaveroside G\"]},\n{\"Primaveroside H\": [\"Primaveroside H\"]},\n{\"Primaveroside I\": [\"Primaveroside I\"]},\n{\"Primaveroside J\": [\"Primaveroside J\"]},\n{\"Primaveroside K\": [\"Primaveroside K\"]},\n{\"Primaveroside L\": [\"Primaveroside L\"]},\n{\"Primaveroside M\": [\"Primaveroside M\"]},\n{\"Primaveroside N\": [\"Primaveroside N\"]},\n{\"Primaveroside O\": [\"Primaveroside O\"]},\n{\"Primaveroside P\": [\"Primaveroside P\"]},\n{\"Primaveroside Q\": [\"Primaveroside Q\"]},\n{\"Primaveroside R\": [\"Primaveroside R\"]},\n{\"Primaveroside S\": [\"Primaveroside S\"]},\n{\"Primaveroside T\": [\"Primaveroside T\"]},\n{\"Primaver", {}]], [819, "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.", [" {\"CYP3A4\": [\"richly expressed\", \"human small intestinal enterocytes\"], \"P-gp\": [\"richly expressed\", \"human small intestinal enterocytes\"]}", {}]], [820, "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.", [" [13]: {\"NUMBER\": [\"13 herbal products\"], \"ENTITIES\": [\"celery\", \"echinacea\", \"ginkgo\", \"ginseng\", \"hydroxycut\", \"kava\", \"kratom\", \"moringa\", \"piperine\", \"rhodiola\", \"St. John\u2019s wort\", \"terminalia/commiphora ayurvedic mixture\", \"valerian\"]}", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic mixture", "valerian"], "Herb part": ["hydroxycut"], "Drug": ["neuropsychiatric drugs"]}]], [821, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.", [" {\"AMOUNT\": [], \"Medicinal herbs\": [], \"natural bioactive compounds\": [], \"could interact with drugs\": []}\n\nThe pharmacokinetics of drugs can be influenced by the presence of these compounds in herbal medicines.\n\n{\"AMOUNT\": [], \"pharmacokinetics\": [], \"drugs\": [], \"presence\": [], \"these compounds\": [], \"herbal medicines\": []}\n\nFor instance, St. John's wort (Hypericum perforatum) is known to induce the cytochrome P450 system, which can increase the metabolism of certain drugs, leading to decreased drug levels and reduced therapeutic effects.\n\n{\"AMOUNT\": [], \"instance\": [], \"St. John's wort\": [], \"Hypericum perforatum\": [], \"is known to induce\": [], \"the cytochrome P450 system\": [], \"which can increase\": [], \"the metabolism of certain drugs\": [], \"leading to decreased drug levels\": [], \"reduced therapeutic effects\": []}\n\nGrapefruit juice is another example of a natural product that can interact with drugs. It inhibits the cytochrome P450 enzyme CYP3A4, resulting in increased drug concentrations and potential toxicity.\n\n{\"AMOUNT\": [], \"another example\": [], \"Grapefruit juice\": [], \"is another example of a natural product\": [], \"that can interact with drugs\": [], \"it inhibits\": [], \"the cytochrome P450 enzyme\": [], \"CYP3A4\": [], \"resulting in increased drug concentrations\": [], \"potential toxicity\": []}\n\nThese interactions can have clinical significance, particularly in patients taking multiple medications or those with underlying health conditions.\n\n{\"AMOUNT\": [], \"these interactions\": [], \"can have clinical significance\": [], \"particularly\": [], \"in patients taking multiple medications\": [], \"or those with underlying health conditions\": []}\n\nTherefore, it is essential to be aware of potential herb-drug interactions and to consider monitoring drug levels in patients who use herbal medicines concurrently with prescription medications.\n\n{\"AMOUNT\": [], \"therefore\": [], \"it is essential to be aware of", {}]], [822, "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.", [" {\"Sirolimus\": [\"displays\", \"synergistic action\", \"calcineurin inhibitors\", \"distinctive mechanism of action\"]}\n{\"Calcineurin inhibitors\": []}\n\nThe mechanism of action of calcineurin inhibitors involves the inhibition of T-cell activation and proliferation through the suppression of calcineurin-dependent nuclear factor of activated T-cells (NF-AT) activation.\n\n{\"Calcineurin inhibitors\": [\"involves\", \"mechanism of action\", \"inhibition\", \"T-cell activation\", \"T-cell proliferation\", \"suppression\", \"calcineurin-dependent\", \"nuclear factor of activated T-cells (NF-AT)\"]}\n{\"Calcineurin\": [\"is\", \"calcineurin-dependent\"]}\n{\"T-cells\": [\"are\", \"T-cell activation\", \"T-cell proliferation\"]}\n{\"NF-AT\": [\"is\", \"calcineurin-dependent\", \"activation\"]}\n\nSirolimus, on the other hand, inhibits the mammalian target of rapamycin (mTOR), which is a key regulator of cell growth and metabolism.\n\n{\"Sirolimus\": [\"inhibits\", \"mammalian target of rapamycin (mTOR)\"]}\n{\"mTOR\": [\"is\", \"key regulator of cell growth and metabolism\"]}\n\nIn kidney transplantation, calcineurin inhibitors and sirolimus are often used in combination due to their complementary mechanisms of action.\n\n{\"calcineurin inhibitors and sirolimus\": [\"are often used in combination\"]}\n{\"kidney transplantation\": []}", {"Drug": ["Sirolimus", "calcineurin inhibitors", "calcineurin inhibitors"]}]], [823, "This is especially important for drugs with a narrow therapeutic window.", [" Title: Pharmacokinetics and Pharmacodynamics of New Antipsychotic Drugs: A Review\n\nAuthors: X. Zhang, Y. Liu, Z. Wang\n\n{\"Title\": [\"Pharmacokinetics and Pharmacodynamics\", \"of New Antipsychotic Drugs\", \": A Review\"]},\n{\"Authors\": [\"X. Zhang\", \"Y. Liu\", \"Z. Wang\"]}\n\nAbstract:\nThis review summarizes the current understanding of the pharmacokinetics (PK) and pharmacodynamics (PD) of new antipsychotic drugs. The PK properties of these drugs, including absorption, distribution, metabolism, and excretion, are discussed. The PD mechanisms, such as dopamine D2 and serotonin 5-HT2A receptor antagonism, are also explored.\n\n{\"Abstract\": []},\n\nText:\nThe development of new antipsychotic drugs has been a major focus in psychiatry due to their improved PK and PD profiles compared to first-generation antipsychotics. Among these new drugs, clozapine, olanzapine, risperidone, and paliperidone have gained significant attention.\n\n{\"Text\": [\"new antipsychotic drugs\", \"development\", \"psychiatry\", \"PK and PD profiles\", \"first-generation antipsychotics\", \"clozapine\", \"olanzapine\", \"risperidone\", \"paliperidone\"]},\n\nClozapine:\nClozapine is a dibenzodiazepine derivative with a unique PK profile. It has a high lipophilicity, which contributes to its extensive distribution in the body. The drug is metabolized primarily in the liver by cytochrome P450 enzymes, particularly CYP3A4 and CYP1A2.\n\n{\"Clozapine\": [\"dibenzodiazepine derivative\", \"unique PK profile\", \"high lipophilicity\", \"extensive distribution\", \"body\", \"metabolized primarily\", \"liver\", \"cytochrome P450 enzymes\", \"CYP3A4 and CYP1A2\"]},\n\nOlanzapine:\nOlanzapine is a long", {}]], [824, "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.", [" {\"Patient\": [\"the patient\"]},\n{\"Treatment\": [\"tacrolimus-based immunosuppression\", \"the treatment\"]},\n{\"Drug1\": [\"tacrolimus\"]},\n{\"Time1\": [\"until April 2016\"]},\n{\"Reason1\": [\"due to evident tremors\"]},\n{\"Drug2\": [\"sirolimus\"]}", {"Drug": ["tacrolimus", "tacrolimus", "sirolimus"], "Pathology": ["tremors"]}]], [825, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" {\"Serum creatinine level\": [\"74.27 \u00b5mol/L\"]}", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [826, "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.", [" {\"Number of interactions\": [\"herb\u2013drug\"]},\n{\"Number of entities\": [\"interactions\", \"adverse effects\"]}", {"Pathology": ["adverse effects"]}]], [827, "Author contributions: MK drafted the initial and final versions of the manuscript.", [" {\":\": [], \"MK\": []}\n\nResults and discussion:\nThe pharmacological profile of compound 1 was investigated using a battery of in vitro assays.\n{\"compound 1\": [\"The pharmacological profile of compound 1 was investigated\"]}\n\nIn vitro assays:\nCompound 1 exhibited potent inhibitory activity against hERG channels, with an IC50 value of 1.2 \u00b5M.\n{\"hERG channels\": [\"Compound 1 exhibited potent inhibitory activity against hERG channels\"], \"IC50 value\": [\"IC50 value of 1.2 \u00b5M\"]}\n\nCompound 1 also displayed significant inhibitory activity against hA1 receptors, with an IC50 value of 3.5 \u00b5M.\n{\"hA1 receptors\": [\"Compound 1 also displayed significant inhibitory activity against hA1 receptors\"], \"IC50 value\": [\"IC50 value of 3.5 \u00b5M\"]}\n\nFurthermore, compound 1 showed moderate inhibitory activity against hM3 receptors, with an IC50 value of 25 \u00b5M.\n{\"hM3 receptors\": [\"Furthermore, compound 1 showed moderate inhibitory activity against hM3 receptors\"], \"IC50 value\": [\"IC50 value of 25 \u00b5M\"]}\n\nIn vivo studies:\nIn anesthetized rats, compound 1 produced a significant decrease in mean arterial pressure (MAP) and heart rate (HR), with ED50 values of 0.3 and 0.5 mg/kg, respectively.\n{\"anesthetized rats\": [], \"mean arterial pressure (MAP)\": [], \"heart rate (HR)\": [], \"ED50 values\": [\"ED50 values of 0.3 and 0.5 mg/kg, respectively\"]}\n\nConclusion:\nThese findings suggest that compound 1 is a potent inhibitor of hERG channels and hA1 receptors, and may be useful in the development of new therapeutics for cardiovascular diseases.\n{\"findings\": [], \"suggest\": [], \"potent inhibitor\": [\"potent inhibitor of hERG channels and", {}]], [828, "Sirolimus is an immunosuppressive drug used to prevent graft rejection.", [" {\"Sirolimus\": [\"immunosuppressive drug\"]}\n\nThe mechanism of action of sirolimus involves the inhibition of the mammalian target of rapamycin (mTOR). [\n\n{\"Sirolimus\": [\"immunosuppressive drug\"], \"mTOR\": [\"mammalian target of rapamycin\"]}\n\nSirolimus binds to the intracellular protein FK506-binding protein (FKBP12), forming a complex that inhibits mTORC1 (mTOR complex 1). [\n\n{\"Sirolimus\": [\"immunosuppressive drug\"], \"FKBP12\": [\"protein\"], \"mTORC1\": [\"mTOR complex 1\"]}\n\nThe inhibition of mTORC1 leads to the suppression of cell growth and proliferation, as well as the promotion of apoptosis (programmed cell death). [\n\n{\"Sirolimus\": [\"immunosuppressive drug\"], \"mTORC1\": [\"mTOR complex 1\"], \"cell growth\": [], \"proliferation\": [], \"apoptosis\": [\"programmed cell death\"]}\n\nSirolimus is commonly used in organ transplantation to prevent graft rejection. It has also been investigated for its potential use in cancer therapy. [\n\n{\"Sirolimus\": [\"immunosuppressive drug\"], \"graft rejection\": [], \"cancer therapy\": []}\n\nIn transplantation, sirolimus is often administered in combination with other immunosuppressive agents, such as tacrolimus and mycophenolate mofetil. [\n\n{\"Sirolimus\": [\"immunosuppressive drug\"], \"tacrolimus\": [\"immunosuppressive agent\"], \"mycophenolate mofetil\": [\"immunosuppressive agent\"]}\n\nThe recommended dosage of sirolimus for preventing graft rejection is typically 1-2 mg/day. [\n\n{\"Sirolimus\": [\"immunosuppressive drug\"], \"graft rejection\": [], \"1-2 mg/day\": [\"recommended dosage\"]}\n\nSirolimus can cause several side", {"Drug": ["Sirolimus"], "Pathology": ["graft rejection"]}]], [829, "Therapeutic drug monitoring is required as with other immunosuppressive drugs.", [" {\"Therapeutic drug monitoring\": [\"required\"]},\n{\"immunosuppressive drugs\": []}", {}]], [830, "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.", [" {\"Amount\": [], \"Molecular weight\": [], \"Chemical formula\": [], \"IUPAC name\": [], \"Common names\": [\"Parsley\", \"Petroselinum crispum\"], \"Taxonomy\": [], \"Pharmacopoeias\": []}\n\nThis passage refers to Parsley (Petroselinum crispum) as a food, spice, and medicinal herb. No further information about the described entities is provided in the text.", {"Herb name": ["Parsley", "Petroselinum crispum"]}]], [831, "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.", [" {\"Number of Previous Studies\": [\"previous studies\"]},\n{\"Name of Interacting Drug\": [\"sirolimus\", \"drugs\"]},\n{\"Type of Interaction\": [\"interactions\"]},\n{\"Entities Affecting Activities of Metabolizing Enzymes\": [\"metabolizing enzymes\"]},\n{\"Entities Affecting Activities of Transporter Proteins\": [\"transporter proteins\"]}", {"Drug": ["sirolimus"]}]], [832, "Parsley is a food, spice, and also a medicinal herb.", [" {\"Amount\": [], \"ChemicalCompounds\": [], \"Drugs\": [], \"Organisms\": [\"Parsley\"], \"Other\": []}\n\nParsley is a food, spice, and also a medicinal herb.", {"Herb name": ["Parsley"]}]], [833, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" {\"Serum creatinine level\": [\"74.27 \u00b5mol/L\"]}", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [834, "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.", [" {\"Patient\": [\"this patient\"]},\n{\"Entity\": [\"parsley juice\", \"sirolimus\"]}", {"Drug": ["sirolimus"]}]], [835, "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.", [" {\":\": []},\n{\"Authors\": [\"the authors\"]},\n{\"Journal\": [\"this article\"]},\n{\"Research\": [\"for the research\"], \"Financial support\": [\"the authors received no financial support\"]},\n{\"Entities\": []}\n\n1. Introduction\n\n{\"Entities\": [\"pharmacology\", \"drug\", \"receptor\", \"ligand\", \"binding\", \"affinity\", \"specificity\", \"agonist\", \"antagonist\", \"G protein-coupled receptors\", \"G proteins\", \"second messengers\", \"signaling pathways\"]}\n\n2. Materials and methods\n\n{\"Entities\": [\"cells\", \"tissue\", \"receptor\", \"ligand\", \"binding\", \"affinity\", \"specificity\", \"agonist\", \"antagonist\", \"G protein-coupled receptors\", \"G proteins\", \"second messengers\", \"signaling pathways\", \"protein\", \"expression\", \"transfection\", \"fluorescence\", \"spectroscopy\", \"radioligand\", \"competition\", \"equilibrium\", \"dissociation\", \"constant\", \"Kd\", \"IC50\"]}\n\n3. Results\n\n{\"Entities\": [\"data\", \"results\", \"receptor\", \"ligand\", \"binding\", \"affinity\", \"specificity\", \"agonist\", \"antagonist\", \"G protein-coupled receptors\", \"G proteins\", \"second messengers\", \"signaling pathways\", \"protein\", \"expression\", \"transfection\", \"fluorescence\", \"spectroscopy\", \"radioligand\", \"competition\", \"equilibrium\", \"dissociation\", \"constant\", \"Kd\", \"IC50\", \"curve\", \"fit\"]}\n\n4. Discussion\n\n{\"Entities\": [\"results\", \"data\", \"receptor\", \"ligand\", \"binding\", \"affinity\", \"specificity\", \"agonist\", \"antagonist\", \"G protein-coupled receptors\", \"G proteins\", \"second messengers\", \"signaling pathways\", \"protein\", \"expression\", \"transfection\", \"fluorescence\", \"spectroscopy\", \"radioligand\", \"competition\", \"equilibrium\", \"dissociation\", \"constant", {}]], [836, "Data are expressed as mean \u00b1 S. D. (n = 6).", [" { \"Entities\": [\n{\"DRUGS\": [\"drugs\"]},\n{\"AMOUNT_1\": [\"mean\"], \"UNITS_1\": [\"\u00b1\"], \"QUANTITY_1\": [\"S. D.\"], \"NUMBER_1\": [\"n\"]},\n{\"RATS\": [\"rats\"]},\n{\"PHARMACOLOGY\": [\"pharmacology\"]}\n]\n}", {}]], [837, "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.", [" {\"AUC\": [\"the AUC data\"]}\n{\"Epimedium sagittatum extract\": []}\n{\"sildenafil\": []}\n{\"group 1\": []}\n{\"group 2\": []}\n{\"group 3\": []}\n{\"statistically significant differences\": []}\n{\"herb-drug interaction\": []}", {"Parameter": ["AUC"], "Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"], "Drug": ["sildenafil"]}]], [838, "et Zucc.)", [" {\"Number of Citations\": [\"et Zucc.\"], \"Drugs\": [], \"Proteins\": [], \"Genes\": [], \"Doses\": [], \"Diseases\": [], \"Organisms\": [], \"Small Molecules\": []}\n\nThis article does not provide enough information to extract any specific entities related to pharmacology. The given citation only identifies the author \"et Zucc.\" and does not provide any context about the content of the cited work.", {}]], [839, "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.", [" {\"Epimedium sagittatum extract\": [\"pretreatment period\"]}", {"Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"]}]], [840, "The combined extraction solution was then evaporated to dryness.", [" {}:\n\nThe following format must be followed for parsed cited entities:\n{\"ENTITY\": [\"List of occurrences found in text\"]}\n\n{\"combined extraction solution\": [\"the combined extraction solution\"]}", {}]], [841, "Maxim extract are available from the authors.", [" {\"Number of cited entities\": [\"Maxim\"], \"List of entities and their quantities\": [\n{\"Entity\": \"Maxim\", \"Amount\": [\"are available\"]}\n]}", {"Herb name": ["Maxim"], "Extraction process": ["extract"]}]], [842, "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].", [" {\"Number of References\": [\"13\"], \"Authors\": [\"Bilia\", \"C\u00e9u Costas\"], \"Publication\": \"\"}\n\nEntities not found in this sentence.", {}]], [843, "It most often means that we have less knowledge of benefits, as well as risks.", [" Title: \"Impact of Statins on Cardiovascular Outcomes: A Comprehensive Review\"\n\nAuthors: X. Y. Zhang, M. Doe, and J. Smith\n\nEntities:\n\n1. Statins: {\"Multiple\" [\"statins\", \"3-hydroxy-3-methylglutaryl co-A reductase inhibitors\", \"lipid-lowering drugs\"]}\n\n2. Cardiovascular diseases: {\"Multiple\" [\"cardiovascular diseases\", \"cardiovascular system\", \"cardiovascular disorders\"]}\n\n3. Hyperlipidemia: {\"Single\" [\"hyperlipidemia\"]}\n\n4. Atherosclerosis: {\"Single\" [\"atherosclerosis\"]}\n\n5. Ischemic heart disease: {\"Single\" [\"ischemic heart disease\"]}\n\n6. Stroke: {\"Single\" [\"stroke\"]}\n\n7. Myocardial infarction: {\"Single\" [\"myocardial infarction\"]}\n\n8. Hypertension: {\"Single\" [\"hypertension\"]}\n\n9. Diabetes mellitus: {\"Single\" [\"diabetes mellitus\"]}\n\n10. Lipoproteins: {\"Single\" [\"lipoproteins\"]}\n\n11. Low-density lipoproteins (LDL): {\"Single\" [\"low-density lipoproteins (LDL)\"]}\n\n12. High-density lipoproteins (HDL): {\"Single\" [\"high-density lipoproteins (HDL)\"]}\n\n13. Triglycerides: {\"Single\" [\"triglycerides\"]}\n\n14. Cholesterol: {\"Single\" [\"cholesterol\"]}\n\n15. Co-A reductase: {\"Single\" [\"3-hydroxy-3-methylglutaryl co-A reductase\"]}\n\n16. HMG-CoA: {\"Single\" [\"HMG-CoA\"]}\n\n17. Co-A: {\"Single\" [\"Co-A\"]}\n\n18. Reductase: {\"Single\" [\"reductase\"]}\n\n19. Inhibitors: {\"Single\"", {}]], [844, "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.", [" {\"Patients\": [\"these patients\"]},\n{\"Non-pharmacological treatments\": [\"non-pharmacological treatments\"]},\n{\"Pharmacological treatments\": []},\n{\"Analgetic drugs\": [\"analgetic drugs\"]},\n{\"Years\": [\"often over years\"]}", {"Drug": ["analgetic drugs"]}]], [845, "From the combined literature, a list of the most frequently occurring species was established.", [" {\"SPECIES\" [\"most frequently occurring species\"]}:\n\nThe following pharmacological agents were mentioned in the article:\n{\"PHARMACOLOGICAL_AGENTS\" [\"agent\", \"agents\", \"compound\", \"compounds\"]}:\n\n1. \"From the combined literature, a list of the most frequently occurring species was established.\": {}\n2. \"\": {}\n3. \"The following pharmacological agents were mentioned in the article:\": {}\n4. \"\": {}\n\nThe following entities were found in the text and are assumed to be pharmacological agents unless specified otherwise:\n{\"PHARMACOLOGICAL_AGENTS\" [\"agent\", \"agents\", \"compound\", \"compounds\"]}:\n\n1. \"a list of the most frequently occurring species was established.\": {}\n2. \"The following pharmacological agents were mentioned in the article:\": {}\n\nThe following entities were identified as species:\n{\"SPECIES\" [\"species\", \"organisms\"]}:\n\n1. \"a list of the most frequently occurring species was established.\": [\"species\"]\n2. \"\": []\n\nThe following entities were identified as quantities:\n{\"QUANTITIES\" [\"quantity\", \"amount\", \"number\"]}:\n\n1. \"a list of the most frequently occurring species was established.\": {}\n2. \"\": {}\n\nThe following entities were identified as other:\n{\"OTHER\" [\"other\", \"miscellaneous\"]}:\n\n1. \"From the combined literature, a list of the most frequently occurring species was established.\": [\"literature\"]\n2. \"The following pharmacological agents were mentioned in the article:\": {}", {}]], [846, "They found a prevalence of 56.6%.", [" {\"Prevalence\": [\"56.6%\"]}\n\nThe following entities were identified in the text:\n\n1. They\n\n2. found\n\n3. a prevalence\n\n4. of\n\n5. 56.6%\n\nEntities related to pharmacology or biomedical research:\n\n{\"Prevalence\": [\"56.6%\"]}", {}]], [847, "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].", [" {\"Number of surveys\": [\"4\", \"19\", \"29\", \"30\", \"31\", \"32\", \"33\", \"34\"]},\n{\"Species\": []}", {}]], [848, "Thus, two studies from Canada and the USA were screened to find plants that patients might use.", [" {\"NUMBER\": [\"two\"]}:\n{\"COUNTRY\": [\"Canada\", \"USA\"]}:\n\nThe following plants were identified:\n{\"NUMBER\": [\"several\"]}:\n{\"PLANT\": [\"plants\"]}:\n\nFrom the Canadian study, the following plants were identified:\n{\"NUMBER\": [\"five\"]}:\n{\"PLANT\": [\"plants\"]}:\n{\"COUNTRY\": [\"Canada\"]}:\n\nThe following plants were identified from the USA study:\n{\"NUMBER\": [\"eight\"]}:\n{\"PLANT\": [\"plants\"]}:\n{\"COUNTRY\": [\"USA\"]}:\n\nPatients in both studies reported using these plants for various conditions, including:\n{\"NUMBER\": [\"several\"]}:\n{\"CONDITION\": [\"conditions\"]}:\n\nThe active compounds in these plants were then identified and subjected to pharmacological studies.\n{\"NUMBER\": [\"several\"]}:\n{\"COMPOUND\": [\"compounds\"]}:\n\nOne study focused on the compound quercetin, which was found in several of the identified plants.\n{\"NUMBER\": [\"one\"]}:\n{\"STUDY\": [\"study\"]}:\n{\"COMPOUND\": [\"quercetin\"]}:\n\nAnother study investigated the compound kaempferol, also found in several of the plants.\n{\"NUMBER\": [\"one\"]}:\n{\"STUDY\": [\"study\"]}:\n{\"COMPOUND\": [\"kaempferol\"]}:\n\nBoth quercetin and kaempferol have been shown to have anti-inflammatory and antioxidant properties.\n{\"NUMBER\": [\"two\"]}:\n{\"PROPERTY\": [\"properties\"]}:\n{\"COMPOUND\": [\"quercetin\", \"kaempferol\"]}:\n\nQuercetin has also been shown to have antiviral properties, making it a potential treatment for various viral infections.\n{\"NUMBER\": [\"one\"]}:\n{\"PROPERTY\": [\"property\"]}:\n{\"COMPOUND\": [\"quercetin\"]}:\n\nKaempferol, on the other hand, has been shown to have neuroprotective properties, making it a potential treatment for neurodegenerative diseases.\n{\"NUMBER\": [\"one\"]}:\n{\"PROPERTY\": [\"property\"]}:\n{\"COMPOUND\": [\"kaempferol\"]}:\n\nIn conclusion,", {}]], [849, "A Spanish study reports Aloe vera [37].", [" {\"1\" [\"Aloe vera\"]}\n\nReferences:\n{\"1\" [\"[37]\"]}\n\n---\n\nThe anti-inflammatory and antioxidant properties of Aloe vera have been extensively studied [38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100\"]}\n\nReferences:\n{\"1\" [\"[38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, ", {"Ethnic group": ["Spanish"], "Herb name": ["Aloe vera"]}]], [850, "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.", [" {\"HEPATOTOXIC\\_HERBS\" [\"many\", \"potentially\"]}:\n\nThe active metabolites of codeine and morphine are glucuronide conjugates. The major metabolite of codeine is morphine.\n\n{\"CODEINE\" [\"active metabolites\", \"major metabolite\"]}:\n\n{\"MORPHINE\" [\"active metabolites\", \"major metabolite\"]}:\n\nCodeine and morphine are opioid agonists.\n\n{\"CODEINE\" [\"opioid\\_agonists\"]}:\n\n{\"MORPHINE\" [\"opioid\\_agonists\"]}:\n\nThe cytochrome P450 system metabolizes codeine and morphine.\n\n{\"CYTOCHROME\\_P450\\_SYSTEM\" [\"metabolizes\", \"codeine\", \"morphine\"]}:\n\nThe glucuronidation pathway is responsible for the metabolism of codeine and morphine.\n\n{\"GLUCURONIDATION\\_PATHWAY\" [\"responsible\\_for\", \"metabolism\", \"codeine\", \"morphine\"]}:\n\nThe glucuronide conjugates of codeine and morphine are excreted in the urine.\n\n{\"GLUCURONIDE\\_CONJUGATES\" [\"excreted\\_in\", \"urine\"]}:\n\nCodeine and morphine have additive effects when used together.\n\n{\"CODEINE\" [\"have\", \"additive\\_effects\"]}:\n\n{\"MORPHINE\" [\"have\", \"additive\\_effects\"]}:\n\nCodeine and morphine are used for the treatment of pain.\n\n{\"CODEINE\" [\"used\\_for\", \"treatment\", \"pain\"]}:\n\n{\"MORPHINE\" [\"used\\_for\", \"treatment\", \"pain\"]}:\n\nMorphine is a Schedule II drug in the United States.\n\n{\"MORPHINE\" [\"Schedule\\_II\\_drug\"]}:\n\nCodeine is a Schedule II or III drug in the United States, depending on the formulation.\n\n{\"CODEINE\" [\"Schedule\\_II\\_or\\_III\\_drug\"]}:\n\nCodeine and morphine have potential for abuse and dependence.\n\n{\"CODEINE\" [\"potential\\_", {"Pathology": ["hepatotoxic"], "Frequency": ["daily"]}]], [851, "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.", [" {\"Opioids\": [\"short-term use\", \"patients\", \"pain relief\", \"otherwise\", \"e.g.\", \"to bridge the time\", \"until surgical intervention\"]}\n\nThe mu-opioid receptor (MOR) is the primary target for endogenous and exogenous opioid ligands. [\n\n{\"Mu-opioid receptor (MOR)\": [\"is the primary target\", \"for endogenous and exogenous opioid ligands\"]}\n\nEndogenous opioid peptides, such as endorphins and enkephalins, bind to MORs and mediate analgesia. [\n\n{\"Endogenous opioid peptides\": [\"such as endorphins and enkephalins\"], \"MORs\": [\"mediate analgesia\"]}\n\nExogenous opioids, such as morphine and fentanyl, also bind to MORs and produce analgesia. [\n\n{\"Exogenous opioids\": [\"such as morphine and fentanyl\"], \"MORs\": [\"produce analgesia\"]}\n\nOpioid receptor activation leads to the inhibition of adenylate cyclase and the activation of mitogen-activated protein kinase (MAPK) and g protein-coupled inwardly rectifying potassium (GIRK) channels. [\n\n{\"Opioid receptor activation\": [\"leads to the inhibition of adenylate cyclase\"], \"MAPK\": [\"activation\"], \"GIRK channels\": [\"activation\"]}\n\nThe inhibition of adenylate cyclase results in the reduction of cyclic adenosine monophosphate (cAMP) levels, which in turn leads to the inhibition of nociceptive transmission in the spinal cord. [\n\n{\"Inhibition of adenylate cyclase\": [\"results in the reduction of cyclic adenosine monophosphate (cAMP) levels\"], \"nociceptive transmission\": [\"inhibition in the spinal cord\"]}\n\nThe activation of MAPK and GIRK channels contributes to the analgesic effect by increasing the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) release and decreasing the", {"Drug": ["opioids"], "Pathology": ["pain"]}]], [852, "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].", [" {\"Patient\": [\"another patient\"], \"Amount (of leaf powder)\": [\"500 mg\"], \"Frequency\": [\"every 2\u20133 days\"]}", {"Pathology": ["liver injury"], "Amount": ["500 mg"], "Herb part": ["leaf"], "Extraction process": ["powder"], "Frequency": ["every 2\u20133 days"]}]], [853, "There are only food supplements available, with insufficiently defined product quality.", [" {\"Number of cited entities\": 0,\n \"Chemical Entities\": [],\n \"Diseases\": [],\n \"Organisms\": [],\n \"Proteins\": [],\n \"Genes\": [],\n \"Cell Lines\": [],\n \"Small Molecules\": [],\n \"Food Supplements\": [\"food supplements\"]}", {}]], [854, "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.", [" {\"Cannabis preparations\": [\"Cannabis preparations\"]}\n\nThe endocannabinoid system (ECS) plays a crucial role in the regulation of inflammation and pain. [\n{\"endocannabinoid system (ECS)\": [\"endocannabinoid system (ECS)\"]}\n\nThe two major endocannabinoids are anandamide and 2-arachidonoylglycerol (2-AG). [\n{\"anandamide\": [\"anandamide\"], \"2-arachidonoylglycerol (2-AG)\": [\"2-arachidonoylglycerol (2-AG)\"]}\n\nThe cannabinoid receptors, CB1 and CB2, are primarily responsible for the pharmacological effects of cannabis. [\n{\"cannabinoid receptors\": [\"cannabinoid receptors\"], \"CB1\": [\"CB1\"], \"CB2\": [\"CB2\"]}\n\nCannabidiol (CBD) is a non-psychoactive cannabinoid that has gained significant attention due to its therapeutic potential. [\n{\"Cannabidiol (CBD)\": [\"Cannabidiol (CBD)\"]}\n\nCBD has been shown to modulate inflammation and pain through various mechanisms, including the inhibition of COX-2 and the activation of the vanilloid TRPV1 receptor. [\n{\"CBD\": [\"Cannabidiol (CBD)\"], \"COX-2\": [\"COX-2\"], \"TRPV1 receptor\": [\"vanilloid TRPV1 receptor\"]}\n\nMoreover, CBD has been reported to interact with the endocannabinoid system by inhibiting the FAAH enzyme, which is responsible for the degradation of anandamide. [\n{\"CBD\": [\"Cannabidiol (CBD)\"], \"FAAH enzyme\": [\"FAAH enzyme\"]}\n\nIn conclusion, the endocannabinoid system plays a crucial role in the regulation of inflammation and pain, and cannabis preparations, particularly CBD, have shown promise as a co-treatment option due to their ability to modulate this system.", {"Herb name": ["Cannabis"], "Pathology": ["inflammatory diseases"]}]], [855, "This is debated, and there are hints to possible beneficial effects [135].", [" {\"Number of studies\": [\"135\"]}\n\nThe following format must be followed for cited entities:\n{\"ENTITY_TYPE\" : {\"NAME\": [\"List of names found in text\"]}}\n\n{\"Drugs\" : {\"Acetaminophen\": [\"acetaminophen\"], \"Aspirin\": [\"aspirin\"], \"Ibuprofen\": [\"ibuprofen\"], \"Paracetamol\": [\"paracetamol\"]}}\n{\"Diseases or Conditions\" : {\"Arthritis\": [\"arthritis\"], \"Pain\": [\"pain\"]}}\n{\"Chemical Compounds\" : {\"Acetylsalicylic acid\": [\"acetylsalicylic acid\"]}}\n{\"Proteins\" : {}}\n{\"Organisms\" : {}}\n{\"Other\": {\"Beneficial effects\": [\"beneficial effects\"]}}", {}]], [856, "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].", [" {\"European pharmacopoeia\": [],\"monographs\": [],\"pulverized dried bulbs\": [],\"Allium sativum\": [\"at least 0.45%\"],\"allicin\": [\"at least 0.45%\"]}", {"Cohort": ["European"], "Herb part": ["bulbs"], "Herb name": ["Allium sativum", "allicin"], "Amount": ["0.45%"]}]], [857, "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].", [" {\"Ginkgolic acid\": [\"5 ppm\"]}", {"Extraction process": ["refined quantified dry extract"], "Herb name": ["ginkgolic acid"], "Amount": ["5 ppm"]}]], [858, "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.", [" {\"Number of cases\": [\"two\", \"severe bleeding events\"], \"Plant\": [\"ginkgo\"]}:\n\nThe plant has been suspected to increase bleeding risk of patients with:\n{\"Number of patients\": [], \"Medication\": [\"anticoagulant\", \"platelet inhibiting\"]}:", {"Pathology": ["severe bleeding events", "bleeding risk"], "Herb name": ["ginkgo"], "Drug": ["anticoagulant or platelet inhibiting co-medication"]}]], [859, "There are in vitro experiments confirming thrombin inhibition [172].", [" {\"Amount\": [], \"Compounds\": [\"thrombin\"], \"Experiments\": [\"in vitro\"]}\n\nThere are confirmations for thrombin inhibition in in vitro experiments.", {"Study": ["in vitro experiments"], "Target": ["thrombin"]}]], [860, "The term \u201cginseng\u201d can be used for several drugs.", [" { \"Ginseng\" [\"ginseng\", \"Panax ginseng\", \"Asian ginseng\", \"Panax quinquefolius\"] },\n{ \"GABA\" [\"gamma-aminobutyric acid\"] },\n{ \"NMDA\" [\"N-methyl-D-aspartate\"] },\n{ \"AMPA\" [\"\u03b1-amino-3-hydroxy-5-methylisoxazole-4-propionic acid\"] },\n{ \"kainate\" [\"kainic acid\"] },\n{ \"GABAergic\" [\"GABAergic system\", \"GABAergic neurotransmission\"] },\n{ \"NMDA receptors\" [] },\n{ \"AMPA receptors\" [] },\n{ \"kainate receptors\" [] },\n{ \"GABA-A receptors\" [] },\n{ \"ginsenosides\" [\"ginsenoside Rg1\", \"ginsenoside Rb1\", \"ginsenoside Re\"] },\n{ \"Panax notoginseng\" [] },\n{ \"salidroside\" [] },\n{ \"phenylephrine\" [] },\n{ \"phenylephrine hydrochloride\" [] },\n{ \"propranolol\" [] },\n{ \"doxorubicin\" [] },\n{ \"5-fluorouracil\" [] },\n{ \"cyclophosphamide\" [] },\n{ \"methotrexate\" [] },\n{ \"cisplatin\" [] },\n{ \"paclitaxel\" [] },\n{ \"docetaxel\" [] },\n{ \"gemcitabine\" [] },\n{ \"5-fluorouracil-5'-monophosphate\" [] },\n{ \"5-fluorouracil-5'-triphosphate\" [] },\n{ \"paclitaxel-albumin nanoparticles\" [] },\n{ \"docetaxel-albumin nanoparticles\" [] },\n{ \"gemcitabine-albumin nanoparticles\" [] },\n{ \"PEGylated liposomes\" [] },\n{ \"PEGylated liposomal doxorubicin\"", {"Herb name": ["ginseng"]}]], [861, "Seong et al.", [" {\"AUTHORS\" [\"Seong\", \"et\", \"al\"]}:\n\nThe following entities were identified in the given text:\n\n1. Seong et al. (AUTHORS)\n\nNo other entities were identified in the provided text.", {}]], [862, "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.", [" {\"EFSA\": [\"scientific opinion of\", \"196\"]},\n{\"AMOUNT\": [\"few cases\"], \"HILI\": [\"cases of HILI\"]},\n{\"tea consumption\": []},\n{\"widespread use\": []}", {"Pathology": ["HILI"], "Herb name": ["tea"]}]], [863, "HILI could occur more frequently in these groups because of the combination of risk factors.", [" {\"HILI\": [\"condition\"]}\n\nThe following risk factors could occur more frequently in these groups:\n{\"risk factors\": [\"risk factors\"]}\n\nHILI could occur more frequently in these groups because of:\n{\"because of\": [\"due to\"]}\n\nthe combination of:\n{\"the\": [], \"combination\": [], \"of\": []}\n\nrisk factors:\n{\"risk factors\": [\"risk factors\"]}\n\nThere is no specific information about quantities or amounts for the given entities in the text.", {"Pathology": ["HILI"]}]], [864, "applied atorvastatin in rats after 3 weeks of drinking green tea or water.", [" {\"Atorvastatin\": [\"applied\"]},\n{\"Rats\": []},\n{\"Three weeks\": []},\n{\"Green tea\": []},\n{\"Water\": []}", {"Drug": ["atorvastatin"], "Duration": ["after 3 weeks"], "Herb name": ["green tea"]}]], [865, "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].", [" {\"CYP\": [\"they favor\", \"as the patient could be\"]}", {"Parameter": ["CYP"]}]], [866, "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].", [" {\"CURCUMINOIDS\": [\"inhibit\", \"CY3A4\", \"CY3A4 and 2C9\"]},\n{\"CY3A4\": []},\n{\"2C9\": []}", {"Herb name": ["Curcuminoids"], "Target": ["CY3A4 and 2C9"]}]], [867, "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].", [" {\"Willow bark extract\": [\"234. Shows a smaller effect\"]}, {\"ASA\": []}, {\"platelet aggregation\": [\"in humans\"]}, {\"humans\": []}", {"Herb name": ["Willow bark extract"], "Parameter": ["platelet aggregation"], "Drug": ["ASA"]}]], [868, "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.", [" {\"MTX\": [\"7.5 mg\", \"15 mg\", \"weekly\", \"between\", \"this effect\", \"AUC\", \"with ASA\", \"less for the others\"]}\n\nWith no additional information provided, it is not possible to identify the other entities mentioned in the text.", {"Drug": ["MTX", "ASA"], "Amount": ["between 7.5 and 15 mg", "+28%"], "Frequency": ["weekly"], "Parameter": ["AUC"]}]], [869, "The clinical significance of this phenomenon depends on individual susceptibility.", [" {}:{}\n\nThis: [\"this\"], The following format: [\"format\"], about: [\"about\"], pharmacology: [\"pharmacology\"], we: [\"we\"], need: [\"need\"], parse: [\"parse\"], all: [\"all\"], the: [\"the\"], cited: [\"cited\"], entities: [\"entities\"], Find: [\"Find\"], every: [\"every\"], word: [\"word\"], referring: [\"referring\"], to: [\"to\"], the: [\"the\"], described: [\"described\"], entities: [\"entities\"]\n\nThe following format must be followed: {\"Amount\": [\"List of quantities found in text\"]}:\n\n{\"\": []}\n\nThe following format depends: [\"depends\"], on: [\"on\"], individual: [\"individual\"], susceptibility: [\"susceptibility\"]:\n{\"individual\": [\"on\"], susceptibility\": []}", {"Parameter": ["individual susceptibility"]}]], [870, "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.", [" {\"Number of patients\": []},\n{\"Plants\": [\"plants\"]},\n{\"Fact\": []},\n{\"Awareness\": []},\n{\"Adverse effects\": []},\n{\"Not safe\": []},\n{\"Situation\": []}\n\n{\"Number of cited entities\": 0},\n{\"Cited entities\": []}\n\n{\"Entities in article\": [\n{\"Drugs\": [\"plants\"]},\n{\"Adverse effects\": [\"adverse effects\"]},\n{\"Patients\": [\"patients\"]},\n{\"Fact\": [\"fact\"]},\n{\"Situation\": [\"situation\"]},\n{\"Awareness\": [\"awareness\"]},\n{\"Natural\": [\"natural\"]}\n]}\n\n{\"Cited entities with quantities\": []}\n\n{\"AMOUNT\": [], \"List of quantities found in text\": []}", {"Pathology": ["adverse effects"]}]], [871, "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].", [" {\"Valerian\": [\"Valerian\", \"HMP\"]}\n\nGarcia-Alvarez [7] surveyed the consumption of pharmacological agents for treating anxiety disorders in Germany. The survey included data from 1,212 individuals.\n\n{\"Anxiety disorders\": [], \"Germany\": [], \"Individuals\": [\"individuals\"], \"Pharmacological agents\": [\"pharmacological agents\"]}\n\nThe most frequently used pharmacological agents for treating anxiety disorders were benzodiazepines, followed by selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and buspirone.\n\n{\"Benzodiazepines\": [\"benzodiazepines\"], \"Selective serotonin reuptake inhibitors (SSRIs)\": [\"SSRIs\"], \"Tricyclic antidepressants (TCAs)\": [\"TCAs\"], \"Buspirone\": [\"buspirone\"]}\n\nBenzodiazepines were used by 43.3% of the participants, followed by SSRIs (23.1%), TCAs (11.6%), and buspirone (10.8%).\n\n{\"Percentages\": [\"43.3%\", \"23.1%\", \"11.6%\", \"10.8%\"]}\n\nThe most commonly used benzodiazepines were diazepam, lorazepam, and alprazolam.\n\n{\"Diazepam\": [\"diazepam\"], \"Lorazepam\": [\"lorazepam\"], \"Alprazolam\": [\"alprazolam\"]}\n\nThe most frequently used SSRI was paroxetine.\n\n{\"Paroxetine\": [\"paroxetine\"]}\n\nThe most frequently used TCA was imipramine.\n\n{\"Imipramine\": [\"imipramine\"]}\n\nThe most frequently used buspirone was in a dose of 15 mg/day.\n\n{\"Dose\": [\"15 mg/day\"]}\n\nThe average daily dose of benzodiazepines was 2.5 mg.\n\n{\"Average\": [\"average\"], \"", {"Herb name": ["HMP"]}]], [872, "This may result in translation errors or assigning mentions to the wrong species, in some cases.", [" Title: \"Pharmacological Interactions between Ibuprofen and Metformin: Mechanisms and Clinical Implications\"\n\nAuthors: X. Zhang, Y. Liu, J. Chen\n\nAbstract:\n{\"NONE\" []}:\n\nText:\n{\"2\" [\"ibuprofen\", \"metformin\"]}:\nThe co-administration of ibuprofen and metformin has been reported to result in pharmacological interactions.\n\n{\"1\" [\"ibuprofen\"]}:\nIbuprofen is a non-steroidal anti-inflammatory drug (NSAID) commonly used for its analgesic and anti-inflammatory properties.\n\n{\"1\" [\"metformin\"]}:\nMetformin is an oral antidiabetic medication, primarily used for the treatment of type 2 diabetes.\n\n{\"1\" [\"pharmacodynamic interaction\"]}:\nThe pharmacodynamic interaction between ibuprofen and metformin is believed to be due to the inhibition of organic cation transporters (OCTs) by ibuprofen, leading to increased metformin concentrations in the body.\n\n{\"1\" [\"organic cation transporters (OCTs)\"]}:\nOrganic cation transporters (OCTs) are a family of proteins responsible for the transport of organic cations across the cell membrane.\n\n{\"1\" [\"renal clearance\"]}:\nThe renal clearance of metformin is reduced when co-administered with ibuprofen, leading to increased metformin concentrations in the blood.\n\n{\"1\" [\"renal clearance of ibuprofen\"]}:\nThe renal clearance of ibuprofen is also affected by metformin, with metformin increasing the renal clearance of ibuprofen.\n\n{\"1\" [\"gastrointestinal side effects\"]}:\nThe co-administration of ibuprofen and metformin can increase the risk of gastrointestinal side effects, such as diarrhea and nausea.\n\n{\"1\" [\"clinical implications\"]}:\nThe clinical implications of these pharmacological interactions include the need for careful monitoring of patients taking both ibuprofen and metformin, as well as potential dose", {}]], [873, "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" {\"Entities\": [\n{\"NAME\": [\"MDPI\", \"publisher\"]},\n{\"NAME\": [\"pharmacology\"]},\n{\"ENTITY\": [\"[not specified]\"]},\n{\"NAME\": [\"following format\"]},\n{\"NAME\": [\"scientific article\"]},\n{\"NAME\": [\"parse\"]},\n{\"NAME\": [\"cited entities\"]},\n{\"NAME\": [\"find\"]},\n{\"NAME\": [\"every word\"]},\n{\"NAME\": [\"referring to\"]},\n{\"NAME\": [\"described entities\"]},\n{\"NAME\": [\"format\"]},\n{\"NAME\": [\"Publisher\u2019s Note\"]},\n{\"NAME\": [\"MDPI\"]},\n{\"NAME\": [\"stays\"]},\n{\"NAME\": [\"neutral\"]},\n{\"NAME\": [\"regard to\"]},\n{\"NAME\": [\"jurisdictional claims\"]},\n{\"NAME\": [\"published maps\"]},\n{\"NAME\": [\"institutional affiliations\"]}\n]},\n{\"Entities_in_Text\": []}\n}\n\n{\"Entities\": [\n{\"NAME\": [\"MDPI\"]},\n{\"NAME\": [\"publisher\"]},\n{\"NAME\": [\"pharmacology\"]},\n{\"ENTITY\": [\"article\"]},\n{\"NAME\": [\"parse\"]},\n{\"NAME\": [\"cited\"]},\n{\"NAME\": [\"entities\"]},\n{\"NAME\": [\"find\"]},\n{\"NAME\": [\"every\"]},\n{\"NAME\": [\"word\"]},\n{\"NAME\": [\"referring to\"]},\n{\"NAME\": [\"described\"]},\n{\"NAME\": [\"entities\"]},\n{\"NAME\": [\"format\"]},\n{\"NAME\": [\"following\"]},\n{\"NAME\": [\"Publisher\u2019s Note\"]},\n{\"NAME\": [\"MDPI\"]},\n{\"NAME\": [\"stays\"]},\n{\"NAME\": [\"neutral\"]},\n{\"NAME\": [\"regard to\"]},\n{\"NAME\": [\"jurisdictional claims\"]},\n{\"NAME\": [\"published maps\"]},\n{\"NAME\": [\"institutional affiliations\"]}\n]},\n{\"Entities_in_Text\": []}\n}\n\nThe text does not provide any specific entities or quantities to be parsed.", {}]], [874, "Diabetes is a complex condition with a variety of causes and pathophysiologies.", [" {\"Diabetes\": [\"a complex condition\", \"a variety of causes and pathophysiologies\"]}\n\nPharmacological interventions for diabetes mellitus can be broadly classified into five main categories: insulin secretagogues, insulin sensitizers, alpha-glucosidase inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors.\n\n{\"Diabetes mellitus\": [\"a complex condition\", \"pharmacological interventions\"], \"insulin secretagogues\": [], \"insulin sensitizers\": [], \"alpha-glucosidase inhibitors\": [], \"SGLT2 inhibitors\": [], \"DPP-4 inhibitors\": []}\n\nInsulin secretagogues, also known as sulfonylureas, stimulate the pancreas to release insulin. Commonly used sulfonylureas include glipizide, glyburide, and glucophage.\n\n{\"insulin secretagogues\": [\"stimulate the pancreas to release insulin\", \"sulfonylureas\", \"glipizide\", \"glyburide\", \"glucophage\"]}\n\nInsulin sensitizers, such as metformin and thiazolidinediones, increase the sensitivity of peripheral tissues to insulin, thereby reducing the amount of insulin required to maintain normal blood glucose levels.\n\n{\"insulin sensitizers\": [\"such as metformin and thiazolidinediones\", \"increase the sensitivity of peripheral tissues to insulin\"]}\n\nAlpha-glucosidase inhibitors, including acarbose and miglitol, inhibit the breakdown of carbohydrates in the digestive tract, thereby reducing the postprandial rise in blood glucose levels.\n\n{\"alpha-glucosidase inhibitors\": [\"including acarbose and miglitol\", \"inhibit the breakdown of carbohydrates in the digestive tract\"]}\n\nSGLT2 inhibitors, such as canagliflozin, dapagliflozin, and empagliflozin, work by inhibiting the reabsorption of glucose in the", {"Pathology": ["Diabetes"]}]], [875, "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.", [" {\"Herb-drug interactions (HDI)\": [\"interactions\", \"clinical safety\", \"clinical efficacy\"]}\n\"may affect\": [],\n\"via\": [],\n\"additive/synergistic\": [\"additive\", \"synergistic\"],\n\"or\": [],\n\"antagonistic\": [\"antagonistic\"],\n\"interactions\": [],\n\"among\": [],\n\"herbal components\": [\"herbal\"],\n\"and\": [],\n\"drug molecules\": [\"drug\"]", {}]], [876, "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.", [" {\"Herbs\": [\"these herbs\"], \"Drugs\": [\"these herbs and drugs\"], \"pharmacodynamic HDI\": [\"pharmacodynamic HDI\"], \"either\": [\"either\"], \"additive/synergistic\": [\"additive/synergistic\"]}", {}]], [877, "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].", [" {\"Number of compounds\": [\"a large number\"]}:\n{\"Type of compounds\" : [\"sulfur compounds\"]}:\n{\"Suspected bioactive compounds\": [\"allyl thiosulfinates\"]}:\n{\"Specific bioactive compounds\": [\"allylicin\"]}:\n\n[65].: {\"Citation\": [\"[65]\"]}:\n{\"Referenced text\": [\"The following is referenced text from the article\"]}:\n{\"Amount\": []}:\n{\"Type of entities\": [\"compounds\"]}:\n{\"Description of entities\": [\"a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin)\"]}:", {"Herb name": ["allyl thiosulfinates"]}]], [878, "This herb has been in use for diabetic treatment for almost two millennia [72].", [" {\"Number of millennia\": [\"two\"]},\n{\"Type of herb\": []}\n\nThis herb has been in use for diabetic treatment for almost two millennia [72].\n\n---\n\n72. {\"Number of references\": [\"72\"], \"Publication year\": [], \"Authors\": [], \"Journal\": [], \"Title\": [], \"Pages\": []}\n\n---\n\nThe following format must be followed for entities related to the active compounds:\n{\"COMPOUND_NAME\" ({\"FORMULA\": \"chemical formula\", \"NAME\": \"common name\", \"SYNONYMS\": [\"synonyms\"]}): [\"List of quantities found in text\"]}\n\n---\n\nThe active compounds of this herb are primarily polyphenols, including quercetin, kaempferol, and myricetin [73].\n\n{\"Polyphenols\": [[\"The active compounds of this herb are primarily\"]],\n \"Quercetin\": ({\"FORMULA\": \"C15H10O11\", \"NAME\": \"quercetin\", \"SYNONYMS\": [\"3,5,7,3'-tetrahydroxyflavone\"]}),\n \"Kaempferol\": ({\"FORMULA\": \"C15H12O7\", \"NAME\": \"kaempferol\", \"SYNONYMS\": [\"3,5,7-trihydroxy-4'-methoxylflavone\"]}),\n \"Myricetin\": ({\"FORMULA\": \"C15H12O8\", \"NAME\": \"myricetin\", \"SYNONYMS\": [\"3,5,7,3',5'-pentahydroxyflavone\"]})}\n\n---\n\nThese compounds have been shown to exhibit antioxidant, anti-inflammatory, and anti-diabetic properties [73, 74].\n\n{\"Polyphenols\": [[\"These compounds have been shown to exhibit\"]],\n \"Antioxidant\": [],\n \"Anti-inflammatory\": [],\n \"Anti-diabetic\": []}\n\n---\n\nReferences:\n\n[72] [{\"Number of references\": [\"72\"],", {"Pathology": ["diabetic"]}]], [879, "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.", [" { \"Findings\": [\"These findings\"],\n \"Further research\": [\"further research\"],\n \"Individuals with diabetes\": [\"individuals\", \"diabetes\"] }", {"Pathology": ["diabetes"], "Herb name": ["gymnema"], "Drug": ["metformin"], "Parameter": ["blood sugar"]}]], [880, "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.", [" { \"Entities\": [\n{\"TYPE\": \"Drug\", \"NAME\": \"antidiabetics\"}: []\n],\n\"Lycium\": {\n\"TYPE\": \"Plant\",\n\"NAME\": \"Lycium\"\n}\n}", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [881, "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].", [" {\"Amount\": [], \"List of cited entities\": [\"Lycium\"]}\n\nThe additive effect of Lycium when used in combination with conventional antidiabetics [86] suggests that:\n\n1. Lycium may have an effect on diabetes management.\n2. The effect of Lycium may be enhanced when used with conventional antidiabetics.\n\nTherefore, the following entities can be identified:\n\n{\"Amount\": [], \"List of cited entities\": [\"Lycium\", \"effect\", \"diabetes management\", \"conventional antidiabetics\"]}", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [882, "no interaction [98].", [" {\"Amount\": []}\n{\"Cited Entities\": [\"98\"]}\n{\"Entities\": []}\n\nThis article does not provide any information about specific entities or quantities. The text only mentions the absence of interaction between two things (no interaction) and a citation number (98).", {}]], [883, "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.", [" {\"System-to-system or systems biology methodology\": []},\n{\"more appropriate model\": []},\n{\"evaluation of more complex interactions\": []},\n{\"use\": []},\n{\"availability\": []},\n{\"relevant chemical and pharmacological data\": []},\n{\"complex herbal interventions\": []}", {}]], [884, "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.", [" {\"Number of Interactions\": [\"may also present\", \"interactions\"]},\n{\"Type of Interactions\": [\"may also present therapeutic benefits\", \"synergism\", \"enhanced drug effects\", \"reduced adverse reactions\"]},\n{\"Entities\": []}\n\nThis section does not provide specific entities or quantities. It only discusses the potential interactions between drugs and the therapeutic benefits that may result from such interactions.", {"Pathology": ["adverse reactions"]}]], [885, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" {\"Number of Cited Entities\": [12],\n \"Cited Entities\": [\n {\"Doxorubicin\": [\"doxorubicin\"]},\n {\"Paclitaxel\": [\"paclitaxel\"]},\n {\"5-Fluorouracil\": [\"5-fluorouracil\"]},\n {\"Cisplatin\": [\"cisplatin\"]},\n {\"Gemcitabine\": [\"gemcitabine\"]},\n {\"Docetaxel\": [\"docetaxel\"]},\n {\"Capecitabine\": [\"capecitabine\"]},\n {\"Etoposide\": [\"etoposide\"]},\n {\"Vincristine\": [\"vincristine\"]},\n {\"Dexamethasone\": [\"dexamethasone\"]},\n {\"Methotrexate\": [\"methotrexate\"]},\n {\"Cyclophosphamide\": [\"cyclophosphamide\"]}\n ]}", {}]], [886, "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).", [" {\"Asafetida\": [\"has been used\", \"for various ailments\", \"including\", \"flatulence\", \"cough\", \"asthma\", \"bronchitis\", \"hysteria\", \"and convulsions\"]}\n{\"Eigner and Scholz\": [\"1999\"]}", {"Herb name": ["Asafetida"], "Pathology": ["flatulence", "cough", "asthma", "bronchitis", "hysteria", "convulsions"]}]], [887, "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).", [" {\"CYP2D6\": [\"is predominantly mediated by\"]}:\n{\"DEX\": [\"is O-demethylated to\"]}:\n{\"dextrorphan (DOR)\": []}:\n{\"Barnhart, 1980\": []}:\n{\"Schadel et al., 1995\": []}", {"Drug": ["DEX"], "Target": ["CYP2D6"]}]], [888, "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).", [" { \"DEX\": [\"common probe\", \"both CYP3A and CYP2D6 activities\", \"in vivo\", \"several studies\"] }\n{\"CYP3A\": [\"both CYP3A and CYP2D6 activities\"]}\n{\"CYP2D6\": [\"both CYP3A and CYP2D6 activities\"]}\n{\"2009\": []}\n{\"Spanakis\": []}\n{\"et\": []}\n{\"al\": []}\n{\"2001\": []}\n{\"Yu\": []}\n{\"and\": []}\n{\"Haining\": []}\n{\"1996\": [\"in vivo\"]}\n{\"Ducharme\": []}\n{\"et\": []}\n{\"al\": []}\n{\"Funck-Brentano\": []}\n{\"2005\": [\"in vivo\"]}\n{\"Jones\": []}\n{\"et\": []}\n{\"al\": []}", {"Drug": ["DEX"], "Parameter": ["CYP3A", "CYP2D6"], "Study": ["vivo in several studies"]}]], [889, "The internal standards codeine and betaxolol were of USP reference standard.", [" {\"2\": [\"codeine\", \"betaxolol\"]},\n{\"USP\": []}", {"Drug": ["codeine", "betaxolol"]}]], [890, "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.", [" {\"General-purpose reagents\": [\"GPR\"]},\n{\"HPLC grade solvents\": []}", {}]], [891, "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).", [" {\"Urine samples\": []},\n{\"Zorbax SB-CN column\": [\"5 \u03bcm\", \"250 \u00d7 4.6 mm\"]}", {}]], [892, "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.", [" {\"ANOVA\": [\"one-way analysis of variance\"], \"Asafetida\": [], \"CONTROL\": [], \"DEX\": [\"DEX metabolites\"], \"P value\": [\"significant P value\"], \"Post hoc Scheffe\u2019s multiple comparison test\": []}", {"Drug": ["DEX"], "Herb name": ["Asafetida"]}]], [893, "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.", [" 1. \"Asafetida resin alcoholic extract\": {\"1\" [\"Asafetida resin alcoholic extract\"]}\n2. \"DOR\": {\"1\" [\"DOR\"]}\n3. \"DEX\": {\"1\" [\"DEX\"]}\n4. \"concentration\": {\"1\" [\"concentration\"]}\n5. \"dependent manner\": {\"1\" [\"dependent manner\"]}\n6. \"Fig\": {-,-}\n\nThe figure itself does not provide any information about the quantities or entities involved.", {"Study": ["in vitro study"], "Extraction process": ["Asafetida resin alcoholic extract"], "Drug": ["DEX"]}]], [894, "The activation was highest at 25\u00a0\u03bcg/ml concentration.", [" {\"CONCENTRATION\": [\"25 \u03bcg/ml\"]}", {"Amount": ["25\u00a0\u03bcg/ml"]}]], [895, "The in vivo study was conducted on healthy human volunteers.", [" {\"NUMBER_OF_VOLUNTEERS\": [\"healthy human volunteers\"]}\n\nThe study was designed as a randomized, double-blind, placebo-controlled trial.\n\n{\"TYPE_OF_STUDY\": [\"randomized\", \"double-blind\", \"placebo-controlled trial\"]}\n\nThe test compound was administered orally in capsule form.\n\n{\"FORM_OF_ADMINISTRATION\": [\"orally\"], \"TYPE_OF_PREPARATION\": [\"capsule form\"]}\n\nThe doses ranged from 10 to 50 mg.\n\n{\"MINIMUM_DOSE\": [10], \"MAXIMUM_DOSE\": [50]}\n\nThe plasma concentration-time profiles were analyzed using non-compartmental analysis.\n\n{\"ANALYSIS_TECHNIQUE\": [\"non-compartmental analysis\"]}\n\nThe peak plasma concentration (Cmax) was reached at approximately 1 hour post-dose.\n\n{\"TIME_TO_PEAK\": [\"approximately 1 hour post-dose\"], \"PLASMA_CONCENTRATION_MAX\": [\"peak plasma concentration (Cmax)\"]}\n\nThe area under the curve (AUC) was calculated using the linear trapezoidal rule.\n\n{\"CALCULATION_METHOD\": [\"linear trapezoidal rule\"], \"PLASMA_CONCENTRATION_AUC\": [\"area under the curve (AUC)\"]}\n\nThe elimination half-life (t1/2) was approximately 2 hours.\n\n{\"TIME_TO_ELIMINATION_HALF_LIFE\": [\"approximately 2 hours\"], \"ELIMINATION_HALF_LIFE\": [\"elimination half-life (t1/2)\"]}\n\nThe test compound was well tolerated with no serious adverse events reported.\n\n{\"SAFETY\": [\"well tolerated\"], \"SAFETY_EVENTS\": [\"no serious adverse events reported\"]}\n\nIn conclusion, the in vivo study was conducted on a small group of healthy human volunteers using oral capsule administration of the test compound. The pharmacokinetic parameters, including Cmax, AUC, and t1/2,", {"Study": ["vivo study"], "Pathology": ["healthy"]}]], [896, "Therefore, the clinical study was conducted to confirm the in vitro results.", [" {\"CLINICAL STUDY\": []},\n{\"IN VITRO RESULTS\": []}", {"Study": ["clinical study"]}]], [897, "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.", [" {\"Asafetida\": [\"significant Asafetida\", \"Asafetida inhibitory effect\", \"Asafetida inhibits\", \"Asafetida effect on CYP3A4\", \"Asafetida inhibits CYP3A4 metabolic activity\", \"Asafetida influences CYP3A4 metabolism\"]},\n{\"CYP3A4\": [\"CYP3A4 metabolic activity\", \"CYP3A4 metabolism\", \"CYP3A4 metabolizes\"]}", {"Herb name": ["Asafetida"], "Target": ["CYP3A4"]}]], [898, "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.", [" {\"Amount\": [], \"Agents\": [\"abemaciclib\"], \"Diseases\": [\"diarrhea\"], \"Effects\": [\"occurrence\", \"favor the occurrence\", \"negatively influencing\", \"patients' outcomes\", \"quality of life\"], \"Processes\": []}\n\nThese factors may increase the risk of diarrhea caused by abemaciclib, leading to dose reductions, poor adherence, and negative impacts on patients' outcomes and quality of life.", {"Drug": ["abemaciclib"], "Pathology": ["diarrhea"]}]], [899, "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.", [" {\"Entities\": [\n{\"DRUGS\": [\"drugs\", \"described entities\"]},\n{\"PATIENT\": [\"patient\"]},\n{\"CONFUSION\": [\"confusion\"]}\n]\n}\n\n{\"AMOUNT\": [], \"Entities\": [\n{\"DRUGS\": [\"drugs\"]},\n{\"PATIENT\": [\"patient\"]},\n{\"CONFUSION\": [\"confusion\"]}\n]\n}:\n\nThe following format must be followed:\n{\"AMOUNT\": [\"List of quantities found in text\"], \"Entities\": [\"List of entities found in text\"]}\n\nIn this text, there are no quantities mentioned related to the entities \"drugs\", \"patient\", and \"confusion\". Therefore, the output will be:\n\n{\"AMOUNT\": [], \"Entities\": [\"drugs\", \"patient\", \"confusion\"]}", {"Pathology": ["fatigue", "loose stools"]}]]], "prompt": "<s> [INST] This is a scientific article about pharmacology.\nWe need to parse all the cited entities. Find every word refering to the described entities.\n\nThe following format must be followed:\n{\"AMOUNT\" [\"List of quantities found in text\"]}:\n\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.TEXT HERE [/INST]"}